id	sid	tid	token	lemma	pos
dpc-5933	1	1	dermatology	dermatology	NOUN
dpc-5933	1	2	:	:	PUNCT
dpc-5933	1	3	practical	practical	ADJ
dpc-5933	1	4	and	and	CCONJ
dpc-5933	1	5	conceptual	conceptual	ADJ
dpc-5933	1	6	original	original	ADJ
dpc-5933	1	7	article	article	NOUN
dpc-5933	1	8	|	|	ADV
dpc-5933	1	9	dermatol	dermatol	ADJ
dpc-5933	1	10	pract	pract	NOUN
dpc-5933	1	11	concept	concept	NOUN
dpc-5933	1	12	.	.	PUNCT
dpc-5933	2	1	2025;15(4):5933	2025;15(4):5933	NUM
dpc-5933	2	2	1	1	NUM
dpc-5933	2	3	secukinumab	secukinumab	NOUN
dpc-5933	2	4	efficacy	efficacy	NOUN
dpc-5933	2	5	predictors	predictor	NOUN
dpc-5933	2	6	in	in	ADP
dpc-5933	2	7	korean	korean	ADJ
dpc-5933	2	8	hidradenitis	hidradenitis	PROPN
dpc-5933	2	9	suppurativa	suppurativa	PROPN
dpc-5933	2	10	:	:	PUNCT
dpc-5933	2	11	a	a	DET
dpc-5933	2	12	48	48	NUM
dpc-5933	2	13	-	-	PUNCT
dpc-5933	2	14	week	week	NOUN
dpc-5933	2	15	clinical	clinical	ADJ
dpc-5933	2	16	trial	trial	NOUN
dpc-5933	2	17	analysis	analysis	NOUN
dpc-5933	2	18	ngoc	ngoc	PROPN
dpc-5933	2	19	ha	ha	INTJ
dpc-5933	2	20	nguyen1,2	nguyen1,2	PROPN
dpc-5933	2	21	,	,	PUNCT
dpc-5933	2	22	sang	sing	VERB
dpc-5933	2	23	gyu	gyu	PROPN
dpc-5933	2	24	lee1	lee1	PROPN
dpc-5933	2	25	,	,	PUNCT
dpc-5933	2	26	seoyoon	seoyoon	PROPN
dpc-5933	2	27	ham1	ham1	PROPN
dpc-5933	2	28	,	,	PUNCT
dpc-5933	2	29	ju	ju	PROPN
dpc-5933	2	30	hee	hee	PROPN
dpc-5933	2	31	lee1,3	lee1,3	PROPN
dpc-5933	2	32	,	,	PUNCT
dpc-5933	2	33	young	young	ADJ
dpc-5933	2	34	in	in	ADP
dpc-5933	2	35	lee1,3	lee1,3	PROPN
dpc-5933	2	36	1	1	NUM
dpc-5933	2	37	department	department	NOUN
dpc-5933	2	38	of	of	ADP
dpc-5933	2	39	dermatology	dermatology	NOUN
dpc-5933	2	40	&	&	CCONJ
dpc-5933	2	41	cutaneous	cutaneous	ADJ
dpc-5933	2	42	biologic	biologic	NOUN
dpc-5933	2	43	research	research	NOUN
dpc-5933	2	44	institute	institute	PROPN
dpc-5933	2	45	,	,	PUNCT
dpc-5933	2	46	yonsei	yonsei	PROPN
dpc-5933	2	47	university	university	PROPN
dpc-5933	2	48	college	college	PROPN
dpc-5933	2	49	of	of	ADP
dpc-5933	2	50	medicine	medicine	NOUN
dpc-5933	2	51	,	,	PUNCT
dpc-5933	2	52	seoul	seoul	PROPN
dpc-5933	2	53	,	,	PUNCT
dpc-5933	2	54	republic	republic	NOUN
dpc-5933	2	55	of	of	ADP
dpc-5933	2	56	korea	korea	PROPN
dpc-5933	2	57	2	2	PROPN
dpc-5933	2	58	department	department	NOUN
dpc-5933	2	59	of	of	ADP
dpc-5933	2	60	dermatology	dermatology	NOUN
dpc-5933	2	61	,	,	PUNCT
dpc-5933	2	62	university	university	NOUN
dpc-5933	2	63	of	of	ADP
dpc-5933	2	64	medicine	medicine	NOUN
dpc-5933	2	65	and	and	CCONJ
dpc-5933	2	66	pharmacy	pharmacy	NOUN
dpc-5933	2	67	at	at	ADP
dpc-5933	2	68	ho	ho	PROPN
dpc-5933	2	69	chi	chi	PROPN
dpc-5933	2	70	minh	minh	PROPN
dpc-5933	2	71	city	city	PROPN
dpc-5933	2	72	,	,	PUNCT
dpc-5933	2	73	ho	ho	PROPN
dpc-5933	2	74	chi	chi	PROPN
dpc-5933	2	75	minh	minh	PROPN
dpc-5933	2	76	city	city	PROPN
dpc-5933	2	77	,	,	PUNCT
dpc-5933	2	78	vietnam	vietnam	PROPN
dpc-5933	2	79	3	3	NUM
dpc-5933	2	80	scar	scar	NOUN
dpc-5933	2	81	laser	laser	NOUN
dpc-5933	2	82	and	and	CCONJ
dpc-5933	2	83	plastic	plastic	ADJ
dpc-5933	2	84	surgery	surgery	NOUN
dpc-5933	2	85	center	center	NOUN
dpc-5933	2	86	,	,	PUNCT
dpc-5933	2	87	yonsei	yonsei	ADJ
dpc-5933	2	88	cancer	cancer	NOUN
dpc-5933	2	89	hospital	hospital	PROPN
dpc-5933	2	90	,	,	PUNCT
dpc-5933	2	91	seoul	seoul	PROPN
dpc-5933	2	92	,	,	PUNCT
dpc-5933	2	93	republic	republic	NOUN
dpc-5933	2	94	of	of	ADP
dpc-5933	2	95	korea	korea	PROPN
dpc-5933	2	96	key	key	PROPN
dpc-5933	2	97	message	message	NOUN
dpc-5933	2	98	:	:	PUNCT
dpc-5933	2	99	faster	fast	ADV
dpc-5933	2	100	initial	initial	ADJ
dpc-5933	2	101	responses	response	NOUN
dpc-5933	2	102	to	to	PART
dpc-5933	2	103	secukinumab	secukinumab	VERB
dpc-5933	2	104	in	in	ADP
dpc-5933	2	105	hidradenitis	hidradenitis	PROPN
dpc-5933	2	106	suppurativa	suppurativa	PROPN
dpc-5933	2	107	patients	patient	NOUN
dpc-5933	2	108	are	be	AUX
dpc-5933	2	109	observed	observe	VERB
dpc-5933	2	110	in	in	ADP
dpc-5933	2	111	those	those	PRON
dpc-5933	2	112	with	with	ADP
dpc-5933	2	113	milder	mild	ADJ
dpc-5933	2	114	disease	disease	NOUN
dpc-5933	2	115	,	,	PUNCT
dpc-5933	2	116	earlier	early	ADJ
dpc-5933	2	117	treatment	treatment	NOUN
dpc-5933	2	118	,	,	PUNCT
dpc-5933	2	119	and	and	CCONJ
dpc-5933	2	120	no	no	DET
dpc-5933	2	121	previous	previous	ADJ
dpc-5933	2	122	biological	biological	ADJ
dpc-5933	2	123	therapy	therapy	NOUN
dpc-5933	2	124	.	.	PUNCT
dpc-5933	3	1	secukinumab	secukinumab	NOUN
dpc-5933	3	2	also	also	ADV
dpc-5933	3	3	significantly	significantly	ADV
dpc-5933	3	4	reduced	reduce	VERB
dpc-5933	3	5	antibiotic	antibiotic	ADJ
dpc-5933	3	6	usage	usage	NOUN
dpc-5933	3	7	.	.	PUNCT
dpc-5933	4	1	key	key	ADJ
dpc-5933	4	2	words	word	NOUN
dpc-5933	4	3	:	:	PUNCT
dpc-5933	4	4	hidradenitis	hidradenitis	PROPN
dpc-5933	4	5	suppurativa	suppurativa	PROPN
dpc-5933	4	6	,	,	PUNCT
dpc-5933	4	7	secukinumab	secukinumab	NOUN
dpc-5933	4	8	,	,	PUNCT
dpc-5933	4	9	korean	korean	ADJ
dpc-5933	4	10	patients	patient	NOUN
dpc-5933	4	11	,	,	PUNCT
dpc-5933	4	12	predictive	predictive	ADJ
dpc-5933	4	13	factors	factor	NOUN
dpc-5933	4	14	,	,	PUNCT
dpc-5933	4	15	ihs4	ihs4	PROPN
dpc-5933	4	16	-	-	PUNCT
dpc-5933	4	17	55	55	NUM
dpc-5933	4	18	citation	citation	NOUN
dpc-5933	4	19	:	:	PUNCT
dpc-5933	4	20	nguyen	nguyen	PROPN
dpc-5933	4	21	nh	nh	PROPN
dpc-5933	4	22	,	,	PUNCT
dpc-5933	4	23	lee	lee	PROPN
dpc-5933	4	24	sg	sg	PROPN
dpc-5933	4	25	,	,	PUNCT
dpc-5933	4	26	ham	ham	PROPN
dpc-5933	4	27	s	s	PROPN
dpc-5933	4	28	,	,	PUNCT
dpc-5933	4	29	lee	lee	PROPN
dpc-5933	4	30	jh	jh	PROPN
dpc-5933	4	31	,	,	PUNCT
dpc-5933	4	32	lee	lee	PROPN
dpc-5933	4	33	yi	yi	PROPN
dpc-5933	4	34	.	.	PROPN
dpc-5933	5	1	secukinumab	secukinumab	PROPN
dpc-5933	5	2	efficacy	efficacy	NOUN
dpc-5933	5	3	predictors	predictor	NOUN
dpc-5933	5	4	in	in	ADP
dpc-5933	5	5	korean	korean	ADJ
dpc-5933	5	6	hidradenitis	hidradenitis	PROPN
dpc-5933	5	7	suppurativa	suppurativa	PROPN
dpc-5933	5	8	:	:	PUNCT
dpc-5933	5	9	a	a	DET
dpc-5933	5	10	48	48	NUM
dpc-5933	5	11	-	-	PUNCT
dpc-5933	5	12	week	week	NOUN
dpc-5933	5	13	clinical	clinical	ADJ
dpc-5933	5	14	trial	trial	NOUN
dpc-5933	5	15	analysis	analysis	NOUN
dpc-5933	5	16	.	.	PUNCT
dpc-5933	6	1	dermatol	dermatol	NOUN
dpc-5933	6	2	pract	pract	PROPN
dpc-5933	6	3	concept	concept	NOUN
dpc-5933	6	4	.	.	PUNCT
dpc-5933	7	1	2025;15(4):5933	2025;15(4):5933	NUM
dpc-5933	7	2	.	.	PUNCT
dpc-5933	8	1	doi	doi	NOUN
dpc-5933	8	2	:	:	PUNCT
dpc-5933	8	3	https://doi.org/10.5826/dpc.1504a5933	https://doi.org/10.5826/dpc.1504a5933	PROPN
dpc-5933	8	4	accepted	accept	VERB
dpc-5933	8	5	:	:	PUNCT
dpc-5933	8	6	june	june	PROPN
dpc-5933	8	7	2	2	NUM
dpc-5933	8	8	,	,	PUNCT
dpc-5933	8	9	2025	2025	NUM
dpc-5933	8	10	;	;	PUNCT
dpc-5933	8	11	published	publish	VERB
dpc-5933	8	12	:	:	PUNCT
dpc-5933	9	1	october	october	PROPN
dpc-5933	9	2	2025	2025	NUM
dpc-5933	9	3	copyright	copyright	NOUN
dpc-5933	9	4	:	:	PUNCT
dpc-5933	9	5	©	©	PROPN
dpc-5933	9	6	2025	2025	NUM
dpc-5933	9	7	nguyen	nguyen	NOUN
dpc-5933	9	8	et	et	PROPN
dpc-5933	9	9	al	al	PROPN
dpc-5933	9	10	.	.	PUNCT
dpc-5933	10	1	this	this	PRON
dpc-5933	10	2	is	be	AUX
dpc-5933	10	3	an	an	DET
dpc-5933	10	4	open	open	ADJ
dpc-5933	10	5	-	-	PUNCT
dpc-5933	10	6	access	access	NOUN
dpc-5933	10	7	article	article	NOUN
dpc-5933	10	8	distributed	distribute	VERB
dpc-5933	10	9	under	under	ADP
dpc-5933	10	10	the	the	DET
dpc-5933	10	11	terms	term	NOUN
dpc-5933	10	12	of	of	ADP
dpc-5933	10	13	the	the	DET
dpc-5933	10	14	creative	creative	ADJ
dpc-5933	10	15	commons	common	NOUN
dpc-5933	10	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-5933	10	17	license	license	NOUN
dpc-5933	10	18	(	(	PUNCT
dpc-5933	10	19	by	by	ADP
dpc-5933	10	20	-	-	PUNCT
dpc-5933	10	21	nc-4.0	nc-4.0	NOUN
dpc-5933	10	22	)	)	PUNCT
dpc-5933	10	23	,	,	PUNCT
dpc-5933	10	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-5933	10	25	,	,	PUNCT
dpc-5933	10	26	which	which	PRON
dpc-5933	10	27	permits	permit	VERB
dpc-5933	10	28	unrestricted	unrestricted	ADJ
dpc-5933	10	29	noncommercial	noncommercial	ADJ
dpc-5933	10	30	use	use	NOUN
dpc-5933	10	31	,	,	PUNCT
dpc-5933	10	32	distribution	distribution	NOUN
dpc-5933	10	33	,	,	PUNCT
dpc-5933	10	34	and	and	CCONJ
dpc-5933	10	35	reproduction	reproduction	NOUN
dpc-5933	10	36	in	in	ADP
dpc-5933	10	37	any	any	DET
dpc-5933	10	38	medium	medium	NOUN
dpc-5933	10	39	,	,	PUNCT
dpc-5933	10	40	provided	provide	VERB
dpc-5933	10	41	the	the	DET
dpc-5933	10	42	original	original	ADJ
dpc-5933	10	43	authors	author	NOUN
dpc-5933	10	44	and	and	CCONJ
dpc-5933	10	45	source	source	NOUN
dpc-5933	10	46	are	be	AUX
dpc-5933	10	47	credited	credit	VERB
dpc-5933	10	48	.	.	PUNCT
dpc-5933	11	1	funding	funding	NOUN
dpc-5933	11	2	:	:	PUNCT
dpc-5933	11	3	none	none	NOUN
dpc-5933	11	4	.	.	PUNCT
dpc-5933	12	1	competing	compete	VERB
dpc-5933	12	2	interests	interest	NOUN
dpc-5933	12	3	:	:	PUNCT
dpc-5933	12	4	none	none	NOUN
dpc-5933	12	5	.	.	PUNCT
dpc-5933	13	1	authorship	authorship	NOUN
dpc-5933	13	2	:	:	PUNCT
dpc-5933	13	3	all	all	DET
dpc-5933	13	4	authors	author	NOUN
dpc-5933	13	5	have	have	AUX
dpc-5933	13	6	contributed	contribute	VERB
dpc-5933	13	7	significantly	significantly	ADV
dpc-5933	13	8	to	to	ADP
dpc-5933	13	9	this	this	DET
dpc-5933	13	10	publication	publication	NOUN
dpc-5933	13	11	.	.	PUNCT
dpc-5933	14	1	corresponding	correspond	VERB
dpc-5933	14	2	author	author	NOUN
dpc-5933	14	3	:	:	PUNCT
dpc-5933	14	4	young	young	ADJ
dpc-5933	14	5	in	in	ADP
dpc-5933	14	6	lee	lee	PROPN
dpc-5933	14	7	,	,	PUNCT
dpc-5933	14	8	m.d	m.d	PROPN
dpc-5933	14	9	.	.	PROPN
dpc-5933	14	10	,	,	PUNCT
dpc-5933	14	11	ph.d	ph.d	PROPN
dpc-5933	14	12	.	.	PUNCT
dpc-5933	15	1	department	department	PROPN
dpc-5933	15	2	of	of	ADP
dpc-5933	15	3	dermatology	dermatology	NOUN
dpc-5933	15	4	&	&	CCONJ
dpc-5933	15	5	cutaneous	cutaneous	ADJ
dpc-5933	15	6	biology	biology	NOUN
dpc-5933	15	7	research	research	NOUN
dpc-5933	15	8	institute	institute	PROPN
dpc-5933	15	9	,	,	PUNCT
dpc-5933	15	10	yonsei	yonsei	PROPN
dpc-5933	15	11	university	university	PROPN
dpc-5933	15	12	college	college	PROPN
dpc-5933	15	13	of	of	ADP
dpc-5933	15	14	medicine	medicine	NOUN
dpc-5933	15	15	,	,	PUNCT
dpc-5933	15	16	seoul	seoul	PROPN
dpc-5933	15	17	,	,	PUNCT
dpc-5933	15	18	republic	republic	NOUN
dpc-5933	15	19	of	of	ADP
dpc-5933	15	20	korea	korea	PROPN
dpc-5933	15	21	,	,	PUNCT
dpc-5933	15	22	50	50	NUM
dpc-5933	15	23	,	,	PUNCT
dpc-5933	15	24	yonsei	yonsei	NOUN
dpc-5933	15	25	-	-	PUNCT
dpc-5933	15	26	ro	ro	NOUN
dpc-5933	15	27	,	,	PUNCT
dpc-5933	15	28	seodaemun	seodaemun	NOUN
dpc-5933	15	29	-	-	PUNCT
dpc-5933	15	30	gu	gu	NOUN
dpc-5933	15	31	,	,	PUNCT
dpc-5933	15	32	seoul	seoul	PROPN
dpc-5933	15	33	03722	03722	NUM
dpc-5933	15	34	,	,	PUNCT
dpc-5933	15	35	republic	republic	NOUN
dpc-5933	15	36	of	of	ADP
dpc-5933	15	37	korea	korea	PROPN
dpc-5933	15	38	.	.	PUNCT
dpc-5933	16	1	orcid	orcid	PROPN
dpc-5933	17	1	i	i	PRON
dpc-5933	17	2	d	d	NOUN
dpc-5933	17	3	:	:	PUNCT
dpc-5933	17	4	0000	0000	NUM
dpc-5933	17	5	-	-	PUNCT
dpc-5933	17	6	0001	0001	NUM
dpc-5933	17	7	-	-	PUNCT
dpc-5933	17	8	6831	6831	NUM
dpc-5933	17	9	-	-	PUNCT
dpc-5933	17	10	7379	7379	NUM
dpc-5933	17	11	.	.	PUNCT
dpc-5933	18	1	e	e	X
dpc-5933	18	2	-	-	NOUN
dpc-5933	18	3	mail	mail	NOUN
dpc-5933	18	4	:	:	PUNCT
dpc-5933	18	5	ylee1124@yuhs.ac	ylee1124@yuhs.ac	NOUN
dpc-5933	18	6	background	background	NOUN
dpc-5933	18	7	:	:	PUNCT
dpc-5933	18	8	hidradenitis	hidradenitis	PROPN
dpc-5933	18	9	suppurativa	suppurativa	PROPN
dpc-5933	18	10	(	(	PUNCT
dpc-5933	18	11	hs	hs	X
dpc-5933	18	12	)	)	PUNCT
dpc-5933	18	13	is	be	AUX
dpc-5933	18	14	a	a	DET
dpc-5933	18	15	chronic	chronic	ADJ
dpc-5933	18	16	inflammatory	inflammatory	ADJ
dpc-5933	18	17	skin	skin	NOUN
dpc-5933	18	18	disease	disease	NOUN
dpc-5933	18	19	characterized	characterize	VERB
dpc-5933	18	20	by	by	ADP
dpc-5933	18	21	painful	painful	ADJ
dpc-5933	18	22	nodules	nodule	NOUN
dpc-5933	18	23	,	,	PUNCT
dpc-5933	18	24	abscesses	abscess	NOUN
dpc-5933	18	25	,	,	PUNCT
dpc-5933	18	26	and	and	CCONJ
dpc-5933	18	27	draining	drain	VERB
dpc-5933	18	28	tunnels	tunnel	NOUN
dpc-5933	18	29	commonly	commonly	ADV
dpc-5933	18	30	occurring	occur	VERB
dpc-5933	18	31	in	in	ADP
dpc-5933	18	32	body	body	NOUN
dpc-5933	18	33	folds	fold	NOUN
dpc-5933	18	34	.	.	PUNCT
dpc-5933	19	1	the	the	DET
dpc-5933	19	2	il-17a	il-17a	PROPN
dpc-5933	19	3	inhibitor	inhibitor	NOUN
dpc-5933	19	4	,	,	PUNCT
dpc-5933	19	5	secukinumab	secukinumab	NOUN
dpc-5933	19	6	,	,	PUNCT
dpc-5933	19	7	has	have	AUX
dpc-5933	19	8	shown	show	VERB
dpc-5933	19	9	efficacy	efficacy	NOUN
dpc-5933	19	10	in	in	ADP
dpc-5933	19	11	reducing	reduce	VERB
dpc-5933	19	12	hs	hs	PROPN
dpc-5933	19	13	lesions	lesion	NOUN
dpc-5933	19	14	in	in	ADP
dpc-5933	19	15	clinical	clinical	ADJ
dpc-5933	19	16	studies	study	NOUN
dpc-5933	19	17	,	,	PUNCT
dpc-5933	19	18	but	but	CCONJ
dpc-5933	19	19	data	datum	NOUN
dpc-5933	19	20	on	on	ADP
dpc-5933	19	21	epidemiologic	epidemiologic	ADJ
dpc-5933	19	22	and	and	CCONJ
dpc-5933	19	23	patient	patient	NOUN
dpc-5933	19	24	-	-	PUNCT
dpc-5933	19	25	specific	specific	ADJ
dpc-5933	19	26	factors	factor	NOUN
dpc-5933	19	27	influencing	influence	VERB
dpc-5933	19	28	response	response	NOUN
dpc-5933	19	29	remain	remain	VERB
dpc-5933	19	30	limited	limited	ADJ
dpc-5933	19	31	.	.	PUNCT
dpc-5933	20	1	objectives	objective	NOUN
dpc-5933	20	2	:	:	PUNCT
dpc-5933	20	3	to	to	PART
dpc-5933	20	4	assess	assess	VERB
dpc-5933	20	5	how	how	SCONJ
dpc-5933	20	6	baseline	baseline	ADJ
dpc-5933	20	7	disease	disease	NOUN
dpc-5933	20	8	severity	severity	NOUN
dpc-5933	20	9	,	,	PUNCT
dpc-5933	20	10	treatment	treatment	NOUN
dpc-5933	20	11	initiation	initiation	NOUN
dpc-5933	20	12	delay	delay	NOUN
dpc-5933	20	13	,	,	PUNCT
dpc-5933	20	14	and	and	CCONJ
dpc-5933	20	15	prior	prior	ADJ
dpc-5933	20	16	biologics	biologic	NOUN
dpc-5933	20	17	exposure	exposure	NOUN
dpc-5933	20	18	influence	influence	NOUN
dpc-5933	20	19	clinical	clinical	ADJ
dpc-5933	20	20	response	response	NOUN
dpc-5933	20	21	to	to	ADP
dpc-5933	20	22	secukinumab	secukinumab	NOUN
dpc-5933	20	23	and	and	CCONJ
dpc-5933	20	24	patterns	pattern	NOUN
dpc-5933	20	25	of	of	ADP
dpc-5933	20	26	antibiotic	antibiotic	ADJ
dpc-5933	20	27	use	use	NOUN
dpc-5933	20	28	.	.	PUNCT
dpc-5933	21	1	materials	material	NOUN
dpc-5933	21	2	and	and	CCONJ
dpc-5933	21	3	methods	method	NOUN
dpc-5933	21	4	:	:	PUNCT
dpc-5933	21	5	this	this	DET
dpc-5933	21	6	48	48	NUM
dpc-5933	21	7	-	-	PUNCT
dpc-5933	21	8	week	week	NOUN
dpc-5933	21	9	real	real	ADJ
dpc-5933	21	10	-	-	PUNCT
dpc-5933	21	11	world	world	NOUN
dpc-5933	21	12	prospective	prospective	ADJ
dpc-5933	21	13	trial	trial	NOUN
dpc-5933	21	14	enrolled	enrol	VERB
dpc-5933	21	15	10	10	NUM
dpc-5933	21	16	korean	korean	ADJ
dpc-5933	21	17	patients	patient	NOUN
dpc-5933	21	18	with	with	ADP
dpc-5933	21	19	moderate	moderate	ADJ
dpc-5933	21	20	-	-	PUNCT
dpc-5933	21	21	to	to	ADP
dpc-5933	21	22	-	-	PUNCT
dpc-5933	21	23	severe	severe	ADJ
dpc-5933	21	24	hs	hs	PROPN
dpc-5933	21	25	.	.	PUNCT
dpc-5933	22	1	patients	patient	NOUN
dpc-5933	22	2	received	receive	VERB
dpc-5933	22	3	secukinumab	secukinumab	NOUN
dpc-5933	22	4	300	300	NUM
dpc-5933	22	5	mg	mg	NOUN
dpc-5933	22	6	subcutaneously	subcutaneously	ADV
dpc-5933	22	7	at	at	ADP
dpc-5933	22	8	weeks	week	NOUN
dpc-5933	22	9	0	0	NUM
dpc-5933	22	10	,	,	PUNCT
dpc-5933	22	11	1	1	NUM
dpc-5933	22	12	,	,	PUNCT
dpc-5933	22	13	2	2	NUM
dpc-5933	22	14	,	,	PUNCT
dpc-5933	22	15	3	3	NUM
dpc-5933	22	16	,	,	PUNCT
dpc-5933	22	17	and	and	CCONJ
dpc-5933	22	18	4	4	NUM
dpc-5933	22	19	,	,	PUNCT
dpc-5933	22	20	then	then	ADV
dpc-5933	22	21	every	every	DET
dpc-5933	22	22	two	two	NUM
dpc-5933	22	23	weeks	week	NOUN
dpc-5933	22	24	.	.	PUNCT
dpc-5933	23	1	outcomes	outcome	NOUN
dpc-5933	23	2	included	include	VERB
dpc-5933	23	3	hidradenitis	hidradenitis	PROPN
dpc-5933	23	4	suppurativa	suppurativa	PROPN
dpc-5933	23	5	clinical	clinical	ADJ
dpc-5933	23	6	response	response	NOUN
dpc-5933	23	7	(	(	PUNCT
dpc-5933	23	8	hiscr	hiscr	PROPN
dpc-5933	23	9	)	)	PUNCT
dpc-5933	23	10	,	,	PUNCT
dpc-5933	23	11	a	a	DET
dpc-5933	23	12	55	55	NUM
dpc-5933	23	13	%	%	NOUN
dpc-5933	23	14	reduction	reduction	NOUN
dpc-5933	23	15	in	in	ADP
dpc-5933	23	16	the	the	DET
dpc-5933	23	17	international	international	ADJ
dpc-5933	23	18	hs	hs	PROPN
dpc-5933	23	19	severity	severity	PROPN
dpc-5933	23	20	score	score	NOUN
dpc-5933	23	21	system	system	NOUN
dpc-5933	23	22	(	(	PUNCT
dpc-5933	23	23	ihs4	ihs4	PROPN
dpc-5933	23	24	-	-	PUNCT
dpc-5933	23	25	55	55	NUM
dpc-5933	23	26	)	)	PUNCT
dpc-5933	23	27	,	,	PUNCT
dpc-5933	23	28	mean	mean	VERB
dpc-5933	23	29	change	change	NOUN
dpc-5933	23	30	in	in	ADP
dpc-5933	23	31	abscesses	abscess	NOUN
dpc-5933	23	32	and	and	CCONJ
dpc-5933	23	33	inflammatory	inflammatory	ADJ
dpc-5933	23	34	nodules	nodule	NOUN
dpc-5933	23	35	,	,	PUNCT
dpc-5933	23	36	a	a	DET
dpc-5933	23	37	≥	≥	NUM
dpc-5933	23	38	30	30	NUM
dpc-5933	23	39	%	%	NOUN
dpc-5933	23	40	reduction	reduction	NOUN
dpc-5933	23	41	in	in	ADP
dpc-5933	23	42	pain	pain	NOUN
dpc-5933	23	43	score	score	NOUN
dpc-5933	23	44	on	on	ADP
dpc-5933	23	45	a	a	DET
dpc-5933	23	46	numeric	numeric	ADJ
dpc-5933	23	47	rating	rating	NOUN
dpc-5933	23	48	scale	scale	NOUN
dpc-5933	23	49	(	(	PUNCT
dpc-5933	23	50	nrs30	nrs30	PROPN
dpc-5933	23	51	)	)	PUNCT
dpc-5933	23	52	,	,	PUNCT
dpc-5933	23	53	and	and	CCONJ
dpc-5933	23	54	duration	duration	NOUN
dpc-5933	23	55	of	of	ADP
dpc-5933	23	56	concomitant	concomitant	ADJ
dpc-5933	23	57	antibiotic	antibiotic	ADJ
dpc-5933	23	58	use	use	NOUN
dpc-5933	23	59	.	.	PUNCT
dpc-5933	24	1	results	result	NOUN
dpc-5933	24	2	:	:	PUNCT
dpc-5933	24	3	at	at	ADP
dpc-5933	24	4	week	week	NOUN
dpc-5933	24	5	48	48	NUM
dpc-5933	24	6	,	,	PUNCT
dpc-5933	24	7	90	90	NUM
dpc-5933	24	8	%	%	NOUN
dpc-5933	24	9	of	of	ADP
dpc-5933	24	10	patients	patient	NOUN
dpc-5933	24	11	achieved	achieve	VERB
dpc-5933	24	12	hiscr	hiscr	NOUN
dpc-5933	24	13	,	,	PUNCT
dpc-5933	24	14	with	with	ADP
dpc-5933	24	15	90	90	NUM
dpc-5933	24	16	%	%	NOUN
dpc-5933	24	17	meeting	meeting	NOUN
dpc-5933	24	18	the	the	DET
dpc-5933	24	19	ihs4	ihs4	PROPN
dpc-5933	24	20	-	-	PUNCT
dpc-5933	24	21	55	55	NUM
dpc-5933	24	22	threshold	threshold	NOUN
dpc-5933	24	23	and	and	CCONJ
dpc-5933	24	24	60	60	NUM
dpc-5933	24	25	%	%	NOUN
dpc-5933	24	26	reaching	reach	VERB
dpc-5933	24	27	the	the	DET
dpc-5933	24	28	nrs30	nrs30	PROPN
dpc-5933	24	29	criteria	criterion	NOUN
dpc-5933	24	30	.	.	PUNCT
dpc-5933	25	1	faster	fast	ADJ
dpc-5933	25	2	responses	response	NOUN
dpc-5933	25	3	were	be	AUX
dpc-5933	25	4	recorded	record	VERB
dpc-5933	25	5	in	in	ADP
dpc-5933	25	6	subjects	subject	NOUN
dpc-5933	25	7	with	with	ADP
dpc-5933	25	8	hurley	hurley	PROPN
dpc-5933	25	9	stage	stage	PROPN
dpc-5933	25	10	ii	ii	PROPN
dpc-5933	25	11	,	,	PUNCT
dpc-5933	25	12	treatment	treatment	NOUN
dpc-5933	25	13	delays	delay	NOUN
dpc-5933	25	14	of	of	ADP
dpc-5933	25	15	<	<	X
dpc-5933	25	16	10	10	NUM
dpc-5933	25	17	years	year	NOUN
dpc-5933	25	18	,	,	PUNCT
dpc-5933	25	19	or	or	CCONJ
dpc-5933	25	20	no	no	DET
dpc-5933	25	21	prior	prior	ADJ
dpc-5933	25	22	biologics	biologic	NOUN
dpc-5933	25	23	use	use	VERB
dpc-5933	25	24	,	,	PUNCT
dpc-5933	25	25	although	although	SCONJ
dpc-5933	25	26	response	response	NOUN
dpc-5933	25	27	rates	rate	NOUN
dpc-5933	25	28	equalized	equalize	VERB
dpc-5933	25	29	by	by	ADP
dpc-5933	25	30	week	week	NOUN
dpc-5933	25	31	abstract	abstract	ADJ
dpc-5933	25	32	2	2	NUM
dpc-5933	25	33	original	original	ADJ
dpc-5933	25	34	article	article	NOUN
dpc-5933	25	35	|	|	ADV
dpc-5933	25	36	dermatol	dermatol	ADJ
dpc-5933	25	37	pract	pract	NOUN
dpc-5933	25	38	concept	concept	NOUN
dpc-5933	25	39	.	.	PUNCT
dpc-5933	26	1	2025;15(4):5933	2025;15(4):5933	NUM
dpc-5933	26	2	introduction	introduction	NOUN
dpc-5933	26	3	hidradenitis	hidradenitis	NOUN
dpc-5933	26	4	suppurativa	suppurativa	PROPN
dpc-5933	26	5	(	(	PUNCT
dpc-5933	26	6	hs	hs	X
dpc-5933	26	7	)	)	PUNCT
dpc-5933	26	8	is	be	AUX
dpc-5933	26	9	a	a	DET
dpc-5933	26	10	chronic	chronic	ADJ
dpc-5933	26	11	inflammatory	inflammatory	ADJ
dpc-5933	26	12	skin	skin	NOUN
dpc-5933	26	13	disorder	disorder	NOUN
dpc-5933	26	14	characterized	characterize	VERB
dpc-5933	26	15	by	by	ADP
dpc-5933	26	16	deep	deep	ADJ
dpc-5933	26	17	-	-	PUNCT
dpc-5933	26	18	seated	seat	VERB
dpc-5933	26	19	abscesses	abscess	NOUN
dpc-5933	26	20	and	and	CCONJ
dpc-5933	26	21	nodules	nodule	NOUN
dpc-5933	26	22	that	that	PRON
dpc-5933	26	23	predominantly	predominantly	ADV
dpc-5933	26	24	occur	occur	VERB
dpc-5933	26	25	in	in	ADP
dpc-5933	26	26	intertriginous	intertriginous	ADJ
dpc-5933	26	27	regions	region	NOUN
dpc-5933	26	28	such	such	ADJ
dpc-5933	26	29	as	as	ADP
dpc-5933	26	30	the	the	DET
dpc-5933	26	31	axillae	axillae	NOUN
dpc-5933	26	32	,	,	PUNCT
dpc-5933	26	33	groin	groin	NOUN
dpc-5933	26	34	,	,	PUNCT
dpc-5933	26	35	and	and	CCONJ
dpc-5933	26	36	perineal	perineal	ADJ
dpc-5933	26	37	areas	area	NOUN
dpc-5933	26	38	.	.	PUNCT
dpc-5933	27	1	over	over	ADP
dpc-5933	27	2	time	time	NOUN
dpc-5933	27	3	,	,	PUNCT
dpc-5933	27	4	the	the	DET
dpc-5933	27	5	condition	condition	NOUN
dpc-5933	27	6	often	often	ADV
dpc-5933	27	7	progresses	progress	VERB
dpc-5933	27	8	to	to	ADP
dpc-5933	27	9	draining	drain	VERB
dpc-5933	27	10	sinus	sinus	NOUN
dpc-5933	27	11	tracts	tract	NOUN
dpc-5933	27	12	and	and	CCONJ
dpc-5933	27	13	extensive	extensive	ADJ
dpc-5933	27	14	scarring	scarring	NOUN
dpc-5933	27	15	[	[	X
dpc-5933	27	16	1	1	NUM
dpc-5933	27	17	]	]	PUNCT
dpc-5933	27	18	.	.	PUNCT
dpc-5933	28	1	the	the	DET
dpc-5933	28	2	disease	disease	NOUN
dpc-5933	28	3	significantly	significantly	ADV
dpc-5933	28	4	impacts	impact	VERB
dpc-5933	28	5	patients	patient	NOUN
dpc-5933	28	6	’	'	PUNCT
dpc-5933	28	7	quality	quality	NOUN
dpc-5933	28	8	of	of	ADP
dpc-5933	28	9	life	life	NOUN
dpc-5933	28	10	(	(	PUNCT
dpc-5933	28	11	qol	qol	NOUN
dpc-5933	28	12	)	)	PUNCT
dpc-5933	28	13	owing	owe	VERB
dpc-5933	28	14	to	to	ADP
dpc-5933	28	15	the	the	DET
dpc-5933	28	16	debilitating	debilitate	VERB
dpc-5933	28	17	pain	pain	NOUN
dpc-5933	28	18	,	,	PUNCT
dpc-5933	28	19	recurrent	recurrent	ADJ
dpc-5933	28	20	lesions	lesion	NOUN
dpc-5933	28	21	,	,	PUNCT
dpc-5933	28	22	and	and	CCONJ
dpc-5933	28	23	social	social	ADJ
dpc-5933	28	24	distress	distress	NOUN
dpc-5933	28	25	caused	cause	VERB
dpc-5933	28	26	by	by	ADP
dpc-5933	28	27	disfigurement	disfigurement	NOUN
dpc-5933	28	28	.	.	PUNCT
dpc-5933	29	1	conventional	conventional	ADJ
dpc-5933	29	2	treatments	treatment	NOUN
dpc-5933	29	3	for	for	ADP
dpc-5933	29	4	hs	hs	PROPN
dpc-5933	29	5	primarily	primarily	ADV
dpc-5933	29	6	aim	aim	VERB
dpc-5933	29	7	to	to	PART
dpc-5933	29	8	control	control	VERB
dpc-5933	29	9	inflammation	inflammation	NOUN
dpc-5933	29	10	,	,	PUNCT
dpc-5933	29	11	secondary	secondary	ADJ
dpc-5933	29	12	infections	infection	NOUN
dpc-5933	29	13	,	,	PUNCT
dpc-5933	29	14	and	and	CCONJ
dpc-5933	29	15	associated	associated	ADJ
dpc-5933	29	16	symptoms	symptom	NOUN
dpc-5933	29	17	,	,	PUNCT
dpc-5933	29	18	including	include	VERB
dpc-5933	29	19	systemic	systemic	ADJ
dpc-5933	29	20	antibiotics	antibiotic	NOUN
dpc-5933	29	21	,	,	PUNCT
dpc-5933	29	22	triamcinolone	triamcinolone	NOUN
dpc-5933	29	23	acetonide	acetonide	ADJ
dpc-5933	29	24	intralesional	intralesional	ADJ
dpc-5933	29	25	injections	injection	NOUN
dpc-5933	29	26	(	(	PUNCT
dpc-5933	29	27	ta	ta	X
dpc-5933	29	28	ili	ili	PROPN
dpc-5933	29	29	)	)	PUNCT
dpc-5933	29	30	,	,	PUNCT
dpc-5933	29	31	and	and	CCONJ
dpc-5933	29	32	surgical	surgical	ADJ
dpc-5933	29	33	interventions	intervention	NOUN
dpc-5933	29	34	such	such	ADJ
dpc-5933	29	35	as	as	ADP
dpc-5933	29	36	incision	incision	NOUN
dpc-5933	29	37	and	and	CCONJ
dpc-5933	29	38	drainage	drainage	NOUN
dpc-5933	29	39	(	(	PUNCT
dpc-5933	29	40	i&d	i&d	PROPN
dpc-5933	29	41	)	)	PUNCT
dpc-5933	30	1	[	[	X
dpc-5933	30	2	2	2	NUM
dpc-5933	30	3	]	]	PUNCT
dpc-5933	30	4	.	.	PUNCT
dpc-5933	31	1	however	however	ADV
dpc-5933	31	2	,	,	PUNCT
dpc-5933	31	3	these	these	DET
dpc-5933	31	4	therapies	therapy	NOUN
dpc-5933	31	5	are	be	AUX
dpc-5933	31	6	often	often	ADV
dpc-5933	31	7	associated	associate	VERB
dpc-5933	31	8	with	with	ADP
dpc-5933	31	9	limited	limited	ADJ
dpc-5933	31	10	efficacy	efficacy	NOUN
dpc-5933	31	11	,	,	PUNCT
dpc-5933	31	12	high	high	ADJ
dpc-5933	31	13	recurrence	recurrence	NOUN
dpc-5933	31	14	rates	rate	NOUN
dpc-5933	31	15	,	,	PUNCT
dpc-5933	31	16	and	and	CCONJ
dpc-5933	31	17	suboptimal	suboptimal	ADJ
dpc-5933	31	18	improvements	improvement	NOUN
dpc-5933	31	19	in	in	ADP
dpc-5933	31	20	qol	qol	NOUN
dpc-5933	31	21	[	[	X
dpc-5933	31	22	3	3	NUM
dpc-5933	31	23	]	]	PUNCT
dpc-5933	31	24	.	.	PUNCT
dpc-5933	32	1	the	the	DET
dpc-5933	32	2	pathogenesis	pathogenesis	NOUN
dpc-5933	32	3	of	of	ADP
dpc-5933	32	4	hs	hs	PROPN
dpc-5933	32	5	remains	remains	AUX
dpc-5933	32	6	incompletely	incompletely	ADV
dpc-5933	32	7	understood	understand	VERB
dpc-5933	32	8	,	,	PUNCT
dpc-5933	32	9	but	but	CCONJ
dpc-5933	32	10	it	it	PRON
dpc-5933	32	11	is	be	AUX
dpc-5933	32	12	believed	believe	VERB
dpc-5933	32	13	to	to	PART
dpc-5933	32	14	involve	involve	VERB
dpc-5933	32	15	a	a	DET
dpc-5933	32	16	combination	combination	NOUN
dpc-5933	32	17	of	of	ADP
dpc-5933	32	18	genetic	genetic	ADJ
dpc-5933	32	19	predisposition	predisposition	NOUN
dpc-5933	32	20	,	,	PUNCT
dpc-5933	32	21	immune	immune	ADJ
dpc-5933	32	22	dysregulation	dysregulation	NOUN
dpc-5933	32	23	,	,	PUNCT
dpc-5933	32	24	and	and	CCONJ
dpc-5933	32	25	proinflammatory	proinflammatory	ADJ
dpc-5933	32	26	cytokines	cytokine	NOUN
dpc-5933	32	27	,	,	PUNCT
dpc-5933	33	1	particularly	particularly	ADV
dpc-5933	33	2	tumor	tumor	NOUN
dpc-5933	33	3	necrosis	necrosis	NOUN
dpc-5933	33	4	factor	factor	NOUN
dpc-5933	33	5	-	-	PUNCT
dpc-5933	33	6	alpha	alpha	NOUN
dpc-5933	33	7	(	(	PUNCT
dpc-5933	33	8	tnf	tnf	PROPN
dpc-5933	33	9	-	-	PUNCT
dpc-5933	33	10	α	α	NOUN
dpc-5933	33	11	)	)	PUNCT
dpc-5933	33	12	and	and	CCONJ
dpc-5933	33	13	interleukin-17	interleukin-17	PROPN
dpc-5933	33	14	(	(	PUNCT
dpc-5933	33	15	il-17	il-17	NUM
dpc-5933	33	16	)	)	PUNCT
dpc-5933	33	17	,	,	PUNCT
dpc-5933	33	18	at	at	ADP
dpc-5933	33	19	the	the	DET
dpc-5933	33	20	pilosebaceous	pilosebaceous	ADJ
dpc-5933	33	21	unit	unit	NOUN
dpc-5933	33	22	[	[	X
dpc-5933	33	23	4	4	NUM
dpc-5933	33	24	]	]	PUNCT
dpc-5933	33	25	.	.	PUNCT
dpc-5933	34	1	to	to	PART
dpc-5933	34	2	better	well	ADV
dpc-5933	34	3	address	address	VERB
dpc-5933	34	4	this	this	DET
dpc-5933	34	5	inflammatory	inflammatory	ADJ
dpc-5933	34	6	nature	nature	NOUN
dpc-5933	34	7	,	,	PUNCT
dpc-5933	34	8	targeted	target	VERB
dpc-5933	34	9	biologic	biologic	NOUN
dpc-5933	34	10	therapies	therapy	NOUN
dpc-5933	34	11	have	have	AUX
dpc-5933	34	12	been	be	AUX
dpc-5933	34	13	explored	explore	VERB
dpc-5933	34	14	.	.	PUNCT
dpc-5933	35	1	adalimumab	adalimumab	PROPN
dpc-5933	35	2	,	,	PUNCT
dpc-5933	35	3	a	a	DET
dpc-5933	35	4	tnf	tnf	PROPN
dpc-5933	35	5	-	-	PUNCT
dpc-5933	35	6	α	α	NOUN
dpc-5933	35	7	inhibitor	inhibitor	NOUN
dpc-5933	35	8	,	,	PUNCT
dpc-5933	35	9	received	receive	VERB
dpc-5933	35	10	fda	fda	PROPN
dpc-5933	35	11	approval	approval	NOUN
dpc-5933	35	12	for	for	ADP
dpc-5933	35	13	the	the	DET
dpc-5933	35	14	management	management	NOUN
dpc-5933	35	15	of	of	ADP
dpc-5933	35	16	hs	hs	PROPN
dpc-5933	35	17	in	in	ADP
dpc-5933	35	18	2015	2015	NUM
dpc-5933	35	19	[	[	X
dpc-5933	35	20	5	5	NUM
dpc-5933	35	21	]	]	PUNCT
dpc-5933	35	22	.	.	PUNCT
dpc-5933	36	1	while	while	SCONJ
dpc-5933	36	2	it	it	PRON
dpc-5933	36	3	has	have	AUX
dpc-5933	36	4	provided	provide	VERB
dpc-5933	36	5	meaningful	meaningful	ADJ
dpc-5933	36	6	clinical	clinical	ADJ
dpc-5933	36	7	benefits	benefit	NOUN
dpc-5933	36	8	,	,	PUNCT
dpc-5933	36	9	concerns	concern	NOUN
dpc-5933	36	10	regarding	regard	VERB
dpc-5933	36	11	safety	safety	NOUN
dpc-5933	36	12	,	,	PUNCT
dpc-5933	36	13	diminishing	diminish	VERB
dpc-5933	36	14	efficacy	efficacy	NOUN
dpc-5933	36	15	over	over	ADP
dpc-5933	36	16	time	time	NOUN
dpc-5933	36	17	,	,	PUNCT
dpc-5933	36	18	and	and	CCONJ
dpc-5933	36	19	variability	variability	NOUN
dpc-5933	36	20	in	in	ADP
dpc-5933	36	21	response	response	NOUN
dpc-5933	36	22	have	have	AUX
dpc-5933	36	23	limited	limit	VERB
dpc-5933	36	24	its	its	PRON
dpc-5933	36	25	utility	utility	NOUN
dpc-5933	36	26	in	in	ADP
dpc-5933	36	27	some	some	DET
dpc-5933	36	28	cases	case	NOUN
dpc-5933	36	29	[	[	X
dpc-5933	36	30	6	6	NUM
dpc-5933	36	31	-	-	SYM
dpc-5933	36	32	8	8	NUM
dpc-5933	36	33	]	]	PUNCT
dpc-5933	36	34	.	.	PUNCT
dpc-5933	37	1	recently	recently	ADV
dpc-5933	37	2	,	,	PUNCT
dpc-5933	37	3	the	the	DET
dpc-5933	37	4	efficacy	efficacy	NOUN
dpc-5933	37	5	and	and	CCONJ
dpc-5933	37	6	safety	safety	NOUN
dpc-5933	37	7	of	of	ADP
dpc-5933	37	8	secukinumab	secukinumab	NOUN
dpc-5933	37	9	,	,	PUNCT
dpc-5933	37	10	an	an	DET
dpc-5933	37	11	il17a	il17a	NOUN
dpc-5933	37	12	inhibitor	inhibitor	NOUN
dpc-5933	37	13	,	,	PUNCT
dpc-5933	37	14	have	have	AUX
dpc-5933	37	15	been	be	AUX
dpc-5933	37	16	demonstrated	demonstrate	VERB
dpc-5933	37	17	in	in	ADP
dpc-5933	37	18	two	two	NUM
dpc-5933	37	19	large	large	ADJ
dpc-5933	37	20	-	-	PUNCT
dpc-5933	37	21	scale	scale	NOUN
dpc-5933	37	22	,	,	PUNCT
dpc-5933	37	23	multicenter	multicenter	NOUN
dpc-5933	37	24	randomized	randomize	VERB
dpc-5933	37	25	controlled	control	VERB
dpc-5933	37	26	trials	trial	NOUN
dpc-5933	37	27	(	(	PUNCT
dpc-5933	37	28	rcts	rct	NOUN
dpc-5933	37	29	):	):	PUNCT
dpc-5933	37	30	sunshine	sunshine	NOUN
dpc-5933	37	31	and	and	CCONJ
dpc-5933	37	32	sunrise	sunrise	VERB
dpc-5933	37	33	[	[	X
dpc-5933	37	34	9	9	NUM
dpc-5933	37	35	]	]	PUNCT
dpc-5933	37	36	.	.	PUNCT
dpc-5933	38	1	these	these	DET
dpc-5933	38	2	trials	trial	NOUN
dpc-5933	38	3	reported	report	VERB
dpc-5933	38	4	response	response	NOUN
dpc-5933	38	5	rates	rate	NOUN
dpc-5933	38	6	of	of	ADP
dpc-5933	38	7	42–45	42–45	NUM
dpc-5933	38	8	%	%	NOUN
dpc-5933	38	9	at	at	ADP
dpc-5933	38	10	16	16	NUM
dpc-5933	38	11	weeks	week	NOUN
dpc-5933	38	12	,	,	PUNCT
dpc-5933	38	13	with	with	ADP
dpc-5933	38	14	continued	continue	VERB
dpc-5933	38	15	improvement	improvement	NOUN
dpc-5933	38	16	observed	observe	VERB
dpc-5933	38	17	at	at	ADP
dpc-5933	38	18	52	52	NUM
dpc-5933	38	19	weeks	week	NOUN
dpc-5933	38	20	,	,	PUNCT
dpc-5933	38	21	underscoring	underscore	VERB
dpc-5933	38	22	the	the	DET
dpc-5933	38	23	drug	drug	NOUN
dpc-5933	38	24	’s	’s	PART
dpc-5933	38	25	potential	potential	NOUN
dpc-5933	38	26	for	for	ADP
dpc-5933	38	27	long	long	ADJ
dpc-5933	38	28	-	-	PUNCT
dpc-5933	38	29	term	term	NOUN
dpc-5933	38	30	disease	disease	NOUN
dpc-5933	38	31	control	control	NOUN
dpc-5933	39	1	[	[	X
dpc-5933	39	2	9	9	NUM
dpc-5933	39	3	]	]	PUNCT
dpc-5933	39	4	.	.	PUNCT
dpc-5933	40	1	subsequent	subsequent	ADJ
dpc-5933	40	2	real	real	ADJ
dpc-5933	40	3	-	-	PUNCT
dpc-5933	40	4	world	world	NOUN
dpc-5933	40	5	studies	study	NOUN
dpc-5933	40	6	have	have	AUX
dpc-5933	40	7	further	far	ADV
dpc-5933	40	8	corroborated	corroborate	VERB
dpc-5933	40	9	the	the	DET
dpc-5933	40	10	effectiveness	effectiveness	NOUN
dpc-5933	40	11	of	of	ADP
dpc-5933	40	12	secukinumab	secukinumab	NOUN
dpc-5933	40	13	[	[	X
dpc-5933	40	14	10	10	NUM
dpc-5933	40	15	-	-	SYM
dpc-5933	40	16	16	16	NUM
dpc-5933	40	17	]	]	PUNCT
dpc-5933	40	18	,	,	PUNCT
dpc-5933	40	19	culminating	culminate	VERB
dpc-5933	40	20	in	in	ADP
dpc-5933	40	21	its	its	PRON
dpc-5933	40	22	fda	fda	PROPN
dpc-5933	40	23	approval	approval	NOUN
dpc-5933	40	24	for	for	ADP
dpc-5933	40	25	moderate	moderate	ADJ
dpc-5933	40	26	-	-	PUNCT
dpc-5933	40	27	to	to	ADP
dpc-5933	40	28	-	-	PUNCT
dpc-5933	40	29	severe	severe	ADJ
dpc-5933	40	30	hs	hs	PROPN
dpc-5933	40	31	on	on	ADP
dpc-5933	40	32	31	31	NUM
dpc-5933	40	33	october	october	PROPN
dpc-5933	40	34	2023	2023	NUM
dpc-5933	40	35	.	.	PUNCT
dpc-5933	41	1	although	although	SCONJ
dpc-5933	41	2	data	datum	NOUN
dpc-5933	41	3	from	from	ADP
dpc-5933	41	4	rcts	rct	NOUN
dpc-5933	41	5	and	and	CCONJ
dpc-5933	41	6	real	real	ADJ
dpc-5933	41	7	-	-	PUNCT
dpc-5933	41	8	world	world	NOUN
dpc-5933	41	9	studies	study	NOUN
dpc-5933	41	10	have	have	AUX
dpc-5933	41	11	established	establish	VERB
dpc-5933	41	12	the	the	DET
dpc-5933	41	13	efficacy	efficacy	NOUN
dpc-5933	41	14	and	and	CCONJ
dpc-5933	41	15	safety	safety	NOUN
dpc-5933	41	16	profile	profile	NOUN
dpc-5933	41	17	of	of	ADP
dpc-5933	41	18	secukinumab	secukinumab	NOUN
dpc-5933	41	19	,	,	PUNCT
dpc-5933	41	20	the	the	DET
dpc-5933	41	21	influence	influence	NOUN
dpc-5933	41	22	of	of	ADP
dpc-5933	41	23	disease	disease	NOUN
dpc-5933	41	24	-	-	PUNCT
dpc-5933	41	25	related	relate	VERB
dpc-5933	41	26	factors	factor	NOUN
dpc-5933	41	27	such	such	ADJ
dpc-5933	41	28	as	as	ADP
dpc-5933	41	29	severity	severity	NOUN
dpc-5933	41	30	,	,	PUNCT
dpc-5933	41	31	treatment	treatment	NOUN
dpc-5933	41	32	delay	delay	NOUN
dpc-5933	41	33	,	,	PUNCT
dpc-5933	41	34	and	and	CCONJ
dpc-5933	41	35	prior	prior	ADJ
dpc-5933	41	36	biologics	biologic	NOUN
dpc-5933	41	37	use	use	VERB
dpc-5933	41	38	on	on	ADP
dpc-5933	41	39	therapeutic	therapeutic	ADJ
dpc-5933	41	40	outcomes	outcome	NOUN
dpc-5933	41	41	remains	remains	AUX
dpc-5933	41	42	insufficiently	insufficiently	ADV
dpc-5933	41	43	explored	explore	VERB
dpc-5933	41	44	.	.	PUNCT
dpc-5933	42	1	severe	severe	ADJ
dpc-5933	42	2	hs	hs	PROPN
dpc-5933	42	3	often	often	ADV
dpc-5933	42	4	presents	present	VERB
dpc-5933	42	5	with	with	ADP
dpc-5933	42	6	extensive	extensive	ADJ
dpc-5933	42	7	scarring	scarring	NOUN
dpc-5933	42	8	and	and	CCONJ
dpc-5933	42	9	multiple	multiple	ADJ
dpc-5933	42	10	interconnected	interconnected	ADJ
dpc-5933	42	11	sinus	sinus	NOUN
dpc-5933	42	12	tracts	tract	NOUN
dpc-5933	42	13	,	,	PUNCT
dpc-5933	42	14	which	which	PRON
dpc-5933	42	15	may	may	AUX
dpc-5933	42	16	hinder	hinder	VERB
dpc-5933	42	17	treatment	treatment	NOUN
dpc-5933	42	18	response	response	NOUN
dpc-5933	42	19	compared	compare	VERB
dpc-5933	42	20	to	to	ADP
dpc-5933	42	21	less	less	ADV
dpc-5933	42	22	advanced	advanced	ADJ
dpc-5933	42	23	diseases	disease	NOUN
dpc-5933	42	24	.	.	PUNCT
dpc-5933	43	1	to	to	PART
dpc-5933	43	2	address	address	VERB
dpc-5933	43	3	this	this	DET
dpc-5933	43	4	gap	gap	NOUN
dpc-5933	43	5	,	,	PUNCT
dpc-5933	43	6	we	we	PRON
dpc-5933	43	7	conducted	conduct	VERB
dpc-5933	43	8	a	a	DET
dpc-5933	43	9	48	48	NUM
dpc-5933	43	10	-	-	PUNCT
dpc-5933	43	11	week	week	NOUN
dpc-5933	43	12	real	real	ADJ
dpc-5933	43	13	-	-	PUNCT
dpc-5933	43	14	world	world	NOUN
dpc-5933	43	15	clinical	clinical	ADJ
dpc-5933	43	16	trial	trial	NOUN
dpc-5933	43	17	on	on	ADP
dpc-5933	43	18	korean	korean	ADJ
dpc-5933	43	19	patients	patient	NOUN
dpc-5933	43	20	with	with	ADP
dpc-5933	43	21	moderate	moderate	ADJ
dpc-5933	43	22	-	-	PUNCT
dpc-5933	43	23	to	to	ADP
dpc-5933	43	24	-	-	PUNCT
dpc-5933	43	25	severe	severe	ADJ
dpc-5933	43	26	hs	hs	PROPN
dpc-5933	43	27	.	.	PROPN
dpc-5933	43	28	objectives	objective	NOUN
dpc-5933	43	29	this	this	DET
dpc-5933	43	30	study	study	NOUN
dpc-5933	43	31	aimed	aim	VERB
dpc-5933	43	32	to	to	PART
dpc-5933	43	33	evaluate	evaluate	VERB
dpc-5933	43	34	how	how	SCONJ
dpc-5933	43	35	baseline	baseline	ADJ
dpc-5933	43	36	disease	disease	NOUN
dpc-5933	43	37	severity	severity	NOUN
dpc-5933	43	38	(	(	PUNCT
dpc-5933	43	39	hurley	hurley	NOUN
dpc-5933	43	40	stage	stage	NOUN
dpc-5933	43	41	)	)	PUNCT
dpc-5933	43	42	,	,	PUNCT
dpc-5933	43	43	treatment	treatment	NOUN
dpc-5933	43	44	delay	delay	NOUN
dpc-5933	43	45	,	,	PUNCT
dpc-5933	43	46	and	and	CCONJ
dpc-5933	43	47	prior	prior	ADJ
dpc-5933	43	48	biologics	biologic	NOUN
dpc-5933	43	49	exposure	exposure	NOUN
dpc-5933	43	50	affect	affect	VERB
dpc-5933	43	51	clinical	clinical	ADJ
dpc-5933	43	52	response	response	NOUN
dpc-5933	43	53	to	to	PART
dpc-5933	43	54	secukinumab	secukinumab	VERB
dpc-5933	43	55	in	in	ADP
dpc-5933	43	56	korean	korean	ADJ
dpc-5933	43	57	patients	patient	NOUN
dpc-5933	43	58	with	with	ADP
dpc-5933	43	59	moderate	moderate	ADJ
dpc-5933	43	60	-	-	PUNCT
dpc-5933	43	61	to	to	ADP
dpc-5933	43	62	-	-	PUNCT
dpc-5933	43	63	severe	severe	ADJ
dpc-5933	43	64	hs	hs	NOUN
dpc-5933	43	65	over	over	ADP
dpc-5933	43	66	a	a	DET
dpc-5933	43	67	48	48	NUM
dpc-5933	43	68	-	-	PUNCT
dpc-5933	43	69	week	week	NOUN
dpc-5933	43	70	treatment	treatment	NOUN
dpc-5933	43	71	period	period	NOUN
dpc-5933	43	72	in	in	ADP
dpc-5933	43	73	a	a	DET
dpc-5933	43	74	real	real	ADJ
dpc-5933	43	75	-	-	PUNCT
dpc-5933	43	76	world	world	NOUN
dpc-5933	43	77	clinical	clinical	ADJ
dpc-5933	43	78	setting	setting	NOUN
dpc-5933	43	79	.	.	PUNCT
dpc-5933	44	1	additionally	additionally	ADV
dpc-5933	44	2	,	,	PUNCT
dpc-5933	44	3	this	this	DET
dpc-5933	44	4	research	research	NOUN
dpc-5933	44	5	sought	seek	VERB
dpc-5933	44	6	to	to	PART
dpc-5933	44	7	examine	examine	VERB
dpc-5933	44	8	the	the	DET
dpc-5933	44	9	impact	impact	NOUN
dpc-5933	44	10	of	of	ADP
dpc-5933	44	11	secukinumab	secukinumab	NOUN
dpc-5933	44	12	on	on	ADP
dpc-5933	44	13	systemic	systemic	ADJ
dpc-5933	44	14	antibiotic	antibiotic	ADJ
dpc-5933	44	15	use	use	NOUN
dpc-5933	44	16	.	.	PUNCT
dpc-5933	45	1	materials	material	NOUN
dpc-5933	45	2	and	and	CCONJ
dpc-5933	45	3	methods	method	NOUN
dpc-5933	45	4	study	study	NOUN
dpc-5933	45	5	design	design	NOUN
dpc-5933	45	6	and	and	CCONJ
dpc-5933	45	7	participants	participant	NOUN
dpc-5933	45	8	this	this	DET
dpc-5933	45	9	prospective	prospective	ADJ
dpc-5933	45	10	,	,	PUNCT
dpc-5933	45	11	non	non	ADJ
dpc-5933	45	12	-	-	ADJ
dpc-5933	45	13	controlled	control	VERB
dpc-5933	45	14	clinical	clinical	ADJ
dpc-5933	45	15	trial	trial	NOUN
dpc-5933	45	16	recruited	recruit	VERB
dpc-5933	45	17	moderate	moderate	ADJ
dpc-5933	45	18	-	-	PUNCT
dpc-5933	45	19	to	to	ADP
dpc-5933	45	20	-	-	PUNCT
dpc-5933	45	21	severe	severe	ADJ
dpc-5933	45	22	hs	hs	PROPN
dpc-5933	45	23	patients	patient	NOUN
dpc-5933	45	24	in	in	ADP
dpc-5933	45	25	a	a	DET
dpc-5933	45	26	real	real	ADJ
dpc-5933	45	27	-	-	PUNCT
dpc-5933	45	28	world	world	NOUN
dpc-5933	45	29	setting	setting	NOUN
dpc-5933	45	30	at	at	ADP
dpc-5933	45	31	the	the	DET
dpc-5933	45	32	department	department	NOUN
dpc-5933	45	33	of	of	ADP
dpc-5933	45	34	dermatology	dermatology	NOUN
dpc-5933	45	35	,	,	PUNCT
dpc-5933	45	36	severance	severance	NOUN
dpc-5933	45	37	hospital	hospital	NOUN
dpc-5933	45	38	,	,	PUNCT
dpc-5933	45	39	seoul	seoul	PROPN
dpc-5933	45	40	,	,	PUNCT
dpc-5933	45	41	republic	republic	NOUN
dpc-5933	45	42	of	of	ADP
dpc-5933	45	43	korea	korea	PROPN
dpc-5933	45	44	from	from	ADP
dpc-5933	45	45	may	may	PROPN
dpc-5933	45	46	2023	2023	NUM
dpc-5933	45	47	to	to	ADP
dpc-5933	45	48	november	november	PROPN
dpc-5933	45	49	2024	2024	NUM
dpc-5933	45	50	.	.	PUNCT
dpc-5933	46	1	to	to	PART
dpc-5933	46	2	facilitate	facilitate	VERB
dpc-5933	46	3	easier	easy	ADJ
dpc-5933	46	4	access	access	NOUN
dpc-5933	46	5	to	to	ADP
dpc-5933	46	6	adequate	adequate	ADJ
dpc-5933	46	7	therapy	therapy	NOUN
dpc-5933	46	8	,	,	PUNCT
dpc-5933	46	9	the	the	DET
dpc-5933	46	10	global	global	ADJ
dpc-5933	46	11	managed	manage	VERB
dpc-5933	46	12	access	access	NOUN
dpc-5933	46	13	program	program	NOUN
dpc-5933	46	14	(	(	PUNCT
dpc-5933	46	15	map	map	NOUN
dpc-5933	46	16	)	)	PUNCT
dpc-5933	46	17	by	by	ADP
dpc-5933	46	18	novartis	novartis	PROPN
dpc-5933	46	19	was	be	AUX
dpc-5933	46	20	established	establish	VERB
dpc-5933	46	21	,	,	PUNCT
dpc-5933	46	22	providing	provide	VERB
dpc-5933	46	23	secukinumab	secukinumab	NOUN
dpc-5933	46	24	treatment	treatment	NOUN
dpc-5933	46	25	to	to	ADP
dpc-5933	46	26	moderate	moderate	ADJ
dpc-5933	46	27	-	-	PUNCT
dpc-5933	46	28	to	to	ADP
dpc-5933	46	29	-	-	PUNCT
dpc-5933	46	30	severe	severe	ADJ
dpc-5933	46	31	hs	hs	PROPN
dpc-5933	46	32	patients	patient	NOUN
dpc-5933	46	33	.	.	PUNCT
dpc-5933	47	1	the	the	DET
dpc-5933	47	2	requesting	request	VERB
dpc-5933	47	3	physician	physician	NOUN
dpc-5933	47	4	submitted	submit	VERB
dpc-5933	47	5	a	a	DET
dpc-5933	47	6	supply	supply	NOUN
dpc-5933	47	7	or	or	CCONJ
dpc-5933	47	8	resupply	resupply	VERB
dpc-5933	47	9	request	request	NOUN
dpc-5933	47	10	for	for	ADP
dpc-5933	47	11	secukinumab	secukinumab	NOUN
dpc-5933	47	12	through	through	ADP
dpc-5933	47	13	the	the	DET
dpc-5933	47	14	grants	grant	NOUN
dpc-5933	47	15	,	,	PUNCT
dpc-5933	47	16	external	external	ADJ
dpc-5933	47	17	requests	request	NOUN
dpc-5933	47	18	,	,	PUNCT
dpc-5933	47	19	and	and	CCONJ
dpc-5933	47	20	managed	manage	VERB
dpc-5933	47	21	access	access	NOUN
dpc-5933	47	22	system	system	NOUN
dpc-5933	47	23	(	(	PUNCT
dpc-5933	47	24	gems	gem	NOUN
dpc-5933	47	25	)	)	PUNCT
dpc-5933	47	26	,	,	PUNCT
dpc-5933	47	27	and	and	CCONJ
dpc-5933	47	28	the	the	DET
dpc-5933	47	29	request	request	NOUN
dpc-5933	47	30	was	be	AUX
dpc-5933	47	31	evaluated	evaluate	VERB
dpc-5933	47	32	based	base	VERB
dpc-5933	47	33	on	on	ADP
dpc-5933	47	34	the	the	DET
dpc-5933	47	35	eligibility	eligibility	NOUN
dpc-5933	47	36	criteria	criterion	NOUN
dpc-5933	47	37	.	.	PUNCT
dpc-5933	48	1	our	our	PRON
dpc-5933	48	2	study	study	NOUN
dpc-5933	48	3	recruited	recruit	VERB
dpc-5933	48	4	hs	hs	PROPN
dpc-5933	48	5	patients	patient	NOUN
dpc-5933	48	6	from	from	ADP
dpc-5933	48	7	map	map	NOUN
dpc-5933	48	8	,	,	PUNCT
dpc-5933	48	9	specifically	specifically	ADV
dpc-5933	48	10	those	those	DET
dpc-5933	48	11	over	over	ADP
dpc-5933	48	12	18	18	NUM
dpc-5933	48	13	years	year	NOUN
dpc-5933	48	14	old	old	ADJ
dpc-5933	48	15	,	,	PUNCT
dpc-5933	48	16	diagnosed	diagnose	VERB
dpc-5933	48	17	with	with	ADP
dpc-5933	48	18	moderate	moderate	ADJ
dpc-5933	48	19	-	-	PUNCT
dpc-5933	48	20	to	to	ADP
dpc-5933	48	21	-	-	PUNCT
dpc-5933	48	22	severe	severe	ADJ
dpc-5933	48	23	hs	hs	INTJ
dpc-5933	48	24	for	for	ADP
dpc-5933	48	25	over	over	ADP
dpc-5933	48	26	six	six	NUM
dpc-5933	48	27	months	month	NOUN
dpc-5933	48	28	(	(	PUNCT
dpc-5933	48	29	defined	define	VERB
dpc-5933	48	30	as	as	ADP
dpc-5933	48	31	having	have	VERB
dpc-5933	48	32	a	a	DET
dpc-5933	48	33	total	total	NOUN
dpc-5933	48	34	of	of	ADP
dpc-5933	48	35	five	five	NUM
dpc-5933	48	36	inflammatory	inflammatory	ADJ
dpc-5933	48	37	lesions	lesion	NOUN
dpc-5933	48	38	,	,	PUNCT
dpc-5933	48	39	namely	namely	ADV
dpc-5933	48	40	abscesses	abscess	NOUN
dpc-5933	48	41	and	and	CCONJ
dpc-5933	48	42	nodules	nodule	NOUN
dpc-5933	48	43	,	,	PUNCT
dpc-5933	48	44	in	in	ADP
dpc-5933	48	45	two	two	NUM
dpc-5933	48	46	different	different	ADJ
dpc-5933	48	47	anatomical	anatomical	ADJ
dpc-5933	48	48	areas	area	NOUN
dpc-5933	48	49	)	)	PUNCT
dpc-5933	48	50	.	.	PUNCT
dpc-5933	49	1	detailed	detailed	ADJ
dpc-5933	49	2	descriptions	description	NOUN
dpc-5933	49	3	of	of	ADP
dpc-5933	49	4	inclusion	inclusion	NOUN
dpc-5933	49	5	and	and	CCONJ
dpc-5933	49	6	exclusion	exclusion	NOUN
dpc-5933	49	7	criteria	criterion	NOUN
dpc-5933	49	8	are	be	AUX
dpc-5933	49	9	provided	provide	VERB
dpc-5933	49	10	in	in	ADP
dpc-5933	49	11	table	table	NOUN
dpc-5933	49	12	s1	s1	NOUN
dpc-5933	49	13	.	.	PUNCT
dpc-5933	50	1	patients	patient	NOUN
dpc-5933	50	2	were	be	AUX
dpc-5933	50	3	administered	administer	VERB
dpc-5933	50	4	300	300	NUM
dpc-5933	50	5	mg	mg	ADP
dpc-5933	50	6	of	of	ADP
dpc-5933	50	7	secukinumab	secukinumab	NOUN
dpc-5933	50	8	subcutaneously	subcutaneously	ADV
dpc-5933	50	9	at	at	ADP
dpc-5933	50	10	weeks	week	NOUN
dpc-5933	50	11	48	48	NUM
dpc-5933	50	12	.	.	PUNCT
dpc-5933	51	1	all	all	DET
dpc-5933	51	2	patients	patient	NOUN
dpc-5933	51	3	,	,	PUNCT
dpc-5933	51	4	particularly	particularly	ADV
dpc-5933	51	5	moderate	moderate	ADJ
dpc-5933	51	6	cases	case	NOUN
dpc-5933	51	7	,	,	PUNCT
dpc-5933	51	8	either	either	CCONJ
dpc-5933	51	9	discontinued	discontinue	VERB
dpc-5933	51	10	or	or	CCONJ
dpc-5933	51	11	transitioned	transition	VERB
dpc-5933	51	12	to	to	ADP
dpc-5933	51	13	monotherapy	monotherapy	NOUN
dpc-5933	51	14	with	with	ADP
dpc-5933	51	15	systemic	systemic	ADJ
dpc-5933	51	16	antibiotics	antibiotic	NOUN
dpc-5933	51	17	.	.	PUNCT
dpc-5933	52	1	conclusions	conclusion	NOUN
dpc-5933	52	2	:	:	PUNCT
dpc-5933	52	3	secukinumab	secukinumab	NOUN
dpc-5933	52	4	demonstrated	demonstrate	VERB
dpc-5933	52	5	efficacy	efficacy	NOUN
dpc-5933	52	6	in	in	ADP
dpc-5933	52	7	alleviating	alleviate	VERB
dpc-5933	52	8	hs	hs	PROPN
dpc-5933	52	9	symptoms	symptom	NOUN
dpc-5933	52	10	in	in	ADP
dpc-5933	52	11	moderate	moderate	ADJ
dpc-5933	52	12	-	-	PUNCT
dpc-5933	52	13	to	to	ADP
dpc-5933	52	14	-	-	PUNCT
dpc-5933	52	15	severe	severe	ADJ
dpc-5933	52	16	cases	case	NOUN
dpc-5933	52	17	.	.	PUNCT
dpc-5933	53	1	patients	patient	NOUN
dpc-5933	53	2	with	with	ADP
dpc-5933	53	3	less	less	ADV
dpc-5933	53	4	severe	severe	ADJ
dpc-5933	53	5	disease	disease	NOUN
dpc-5933	53	6	,	,	PUNCT
dpc-5933	53	7	shorter	short	ADJ
dpc-5933	53	8	treatment	treatment	NOUN
dpc-5933	53	9	delays	delay	NOUN
dpc-5933	53	10	,	,	PUNCT
dpc-5933	53	11	and/or	and/or	CCONJ
dpc-5933	53	12	no	no	DET
dpc-5933	53	13	prior	prior	ADJ
dpc-5933	53	14	biologic	biologic	NOUN
dpc-5933	53	15	therapy	therapy	NOUN
dpc-5933	53	16	exhibited	exhibit	VERB
dpc-5933	53	17	more	more	ADV
dpc-5933	53	18	rapid	rapid	ADJ
dpc-5933	53	19	initial	initial	ADJ
dpc-5933	53	20	responses	response	NOUN
dpc-5933	53	21	.	.	PUNCT
dpc-5933	54	1	additionally	additionally	ADV
dpc-5933	54	2	,	,	PUNCT
dpc-5933	54	3	the	the	DET
dpc-5933	54	4	majority	majority	NOUN
dpc-5933	54	5	of	of	ADP
dpc-5933	54	6	patients	patient	NOUN
dpc-5933	54	7	experienced	experience	VERB
dpc-5933	54	8	a	a	DET
dpc-5933	54	9	significant	significant	ADJ
dpc-5933	54	10	duration	duration	NOUN
dpc-5933	54	11	of	of	ADP
dpc-5933	54	12	antibiotic	antibiotic	ADJ
dpc-5933	54	13	cessation	cessation	NOUN
dpc-5933	54	14	,	,	PUNCT
dpc-5933	54	15	underscoring	underscore	VERB
dpc-5933	54	16	the	the	DET
dpc-5933	54	17	importance	importance	NOUN
dpc-5933	54	18	of	of	ADP
dpc-5933	54	19	early	early	ADJ
dpc-5933	54	20	intervention	intervention	NOUN
dpc-5933	54	21	.	.	PUNCT
dpc-5933	55	1	future	future	ADJ
dpc-5933	55	2	studies	study	NOUN
dpc-5933	55	3	with	with	ADP
dpc-5933	55	4	larger	large	ADJ
dpc-5933	55	5	populations	population	NOUN
dpc-5933	55	6	are	be	AUX
dpc-5933	55	7	required	require	VERB
dpc-5933	55	8	to	to	PART
dpc-5933	55	9	substantiate	substantiate	VERB
dpc-5933	55	10	these	these	DET
dpc-5933	55	11	findings	finding	NOUN
dpc-5933	55	12	.	.	PUNCT
dpc-5933	56	1	original	original	ADJ
dpc-5933	56	2	article	article	NOUN
dpc-5933	56	3	|	|	ADV
dpc-5933	56	4	dermatol	dermatol	ADJ
dpc-5933	56	5	pract	pract	NOUN
dpc-5933	56	6	concept	concept	NOUN
dpc-5933	56	7	.	.	PUNCT
dpc-5933	57	1	2025;15(4):5933	2025;15(4):5933	NUM
dpc-5933	57	2	3	3	NUM
dpc-5933	57	3	0	0	NUM
dpc-5933	57	4	,	,	PUNCT
dpc-5933	57	5	1	1	NUM
dpc-5933	57	6	,	,	PUNCT
dpc-5933	57	7	2	2	NUM
dpc-5933	57	8	,	,	PUNCT
dpc-5933	57	9	3	3	NUM
dpc-5933	57	10	,	,	PUNCT
dpc-5933	57	11	and	and	CCONJ
dpc-5933	57	12	4	4	NUM
dpc-5933	57	13	,	,	PUNCT
dpc-5933	57	14	then	then	ADV
dpc-5933	57	15	every	every	DET
dpc-5933	57	16	two	two	NUM
dpc-5933	57	17	weeks	week	NOUN
dpc-5933	57	18	until	until	ADP
dpc-5933	57	19	48	48	NUM
dpc-5933	57	20	weeks	week	NOUN
dpc-5933	57	21	.	.	PUNCT
dpc-5933	58	1	other	other	ADJ
dpc-5933	58	2	concurrent	concurrent	ADJ
dpc-5933	58	3	treatments	treatment	NOUN
dpc-5933	58	4	,	,	PUNCT
dpc-5933	58	5	namely	namely	ADV
dpc-5933	58	6	systemic	systemic	ADJ
dpc-5933	58	7	antibiotics	antibiotic	NOUN
dpc-5933	58	8	,	,	PUNCT
dpc-5933	58	9	ta	ta	PROPN
dpc-5933	58	10	ili	ili	PROPN
dpc-5933	58	11	,	,	PUNCT
dpc-5933	58	12	and	and	CCONJ
dpc-5933	58	13	i&d	i&d	PROPN
dpc-5933	58	14	,	,	PUNCT
dpc-5933	58	15	were	be	AUX
dpc-5933	58	16	permitted	permit	VERB
dpc-5933	58	17	for	for	ADP
dpc-5933	58	18	continuation	continuation	NOUN
dpc-5933	58	19	based	base	VERB
dpc-5933	58	20	on	on	ADP
dpc-5933	58	21	clinical	clinical	ADJ
dpc-5933	58	22	guidelines	guideline	NOUN
dpc-5933	58	23	and	and	CCONJ
dpc-5933	58	24	recommendations	recommendation	NOUN
dpc-5933	58	25	.	.	PUNCT
dpc-5933	59	1	baseline	baseline	PROPN
dpc-5933	59	2	characteristics	characteristic	NOUN
dpc-5933	59	3	at	at	ADP
dpc-5933	59	4	baseline	baseline	NOUN
dpc-5933	59	5	,	,	PUNCT
dpc-5933	59	6	demographic	demographic	ADJ
dpc-5933	59	7	and	and	CCONJ
dpc-5933	59	8	clinical	clinical	ADJ
dpc-5933	59	9	data	datum	NOUN
dpc-5933	59	10	were	be	AUX
dpc-5933	59	11	collected	collect	VERB
dpc-5933	59	12	,	,	PUNCT
dpc-5933	59	13	specifically	specifically	ADV
dpc-5933	59	14	sex	sex	NOUN
dpc-5933	59	15	,	,	PUNCT
dpc-5933	59	16	age	age	NOUN
dpc-5933	59	17	,	,	PUNCT
dpc-5933	59	18	age	age	NOUN
dpc-5933	59	19	at	at	ADP
dpc-5933	59	20	onset	onset	NOUN
dpc-5933	59	21	,	,	PUNCT
dpc-5933	59	22	body	body	NOUN
dpc-5933	59	23	mass	mass	NOUN
dpc-5933	59	24	index	index	NOUN
dpc-5933	59	25	(	(	PUNCT
dpc-5933	59	26	bmi	bmi	PROPN
dpc-5933	59	27	)	)	PUNCT
dpc-5933	59	28	,	,	PUNCT
dpc-5933	59	29	smoking	smoking	NOUN
dpc-5933	59	30	habit	habit	NOUN
dpc-5933	59	31	,	,	PUNCT
dpc-5933	59	32	family	family	NOUN
dpc-5933	59	33	history	history	NOUN
dpc-5933	59	34	of	of	ADP
dpc-5933	59	35	hs	hs	PROPN
dpc-5933	59	36	,	,	PUNCT
dpc-5933	59	37	treatment	treatment	NOUN
dpc-5933	59	38	delay	delay	NOUN
dpc-5933	59	39	(	(	PUNCT
dpc-5933	59	40	defined	define	VERB
dpc-5933	59	41	as	as	ADP
dpc-5933	59	42	the	the	DET
dpc-5933	59	43	duration	duration	NOUN
dpc-5933	59	44	from	from	ADP
dpc-5933	59	45	disease	disease	NOUN
dpc-5933	59	46	onset	onset	VERB
dpc-5933	59	47	to	to	ADP
dpc-5933	59	48	the	the	DET
dpc-5933	59	49	initiation	initiation	NOUN
dpc-5933	59	50	of	of	ADP
dpc-5933	59	51	secukinumab	secukinumab	NOUN
dpc-5933	59	52	,	,	PUNCT
dpc-5933	59	53	categorized	categorize	VERB
dpc-5933	59	54	as	as	ADP
dpc-5933	59	55	<	<	X
dpc-5933	59	56	10	10	NUM
dpc-5933	59	57	years	year	NOUN
dpc-5933	59	58	and	and	CCONJ
dpc-5933	59	59	≥10	≥10	ADJ
dpc-5933	59	60	years	year	NOUN
dpc-5933	59	61	)	)	PUNCT
dpc-5933	59	62	,	,	PUNCT
dpc-5933	59	63	comorbidities	comorbiditie	NOUN
dpc-5933	59	64	,	,	PUNCT
dpc-5933	59	65	and	and	CCONJ
dpc-5933	59	66	prior	prior	ADJ
dpc-5933	59	67	treatments	treatment	NOUN
dpc-5933	59	68	of	of	ADP
dpc-5933	59	69	hs	hs	PROPN
dpc-5933	59	70	.	.	PROPN
dpc-5933	59	71	assessment	assessment	NOUN
dpc-5933	59	72	of	of	ADP
dpc-5933	59	73	clinical	clinical	ADJ
dpc-5933	59	74	endpoints	endpoint	NOUN
dpc-5933	59	75	of	of	ADP
dpc-5933	59	76	secukinumab	secukinumab	NOUN
dpc-5933	59	77	treatment	treatment	NOUN
dpc-5933	59	78	at	at	ADP
dpc-5933	59	79	baseline	baseline	NOUN
dpc-5933	59	80	,	,	PUNCT
dpc-5933	59	81	clinical	clinical	ADJ
dpc-5933	59	82	symptoms	symptom	NOUN
dpc-5933	59	83	,	,	PUNCT
dpc-5933	59	84	namely	namely	ADV
dpc-5933	59	85	inflammatory	inflammatory	ADJ
dpc-5933	59	86	nodules	nodule	NOUN
dpc-5933	59	87	,	,	PUNCT
dpc-5933	59	88	abscesses	abscess	NOUN
dpc-5933	59	89	,	,	PUNCT
dpc-5933	59	90	and	and	CCONJ
dpc-5933	59	91	draining	drain	VERB
dpc-5933	59	92	tunnels	tunnel	NOUN
dpc-5933	59	93	,	,	PUNCT
dpc-5933	59	94	were	be	AUX
dpc-5933	59	95	assessed	assess	VERB
dpc-5933	59	96	and	and	CCONJ
dpc-5933	59	97	quantified	quantify	VERB
dpc-5933	59	98	.	.	PUNCT
dpc-5933	60	1	abscesses	abscess	NOUN
dpc-5933	60	2	presented	present	VERB
dpc-5933	60	3	as	as	ADP
dpc-5933	60	4	a	a	DET
dpc-5933	60	5	soft	soft	ADJ
dpc-5933	60	6	mass	mass	NOUN
dpc-5933	60	7	larger	large	ADJ
dpc-5933	60	8	than	than	ADP
dpc-5933	60	9	10	10	NUM
dpc-5933	60	10	mm	mm	NOUN
dpc-5933	60	11	in	in	ADP
dpc-5933	60	12	diameter	diameter	NOUN
dpc-5933	60	13	,	,	PUNCT
dpc-5933	60	14	surrounded	surround	VERB
dpc-5933	60	15	by	by	ADP
dpc-5933	60	16	a	a	DET
dpc-5933	60	17	red	red	ADJ
dpc-5933	60	18	area	area	NOUN
dpc-5933	60	19	,	,	PUNCT
dpc-5933	60	20	with	with	ADP
dpc-5933	60	21	central	central	ADJ
dpc-5933	60	22	purulent	purulent	ADJ
dpc-5933	60	23	material	material	NOUN
dpc-5933	60	24	,	,	PUNCT
dpc-5933	60	25	often	often	ADV
dpc-5933	60	26	associated	associate	VERB
dpc-5933	60	27	with	with	ADP
dpc-5933	60	28	inflammation	inflammation	NOUN
dpc-5933	60	29	,	,	PUNCT
dpc-5933	60	30	pain	pain	NOUN
dpc-5933	60	31	,	,	PUNCT
dpc-5933	60	32	and	and	CCONJ
dpc-5933	60	33	tenderness	tenderness	NOUN
dpc-5933	60	34	.	.	PUNCT
dpc-5933	61	1	inflammatory	inflammatory	ADJ
dpc-5933	61	2	nodules	nodule	NOUN
dpc-5933	61	3	were	be	AUX
dpc-5933	61	4	raised	raise	VERB
dpc-5933	61	5	,	,	PUNCT
dpc-5933	61	6	deep	deep	ADJ
dpc-5933	61	7	,	,	PUNCT
dpc-5933	61	8	three	three	NUM
dpc-5933	61	9	-	-	PUNCT
dpc-5933	61	10	dimensional	dimensional	ADJ
dpc-5933	61	11	round	round	ADJ
dpc-5933	61	12	lesions	lesion	NOUN
dpc-5933	61	13	that	that	PRON
dpc-5933	61	14	were	be	AUX
dpc-5933	61	15	tender	tender	ADJ
dpc-5933	61	16	,	,	PUNCT
dpc-5933	61	17	red	red	ADJ
dpc-5933	61	18	,	,	PUNCT
dpc-5933	61	19	and	and	CCONJ
dpc-5933	61	20	infiltrated	infiltrate	VERB
dpc-5933	61	21	,	,	PUNCT
dpc-5933	61	22	potentially	potentially	ADV
dpc-5933	61	23	forming	form	VERB
dpc-5933	61	24	pyogenic	pyogenic	ADJ
dpc-5933	61	25	granulomas	granuloma	NOUN
dpc-5933	61	26	and	and	CCONJ
dpc-5933	61	27	measuring	measure	VERB
dpc-5933	61	28	over	over	ADP
dpc-5933	61	29	10	10	NUM
dpc-5933	61	30	mm	mm	NOUN
dpc-5933	61	31	in	in	ADP
dpc-5933	61	32	diameter	diameter	NOUN
dpc-5933	61	33	.	.	PUNCT
dpc-5933	62	1	draining	drain	VERB
dpc-5933	62	2	fistulae	fistulae	NOUN
dpc-5933	62	3	were	be	AUX
dpc-5933	62	4	raised	raise	VERB
dpc-5933	62	5	sinus	sinus	NOUN
dpc-5933	62	6	tracts	tract	NOUN
dpc-5933	62	7	,	,	PUNCT
dpc-5933	62	8	tender	tender	VERB
dpc-5933	62	9	with	with	ADP
dpc-5933	62	10	fluctuating	fluctuate	VERB
dpc-5933	62	11	tunnels	tunnel	NOUN
dpc-5933	62	12	of	of	ADP
dpc-5933	62	13	varying	vary	VERB
dpc-5933	62	14	length	length	NOUN
dpc-5933	62	15	and	and	CCONJ
dpc-5933	62	16	depth	depth	NOUN
dpc-5933	62	17	,	,	PUNCT
dpc-5933	62	18	connected	connect	VERB
dpc-5933	62	19	to	to	ADP
dpc-5933	62	20	the	the	DET
dpc-5933	62	21	skin	skin	NOUN
dpc-5933	62	22	surface	surface	NOUN
dpc-5933	62	23	,	,	PUNCT
dpc-5933	62	24	and	and	CCONJ
dpc-5933	62	25	exuding	exuding	ADJ
dpc-5933	62	26	purulent	purulent	ADJ
dpc-5933	62	27	fluid	fluid	NOUN
dpc-5933	63	1	[	[	X
dpc-5933	63	2	9	9	NUM
dpc-5933	63	3	]	]	PUNCT
dpc-5933	63	4	.	.	PUNCT
dpc-5933	64	1	subsequently	subsequently	ADV
dpc-5933	64	2	,	,	PUNCT
dpc-5933	64	3	disease	disease	NOUN
dpc-5933	64	4	severity	severity	NOUN
dpc-5933	64	5	was	be	AUX
dpc-5933	64	6	categorized	categorize	VERB
dpc-5933	64	7	based	base	VERB
dpc-5933	64	8	on	on	ADP
dpc-5933	64	9	the	the	DET
dpc-5933	64	10	hurley	hurley	NOUN
dpc-5933	64	11	staging	staging	NOUN
dpc-5933	64	12	system	system	NOUN
dpc-5933	64	13	:	:	PUNCT
dpc-5933	64	14	stage	stage	NOUN
dpc-5933	64	15	i	i	PRON
dpc-5933	64	16	(	(	PUNCT
dpc-5933	64	17	mild	mild	ADJ
dpc-5933	64	18	)	)	PUNCT
dpc-5933	64	19	,	,	PUNCT
dpc-5933	64	20	distinguished	distinguish	VERB
dpc-5933	64	21	by	by	ADP
dpc-5933	64	22	single	single	ADJ
dpc-5933	64	23	or	or	CCONJ
dpc-5933	64	24	multiple	multiple	ADJ
dpc-5933	64	25	abscesses	abscess	NOUN
dpc-5933	64	26	without	without	ADP
dpc-5933	64	27	the	the	DET
dpc-5933	64	28	formation	formation	NOUN
dpc-5933	64	29	of	of	ADP
dpc-5933	64	30	sinus	sinus	NOUN
dpc-5933	64	31	tracts	tract	NOUN
dpc-5933	64	32	or	or	CCONJ
dpc-5933	64	33	scarring	scarring	NOUN
dpc-5933	64	34	;	;	PUNCT
dpc-5933	64	35	stage	stage	NOUN
dpc-5933	64	36	ii	ii	PROPN
dpc-5933	64	37	(	(	PUNCT
dpc-5933	64	38	moderate	moderate	ADJ
dpc-5933	64	39	)	)	PUNCT
dpc-5933	64	40	,	,	PUNCT
dpc-5933	64	41	involving	involve	VERB
dpc-5933	64	42	recurrent	recurrent	ADJ
dpc-5933	64	43	abscesses	abscess	NOUN
dpc-5933	64	44	with	with	ADP
dpc-5933	64	45	one	one	NUM
dpc-5933	64	46	or	or	CCONJ
dpc-5933	64	47	more	more	ADJ
dpc-5933	64	48	sinus	sinus	NOUN
dpc-5933	64	49	tracts	tract	NOUN
dpc-5933	64	50	and	and	CCONJ
dpc-5933	64	51	scarring	scarring	NOUN
dpc-5933	64	52	that	that	PRON
dpc-5933	64	53	are	be	AUX
dpc-5933	64	54	widely	widely	ADV
dpc-5933	64	55	separated	separate	VERB
dpc-5933	64	56	by	by	ADP
dpc-5933	64	57	areas	area	NOUN
dpc-5933	64	58	of	of	ADP
dpc-5933	64	59	normal	normal	ADJ
dpc-5933	64	60	skin	skin	NOUN
dpc-5933	64	61	;	;	PUNCT
dpc-5933	64	62	stage	stage	NOUN
dpc-5933	64	63	iii	iii	PROPN
dpc-5933	64	64	(	(	PUNCT
dpc-5933	64	65	severe	severe	ADJ
dpc-5933	64	66	)	)	PUNCT
dpc-5933	64	67	,	,	PUNCT
dpc-5933	64	68	marked	mark	VERB
dpc-5933	64	69	by	by	ADP
dpc-5933	64	70	widespread	widespread	ADJ
dpc-5933	64	71	involvement	involvement	NOUN
dpc-5933	64	72	with	with	ADP
dpc-5933	64	73	multiple	multiple	ADJ
dpc-5933	64	74	sinus	sinus	NOUN
dpc-5933	64	75	tracts	tract	NOUN
dpc-5933	64	76	and	and	CCONJ
dpc-5933	64	77	no	no	DET
dpc-5933	64	78	areas	area	NOUN
dpc-5933	64	79	of	of	ADP
dpc-5933	64	80	normal	normal	ADJ
dpc-5933	64	81	skin	skin	NOUN
dpc-5933	64	82	in	in	ADP
dpc-5933	64	83	between	between	ADP
dpc-5933	64	84	[	[	X
dpc-5933	64	85	17	17	NUM
dpc-5933	64	86	]	]	PUNCT
dpc-5933	64	87	.	.	PUNCT
dpc-5933	65	1	moreover	moreover	ADV
dpc-5933	65	2	,	,	PUNCT
dpc-5933	65	3	skin	skin	NOUN
dpc-5933	65	4	pain	pain	NOUN
dpc-5933	65	5	was	be	AUX
dpc-5933	65	6	reported	report	VERB
dpc-5933	65	7	by	by	ADP
dpc-5933	65	8	the	the	DET
dpc-5933	65	9	patients	patient	NOUN
dpc-5933	65	10	via	via	ADP
dpc-5933	65	11	the	the	DET
dpc-5933	65	12	patient	patient	NOUN
dpc-5933	65	13	’s	’s	PART
dpc-5933	65	14	global	global	ADJ
dpc-5933	65	15	assessment	assessment	NOUN
dpc-5933	65	16	of	of	ADP
dpc-5933	65	17	skin	skin	NOUN
dpc-5933	65	18	pain	pain	NOUN
dpc-5933	65	19	numeric	numeric	ADJ
dpc-5933	65	20	rating	rating	NOUN
dpc-5933	65	21	scale	scale	NOUN
dpc-5933	65	22	(	(	PUNCT
dpc-5933	65	23	nrs	nrs	PROPN
dpc-5933	65	24	)	)	PUNCT
dpc-5933	65	25	at	at	ADP
dpc-5933	65	26	the	the	DET
dpc-5933	65	27	worst	bad	ADJ
dpc-5933	65	28	level	level	NOUN
dpc-5933	65	29	within	within	ADP
dpc-5933	65	30	the	the	DET
dpc-5933	65	31	previous	previous	ADJ
dpc-5933	65	32	24	24	NUM
dpc-5933	65	33	hours	hour	NOUN
dpc-5933	65	34	,	,	PUNCT
dpc-5933	65	35	varying	vary	VERB
dpc-5933	65	36	from	from	ADP
dpc-5933	65	37	0	0	NUM
dpc-5933	65	38	(	(	PUNCT
dpc-5933	65	39	no	no	DET
dpc-5933	65	40	skin	skin	NOUN
dpc-5933	65	41	pain	pain	NOUN
dpc-5933	65	42	)	)	PUNCT
dpc-5933	65	43	to	to	ADP
dpc-5933	65	44	10	10	NUM
dpc-5933	65	45	(	(	PUNCT
dpc-5933	65	46	the	the	DET
dpc-5933	65	47	worst	bad	ADJ
dpc-5933	65	48	skin	skin	NOUN
dpc-5933	65	49	pain	pain	NOUN
dpc-5933	65	50	conceivable	conceivable	ADJ
dpc-5933	65	51	)	)	PUNCT
dpc-5933	65	52	.	.	PUNCT
dpc-5933	66	1	all	all	DET
dpc-5933	66	2	patients	patient	NOUN
dpc-5933	66	3	were	be	AUX
dpc-5933	66	4	examined	examine	VERB
dpc-5933	66	5	and	and	CCONJ
dpc-5933	66	6	evaluated	evaluate	VERB
dpc-5933	66	7	for	for	ADP
dpc-5933	66	8	clinical	clinical	ADJ
dpc-5933	66	9	symptoms	symptom	NOUN
dpc-5933	66	10	and	and	CCONJ
dpc-5933	66	11	skin	skin	NOUN
dpc-5933	66	12	pain	pain	NOUN
dpc-5933	66	13	at	at	ADP
dpc-5933	66	14	baseline	baseline	NOUN
dpc-5933	66	15	and	and	CCONJ
dpc-5933	66	16	at	at	ADP
dpc-5933	66	17	weeks	week	NOUN
dpc-5933	66	18	4	4	NUM
dpc-5933	66	19	,	,	PUNCT
dpc-5933	66	20	8	8	NUM
dpc-5933	66	21	,	,	PUNCT
dpc-5933	66	22	16	16	NUM
dpc-5933	66	23	,	,	PUNCT
dpc-5933	66	24	32	32	NUM
dpc-5933	66	25	,	,	PUNCT
dpc-5933	66	26	and	and	CCONJ
dpc-5933	66	27	48	48	NUM
dpc-5933	66	28	.	.	PUNCT
dpc-5933	67	1	our	our	PRON
dpc-5933	67	2	main	main	ADJ
dpc-5933	67	3	clinical	clinical	ADJ
dpc-5933	67	4	endpoints	endpoint	NOUN
dpc-5933	67	5	include	include	VERB
dpc-5933	67	6	:	:	PUNCT
dpc-5933	67	7	•	•	NUM
dpc-5933	67	8	hidradenitis	hidradenitis	PROPN
dpc-5933	67	9	suppurativa	suppurativa	PROPN
dpc-5933	67	10	clinical	clinical	ADJ
dpc-5933	67	11	response	response	NOUN
dpc-5933	67	12	(	(	PUNCT
dpc-5933	67	13	hiscr	hiscr	PROPN
dpc-5933	67	14	):	):	PUNCT
dpc-5933	67	15	a	a	DET
dpc-5933	67	16	reduction	reduction	NOUN
dpc-5933	67	17	of	of	ADP
dpc-5933	67	18	50	50	NUM
dpc-5933	67	19	%	%	NOUN
dpc-5933	67	20	or	or	CCONJ
dpc-5933	67	21	more	more	ADJ
dpc-5933	67	22	from	from	ADP
dpc-5933	67	23	baseline	baseline	NOUN
dpc-5933	67	24	in	in	ADP
dpc-5933	67	25	the	the	DET
dpc-5933	67	26	count	count	NOUN
dpc-5933	67	27	of	of	ADP
dpc-5933	67	28	abscesses	abscess	NOUN
dpc-5933	67	29	and	and	CCONJ
dpc-5933	67	30	inflammatory	inflammatory	ADJ
dpc-5933	67	31	nodules	nodule	NOUN
dpc-5933	67	32	(	(	PUNCT
dpc-5933	67	33	an	an	NOUN
dpc-5933	67	34	)	)	PUNCT
dpc-5933	67	35	,	,	PUNCT
dpc-5933	67	36	without	without	ADP
dpc-5933	67	37	any	any	DET
dpc-5933	67	38	increase	increase	NOUN
dpc-5933	67	39	in	in	ADP
dpc-5933	67	40	the	the	DET
dpc-5933	67	41	number	number	NOUN
dpc-5933	67	42	of	of	ADP
dpc-5933	67	43	abscesses	abscess	NOUN
dpc-5933	67	44	or	or	CCONJ
dpc-5933	67	45	draining	drain	VERB
dpc-5933	67	46	tunnels	tunnel	NOUN
dpc-5933	67	47	[	[	X
dpc-5933	67	48	18	18	NUM
dpc-5933	67	49	]	]	PUNCT
dpc-5933	67	50	.	.	PUNCT
dpc-5933	68	1	•	•	NUM
dpc-5933	68	2	ihs4	ihs4	PROPN
dpc-5933	68	3	-	-	PUNCT
dpc-5933	68	4	55	55	NUM
dpc-5933	68	5	:	:	PUNCT
dpc-5933	68	6	a	a	DET
dpc-5933	68	7	decrease	decrease	NOUN
dpc-5933	68	8	of	of	ADP
dpc-5933	68	9	at	at	ADV
dpc-5933	68	10	least	least	ADV
dpc-5933	68	11	55	55	NUM
dpc-5933	68	12	%	%	NOUN
dpc-5933	68	13	from	from	ADP
dpc-5933	68	14	baseline	baseline	NOUN
dpc-5933	68	15	in	in	ADP
dpc-5933	68	16	the	the	DET
dpc-5933	68	17	international	international	ADJ
dpc-5933	68	18	hidradenitis	hidradenitis	PROPN
dpc-5933	68	19	suppurativa	suppurativa	PROPN
dpc-5933	68	20	severity	severity	NOUN
dpc-5933	68	21	score	score	NOUN
dpc-5933	68	22	system	system	NOUN
dpc-5933	68	23	(	(	PUNCT
dpc-5933	68	24	ihs4	ihs4	PROPN
dpc-5933	68	25	)	)	PUNCT
dpc-5933	68	26	,	,	PUNCT
dpc-5933	68	27	calculated	calculate	VERB
dpc-5933	68	28	using	use	VERB
dpc-5933	68	29	the	the	DET
dpc-5933	68	30	formula	formula	NOUN
dpc-5933	68	31	:	:	PUNCT
dpc-5933	68	32	number	number	NOUN
dpc-5933	68	33	of	of	ADP
dpc-5933	68	34	nodules	nodule	NOUN
dpc-5933	68	35	+	+	CCONJ
dpc-5933	68	36	(	(	PUNCT
dpc-5933	68	37	number	number	NOUN
dpc-5933	68	38	of	of	ADP
dpc-5933	68	39	abscesses	abscess	NOUN
dpc-5933	68	40	x	x	SYM
dpc-5933	68	41	2	2	X
dpc-5933	68	42	)	)	PUNCT
dpc-5933	68	43	+	+	CCONJ
dpc-5933	68	44	(	(	PUNCT
dpc-5933	68	45	number	number	NOUN
dpc-5933	68	46	of	of	ADP
dpc-5933	68	47	draining	drain	VERB
dpc-5933	68	48	tunnels	tunnel	NOUN
dpc-5933	68	49	x	x	PUNCT
dpc-5933	68	50	4	4	X
dpc-5933	68	51	)	)	PUNCT
dpc-5933	69	1	[	[	X
dpc-5933	69	2	19,20	19,20	X
dpc-5933	69	3	]	]	PUNCT
dpc-5933	69	4	.	.	PUNCT
dpc-5933	70	1	•	•	NUM
dpc-5933	70	2	mean	mean	NOUN
dpc-5933	70	3	change	change	NOUN
dpc-5933	70	4	in	in	ADP
dpc-5933	70	5	an	an	DET
dpc-5933	70	6	count	count	NOUN
dpc-5933	70	7	from	from	ADP
dpc-5933	70	8	baseline	baseline	NOUN
dpc-5933	70	9	:	:	PUNCT
dpc-5933	70	10	the	the	DET
dpc-5933	70	11	average	average	ADJ
dpc-5933	70	12	percentage	percentage	NOUN
dpc-5933	70	13	change	change	NOUN
dpc-5933	70	14	from	from	ADP
dpc-5933	70	15	baseline	baseline	NOUN
dpc-5933	70	16	in	in	ADP
dpc-5933	70	17	the	the	DET
dpc-5933	70	18	an	an	DET
dpc-5933	70	19	count	count	NOUN
dpc-5933	70	20	.	.	PUNCT
dpc-5933	71	1	•	•	NUM
dpc-5933	71	2	nrs30	nrs30	PROPN
dpc-5933	71	3	:	:	PUNCT
dpc-5933	71	4	a	a	DET
dpc-5933	71	5	reduction	reduction	NOUN
dpc-5933	71	6	of	of	ADP
dpc-5933	71	7	30	30	NUM
dpc-5933	71	8	%	%	NOUN
dpc-5933	71	9	or	or	CCONJ
dpc-5933	71	10	more	more	ADJ
dpc-5933	71	11	,	,	PUNCT
dpc-5933	71	12	along	along	ADP
dpc-5933	71	13	with	with	ADP
dpc-5933	71	14	a	a	DET
dpc-5933	71	15	decrease	decrease	NOUN
dpc-5933	71	16	of	of	ADP
dpc-5933	71	17	at	at	ADV
dpc-5933	71	18	least	least	ADV
dpc-5933	71	19	two	two	NUM
dpc-5933	71	20	points	point	NOUN
dpc-5933	71	21	,	,	PUNCT
dpc-5933	71	22	from	from	ADP
dpc-5933	71	23	baseline	baseline	NOUN
dpc-5933	71	24	in	in	ADP
dpc-5933	71	25	skin	skin	NOUN
dpc-5933	71	26	pain	pain	NOUN
dpc-5933	71	27	assessed	assess	VERB
dpc-5933	71	28	on	on	ADP
dpc-5933	71	29	a	a	DET
dpc-5933	71	30	continuous	continuous	ADJ
dpc-5933	71	31	nrs	nrs	NOUN
dpc-5933	71	32	,	,	PUNCT
dpc-5933	71	33	applicable	applicable	ADJ
dpc-5933	71	34	for	for	ADP
dpc-5933	71	35	those	those	PRON
dpc-5933	71	36	with	with	ADP
dpc-5933	71	37	a	a	DET
dpc-5933	71	38	baseline	baseline	ADJ
dpc-5933	71	39	nrs	nrs	NOUN
dpc-5933	71	40	of	of	ADP
dpc-5933	71	41	three	three	NUM
dpc-5933	71	42	or	or	CCONJ
dpc-5933	71	43	higher	high	ADJ
dpc-5933	71	44	[	[	X
dpc-5933	71	45	9	9	NUM
dpc-5933	71	46	]	]	PUNCT
dpc-5933	71	47	.	.	PUNCT
dpc-5933	72	1	the	the	DET
dpc-5933	72	2	duration	duration	NOUN
dpc-5933	72	3	of	of	ADP
dpc-5933	72	4	single	single	ADJ
dpc-5933	72	5	and	and	CCONJ
dpc-5933	72	6	multiple	multiple	ADJ
dpc-5933	72	7	systemic	systemic	ADJ
dpc-5933	72	8	antibiotic	antibiotic	ADJ
dpc-5933	72	9	medications	medication	NOUN
dpc-5933	72	10	was	be	AUX
dpc-5933	72	11	quantified	quantify	VERB
dpc-5933	72	12	from	from	ADP
dpc-5933	72	13	the	the	DET
dpc-5933	72	14	start	start	NOUN
dpc-5933	72	15	to	to	ADP
dpc-5933	72	16	the	the	DET
dpc-5933	72	17	end	end	NOUN
dpc-5933	72	18	of	of	ADP
dpc-5933	72	19	the	the	DET
dpc-5933	72	20	study	study	NOUN
dpc-5933	72	21	,	,	PUNCT
dpc-5933	72	22	measured	measure	VERB
dpc-5933	72	23	in	in	ADP
dpc-5933	72	24	week	week	NOUN
dpc-5933	72	25	(	(	PUNCT
dpc-5933	72	26	s	s	NOUN
dpc-5933	72	27	)	)	PUNCT
dpc-5933	72	28	.	.	PUNCT
dpc-5933	73	1	all	all	DET
dpc-5933	73	2	patients	patient	NOUN
dpc-5933	73	3	were	be	AUX
dpc-5933	73	4	asked	ask	VERB
dpc-5933	73	5	to	to	PART
dpc-5933	73	6	report	report	VERB
dpc-5933	73	7	any	any	DET
dpc-5933	73	8	adverse	adverse	ADJ
dpc-5933	73	9	event	event	NOUN
dpc-5933	73	10	during	during	ADP
dpc-5933	73	11	secukinumab	secukinumab	NOUN
dpc-5933	73	12	treatment	treatment	NOUN
dpc-5933	73	13	.	.	PUNCT
dpc-5933	74	1	ethics	ethic	NOUN
dpc-5933	74	2	this	this	DET
dpc-5933	74	3	study	study	NOUN
dpc-5933	74	4	was	be	AUX
dpc-5933	74	5	approved	approve	VERB
dpc-5933	74	6	by	by	ADP
dpc-5933	74	7	the	the	DET
dpc-5933	74	8	institutional	institutional	ADJ
dpc-5933	74	9	review	review	PROPN
dpc-5933	74	10	board	board	NOUN
dpc-5933	74	11	of	of	ADP
dpc-5933	74	12	yonsei	yonsei	PROPN
dpc-5933	74	13	university	university	PROPN
dpc-5933	74	14	hospital	hospital	NOUN
dpc-5933	74	15	(	(	PUNCT
dpc-5933	74	16	irb	irb	VERB
dpc-5933	74	17	no	no	NOUN
dpc-5933	74	18	.	.	NOUN
dpc-5933	75	1	4	4	NUM
dpc-5933	75	2	-	-	SYM
dpc-5933	75	3	2023	2023	NUM
dpc-5933	75	4	-	-	NUM
dpc-5933	75	5	0201	0201	NUM
dpc-5933	75	6	)	)	PUNCT
dpc-5933	75	7	.	.	PUNCT
dpc-5933	76	1	all	all	DET
dpc-5933	76	2	patients	patient	NOUN
dpc-5933	76	3	provided	provide	VERB
dpc-5933	76	4	written	write	VERB
dpc-5933	76	5	informed	inform	VERB
dpc-5933	76	6	consent	consent	NOUN
dpc-5933	76	7	before	before	ADP
dpc-5933	76	8	participation	participation	NOUN
dpc-5933	76	9	,	,	PUNCT
dpc-5933	76	10	in	in	ADP
dpc-5933	76	11	accordance	accordance	NOUN
dpc-5933	76	12	with	with	ADP
dpc-5933	76	13	the	the	DET
dpc-5933	76	14	declaration	declaration	NOUN
dpc-5933	76	15	of	of	ADP
dpc-5933	76	16	helsinki	helsinki	PROPN
dpc-5933	76	17	.	.	PUNCT
dpc-5933	77	1	statistical	statistical	ADJ
dpc-5933	77	2	analysis	analysis	NOUN
dpc-5933	77	3	means	mean	NOUN
dpc-5933	77	4	and	and	CCONJ
dpc-5933	77	5	standard	standard	ADJ
dpc-5933	77	6	deviation	deviation	NOUN
dpc-5933	77	7	(	(	PUNCT
dpc-5933	77	8	sd	sd	NOUN
dpc-5933	77	9	)	)	PUNCT
dpc-5933	77	10	are	be	AUX
dpc-5933	77	11	used	use	VERB
dpc-5933	77	12	to	to	PART
dpc-5933	77	13	describe	describe	VERB
dpc-5933	77	14	continuous	continuous	ADJ
dpc-5933	77	15	variables	variable	NOUN
dpc-5933	77	16	.	.	PUNCT
dpc-5933	78	1	qualitative	qualitative	ADJ
dpc-5933	78	2	variables	variable	NOUN
dpc-5933	78	3	are	be	AUX
dpc-5933	78	4	displayed	display	VERB
dpc-5933	78	5	as	as	ADP
dpc-5933	78	6	a	a	DET
dpc-5933	78	7	frequency	frequency	NOUN
dpc-5933	78	8	distribution	distribution	NOUN
dpc-5933	78	9	.	.	PUNCT
dpc-5933	79	1	comparisons	comparison	NOUN
dpc-5933	79	2	between	between	ADP
dpc-5933	79	3	continuous	continuous	ADJ
dpc-5933	79	4	variables	variable	NOUN
dpc-5933	79	5	were	be	AUX
dpc-5933	79	6	conducted	conduct	VERB
dpc-5933	79	7	by	by	ADP
dpc-5933	79	8	an	an	DET
dpc-5933	79	9	independent	independent	ADJ
dpc-5933	79	10	student	student	NOUN
dpc-5933	79	11	t	t	PROPN
dpc-5933	79	12	-	-	PUNCT
dpc-5933	79	13	test	test	NOUN
dpc-5933	79	14	or	or	CCONJ
dpc-5933	79	15	mann	mann	PROPN
dpc-5933	79	16	-	-	PUNCT
dpc-5933	79	17	whitney	whitney	PROPN
dpc-5933	79	18	test	test	NOUN
dpc-5933	79	19	based	base	VERB
dpc-5933	79	20	on	on	ADP
dpc-5933	79	21	normality	normality	NOUN
dpc-5933	79	22	results	result	NOUN
dpc-5933	79	23	via	via	ADP
dpc-5933	79	24	the	the	DET
dpc-5933	79	25	shapiro	shapiro	PROPN
dpc-5933	79	26	-	-	PUNCT
dpc-5933	79	27	wilk	wilk	NOUN
dpc-5933	79	28	test	test	NOUN
dpc-5933	79	29	.	.	PUNCT
dpc-5933	80	1	for	for	ADP
dpc-5933	80	2	nominal	nominal	ADJ
dpc-5933	80	3	variables	variable	NOUN
dpc-5933	80	4	,	,	PUNCT
dpc-5933	80	5	the	the	DET
dpc-5933	80	6	χ2	χ2	PROPN
dpc-5933	80	7	test	test	NOUN
dpc-5933	80	8	or	or	CCONJ
dpc-5933	80	9	fisher	fisher	PROPN
dpc-5933	80	10	’s	’s	PART
dpc-5933	80	11	exact	exact	ADJ
dpc-5933	80	12	test	test	NOUN
dpc-5933	80	13	was	be	AUX
dpc-5933	80	14	utilized	utilize	VERB
dpc-5933	80	15	for	for	ADP
dpc-5933	80	16	comparison	comparison	NOUN
dpc-5933	80	17	,	,	PUNCT
dpc-5933	80	18	as	as	ADP
dpc-5933	80	19	appropriate	appropriate	ADJ
dpc-5933	80	20	,	,	PUNCT
dpc-5933	80	21	and	and	CCONJ
dpc-5933	80	22	the	the	DET
dpc-5933	80	23	relative	relative	ADJ
dpc-5933	80	24	risk	risk	NOUN
dpc-5933	80	25	(	(	PUNCT
dpc-5933	80	26	rr	rr	NOUN
dpc-5933	80	27	)	)	PUNCT
dpc-5933	80	28	was	be	AUX
dpc-5933	80	29	calculated	calculate	VERB
dpc-5933	80	30	with	with	ADP
dpc-5933	80	31	a	a	DET
dpc-5933	80	32	95	95	NUM
dpc-5933	80	33	%	%	NOUN
dpc-5933	80	34	confidence	confidence	NOUN
dpc-5933	80	35	interval	interval	NOUN
dpc-5933	80	36	(	(	PUNCT
dpc-5933	80	37	ci	ci	NOUN
dpc-5933	80	38	)	)	PUNCT
dpc-5933	80	39	.	.	PUNCT
dpc-5933	81	1	logistic	logistic	ADJ
dpc-5933	81	2	regression	regression	NOUN
dpc-5933	81	3	analysis	analysis	NOUN
dpc-5933	81	4	was	be	AUX
dpc-5933	81	5	conducted	conduct	VERB
dpc-5933	81	6	to	to	PART
dpc-5933	81	7	assess	assess	VERB
dpc-5933	81	8	any	any	DET
dpc-5933	81	9	correlation	correlation	NOUN
dpc-5933	81	10	between	between	ADP
dpc-5933	81	11	nominal	nominal	ADJ
dpc-5933	81	12	endpoints	endpoint	NOUN
dpc-5933	81	13	(	(	PUNCT
dpc-5933	81	14	hiscr	hiscr	X
dpc-5933	81	15	,	,	PUNCT
dpc-5933	81	16	ihs4	ihs4	PROPN
dpc-5933	81	17	-	-	PUNCT
dpc-5933	81	18	55	55	NUM
dpc-5933	81	19	,	,	PUNCT
dpc-5933	81	20	nrs30	nrs30	PROPN
dpc-5933	81	21	)	)	PUNCT
dpc-5933	81	22	and	and	CCONJ
dpc-5933	81	23	patients	patient	NOUN
dpc-5933	81	24	’	'	PUNCT
dpc-5933	81	25	demographic	demographic	ADJ
dpc-5933	81	26	characteristics	characteristic	NOUN
dpc-5933	81	27	.	.	PUNCT
dpc-5933	82	1	simple	simple	ADJ
dpc-5933	82	2	linear	linear	ADJ
dpc-5933	82	3	regression	regression	NOUN
dpc-5933	82	4	was	be	AUX
dpc-5933	82	5	used	use	VERB
dpc-5933	82	6	to	to	PART
dpc-5933	82	7	test	test	VERB
dpc-5933	82	8	possible	possible	ADJ
dpc-5933	82	9	related	related	ADJ
dpc-5933	82	10	factors	factor	NOUN
dpc-5933	82	11	for	for	ADP
dpc-5933	82	12	the	the	DET
dpc-5933	82	13	quantitative	quantitative	ADJ
dpc-5933	82	14	endpoint	endpoint	NOUN
dpc-5933	82	15	(	(	PUNCT
dpc-5933	82	16	mean	mean	VERB
dpc-5933	82	17	change	change	NOUN
dpc-5933	82	18	in	in	ADP
dpc-5933	82	19	an	an	DET
dpc-5933	82	20	count	count	NOUN
dpc-5933	82	21	from	from	ADP
dpc-5933	82	22	baseline	baseline	NOUN
dpc-5933	82	23	)	)	PUNCT
dpc-5933	82	24	.	.	PUNCT
dpc-5933	83	1	statistical	statistical	ADJ
dpc-5933	83	2	significance	significance	NOUN
dpc-5933	83	3	was	be	AUX
dpc-5933	83	4	set	set	VERB
dpc-5933	83	5	at	at	ADP
dpc-5933	83	6	p<0.05	p<0.05	NOUN
dpc-5933	83	7	.	.	PUNCT
dpc-5933	84	1	statistical	statistical	ADJ
dpc-5933	84	2	analyses	analysis	NOUN
dpc-5933	84	3	were	be	AUX
dpc-5933	84	4	performed	perform	VERB
dpc-5933	84	5	using	use	VERB
dpc-5933	84	6	the	the	DET
dpc-5933	84	7	r	r	NOUN
dpc-5933	84	8	software	software	NOUN
dpc-5933	84	9	(	(	PUNCT
dpc-5933	84	10	version	version	NOUN
dpc-5933	84	11	4.3.1	4.3.1	NUM
dpc-5933	84	12	)	)	PUNCT
dpc-5933	84	13	.	.	PUNCT
dpc-5933	85	1	the	the	DET
dpc-5933	85	2	graphing	graphing	NOUN
dpc-5933	85	3	of	of	ADP
dpc-5933	85	4	results	result	NOUN
dpc-5933	85	5	was	be	AUX
dpc-5933	85	6	done	do	VERB
dpc-5933	85	7	via	via	ADP
dpc-5933	85	8	the	the	DET
dpc-5933	85	9	graphpad	graphpad	NOUN
dpc-5933	85	10	prism	prism	NOUN
dpc-5933	85	11	software	software	NOUN
dpc-5933	85	12	(	(	PUNCT
dpc-5933	85	13	version	version	NOUN
dpc-5933	85	14	10.2.2	10.2.2	NOUN
dpc-5933	85	15	)	)	PUNCT
dpc-5933	85	16	.	.	PUNCT
dpc-5933	86	1	results	result	VERB
dpc-5933	86	2	ten	ten	NUM
dpc-5933	86	3	patients	patient	NOUN
dpc-5933	86	4	with	with	ADP
dpc-5933	86	5	moderate	moderate	ADJ
dpc-5933	86	6	-	-	PUNCT
dpc-5933	86	7	to	to	ADP
dpc-5933	86	8	-	-	PUNCT
dpc-5933	86	9	severe	severe	ADJ
dpc-5933	86	10	hs	hs	PROPN
dpc-5933	86	11	were	be	AUX
dpc-5933	86	12	enrolled	enrol	VERB
dpc-5933	86	13	and	and	CCONJ
dpc-5933	86	14	monitored	monitor	VERB
dpc-5933	86	15	over	over	ADP
dpc-5933	86	16	48	48	NUM
dpc-5933	86	17	weeks	week	NOUN
dpc-5933	86	18	.	.	PUNCT
dpc-5933	87	1	baseline	baseline	VERB
dpc-5933	87	2	demographic	demographic	ADJ
dpc-5933	87	3	and	and	CCONJ
dpc-5933	87	4	clinical	clinical	ADJ
dpc-5933	87	5	characteristics	characteristic	NOUN
dpc-5933	87	6	are	be	AUX
dpc-5933	87	7	summarized	summarize	VERB
dpc-5933	87	8	in	in	ADP
dpc-5933	87	9	table	table	NOUN
dpc-5933	87	10	1	1	NUM
dpc-5933	87	11	,	,	PUNCT
dpc-5933	87	12	while	while	SCONJ
dpc-5933	87	13	baseline	baseline	ADJ
dpc-5933	87	14	features	feature	NOUN
dpc-5933	87	15	categorized	categorize	VERB
dpc-5933	87	16	by	by	ADP
dpc-5933	87	17	hurley	hurley	NOUN
dpc-5933	87	18	stage	stage	NOUN
dpc-5933	87	19	,	,	PUNCT
dpc-5933	87	20	treatment	treatment	NOUN
dpc-5933	87	21	delay	delay	NOUN
dpc-5933	87	22	,	,	PUNCT
dpc-5933	87	23	and	and	CCONJ
dpc-5933	87	24	prior	prior	ADJ
dpc-5933	87	25	biologics	biologic	NOUN
dpc-5933	87	26	use	use	NOUN
dpc-5933	87	27	are	be	AUX
dpc-5933	87	28	presented	present	VERB
dpc-5933	87	29	in	in	ADP
dpc-5933	87	30	table	table	NOUN
dpc-5933	87	31	2	2	NUM
dpc-5933	87	32	.	.	PUNCT
dpc-5933	88	1	notably	notably	ADV
dpc-5933	88	2	,	,	PUNCT
dpc-5933	88	3	70	70	NUM
dpc-5933	88	4	%	%	NOUN
dpc-5933	88	5	of	of	ADP
dpc-5933	88	6	patients	patient	NOUN
dpc-5933	88	7	(	(	PUNCT
dpc-5933	88	8	n=7	n=7	PROPN
dpc-5933	88	9	)	)	PUNCT
dpc-5933	88	10	were	be	AUX
dpc-5933	88	11	classified	classify	VERB
dpc-5933	88	12	as	as	ADP
dpc-5933	88	13	hurley	hurley	PROPN
dpc-5933	88	14	stage	stage	PROPN
dpc-5933	88	15	ii	ii	PROPN
dpc-5933	88	16	,	,	PUNCT
dpc-5933	88	17	while	while	SCONJ
dpc-5933	88	18	the	the	DET
dpc-5933	88	19	remaining	remain	VERB
dpc-5933	88	20	30	30	NUM
dpc-5933	88	21	%	%	NOUN
dpc-5933	88	22	(	(	PUNCT
dpc-5933	88	23	n=3	n=3	NOUN
dpc-5933	88	24	)	)	PUNCT
dpc-5933	88	25	were	be	AUX
dpc-5933	88	26	hurley	hurley	PROPN
dpc-5933	88	27	stage	stage	PROPN
dpc-5933	88	28	iii	iii	PROPN
dpc-5933	88	29	.	.	PUNCT
dpc-5933	89	1	all	all	DET
dpc-5933	89	2	patients	patient	NOUN
dpc-5933	89	3	had	have	VERB
dpc-5933	89	4	prior	prior	ADJ
dpc-5933	89	5	treatments	treatment	NOUN
dpc-5933	89	6	with	with	ADP
dpc-5933	89	7	antibiotics	antibiotic	NOUN
dpc-5933	89	8	and	and	CCONJ
dpc-5933	89	9	ta	ta	X
dpc-5933	89	10	ili	ili	PROPN
dpc-5933	89	11	,	,	PUNCT
dpc-5933	89	12	and	and	CCONJ
dpc-5933	89	13	40	40	NUM
dpc-5933	89	14	%	%	NOUN
dpc-5933	89	15	(	(	PUNCT
dpc-5933	89	16	n=4	n=4	NOUN
dpc-5933	89	17	)	)	PUNCT
dpc-5933	89	18	had	have	AUX
dpc-5933	89	19	previously	previously	ADV
dpc-5933	89	20	received	receive	VERB
dpc-5933	89	21	an	an	DET
dpc-5933	89	22	anti	anti	ADJ
dpc-5933	89	23	-	-	ADJ
dpc-5933	89	24	tnf	tnf	ADJ
dpc-5933	89	25	-	-	PUNCT
dpc-5933	89	26	α	α	PROPN
dpc-5933	89	27	biologic	biologic	NOUN
dpc-5933	89	28	agent	agent	NOUN
dpc-5933	89	29	,	,	PUNCT
dpc-5933	89	30	specifically	specifically	ADV
dpc-5933	89	31	adalimumab	adalimumab	NOUN
dpc-5933	89	32	.	.	PUNCT
dpc-5933	90	1	patients	patient	NOUN
dpc-5933	90	2	with	with	ADP
dpc-5933	90	3	hurley	hurley	PROPN
dpc-5933	90	4	stage	stage	PROPN
dpc-5933	90	5	ii	ii	PROPN
dpc-5933	90	6	or	or	CCONJ
dpc-5933	90	7	no	no	DET
dpc-5933	90	8	4	4	NUM
dpc-5933	90	9	original	original	ADJ
dpc-5933	90	10	article	article	NOUN
dpc-5933	90	11	|	|	ADV
dpc-5933	90	12	dermatol	dermatol	ADJ
dpc-5933	90	13	pract	pract	NOUN
dpc-5933	90	14	concept	concept	NOUN
dpc-5933	90	15	.	.	PUNCT
dpc-5933	91	1	2025;15(4):5933	2025;15(4):5933	NUM
dpc-5933	91	2	t	t	PROPN
dpc-5933	91	3	ab	ab	PROPN
dpc-5933	91	4	le	le	PROPN
dpc-5933	91	5	1	1	NUM
dpc-5933	91	6	.	.	PUNCT
dpc-5933	92	1	b	b	X
dpc-5933	92	2	as	as	ADP
dpc-5933	92	3	el	el	PROPN
dpc-5933	92	4	in	in	ADP
dpc-5933	92	5	e	e	PROPN
dpc-5933	92	6	c	c	NOUN
dpc-5933	92	7	ha	ha	INTJ
dpc-5933	92	8	ra	ra	INTJ
dpc-5933	92	9	ct	ct	INTJ
dpc-5933	92	10	er	er	INTJ
dpc-5933	92	11	is	be	AUX
dpc-5933	92	12	ti	ti	X
dpc-5933	92	13	cs	cs	ADJ
dpc-5933	92	14	o	o	NOUN
dpc-5933	92	15	f	f	NOUN
dpc-5933	92	16	pa	pa	PROPN
dpc-5933	92	17	ti	ti	PROPN
dpc-5933	92	18	en	en	X
dpc-5933	92	19	ts	ts	X
dpc-5933	92	20	.	.	PUNCT
dpc-5933	93	1	pa	pa	PROPN
dpc-5933	93	2	ti	ti	PROPN
dpc-5933	93	3	en	en	PROPN
dpc-5933	93	4	t	t	PROPN
dpc-5933	93	5	nu	nu	AUX
dpc-5933	93	6	m	m	AUX
dpc-5933	93	7	be	be	VERB
dpc-5933	93	8	r	r	NOUN
dpc-5933	93	9	se	se	X
dpc-5933	93	10	x	x	PROPN
dpc-5933	93	11	a	a	DET
dpc-5933	93	12	ge	ge	PROPN
dpc-5933	93	13	a	a	DET
dpc-5933	93	14	ge	ge	PROPN
dpc-5933	93	15	a	a	DET
dpc-5933	93	16	t	t	NOUN
dpc-5933	93	17	on	on	ADP
dpc-5933	94	1	se	se	PROPN
dpc-5933	94	2	t	t	PROPN
dpc-5933	94	3	se	se	PROPN
dpc-5933	94	4	cu	cu	PROPN
dpc-5933	94	5	ki	ki	PROPN
dpc-5933	94	6	nu	nu	PROPN
dpc-5933	94	7	m	m	VERB
dpc-5933	94	8	ab	ab	PROPN
dpc-5933	94	9	tr	tr	PROPN
dpc-5933	94	10	ea	ea	X
dpc-5933	94	11	tm	tm	PROPN
dpc-5933	94	12	en	en	PROPN
dpc-5933	94	13	t	t	PROPN
dpc-5933	94	14	de	de	PROPN
dpc-5933	94	15	la	la	PROPN
dpc-5933	94	16	y	y	PROPN
dpc-5933	95	1	fa	fa	INTJ
dpc-5933	95	2	m	m	VERB
dpc-5933	95	3	ily	ily	ADV
dpc-5933	95	4	hi	hi	INTJ
dpc-5933	95	5	st	st	PROPN
dpc-5933	95	6	or	or	CCONJ
dpc-5933	95	7	y	y	PROPN
dpc-5933	95	8	b	b	PROPN
dpc-5933	95	9	od	od	INTJ
dpc-5933	95	10	y	y	PROPN
dpc-5933	95	11	m	m	ADV
dpc-5933	95	12	as	as	ADP
dpc-5933	95	13	s	s	PRON
dpc-5933	95	14	in	in	ADP
dpc-5933	95	15	de	de	X
dpc-5933	95	16	x	x	X
dpc-5933	95	17	(	(	PUNCT
dpc-5933	95	18	k	k	X
dpc-5933	95	19	g/	g/	NOUN
dpc-5933	95	20	m	m	VERB
dpc-5933	95	21	2	2	NUM
dpc-5933	95	22	)	)	PUNCT
dpc-5933	95	23	sm	sm	INTJ
dpc-5933	95	24	ok	ok	INTJ
dpc-5933	95	25	in	in	ADP
dpc-5933	95	26	g	g	PROPN
dpc-5933	95	27	ha	ha	INTJ
dpc-5933	95	28	bi	bi	PROPN
dpc-5933	96	1	t	t	PROPN
dpc-5933	96	2	c	c	PROPN
dpc-5933	96	3	om	om	PROPN
dpc-5933	96	4	or	or	CCONJ
dpc-5933	96	5	bi	bi	NOUN
dpc-5933	96	6	di	di	NOUN
dpc-5933	96	7	ti	ti	PROPN
dpc-5933	96	8	es	es	VERB
dpc-5933	96	9	pr	pr	X
dpc-5933	96	10	io	io	NOUN
dpc-5933	96	11	r	r	NOUN
dpc-5933	96	12	tr	tr	NOUN
dpc-5933	96	13	ea	ea	X
dpc-5933	96	14	tm	tm	PROPN
dpc-5933	96	15	en	en	PROPN
dpc-5933	96	16	t	t	PROPN
dpc-5933	96	17	b	b	PROPN
dpc-5933	96	18	as	as	ADP
dpc-5933	96	19	el	el	PROPN
dpc-5933	96	20	in	in	ADP
dpc-5933	96	21	e	e	PROPN
dpc-5933	96	22	h	h	NOUN
dpc-5933	96	23	ur	ur	INTJ
dpc-5933	96	24	le	le	PROPN
dpc-5933	96	25	y	y	PROPN
dpc-5933	96	26	st	st	PROPN
dpc-5933	96	27	ag	ag	PROPN
dpc-5933	96	28	e	e	PROPN
dpc-5933	96	29	b	b	PROPN
dpc-5933	96	30	as	as	ADP
dpc-5933	96	31	el	el	PROPN
dpc-5933	96	32	in	in	ADP
dpc-5933	96	33	e	e	PROPN
dpc-5933	96	34	ih	ih	PROPN
dpc-5933	96	35	s4	s4	PROPN
dpc-5933	96	36	b	b	PROPN
dpc-5933	96	37	as	as	ADP
dpc-5933	96	38	el	el	PROPN
dpc-5933	96	39	in	in	ADP
dpc-5933	96	40	e	e	PROPN
dpc-5933	96	41	n	n	ADP
dpc-5933	96	42	r	r	NOUN
dpc-5933	96	43	s	s	PROPN
dpc-5933	96	44	1	1	NUM
dpc-5933	96	45	m	m	NOUN
dpc-5933	96	46	20	20	NUM
dpc-5933	96	47	15	15	NUM
dpc-5933	97	1	5	5	NUM
dpc-5933	97	2	y	y	NOUN
dpc-5933	97	3	es	es	ADP
dpc-5933	97	4	24	24	NUM
dpc-5933	97	5	.9	.9	NUM
dpc-5933	97	6	7	7	NUM
dpc-5933	97	7	y	y	PROPN
dpc-5933	97	8	es	es	ADP
dpc-5933	97	9	a	a	DET
dpc-5933	97	10	cn	cn	PROPN
dpc-5933	97	11	e	e	X
dpc-5933	97	12	co	co	NOUN
dpc-5933	97	13	ng	ng	PROPN
dpc-5933	97	14	lo	lo	PROPN
dpc-5933	97	15	ba	ba	PROPN
dpc-5933	98	1	ta	ta	PROPN
dpc-5933	98	2	a	a	DET
dpc-5933	98	3	nt	not	PART
dpc-5933	98	4	ib	ib	X
dpc-5933	98	5	io	io	X
dpc-5933	98	6	ti	ti	PROPN
dpc-5933	98	7	cs	cs	PROPN
dpc-5933	98	8	t	t	PROPN
dpc-5933	98	9	a	a	PRON
dpc-5933	99	1	i	i	NOUN
dpc-5933	99	2	l	l	NOUN
dpc-5933	100	1	i	i	PRON
dpc-5933	100	2	i	i	PRON
dpc-5933	100	3	&	&	CCONJ
dpc-5933	100	4	d	d	PROPN
dpc-5933	100	5	3	3	NUM
dpc-5933	100	6	46	46	NUM
dpc-5933	100	7	5	5	NUM
dpc-5933	100	8	2	2	NUM
dpc-5933	100	9	f	f	NOUN
dpc-5933	100	10	23	23	NUM
dpc-5933	100	11	17	17	NUM
dpc-5933	100	12	7	7	NUM
dpc-5933	100	13	n	n	NUM
dpc-5933	100	14	o	o	NOUN
dpc-5933	100	15	20	20	NUM
dpc-5933	100	16	.3	.3	NUM
dpc-5933	100	17	7	7	NUM
dpc-5933	100	18	n	n	NUM
dpc-5933	100	19	o	o	NOUN
dpc-5933	100	20	a	a	DET
dpc-5933	100	21	cn	cn	X
dpc-5933	100	22	e	e	X
dpc-5933	100	23	co	co	NOUN
dpc-5933	100	24	ng	ng	PROPN
dpc-5933	101	1	lo	lo	PROPN
dpc-5933	101	2	ba	ba	PROPN
dpc-5933	102	1	ta	ta	ADP
dpc-5933	102	2	a	a	DET
dpc-5933	102	3	da	da	PROPN
dpc-5933	102	4	lim	lim	PROPN
dpc-5933	103	1	um	um	INTJ
dpc-5933	103	2	ab	ab	PROPN
dpc-5933	103	3	a	a	PRON
dpc-5933	103	4	nt	not	PART
dpc-5933	103	5	ib	ib	X
dpc-5933	103	6	io	io	X
dpc-5933	103	7	ti	ti	PROPN
dpc-5933	103	8	cs	cs	PROPN
dpc-5933	103	9	t	t	PROPN
dpc-5933	103	10	a	a	PRON
dpc-5933	104	1	i	i	NOUN
dpc-5933	104	2	l	l	NOUN
dpc-5933	104	3	i	i	NOUN
dpc-5933	104	4	3	3	NUM
dpc-5933	104	5	31	31	NUM
dpc-5933	104	6	3	3	NUM
dpc-5933	104	7	3	3	NUM
dpc-5933	104	8	m	m	PROPN
dpc-5933	104	9	19	19	NUM
dpc-5933	104	10	17	17	NUM
dpc-5933	104	11	2	2	NUM
dpc-5933	104	12	n	n	NUM
dpc-5933	104	13	o	o	NOUN
dpc-5933	104	14	23	23	NUM
dpc-5933	104	15	.8	.8	NUM
dpc-5933	104	16	9	9	NUM
dpc-5933	104	17	n	n	NOUN
dpc-5933	104	18	o	o	NOUN
dpc-5933	104	19	a	a	DET
dpc-5933	104	20	cn	cn	X
dpc-5933	104	21	e	e	X
dpc-5933	104	22	co	co	NOUN
dpc-5933	104	23	ng	ng	PROPN
dpc-5933	105	1	lo	lo	PROPN
dpc-5933	105	2	ba	ba	PROPN
dpc-5933	106	1	ta	ta	PROPN
dpc-5933	106	2	a	a	DET
dpc-5933	106	3	nt	not	PART
dpc-5933	106	4	ib	ib	X
dpc-5933	106	5	io	io	X
dpc-5933	106	6	ti	ti	PROPN
dpc-5933	106	7	cs	cs	PROPN
dpc-5933	106	8	t	t	PROPN
dpc-5933	107	1	a	a	PRON
dpc-5933	108	1	i	i	NOUN
dpc-5933	109	1	l	l	NOUN
dpc-5933	110	1	i	i	PRON
dpc-5933	111	1	i	i	PRON
dpc-5933	111	2	&	&	CCONJ
dpc-5933	111	3	d	d	PROPN
dpc-5933	111	4	3	3	NUM
dpc-5933	111	5	31	31	NUM
dpc-5933	111	6	4	4	NUM
dpc-5933	111	7	4	4	NUM
dpc-5933	111	8	m	m	NUM
dpc-5933	111	9	31	31	NUM
dpc-5933	111	10	18	18	NUM
dpc-5933	111	11	13	13	NUM
dpc-5933	111	12	n	n	NUM
dpc-5933	111	13	o	o	NOUN
dpc-5933	111	14	25	25	NUM
dpc-5933	111	15	.5	.5	NUM
dpc-5933	111	16	1	1	NUM
dpc-5933	111	17	y	y	PROPN
dpc-5933	111	18	es	es	ADP
dpc-5933	111	19	a	a	DET
dpc-5933	111	20	ge	ge	PROPN
dpc-5933	112	1	nt	not	PART
dpc-5933	112	2	r	r	NOUN
dpc-5933	112	3	es	es	NOUN
dpc-5933	112	4	is	be	AUX
dpc-5933	112	5	ta	ta	ADP
dpc-5933	112	6	nt	not	PART
dpc-5933	112	7	t	t	PROPN
dpc-5933	113	1	o	o	NOUN
dpc-5933	113	2	m	m	VERB
dpc-5933	113	3	ul	ul	INTJ
dpc-5933	113	4	ti	ti	X
dpc-5933	113	5	pl	pl	X
dpc-5933	113	6	e	e	NOUN
dpc-5933	113	7	an	an	DET
dpc-5933	113	8	ti	ti	NOUN
dpc-5933	113	9	bi	bi	NOUN
dpc-5933	113	10	ot	ot	INTJ
dpc-5933	113	11	ic	ic	PROPN
dpc-5933	113	12	s	s	PROPN
dpc-5933	113	13	a	a	DET
dpc-5933	113	14	da	da	X
dpc-5933	113	15	lim	lim	PROPN
dpc-5933	114	1	um	um	INTJ
dpc-5933	114	2	ab	ab	PROPN
dpc-5933	114	3	a	a	PRON
dpc-5933	114	4	nt	not	PART
dpc-5933	114	5	ib	ib	X
dpc-5933	114	6	io	io	X
dpc-5933	114	7	ti	ti	PROPN
dpc-5933	114	8	cs	cs	PROPN
dpc-5933	114	9	i	i	PROPN
dpc-5933	114	10	&	&	CCONJ
dpc-5933	114	11	d	d	PROPN
dpc-5933	114	12	t	t	PROPN
dpc-5933	114	13	a	a	PRON
dpc-5933	115	1	i	i	NOUN
dpc-5933	115	2	l	l	NOUN
dpc-5933	116	1	i	i	NOUN
dpc-5933	116	2	2	2	NUM
dpc-5933	116	3	13	13	NUM
dpc-5933	116	4	5	5	NUM
dpc-5933	116	5	5	5	NUM
dpc-5933	116	6	f	f	NOUN
dpc-5933	116	7	28	28	NUM
dpc-5933	116	8	18	18	NUM
dpc-5933	116	9	10	10	NUM
dpc-5933	116	10	n	n	NUM
dpc-5933	116	11	o	o	NOUN
dpc-5933	116	12	22	22	NUM
dpc-5933	116	13	.3	.3	NUM
dpc-5933	116	14	1	1	NUM
dpc-5933	116	15	n	n	NUM
dpc-5933	116	16	o	o	NOUN
dpc-5933	116	17	a	a	DET
dpc-5933	116	18	cn	cn	X
dpc-5933	116	19	e	e	PROPN
dpc-5933	116	20	vu	vu	PROPN
dpc-5933	116	21	lg	lg	PROPN
dpc-5933	116	22	ar	ar	PROPN
dpc-5933	116	23	is	be	AUX
dpc-5933	116	24	a	a	DET
dpc-5933	116	25	da	da	PROPN
dpc-5933	116	26	lim	lim	PROPN
dpc-5933	116	27	um	um	INTJ
dpc-5933	116	28	ab	ab	PROPN
dpc-5933	116	29	a	a	PRON
dpc-5933	116	30	nt	not	PART
dpc-5933	116	31	ib	ib	X
dpc-5933	116	32	io	io	X
dpc-5933	116	33	ti	ti	PROPN
dpc-5933	116	34	cs	cs	PROPN
dpc-5933	116	35	t	t	PROPN
dpc-5933	116	36	a	a	PRON
dpc-5933	117	1	i	i	NOUN
dpc-5933	117	2	l	l	NOUN
dpc-5933	118	1	i	i	PRON
dpc-5933	118	2	i	i	PRON
dpc-5933	118	3	&	&	CCONJ
dpc-5933	118	4	d	d	PROPN
dpc-5933	118	5	2	2	NUM
dpc-5933	118	6	20	20	NUM
dpc-5933	118	7	6	6	NUM
dpc-5933	118	8	.	.	NOUN
dpc-5933	119	1	5	5	NUM
dpc-5933	119	2	6	6	NUM
dpc-5933	119	3	f	f	NOUN
dpc-5933	119	4	22	22	NUM
dpc-5933	119	5	6	6	NUM
dpc-5933	119	6	17	17	NUM
dpc-5933	119	7	y	y	PROPN
dpc-5933	119	8	es	es	ADP
dpc-5933	119	9	25	25	NUM
dpc-5933	119	10	.6	.6	NUM
dpc-5933	119	11	6	6	NUM
dpc-5933	119	12	n	n	NUM
dpc-5933	119	13	o	o	X
dpc-5933	119	14	fe	fe	X
dpc-5933	119	15	m	m	NOUN
dpc-5933	119	16	al	al	PROPN
dpc-5933	119	17	e	e	PROPN
dpc-5933	119	18	pa	pa	PROPN
dpc-5933	119	19	tt	tt	PROPN
dpc-5933	119	20	er	er	INTJ
dpc-5933	119	21	n	n	ADV
dpc-5933	119	22	al	al	PROPN
dpc-5933	119	23	op	op	PROPN
dpc-5933	119	24	ec	ec	PROPN
dpc-5933	119	25	ia	ia	PROPN
dpc-5933	119	26	a	a	PROPN
dpc-5933	119	27	da	da	PROPN
dpc-5933	119	28	lim	lim	PROPN
dpc-5933	119	29	um	um	INTJ
dpc-5933	119	30	ab	ab	PROPN
dpc-5933	119	31	a	a	PRON
dpc-5933	119	32	nt	not	PART
dpc-5933	119	33	ib	ib	X
dpc-5933	119	34	io	io	X
dpc-5933	119	35	ti	ti	PROPN
dpc-5933	119	36	cs	cs	PROPN
dpc-5933	119	37	i	i	PROPN
dpc-5933	119	38	&	&	CCONJ
dpc-5933	119	39	d	d	PROPN
dpc-5933	119	40	t	t	PROPN
dpc-5933	119	41	a	a	PRON
dpc-5933	120	1	i	i	NOUN
dpc-5933	120	2	l	l	NOUN
dpc-5933	121	1	i	i	NOUN
dpc-5933	121	2	2	2	NUM
dpc-5933	121	3	8	8	NUM
dpc-5933	121	4	8	8	NUM
dpc-5933	121	5	7	7	NUM
dpc-5933	121	6	m	m	NOUN
dpc-5933	121	7	22	22	NUM
dpc-5933	121	8	20	20	NUM
dpc-5933	121	9	2	2	NUM
dpc-5933	121	10	y	y	NOUN
dpc-5933	121	11	es	es	ADP
dpc-5933	121	12	25	25	NUM
dpc-5933	121	13	.0	.0	NUM
dpc-5933	121	14	8	8	NUM
dpc-5933	121	15	n	n	NUM
dpc-5933	121	16	o	o	NOUN
dpc-5933	121	17	a	a	DET
dpc-5933	121	18	cn	cn	X
dpc-5933	121	19	e	e	X
dpc-5933	121	20	co	co	NOUN
dpc-5933	121	21	ng	ng	PROPN
dpc-5933	122	1	lo	lo	PROPN
dpc-5933	122	2	ba	ba	PROPN
dpc-5933	123	1	ta	ta	PROPN
dpc-5933	123	2	a	a	DET
dpc-5933	123	3	nt	not	PART
dpc-5933	123	4	ib	ib	X
dpc-5933	123	5	io	io	X
dpc-5933	123	6	ti	ti	PROPN
dpc-5933	123	7	cs	cs	PROPN
dpc-5933	123	8	t	t	PROPN
dpc-5933	124	1	a	a	PRON
dpc-5933	125	1	i	i	NOUN
dpc-5933	126	1	l	l	NOUN
dpc-5933	127	1	i	i	NOUN
dpc-5933	128	1	2	2	NUM
dpc-5933	128	2	16	16	NUM
dpc-5933	128	3	1	1	NUM
dpc-5933	128	4	8	8	NUM
dpc-5933	128	5	m	m	NUM
dpc-5933	128	6	23	23	NUM
dpc-5933	128	7	9	9	NUM
dpc-5933	128	8	15	15	NUM
dpc-5933	128	9	n	n	NUM
dpc-5933	128	10	o	o	NOUN
dpc-5933	128	11	27	27	NUM
dpc-5933	128	12	.1	.1	NUM
dpc-5933	128	13	7	7	NUM
dpc-5933	128	14	y	y	NOUN
dpc-5933	128	15	es	es	ADP
dpc-5933	128	16	a	a	PRON
dpc-5933	128	17	nt	not	PART
dpc-5933	128	18	ib	ib	X
dpc-5933	128	19	io	io	X
dpc-5933	128	20	ti	ti	PROPN
dpc-5933	128	21	cs	cs	PROPN
dpc-5933	128	22	t	t	PROPN
dpc-5933	128	23	a	a	PRON
dpc-5933	129	1	i	i	NOUN
dpc-5933	129	2	l	l	NOUN
dpc-5933	130	1	i	i	NOUN
dpc-5933	130	2	2	2	NUM
dpc-5933	130	3	11	11	NUM
dpc-5933	130	4	3	3	NUM
dpc-5933	130	5	9	9	NUM
dpc-5933	130	6	f	f	SYM
dpc-5933	130	7	54	54	NUM
dpc-5933	131	1	52	52	NUM
dpc-5933	131	2	3	3	NUM
dpc-5933	131	3	y	y	NOUN
dpc-5933	131	4	es	es	ADP
dpc-5933	131	5	32	32	NUM
dpc-5933	131	6	.3	.3	NUM
dpc-5933	131	7	7	7	NUM
dpc-5933	131	8	n	n	NUM
dpc-5933	131	9	o	o	NOUN
dpc-5933	131	10	a	a	DET
dpc-5933	131	11	cn	cn	X
dpc-5933	131	12	e	e	X
dpc-5933	131	13	co	co	NOUN
dpc-5933	131	14	ng	ng	PROPN
dpc-5933	131	15	lo	lo	PROPN
dpc-5933	131	16	ba	ba	PROPN
dpc-5933	132	1	ta	ta	PROPN
dpc-5933	132	2	a	a	DET
dpc-5933	132	3	nt	not	PART
dpc-5933	132	4	ib	ib	X
dpc-5933	132	5	io	io	X
dpc-5933	132	6	ti	ti	PROPN
dpc-5933	132	7	cs	cs	PROPN
dpc-5933	132	8	t	t	PROPN
dpc-5933	132	9	a	a	PRON
dpc-5933	133	1	i	i	NOUN
dpc-5933	133	2	l	l	NOUN
dpc-5933	134	1	i	i	PRON
dpc-5933	134	2	i	i	PRON
dpc-5933	134	3	&	&	CCONJ
dpc-5933	134	4	d	d	PROPN
dpc-5933	134	5	2	2	NUM
dpc-5933	134	6	12	12	NUM
dpc-5933	134	7	3	3	NUM
dpc-5933	134	8	10	10	NUM
dpc-5933	134	9	m	m	NUM
dpc-5933	134	10	31	31	NUM
dpc-5933	134	11	17	17	NUM
dpc-5933	134	12	15	15	NUM
dpc-5933	134	13	y	y	NOUN
dpc-5933	134	14	es	es	ADP
dpc-5933	134	15	30	30	NUM
dpc-5933	134	16	.7	.7	NUM
dpc-5933	134	17	9	9	NUM
dpc-5933	134	18	y	y	NOUN
dpc-5933	134	19	es	es	ADP
dpc-5933	134	20	a	a	PRON
dpc-5933	134	21	nt	not	PART
dpc-5933	134	22	ib	ib	X
dpc-5933	134	23	io	io	X
dpc-5933	134	24	ti	ti	PROPN
dpc-5933	134	25	cs	cs	PROPN
dpc-5933	134	26	t	t	PROPN
dpc-5933	134	27	a	a	PRON
dpc-5933	135	1	i	i	NOUN
dpc-5933	135	2	l	l	NOUN
dpc-5933	136	1	i	i	PRON
dpc-5933	136	2	i	i	PRON
dpc-5933	136	3	&	&	CCONJ
dpc-5933	136	4	d	d	PROPN
dpc-5933	136	5	2	2	NUM
dpc-5933	136	6	9	9	NUM
dpc-5933	136	7	0	0	NUM
dpc-5933	136	8	a	a	DET
dpc-5933	136	9	bb	bb	INTJ
dpc-5933	136	10	re	re	X
dpc-5933	136	11	vi	vi	PROPN
dpc-5933	136	12	at	at	ADP
dpc-5933	136	13	io	io	X
dpc-5933	136	14	ns	ns	NUM
dpc-5933	136	15	:	:	PUNCT
dpc-5933	136	16	ih	ih	NOUN
dpc-5933	136	17	s4	s4	PROPN
dpc-5933	136	18	,	,	PUNCT
dpc-5933	136	19	in	in	ADP
dpc-5933	136	20	te	te	PROPN
dpc-5933	136	21	rn	rn	PROPN
dpc-5933	136	22	at	at	ADP
dpc-5933	136	23	io	io	PROPN
dpc-5933	136	24	na	na	PROPN
dpc-5933	136	25	l	l	NOUN
dpc-5933	136	26	h	h	NOUN
dpc-5933	137	1	i	i	PROPN
dpc-5933	137	2	d	d	PROPN
dpc-5933	137	3	ra	ra	PROPN
dpc-5933	137	4	de	de	PROPN
dpc-5933	137	5	ni	ni	PROPN
dpc-5933	137	6	ti	ti	PROPN
dpc-5933	137	7	s	s	PROPN
dpc-5933	137	8	su	su	NOUN
dpc-5933	138	1	pp	pp	ADV
dpc-5933	138	2	ur	ur	INTJ
dpc-5933	138	3	at	at	ADP
dpc-5933	138	4	iv	iv	NUM
dpc-5933	138	5	a	a	DET
dpc-5933	138	6	se	se	X
dpc-5933	138	7	ve	ve	VERB
dpc-5933	138	8	ri	ri	VERB
dpc-5933	139	1	ty	ty	INTJ
dpc-5933	139	2	s	s	VERB
dpc-5933	139	3	co	co	X
dpc-5933	139	4	re	re	ADP
dpc-5933	139	5	s	s	PROPN
dpc-5933	139	6	ys	ys	NOUN
dpc-5933	139	7	te	te	PROPN
dpc-5933	139	8	m	m	PRON
dpc-5933	139	9	;	;	PUNCT
dpc-5933	139	10	n	n	CCONJ
dpc-5933	139	11	r	r	NOUN
dpc-5933	139	12	s	s	PROPN
dpc-5933	139	13	,	,	PUNCT
dpc-5933	139	14	p	p	X
dpc-5933	139	15	at	at	ADP
dpc-5933	139	16	ie	ie	ADV
dpc-5933	139	17	nt	not	PART
dpc-5933	139	18	’s	’	VERB
dpc-5933	139	19	g	g	PROPN
dpc-5933	139	20	lo	lo	PROPN
dpc-5933	139	21	ba	ba	PROPN
dpc-5933	139	22	l	l	NOUN
dpc-5933	140	1	a	a	PRON
dpc-5933	140	2	ss	ss	NOUN
dpc-5933	140	3	es	es	X
dpc-5933	140	4	sm	sm	PROPN
dpc-5933	140	5	en	en	PROPN
dpc-5933	140	6	t	t	PROPN
dpc-5933	140	7	of	of	ADP
dpc-5933	140	8	s	s	PRON
dpc-5933	140	9	ki	ki	PROPN
dpc-5933	140	10	n	n	PROPN
dpc-5933	140	11	pa	pa	PROPN
dpc-5933	140	12	in	in	ADP
dpc-5933	140	13	o	o	PROPN
dpc-5933	140	14	n	n	PRON
dpc-5933	140	15	a	a	DET
dpc-5933	140	16	co	co	NOUN
dpc-5933	140	17	nt	not	PART
dpc-5933	140	18	in	in	ADP
dpc-5933	140	19	uo	uo	NOUN
dpc-5933	140	20	us	we	PRON
dpc-5933	141	1	n	n	INTJ
dpc-5933	141	2	um	um	INTJ
dpc-5933	141	3	er	er	INTJ
dpc-5933	141	4	ic	ic	INTJ
dpc-5933	141	5	r	r	NOUN
dpc-5933	141	6	at	at	ADP
dpc-5933	141	7	in	in	ADP
dpc-5933	141	8	g	g	PROPN
dpc-5933	141	9	sc	sc	PROPN
dpc-5933	141	10	al	al	PROPN
dpc-5933	141	11	e	e	PROPN
dpc-5933	141	12	;	;	PUNCT
dpc-5933	141	13	t	t	PROPN
dpc-5933	141	14	a	a	PRON
dpc-5933	142	1	i	i	NOUN
dpc-5933	142	2	l	l	NOUN
dpc-5933	143	1	i	i	PRON
dpc-5933	143	2	,	,	PUNCT
dpc-5933	143	3	tr	tr	PROPN
dpc-5933	143	4	ia	ia	PROPN
dpc-5933	143	5	m	m	PROPN
dpc-5933	143	6	ci	ci	NOUN
dpc-5933	144	1	no	no	INTJ
dpc-5933	144	2	lo	lo	PROPN
dpc-5933	144	3	ne	ne	PROPN
dpc-5933	144	4	a	a	PROPN
dpc-5933	144	5	ce	ce	PROPN
dpc-5933	144	6	to	to	ADP
dpc-5933	144	7	ni	ni	PROPN
dpc-5933	144	8	de	de	PROPN
dpc-5933	144	9	in	in	ADP
dpc-5933	144	10	tr	tr	PROPN
dpc-5933	144	11	al	al	PROPN
dpc-5933	144	12	es	es	NOUN
dpc-5933	144	13	io	io	X
dpc-5933	144	14	na	na	NOUN
dpc-5933	144	15	l	l	NOUN
dpc-5933	145	1	i	i	PRON
dpc-5933	145	2	nj	nj	INTJ
dpc-5933	145	3	ec	ec	PROPN
dpc-5933	145	4	ti	ti	PROPN
dpc-5933	145	5	on	on	ADP
dpc-5933	145	6	;	;	PUNCT
dpc-5933	145	7	i	i	PROPN
dpc-5933	145	8	&	&	CCONJ
dpc-5933	145	9	d	d	PROPN
dpc-5933	145	10	,	,	PUNCT
dpc-5933	145	11	i	i	PRON
dpc-5933	145	12	nc	nc	PROPN
dpc-5933	145	13	is	be	AUX
dpc-5933	145	14	io	io	PROPN
dpc-5933	145	15	n	n	PROPN
dpc-5933	145	16	&	&	CCONJ
dpc-5933	145	17	d	d	PROPN
dpc-5933	145	18	ra	ra	PROPN
dpc-5933	145	19	in	in	ADP
dpc-5933	145	20	ag	ag	PROPN
dpc-5933	145	21	e.	e.	PROPN
dpc-5933	145	22	original	original	ADJ
dpc-5933	145	23	article	article	NOUN
dpc-5933	145	24	|	|	ADV
dpc-5933	145	25	dermatol	dermatol	ADJ
dpc-5933	145	26	pract	pract	NOUN
dpc-5933	145	27	concept	concept	NOUN
dpc-5933	145	28	.	.	PUNCT
dpc-5933	146	1	2025;15(4):5933	2025;15(4):5933	NUM
dpc-5933	146	2	5	5	NUM
dpc-5933	146	3	t	t	PROPN
dpc-5933	146	4	ab	ab	PROPN
dpc-5933	146	5	le	le	X
dpc-5933	146	6	2	2	NUM
dpc-5933	146	7	.	.	PUNCT
dpc-5933	147	1	s	s	VERB
dpc-5933	147	2	um	um	INTJ
dpc-5933	147	3	m	m	PROPN
dpc-5933	147	4	ar	ar	NOUN
dpc-5933	147	5	iz	iz	INTJ
dpc-5933	147	6	ed	ed	NOUN
dpc-5933	148	1	c	c	PROPN
dpc-5933	148	2	ha	ha	INTJ
dpc-5933	149	1	ra	ra	INTJ
dpc-5933	149	2	ct	ct	INTJ
dpc-5933	149	3	er	er	INTJ
dpc-5933	149	4	is	be	AUX
dpc-5933	149	5	ti	ti	X
dpc-5933	149	6	cs	cs	ADJ
dpc-5933	149	7	o	o	NOUN
dpc-5933	149	8	f	f	NOUN
dpc-5933	149	9	pa	pa	PROPN
dpc-5933	149	10	ti	ti	PROPN
dpc-5933	149	11	en	en	ADP
dpc-5933	149	12	ts	ts	X
dpc-5933	149	13	,	,	PUNCT
dpc-5933	149	14	s	s	VERB
dpc-5933	149	15	tr	tr	VERB
dpc-5933	149	16	at	at	ADP
dpc-5933	149	17	ifi	ifi	PROPN
dpc-5933	149	18	ed	ed	PROPN
dpc-5933	149	19	b	b	PROPN
dpc-5933	150	1	y	y	PROPN
dpc-5933	150	2	h	h	INTJ
dpc-5933	150	3	ur	ur	INTJ
dpc-5933	150	4	le	le	PROPN
dpc-5933	150	5	y	y	PROPN
dpc-5933	150	6	st	st	PROPN
dpc-5933	150	7	ag	ag	PROPN
dpc-5933	150	8	e	e	PROPN
dpc-5933	150	9	,	,	PUNCT
dpc-5933	150	10	t	t	PROPN
dpc-5933	150	11	re	re	NOUN
dpc-5933	150	12	at	at	ADP
dpc-5933	150	13	m	m	PROPN
dpc-5933	150	14	en	en	ADP
dpc-5933	150	15	t	t	PROPN
dpc-5933	150	16	d	d	X
dpc-5933	150	17	el	el	PROPN
dpc-5933	150	18	ay	ay	PROPN
dpc-5933	150	19	,	,	PUNCT
dpc-5933	150	20	a	a	DET
dpc-5933	150	21	nd	nd	NOUN
dpc-5933	150	22	p	p	X
dpc-5933	150	23	ri	ri	NOUN
dpc-5933	150	24	or	or	CCONJ
dpc-5933	150	25	b	b	PROPN
dpc-5933	150	26	io	io	X
dpc-5933	150	27	lo	lo	PROPN
dpc-5933	150	28	gi	gi	VERB
dpc-5933	150	29	cs	cs	PROPN
dpc-5933	150	30	u	u	PROPN
dpc-5933	150	31	se	se	X
dpc-5933	150	32	.	.	PUNCT
dpc-5933	151	1	o	o	INTJ
dpc-5933	152	1	ve	ve	VERB
dpc-5933	152	2	ra	ra	INTJ
dpc-5933	152	3	ll	ll	AUX
dpc-5933	152	4	h	h	INTJ
dpc-5933	152	5	ur	ur	INTJ
dpc-5933	152	6	le	le	PROPN
dpc-5933	152	7	y	y	PROPN
dpc-5933	152	8	st	st	PROPN
dpc-5933	152	9	ag	ag	PROPN
dpc-5933	152	10	e	e	PROPN
dpc-5933	152	11	t	t	PROPN
dpc-5933	152	12	re	re	VERB
dpc-5933	152	13	at	at	ADP
dpc-5933	152	14	m	m	PROPN
dpc-5933	152	15	en	en	ADP
dpc-5933	152	16	t	t	X
dpc-5933	152	17	de	de	PROPN
dpc-5933	152	18	la	la	PROPN
dpc-5933	152	19	y	y	PROPN
dpc-5933	152	20	pr	pr	VERB
dpc-5933	152	21	io	io	NOUN
dpc-5933	152	22	r	r	NOUN
dpc-5933	152	23	bi	bi	NOUN
dpc-5933	153	1	ol	ol	PROPN
dpc-5933	153	2	og	og	PROPN
dpc-5933	153	3	ic	ic	PROPN
dpc-5933	153	4	s	s	PROPN
dpc-5933	153	5	us	us	PROPN
dpc-5933	153	6	e	e	PROPN
dpc-5933	153	7	ii	ii	PROPN
dpc-5933	153	8	(	(	PUNCT
dpc-5933	153	9	n	n	NOUN
dpc-5933	153	10	=	=	SYM
dpc-5933	153	11	7	7	NUM
dpc-5933	153	12	)	)	PUNCT
dpc-5933	153	13	ii	ii	NOUN
dpc-5933	154	1	i	i	PRON
dpc-5933	154	2	(	(	PUNCT
dpc-5933	154	3	n	n	CCONJ
dpc-5933	154	4	=3	=3	VERB
dpc-5933	154	5	)	)	PUNCT
dpc-5933	154	6	<	<	X
dpc-5933	154	7	10	10	NUM
dpc-5933	154	8	y	y	SYM
dpc-5933	154	9	ea	ea	NOUN
dpc-5933	154	10	rs	rs	X
dpc-5933	154	11	(	(	PUNCT
dpc-5933	154	12	n	n	NOUN
dpc-5933	154	13	=	=	NOUN
dpc-5933	154	14	5	5	NUM
dpc-5933	154	15	)	)	PUNCT
dpc-5933	154	16	≥	≥	NOUN
dpc-5933	154	17	10	10	NUM
dpc-5933	154	18	y	y	SYM
dpc-5933	154	19	ea	ea	NOUN
dpc-5933	154	20	rs	rs	X
dpc-5933	154	21	(	(	PUNCT
dpc-5933	154	22	n	n	NOUN
dpc-5933	154	23	=	=	NOUN
dpc-5933	154	24	5	5	NUM
dpc-5933	154	25	)	)	PUNCT
dpc-5933	154	26	b	b	PROPN
dpc-5933	154	27	io	io	X
dpc-5933	154	28	lo	lo	PROPN
dpc-5933	154	29	gi	gi	VERB
dpc-5933	154	30	cs	cs	PROPN
dpc-5933	154	31	-e	-e	PROPN
dpc-5933	154	32	xp	xp	INTJ
dpc-5933	154	33	er	er	INTJ
dpc-5933	154	34	ie	ie	X
dpc-5933	154	35	nc	nc	PROPN
dpc-5933	154	36	ed	ed	PROPN
dpc-5933	154	37	(	(	PUNCT
dpc-5933	154	38	n	n	NOUN
dpc-5933	154	39	=	=	NOUN
dpc-5933	154	40	4	4	NUM
dpc-5933	154	41	)	)	PUNCT
dpc-5933	154	42	b	b	PROPN
dpc-5933	154	43	io	io	X
dpc-5933	154	44	lo	lo	PROPN
dpc-5933	154	45	gi	gi	VERB
dpc-5933	154	46	cs	cs	PROPN
dpc-5933	155	1	-n	-n	X
dpc-5933	155	2	aï	aï	INTJ
dpc-5933	155	3	ve	ve	PROPN
dpc-5933	155	4	(	(	PUNCT
dpc-5933	155	5	n	n	NOUN
dpc-5933	155	6	=	=	NOUN
dpc-5933	155	7	6	6	NUM
dpc-5933	155	8	)	)	PUNCT
dpc-5933	155	9	se	se	PROPN
dpc-5933	155	10	x	x	PROPN
dpc-5933	155	11	,	,	PUNCT
dpc-5933	155	12	n	n	PROPN
dpc-5933	155	13	(	(	PUNCT
dpc-5933	155	14	%	%	NOUN
dpc-5933	155	15	)	)	PUNCT
dpc-5933	155	16	m	m	VERB
dpc-5933	155	17	al	al	PROPN
dpc-5933	155	18	e	e	PROPN
dpc-5933	155	19	6	6	NUM
dpc-5933	155	20	(	(	PUNCT
dpc-5933	155	21	6	6	NUM
dpc-5933	155	22	0	0	NUM
dpc-5933	155	23	)	)	PUNCT
dpc-5933	155	24	5	5	NUM
dpc-5933	155	25	(	(	PUNCT
dpc-5933	155	26	7	7	NUM
dpc-5933	155	27	1	1	NUM
dpc-5933	155	28	.	.	NOUN
dpc-5933	155	29	43	43	NUM
dpc-5933	155	30	)	)	PUNCT
dpc-5933	155	31	1	1	NUM
dpc-5933	155	32	(	(	PUNCT
dpc-5933	155	33	3	3	NUM
dpc-5933	155	34	3	3	NUM
dpc-5933	155	35	.	.	NOUN
dpc-5933	155	36	33	33	NUM
dpc-5933	155	37	)	)	PUNCT
dpc-5933	155	38	3	3	NUM
dpc-5933	155	39	(	(	PUNCT
dpc-5933	155	40	6	6	NUM
dpc-5933	155	41	0	0	NUM
dpc-5933	155	42	)	)	PUNCT
dpc-5933	155	43	3	3	NUM
dpc-5933	155	44	(	(	PUNCT
dpc-5933	155	45	6	6	NUM
dpc-5933	155	46	0	0	NUM
dpc-5933	155	47	)	)	PUNCT
dpc-5933	155	48	1	1	NUM
dpc-5933	155	49	(	(	PUNCT
dpc-5933	155	50	2	2	NUM
dpc-5933	155	51	5	5	NUM
dpc-5933	155	52	)	)	PUNCT
dpc-5933	155	53	5	5	NUM
dpc-5933	155	54	(	(	PUNCT
dpc-5933	155	55	8	8	NUM
dpc-5933	155	56	3	3	NUM
dpc-5933	155	57	.	.	NOUN
dpc-5933	155	58	33	33	NUM
dpc-5933	155	59	)	)	PUNCT
dpc-5933	155	60	fe	fe	X
dpc-5933	155	61	m	m	NOUN
dpc-5933	155	62	al	al	PROPN
dpc-5933	155	63	e	e	PROPN
dpc-5933	155	64	4	4	NUM
dpc-5933	155	65	(	(	PUNCT
dpc-5933	155	66	4	4	NUM
dpc-5933	155	67	0	0	NUM
dpc-5933	155	68	)	)	PUNCT
dpc-5933	155	69	2	2	NUM
dpc-5933	155	70	(	(	PUNCT
dpc-5933	155	71	2	2	NUM
dpc-5933	155	72	8	8	NUM
dpc-5933	155	73	.	.	NOUN
dpc-5933	155	74	57	57	NUM
dpc-5933	155	75	)	)	PUNCT
dpc-5933	155	76	2	2	NUM
dpc-5933	155	77	(	(	PUNCT
dpc-5933	155	78	6	6	NUM
dpc-5933	155	79	6	6	NUM
dpc-5933	155	80	.	.	NOUN
dpc-5933	155	81	67	67	NUM
dpc-5933	155	82	)	)	PUNCT
dpc-5933	155	83	2	2	NUM
dpc-5933	155	84	(	(	PUNCT
dpc-5933	155	85	4	4	NUM
dpc-5933	155	86	0	0	NUM
dpc-5933	155	87	)	)	PUNCT
dpc-5933	155	88	2	2	NUM
dpc-5933	155	89	(	(	PUNCT
dpc-5933	155	90	4	4	NUM
dpc-5933	155	91	0	0	NUM
dpc-5933	155	92	)	)	PUNCT
dpc-5933	155	93	3	3	NUM
dpc-5933	155	94	(	(	PUNCT
dpc-5933	155	95	7	7	NUM
dpc-5933	155	96	5	5	NUM
dpc-5933	155	97	)	)	PUNCT
dpc-5933	155	98	1	1	NUM
dpc-5933	155	99	(	(	PUNCT
dpc-5933	155	100	1	1	NUM
dpc-5933	155	101	6	6	NUM
dpc-5933	155	102	.	.	NOUN
dpc-5933	155	103	67	67	NUM
dpc-5933	155	104	)	)	PUNCT
dpc-5933	155	105	a	a	DET
dpc-5933	155	106	ge	ge	PROPN
dpc-5933	155	107	,	,	PUNCT
dpc-5933	155	108	y	y	PROPN
dpc-5933	155	109	ea	ea	PROPN
dpc-5933	156	1	rs	rs	PROPN
dpc-5933	156	2	27	27	NUM
dpc-5933	156	3	.3	.3	NUM
dpc-5933	156	4	±	±	NUM
dpc-5933	156	5	1	1	NUM
dpc-5933	156	6	0	0	NUM
dpc-5933	156	7	.	.	PUNCT
dpc-5933	156	8	31	31	NUM
dpc-5933	156	9	27	27	NUM
dpc-5933	156	10	.4	.4	NUM
dpc-5933	156	11	3	3	NUM
dpc-5933	156	12	±	±	NUM
dpc-5933	156	13	12	12	NUM
dpc-5933	156	14	.3	.3	NUM
dpc-5933	156	15	4	4	NUM
dpc-5933	156	16	27	27	NUM
dpc-5933	156	17	±	±	NUM
dpc-5933	156	18	4	4	NUM
dpc-5933	156	19	.5	.5	NUM
dpc-5933	156	20	8	8	NUM
dpc-5933	156	21	27	27	NUM
dpc-5933	156	22	.6	.6	NUM
dpc-5933	156	23	±	±	NUM
dpc-5933	156	24	1	1	NUM
dpc-5933	156	25	4	4	NUM
dpc-5933	156	26	.	.	PUNCT
dpc-5933	156	27	84	84	NUM
dpc-5933	156	28	27	27	NUM
dpc-5933	156	29	±	±	NUM
dpc-5933	156	30	4	4	NUM
dpc-5933	156	31	.3	.3	NUM
dpc-5933	156	32	26	26	NUM
dpc-5933	156	33	±	±	NUM
dpc-5933	156	34	4	4	NUM
dpc-5933	156	35	.2	.2	NUM
dpc-5933	156	36	4	4	NUM
dpc-5933	156	37	28	28	NUM
dpc-5933	156	38	.1	.1	NUM
dpc-5933	156	39	7	7	NUM
dpc-5933	156	40	±	±	NUM
dpc-5933	156	41	13	13	NUM
dpc-5933	156	42	.3	.3	NUM
dpc-5933	156	43	5	5	NUM
dpc-5933	156	44	a	a	DET
dpc-5933	156	45	ge	ge	PROPN
dpc-5933	156	46	a	a	DET
dpc-5933	156	47	t	t	NOUN
dpc-5933	156	48	on	on	ADP
dpc-5933	156	49	se	se	PROPN
dpc-5933	156	50	t	t	PROPN
dpc-5933	156	51	,	,	PUNCT
dpc-5933	156	52	ye	ye	PROPN
dpc-5933	156	53	ar	ar	PROPN
dpc-5933	156	54	s	s	PROPN
dpc-5933	156	55	18	18	NUM
dpc-5933	156	56	.9	.9	NUM
dpc-5933	156	57	±	±	NUM
dpc-5933	156	58	1	1	NUM
dpc-5933	156	59	2	2	NUM
dpc-5933	156	60	.	.	X
dpc-5933	156	61	42	42	NUM
dpc-5933	156	62	21	21	NUM
dpc-5933	156	63	.6	.6	NUM
dpc-5933	156	64	7	7	NUM
dpc-5933	156	65	±	±	NUM
dpc-5933	156	66	15	15	NUM
dpc-5933	156	67	.3	.3	NUM
dpc-5933	156	68	1	1	NUM
dpc-5933	156	69	14	14	NUM
dpc-5933	156	70	.7	.7	NUM
dpc-5933	156	71	5	5	NUM
dpc-5933	156	72	±	±	NUM
dpc-5933	156	73	5	5	NUM
dpc-5933	156	74	.	.	NOUN
dpc-5933	156	75	85	85	NUM
dpc-5933	156	76	24	24	NUM
dpc-5933	156	77	.2	.2	NUM
dpc-5933	156	78	±	±	NUM
dpc-5933	156	79	1	1	NUM
dpc-5933	156	80	5	5	NUM
dpc-5933	156	81	.	.	NUM
dpc-5933	156	82	64	64	NUM
dpc-5933	156	83	13	13	NUM
dpc-5933	156	84	.6	.6	NUM
dpc-5933	156	85	±	±	NUM
dpc-5933	156	86	5	5	NUM
dpc-5933	156	87	.6	.6	NUM
dpc-5933	156	88	8	8	NUM
dpc-5933	156	89	14	14	NUM
dpc-5933	156	90	.7	.7	NUM
dpc-5933	156	91	5	5	NUM
dpc-5933	156	92	±	±	NUM
dpc-5933	156	93	5	5	NUM
dpc-5933	156	94	.	.	NOUN
dpc-5933	156	95	85	85	NUM
dpc-5933	156	96	21	21	NUM
dpc-5933	156	97	.6	.6	NUM
dpc-5933	156	98	7	7	NUM
dpc-5933	156	99	±	±	NUM
dpc-5933	156	100	15	15	NUM
dpc-5933	156	101	.3	.3	NUM
dpc-5933	156	102	1	1	NUM
dpc-5933	156	103	d	d	NOUN
dpc-5933	156	104	is	be	AUX
dpc-5933	156	105	ea	ea	X
dpc-5933	156	106	se	se	PROPN
dpc-5933	157	1	d	d	X
dpc-5933	157	2	ur	ur	INTJ
dpc-5933	157	3	at	at	ADP
dpc-5933	157	4	io	io	PROPN
dpc-5933	157	5	n	n	CCONJ
dpc-5933	157	6	,	,	PUNCT
dpc-5933	157	7	y	y	PROPN
dpc-5933	157	8	ea	ea	PROPN
dpc-5933	157	9	rs	rs	ADJ
dpc-5933	157	10	8	8	NUM
dpc-5933	157	11	.	.	X
dpc-5933	157	12	9	9	NUM
dpc-5933	157	13	±	±	NUM
dpc-5933	157	14	5	5	NUM
dpc-5933	157	15	.	.	PUNCT
dpc-5933	157	16	84	84	NUM
dpc-5933	157	17	7	7	NUM
dpc-5933	157	18	.	.	PUNCT
dpc-5933	157	19	00	00	NUM
dpc-5933	158	1	±	±	NUM
dpc-5933	158	2	6	6	NUM
dpc-5933	158	3	.2	.2	NUM
dpc-5933	158	4	9	9	NUM
dpc-5933	158	5	11	11	NUM
dpc-5933	158	6	.7	.7	NUM
dpc-5933	158	7	5	5	NUM
dpc-5933	158	8	±	±	NUM
dpc-5933	158	9	4	4	NUM
dpc-5933	158	10	.	.	PUNCT
dpc-5933	158	11	27	27	NUM
dpc-5933	158	12	3	3	NUM
dpc-5933	158	13	.	.	NOUN
dpc-5933	158	14	8	8	NUM
dpc-5933	158	15	±	±	NUM
dpc-5933	158	16	2	2	NUM
dpc-5933	158	17	.	.	NUM
dpc-5933	158	18	17	17	NUM
dpc-5933	158	19	14	14	NUM
dpc-5933	158	20	±	±	NUM
dpc-5933	158	21	2	2	NUM
dpc-5933	158	22	.6	.6	NUM
dpc-5933	158	23	5	5	NUM
dpc-5933	158	24	11	11	NUM
dpc-5933	158	25	.7	.7	NUM
dpc-5933	158	26	5	5	NUM
dpc-5933	158	27	±	±	NUM
dpc-5933	158	28	4	4	NUM
dpc-5933	158	29	.	.	PUNCT
dpc-5933	158	30	27	27	NUM
dpc-5933	158	31	7	7	NUM
dpc-5933	158	32	±	±	NUM
dpc-5933	158	33	6	6	NUM
dpc-5933	158	34	.	.	SYM
dpc-5933	158	35	29	29	NUM
dpc-5933	159	1	fa	fa	NOUN
dpc-5933	159	2	m	m	VERB
dpc-5933	160	1	ily	ily	ADV
dpc-5933	161	1	h	h	NOUN
dpc-5933	161	2	is	be	AUX
dpc-5933	161	3	to	to	PART
dpc-5933	161	4	ry	ry	VERB
dpc-5933	161	5	,	,	PUNCT
dpc-5933	161	6	n	n	PROPN
dpc-5933	161	7	(	(	PUNCT
dpc-5933	161	8	%	%	NOUN
dpc-5933	161	9	)	)	PUNCT
dpc-5933	161	10	5	5	NUM
dpc-5933	161	11	(	(	PUNCT
dpc-5933	161	12	5	5	NUM
dpc-5933	161	13	0	0	NUM
dpc-5933	161	14	)	)	PUNCT
dpc-5933	161	15	4	4	NUM
dpc-5933	161	16	(	(	PUNCT
dpc-5933	161	17	5	5	NUM
dpc-5933	161	18	7	7	NUM
dpc-5933	161	19	.	.	NOUN
dpc-5933	161	20	15	15	NUM
dpc-5933	161	21	)	)	PUNCT
dpc-5933	161	22	1	1	NUM
dpc-5933	161	23	(	(	PUNCT
dpc-5933	161	24	3	3	NUM
dpc-5933	161	25	3	3	NUM
dpc-5933	161	26	.	.	NOUN
dpc-5933	161	27	33	33	NUM
dpc-5933	161	28	)	)	PUNCT
dpc-5933	161	29	3	3	NUM
dpc-5933	161	30	(	(	PUNCT
dpc-5933	161	31	6	6	NUM
dpc-5933	161	32	0	0	NUM
dpc-5933	161	33	)	)	PUNCT
dpc-5933	161	34	2	2	NUM
dpc-5933	161	35	(	(	PUNCT
dpc-5933	161	36	4	4	NUM
dpc-5933	161	37	0	0	NUM
dpc-5933	161	38	)	)	PUNCT
dpc-5933	161	39	1	1	NUM
dpc-5933	161	40	(	(	PUNCT
dpc-5933	161	41	2	2	NUM
dpc-5933	161	42	5	5	NUM
dpc-5933	161	43	)	)	PUNCT
dpc-5933	161	44	4	4	NUM
dpc-5933	161	45	(	(	PUNCT
dpc-5933	161	46	6	6	NUM
dpc-5933	161	47	6	6	NUM
dpc-5933	161	48	.	.	NOUN
dpc-5933	161	49	7	7	NUM
dpc-5933	161	50	)	)	PUNCT
dpc-5933	161	51	b	b	NOUN
dpc-5933	162	1	od	od	NUM
dpc-5933	162	2	y	y	PROPN
dpc-5933	162	3	m	m	ADV
dpc-5933	162	4	as	as	ADP
dpc-5933	162	5	s	s	PRON
dpc-5933	162	6	in	in	ADP
dpc-5933	162	7	de	de	X
dpc-5933	162	8	x	x	X
dpc-5933	162	9	,	,	PUNCT
dpc-5933	162	10	k	k	PROPN
dpc-5933	162	11	g/	g/	NOUN
dpc-5933	162	12	m	m	VERB
dpc-5933	162	13	2	2	NUM
dpc-5933	162	14	25	25	NUM
dpc-5933	162	15	.8	.8	NUM
dpc-5933	162	16	1	1	NUM
dpc-5933	162	17	±	±	NUM
dpc-5933	162	18	3	3	NUM
dpc-5933	162	19	.	.	NOUN
dpc-5933	162	20	6	6	NUM
dpc-5933	162	21	26	26	NUM
dpc-5933	162	22	.3	.3	NUM
dpc-5933	162	23	8	8	NUM
dpc-5933	162	24	±	±	NUM
dpc-5933	162	25	4	4	NUM
dpc-5933	162	26	.	.	NOUN
dpc-5933	162	27	12	12	NUM
dpc-5933	162	28	24	24	NUM
dpc-5933	162	29	.4	.4	NUM
dpc-5933	162	30	9	9	NUM
dpc-5933	162	31	±	±	NUM
dpc-5933	162	32	1	1	NUM
dpc-5933	162	33	.	.	NUM
dpc-5933	162	34	89	89	NUM
dpc-5933	162	35	25	25	NUM
dpc-5933	162	36	.3	.3	NUM
dpc-5933	162	37	3	3	NUM
dpc-5933	162	38	±	±	NUM
dpc-5933	162	39	4	4	NUM
dpc-5933	162	40	.	.	PUNCT
dpc-5933	162	41	37	37	NUM
dpc-5933	162	42	26	26	NUM
dpc-5933	162	43	.2	.2	NUM
dpc-5933	162	44	9	9	NUM
dpc-5933	162	45	±	±	NUM
dpc-5933	162	46	3	3	NUM
dpc-5933	162	47	.	.	NOUN
dpc-5933	162	48	08	08	NUM
dpc-5933	162	49	23	23	NUM
dpc-5933	163	1	.4	.4	NUM
dpc-5933	163	2	6	6	NUM
dpc-5933	163	3	±	±	NUM
dpc-5933	163	4	2	2	NUM
dpc-5933	163	5	.	.	PUNCT
dpc-5933	163	6	58	58	NUM
dpc-5933	163	7	27	27	NUM
dpc-5933	163	8	.3	.3	NUM
dpc-5933	163	9	8	8	NUM
dpc-5933	163	10	±	±	NUM
dpc-5933	163	11	3	3	NUM
dpc-5933	163	12	.	.	X
dpc-5933	163	13	46	46	NUM
dpc-5933	163	14	sm	sm	INTJ
dpc-5933	163	15	ok	ok	INTJ
dpc-5933	163	16	in	in	ADP
dpc-5933	163	17	g	g	PROPN
dpc-5933	163	18	ha	ha	INTJ
dpc-5933	163	19	bi	bi	PROPN
dpc-5933	163	20	t	t	PROPN
dpc-5933	163	21	,	,	PUNCT
dpc-5933	163	22	n	n	PROPN
dpc-5933	163	23	(	(	PUNCT
dpc-5933	163	24	%	%	NOUN
dpc-5933	163	25	)	)	PUNCT
dpc-5933	163	26	4	4	NUM
dpc-5933	163	27	(	(	PUNCT
dpc-5933	163	28	4	4	NUM
dpc-5933	163	29	0	0	NUM
dpc-5933	163	30	)	)	PUNCT
dpc-5933	163	31	3	3	NUM
dpc-5933	163	32	(	(	PUNCT
dpc-5933	163	33	4	4	NUM
dpc-5933	163	34	2	2	NUM
dpc-5933	163	35	.	.	NOUN
dpc-5933	163	36	85	85	NUM
dpc-5933	163	37	)	)	PUNCT
dpc-5933	163	38	1	1	NUM
dpc-5933	163	39	(	(	PUNCT
dpc-5933	163	40	3	3	NUM
dpc-5933	163	41	3	3	NUM
dpc-5933	163	42	.	.	NOUN
dpc-5933	163	43	33	33	NUM
dpc-5933	163	44	)	)	PUNCT
dpc-5933	163	45	1	1	NUM
dpc-5933	163	46	(	(	PUNCT
dpc-5933	163	47	2	2	NUM
dpc-5933	163	48	0	0	NUM
dpc-5933	163	49	)	)	PUNCT
dpc-5933	163	50	3	3	NUM
dpc-5933	163	51	(	(	PUNCT
dpc-5933	163	52	6	6	NUM
dpc-5933	163	53	0	0	NUM
dpc-5933	163	54	)	)	PUNCT
dpc-5933	163	55	1	1	NUM
dpc-5933	163	56	(	(	PUNCT
dpc-5933	163	57	2	2	NUM
dpc-5933	163	58	5	5	NUM
dpc-5933	163	59	)	)	PUNCT
dpc-5933	163	60	3	3	NUM
dpc-5933	163	61	(	(	PUNCT
dpc-5933	163	62	5	5	NUM
dpc-5933	163	63	0	0	NUM
dpc-5933	163	64	)	)	PUNCT
dpc-5933	163	65	pr	pr	NOUN
dpc-5933	163	66	io	io	NOUN
dpc-5933	163	67	r	r	NOUN
dpc-5933	163	68	tr	tr	NOUN
dpc-5933	163	69	ea	ea	X
dpc-5933	163	70	tm	tm	NOUN
dpc-5933	163	71	en	en	ADP
dpc-5933	163	72	ts	ts	X
dpc-5933	163	73	,	,	PUNCT
dpc-5933	163	74	n	n	PROPN
dpc-5933	163	75	(	(	PUNCT
dpc-5933	163	76	%	%	NOUN
dpc-5933	163	77	)	)	PUNCT
dpc-5933	163	78	a	a	DET
dpc-5933	163	79	da	da	PROPN
dpc-5933	163	80	lim	lim	PROPN
dpc-5933	163	81	um	um	INTJ
dpc-5933	163	82	ab	ab	PROPN
dpc-5933	163	83	4	4	NUM
dpc-5933	163	84	(	(	PUNCT
dpc-5933	163	85	4	4	NUM
dpc-5933	163	86	0	0	NUM
dpc-5933	163	87	)	)	PUNCT
dpc-5933	163	88	1	1	NUM
dpc-5933	163	89	(	(	PUNCT
dpc-5933	163	90	1	1	NUM
dpc-5933	163	91	4	4	NUM
dpc-5933	163	92	.	.	NOUN
dpc-5933	163	93	28	28	NUM
dpc-5933	163	94	)	)	PUNCT
dpc-5933	163	95	3	3	NUM
dpc-5933	163	96	(	(	PUNCT
dpc-5933	163	97	1	1	NUM
dpc-5933	163	98	00	00	NUM
dpc-5933	163	99	)	)	PUNCT
dpc-5933	163	100	1	1	NUM
dpc-5933	163	101	(	(	PUNCT
dpc-5933	163	102	2	2	NUM
dpc-5933	163	103	0	0	NUM
dpc-5933	163	104	)	)	PUNCT
dpc-5933	163	105	3	3	NUM
dpc-5933	163	106	(	(	PUNCT
dpc-5933	163	107	6	6	NUM
dpc-5933	163	108	0	0	NUM
dpc-5933	163	109	)	)	PUNCT
dpc-5933	163	110	4	4	NUM
dpc-5933	163	111	(	(	PUNCT
dpc-5933	163	112	1	1	NUM
dpc-5933	163	113	00	00	NUM
dpc-5933	163	114	)	)	PUNCT
dpc-5933	163	115	0	0	PUNCT
dpc-5933	164	1	(	(	PUNCT
dpc-5933	164	2	0	0	NUM
dpc-5933	164	3	)	)	PUNCT
dpc-5933	164	4	a	a	PRON
dpc-5933	164	5	nt	not	PART
dpc-5933	164	6	ib	ib	X
dpc-5933	164	7	io	io	X
dpc-5933	164	8	ti	ti	PROPN
dpc-5933	164	9	cs	cs	PROPN
dpc-5933	164	10	10	10	NUM
dpc-5933	164	11	(	(	PUNCT
dpc-5933	164	12	10	10	NUM
dpc-5933	164	13	0	0	NUM
dpc-5933	164	14	)	)	PUNCT
dpc-5933	164	15	7	7	NUM
dpc-5933	164	16	(	(	PUNCT
dpc-5933	164	17	1	1	NUM
dpc-5933	164	18	00	00	NUM
dpc-5933	164	19	)	)	PUNCT
dpc-5933	164	20	3	3	NUM
dpc-5933	164	21	(	(	PUNCT
dpc-5933	164	22	1	1	NUM
dpc-5933	164	23	00	00	NUM
dpc-5933	164	24	)	)	PUNCT
dpc-5933	164	25	5	5	NUM
dpc-5933	164	26	(	(	PUNCT
dpc-5933	164	27	1	1	NUM
dpc-5933	164	28	00	00	NUM
dpc-5933	164	29	)	)	PUNCT
dpc-5933	164	30	5	5	NUM
dpc-5933	164	31	(	(	PUNCT
dpc-5933	164	32	1	1	NUM
dpc-5933	164	33	00	00	NUM
dpc-5933	164	34	)	)	PUNCT
dpc-5933	164	35	4	4	NUM
dpc-5933	164	36	(	(	PUNCT
dpc-5933	164	37	1	1	NUM
dpc-5933	164	38	00	00	NUM
dpc-5933	164	39	)	)	PUNCT
dpc-5933	164	40	6	6	NUM
dpc-5933	164	41	(	(	PUNCT
dpc-5933	164	42	1	1	NUM
dpc-5933	164	43	00	00	NUM
dpc-5933	164	44	)	)	PUNCT
dpc-5933	164	45	t	t	PROPN
dpc-5933	164	46	a	a	PRON
dpc-5933	165	1	i	i	NOUN
dpc-5933	165	2	l	l	NOUN
dpc-5933	166	1	i	i	PRON
dpc-5933	166	2	10	10	NUM
dpc-5933	166	3	(	(	PUNCT
dpc-5933	166	4	10	10	NUM
dpc-5933	166	5	0	0	NUM
dpc-5933	166	6	)	)	PUNCT
dpc-5933	166	7	7	7	NUM
dpc-5933	166	8	(	(	PUNCT
dpc-5933	166	9	1	1	NUM
dpc-5933	166	10	00	00	NUM
dpc-5933	166	11	)	)	PUNCT
dpc-5933	166	12	3	3	NUM
dpc-5933	166	13	(	(	PUNCT
dpc-5933	166	14	1	1	NUM
dpc-5933	166	15	00	00	NUM
dpc-5933	166	16	)	)	PUNCT
dpc-5933	166	17	5	5	NUM
dpc-5933	166	18	(	(	PUNCT
dpc-5933	166	19	1	1	NUM
dpc-5933	166	20	00	00	NUM
dpc-5933	166	21	)	)	PUNCT
dpc-5933	166	22	5	5	NUM
dpc-5933	166	23	(	(	PUNCT
dpc-5933	166	24	1	1	NUM
dpc-5933	166	25	00	00	NUM
dpc-5933	166	26	)	)	PUNCT
dpc-5933	166	27	4	4	NUM
dpc-5933	166	28	(	(	PUNCT
dpc-5933	166	29	1	1	NUM
dpc-5933	166	30	00	00	NUM
dpc-5933	166	31	)	)	PUNCT
dpc-5933	166	32	6	6	NUM
dpc-5933	166	33	(	(	PUNCT
dpc-5933	166	34	1	1	NUM
dpc-5933	166	35	00	00	NUM
dpc-5933	166	36	)	)	PUNCT
dpc-5933	167	1	i	i	PRON
dpc-5933	167	2	&	&	CCONJ
dpc-5933	167	3	d	d	PROPN
dpc-5933	167	4	6	6	NUM
dpc-5933	167	5	(	(	PUNCT
dpc-5933	167	6	6	6	NUM
dpc-5933	167	7	0	0	NUM
dpc-5933	167	8	)	)	PUNCT
dpc-5933	167	9	4	4	NUM
dpc-5933	167	10	(	(	PUNCT
dpc-5933	167	11	5	5	NUM
dpc-5933	167	12	7	7	NUM
dpc-5933	167	13	.	.	NOUN
dpc-5933	167	14	14	14	NUM
dpc-5933	167	15	)	)	PUNCT
dpc-5933	167	16	2	2	NUM
dpc-5933	167	17	(	(	PUNCT
dpc-5933	167	18	6	6	NUM
dpc-5933	167	19	6	6	NUM
dpc-5933	167	20	.	.	NOUN
dpc-5933	167	21	67	67	NUM
dpc-5933	167	22	)	)	PUNCT
dpc-5933	167	23	3	3	NUM
dpc-5933	167	24	(	(	PUNCT
dpc-5933	167	25	6	6	NUM
dpc-5933	167	26	0	0	NUM
dpc-5933	167	27	)	)	PUNCT
dpc-5933	167	28	3	3	NUM
dpc-5933	167	29	(	(	PUNCT
dpc-5933	167	30	6	6	NUM
dpc-5933	167	31	0	0	NUM
dpc-5933	167	32	)	)	PUNCT
dpc-5933	167	33	2	2	NUM
dpc-5933	167	34	(	(	PUNCT
dpc-5933	167	35	5	5	NUM
dpc-5933	167	36	0	0	NUM
dpc-5933	167	37	)	)	PUNCT
dpc-5933	167	38	4	4	NUM
dpc-5933	167	39	(	(	PUNCT
dpc-5933	167	40	6	6	NUM
dpc-5933	167	41	6	6	NUM
dpc-5933	167	42	.	.	NOUN
dpc-5933	167	43	7	7	NUM
dpc-5933	167	44	)	)	PUNCT
dpc-5933	167	45	t	t	NOUN
dpc-5933	167	46	a	a	PRON
dpc-5933	167	47	i	i	NOUN
dpc-5933	167	48	l	l	NOUN
dpc-5933	168	1	i	i	PRON
dpc-5933	168	2	,	,	PUNCT
dpc-5933	168	3	tr	tr	PROPN
dpc-5933	168	4	ia	ia	PROPN
dpc-5933	168	5	m	m	PROPN
dpc-5933	168	6	ci	ci	NOUN
dpc-5933	169	1	no	no	INTJ
dpc-5933	169	2	lo	lo	PROPN
dpc-5933	169	3	ne	ne	PROPN
dpc-5933	169	4	a	a	PROPN
dpc-5933	169	5	ce	ce	PROPN
dpc-5933	169	6	to	to	ADP
dpc-5933	169	7	ni	ni	PROPN
dpc-5933	169	8	de	de	PROPN
dpc-5933	169	9	in	in	ADP
dpc-5933	169	10	tr	tr	PROPN
dpc-5933	169	11	al	al	PROPN
dpc-5933	169	12	es	es	NOUN
dpc-5933	169	13	io	io	X
dpc-5933	169	14	na	na	NOUN
dpc-5933	169	15	l	l	NOUN
dpc-5933	170	1	i	i	PRON
dpc-5933	170	2	nj	nj	INTJ
dpc-5933	170	3	ec	ec	PROPN
dpc-5933	170	4	ti	ti	PROPN
dpc-5933	170	5	on	on	ADP
dpc-5933	170	6	;	;	PUNCT
dpc-5933	170	7	i	i	PROPN
dpc-5933	170	8	&	&	CCONJ
dpc-5933	170	9	d	d	PROPN
dpc-5933	170	10	,	,	PUNCT
dpc-5933	170	11	i	i	PRON
dpc-5933	170	12	nc	nc	PROPN
dpc-5933	170	13	is	be	AUX
dpc-5933	170	14	io	io	PROPN
dpc-5933	170	15	n	n	PROPN
dpc-5933	170	16	&	&	CCONJ
dpc-5933	170	17	d	d	PROPN
dpc-5933	170	18	ra	ra	PROPN
dpc-5933	170	19	in	in	ADP
dpc-5933	170	20	ag	ag	PROPN
dpc-5933	170	21	e	e	PROPN
dpc-5933	170	22	6	6	NUM
dpc-5933	170	23	original	original	ADJ
dpc-5933	170	24	article	article	NOUN
dpc-5933	170	25	|	|	ADV
dpc-5933	170	26	dermatol	dermatol	ADJ
dpc-5933	170	27	pract	pract	NOUN
dpc-5933	170	28	concept	concept	NOUN
dpc-5933	170	29	.	.	PUNCT
dpc-5933	171	1	2025;15(4):5933	2025;15(4):5933	NUM
dpc-5933	171	2	figure	figure	NOUN
dpc-5933	171	3	1	1	NUM
dpc-5933	171	4	.	.	PUNCT
dpc-5933	171	5	visual	visual	ADJ
dpc-5933	171	6	improvements	improvement	NOUN
dpc-5933	171	7	in	in	ADP
dpc-5933	171	8	lesions	lesion	NOUN
dpc-5933	171	9	before	before	ADV
dpc-5933	171	10	and	and	CCONJ
dpc-5933	171	11	after	after	ADP
dpc-5933	171	12	the	the	DET
dpc-5933	171	13	use	use	NOUN
dpc-5933	171	14	of	of	ADP
dpc-5933	171	15	secukinumab	secukinumab	NOUN
dpc-5933	171	16	in	in	ADP
dpc-5933	171	17	moderate	moderate	ADJ
dpc-5933	171	18	and	and	CCONJ
dpc-5933	171	19	severe	severe	ADJ
dpc-5933	171	20	hs	hs	PROPN
dpc-5933	171	21	patients	patient	NOUN
dpc-5933	171	22	.	.	PUNCT
dpc-5933	172	1	inflammatory	inflammatory	ADJ
dpc-5933	172	2	nodules	nodule	NOUN
dpc-5933	172	3	and	and	CCONJ
dpc-5933	172	4	abscesses	abscess	NOUN
dpc-5933	172	5	before	before	ADP
dpc-5933	172	6	treatment	treatment	NOUN
dpc-5933	172	7	in	in	ADP
dpc-5933	172	8	the	the	DET
dpc-5933	172	9	right	right	ADJ
dpc-5933	172	10	axillae	axillae	NOUN
dpc-5933	172	11	(	(	PUNCT
dpc-5933	172	12	a	a	NOUN
dpc-5933	172	13	)	)	PUNCT
dpc-5933	172	14	and	and	CCONJ
dpc-5933	172	15	left	leave	VERB
dpc-5933	172	16	axillae	axillae	NOUN
dpc-5933	172	17	(	(	PUNCT
dpc-5933	172	18	c	c	NOUN
dpc-5933	172	19	,	,	PUNCT
dpc-5933	172	20	e	e	NOUN
dpc-5933	172	21	)	)	PUNCT
dpc-5933	172	22	of	of	ADP
dpc-5933	172	23	hurley	hurley	PROPN
dpc-5933	172	24	stage	stage	PROPN
dpc-5933	172	25	ii	ii	PROPN
dpc-5933	172	26	patients	patient	NOUN
dpc-5933	172	27	and	and	CCONJ
dpc-5933	172	28	after	after	ADP
dpc-5933	172	29	48	48	NUM
dpc-5933	172	30	weeks	week	NOUN
dpc-5933	172	31	of	of	ADP
dpc-5933	172	32	secukinumab	secukinumab	PROPN
dpc-5933	172	33	administration	administration	PROPN
dpc-5933	172	34	(	(	PUNCT
dpc-5933	172	35	b	b	PROPN
dpc-5933	172	36	,	,	PUNCT
dpc-5933	172	37	d	d	PROPN
dpc-5933	172	38	,	,	PUNCT
dpc-5933	172	39	f	f	NOUN
dpc-5933	172	40	)	)	PUNCT
dpc-5933	172	41	.	.	PUNCT
dpc-5933	173	1	inflammatory	inflammatory	ADJ
dpc-5933	173	2	nodules	nodule	NOUN
dpc-5933	173	3	,	,	PUNCT
dpc-5933	173	4	abscesses	abscess	NOUN
dpc-5933	173	5	,	,	PUNCT
dpc-5933	173	6	and	and	CCONJ
dpc-5933	173	7	draining	drain	VERB
dpc-5933	173	8	fistula	fistula	NOUN
dpc-5933	173	9	before	before	ADP
dpc-5933	173	10	treatment	treatment	NOUN
dpc-5933	173	11	in	in	ADP
dpc-5933	173	12	the	the	DET
dpc-5933	173	13	left	left	ADJ
dpc-5933	173	14	axillae	axillae	NOUN
dpc-5933	173	15	(	(	PUNCT
dpc-5933	173	16	g	g	NOUN
dpc-5933	173	17	)	)	PUNCT
dpc-5933	173	18	,	,	PUNCT
dpc-5933	173	19	inguinal	inguinal	PROPN
dpc-5933	173	20	(	(	PUNCT
dpc-5933	173	21	i	i	NOUN
dpc-5933	173	22	)	)	PUNCT
dpc-5933	173	23	,	,	PUNCT
dpc-5933	173	24	and	and	CCONJ
dpc-5933	173	25	gluteal	gluteal	NOUN
dpc-5933	173	26	area	area	NOUN
dpc-5933	173	27	(	(	PUNCT
dpc-5933	173	28	k	k	NOUN
dpc-5933	173	29	)	)	PUNCT
dpc-5933	173	30	of	of	ADP
dpc-5933	173	31	hurley	hurley	PROPN
dpc-5933	173	32	stage	stage	PROPN
dpc-5933	173	33	iii	iii	NUM
dpc-5933	173	34	patients	patient	NOUN
dpc-5933	173	35	and	and	CCONJ
dpc-5933	173	36	after	after	ADP
dpc-5933	173	37	48	48	NUM
dpc-5933	173	38	weeks	week	NOUN
dpc-5933	173	39	of	of	ADP
dpc-5933	173	40	secukinumab	secukinumab	PROPN
dpc-5933	173	41	administration	administration	PROPN
dpc-5933	173	42	(	(	PUNCT
dpc-5933	173	43	h	h	PROPN
dpc-5933	173	44	,	,	PUNCT
dpc-5933	173	45	j	j	PROPN
dpc-5933	173	46	,	,	PUNCT
dpc-5933	173	47	l	l	NOUN
dpc-5933	173	48	)	)	PUNCT
dpc-5933	173	49	.	.	PUNCT
dpc-5933	174	1	prior	prior	ADJ
dpc-5933	174	2	biologics	biologic	NOUN
dpc-5933	174	3	use	use	NOUN
dpc-5933	174	4	had	have	VERB
dpc-5933	174	5	shorter	short	ADJ
dpc-5933	174	6	disease	disease	NOUN
dpc-5933	174	7	duration	duration	NOUN
dpc-5933	174	8	than	than	ADP
dpc-5933	174	9	those	those	PRON
dpc-5933	174	10	with	with	ADP
dpc-5933	174	11	hurley	hurley	PROPN
dpc-5933	174	12	stage	stage	PROPN
dpc-5933	174	13	iii	iii	PROPN
dpc-5933	174	14	or	or	CCONJ
dpc-5933	174	15	prior	prior	ADJ
dpc-5933	174	16	biologics	biologic	NOUN
dpc-5933	174	17	exposure	exposure	NOUN
dpc-5933	174	18	.	.	PUNCT
dpc-5933	175	1	reductions	reduction	NOUN
dpc-5933	175	2	in	in	ADP
dpc-5933	175	3	inflammatory	inflammatory	ADJ
dpc-5933	175	4	lesions	lesion	NOUN
dpc-5933	175	5	following	follow	VERB
dpc-5933	175	6	treatment	treatment	NOUN
dpc-5933	175	7	are	be	AUX
dpc-5933	175	8	illustrated	illustrate	VERB
dpc-5933	175	9	in	in	ADP
dpc-5933	175	10	figure	figure	NOUN
dpc-5933	175	11	1	1	NUM
dpc-5933	175	12	,	,	PUNCT
dpc-5933	175	13	with	with	ADP
dpc-5933	175	14	significant	significant	ADJ
dpc-5933	175	15	diminishment	diminishment	NOUN
dpc-5933	175	16	of	of	ADP
dpc-5933	175	17	abscesses	abscess	NOUN
dpc-5933	175	18	and	and	CCONJ
dpc-5933	175	19	inflammatory	inflammatory	ADJ
dpc-5933	175	20	nodules	nodule	NOUN
dpc-5933	175	21	across	across	ADP
dpc-5933	175	22	all	all	DET
dpc-5933	175	23	hurley	hurley	NOUN
dpc-5933	175	24	stages	stage	NOUN
dpc-5933	175	25	.	.	PUNCT
dpc-5933	176	1	however	however	ADV
dpc-5933	176	2	,	,	PUNCT
dpc-5933	176	3	sinus	sinus	NOUN
dpc-5933	176	4	tract	tract	NOUN
dpc-5933	176	5	attenuation	attenuation	NOUN
dpc-5933	176	6	was	be	AUX
dpc-5933	176	7	less	less	ADV
dpc-5933	176	8	pronounced	pronounce	VERB
dpc-5933	176	9	,	,	PUNCT
dpc-5933	176	10	particularly	particularly	ADV
dpc-5933	176	11	in	in	ADP
dpc-5933	176	12	patients	patient	NOUN
dpc-5933	176	13	with	with	ADP
dpc-5933	176	14	more	more	ADV
dpc-5933	176	15	severe	severe	ADJ
dpc-5933	176	16	disease	disease	NOUN
dpc-5933	176	17	.	.	PUNCT
dpc-5933	177	1	the	the	DET
dpc-5933	177	2	overall	overall	ADJ
dpc-5933	177	3	efficacy	efficacy	NOUN
dpc-5933	177	4	of	of	ADP
dpc-5933	177	5	secukinumab	secukinumab	NOUN
dpc-5933	177	6	is	be	AUX
dpc-5933	177	7	presented	present	VERB
dpc-5933	177	8	in	in	ADP
dpc-5933	177	9	figure	figure	NOUN
dpc-5933	177	10	2	2	NUM
dpc-5933	177	11	.	.	PUNCT
dpc-5933	177	12	rapid	rapid	ADJ
dpc-5933	177	13	responses	response	NOUN
dpc-5933	177	14	were	be	AUX
dpc-5933	177	15	evident	evident	ADJ
dpc-5933	177	16	across	across	ADP
dpc-5933	177	17	all	all	DET
dpc-5933	177	18	endpoints	endpoint	NOUN
dpc-5933	177	19	by	by	ADP
dpc-5933	177	20	week	week	NOUN
dpc-5933	177	21	4	4	NUM
dpc-5933	177	22	,	,	PUNCT
dpc-5933	177	23	with	with	ADP
dpc-5933	177	24	30	30	NUM
dpc-5933	177	25	%	%	NOUN
dpc-5933	177	26	of	of	ADP
dpc-5933	177	27	patients	patient	NOUN
dpc-5933	177	28	achieving	achieve	VERB
dpc-5933	177	29	ihs4	ihs4	PROPN
dpc-5933	177	30	-	-	PUNCT
dpc-5933	177	31	55	55	NUM
dpc-5933	177	32	,	,	PUNCT
dpc-5933	177	33	70	70	NUM
dpc-5933	177	34	%	%	NOUN
dpc-5933	177	35	achieving	achieve	VERB
dpc-5933	177	36	hiscr	hiscr	NOUN
dpc-5933	177	37	,	,	PUNCT
dpc-5933	177	38	and	and	CCONJ
dpc-5933	177	39	40	40	NUM
dpc-5933	177	40	%	%	NOUN
dpc-5933	177	41	achieving	achieve	VERB
dpc-5933	177	42	nrs30	nrs30	PROPN
dpc-5933	177	43	.	.	PUNCT
dpc-5933	178	1	mean	mean	VERB
dpc-5933	178	2	reductions	reduction	NOUN
dpc-5933	178	3	included	include	VERB
dpc-5933	178	4	a	a	DET
dpc-5933	178	5	-64.18	-64.18	ADJ
dpc-5933	178	6	±	±	NUM
dpc-5933	178	7	27.89	27.89	NUM
dpc-5933	178	8	%	%	NOUN
dpc-5933	178	9	decrease	decrease	NOUN
dpc-5933	178	10	in	in	ADP
dpc-5933	178	11	an	an	DET
dpc-5933	178	12	count	count	NOUN
dpc-5933	178	13	,	,	PUNCT
dpc-5933	178	14	ihs4	ihs4	NOUN
dpc-5933	178	15	reduction	reduction	NOUN
dpc-5933	178	16	from	from	ADP
dpc-5933	178	17	19.4	19.4	NUM
dpc-5933	178	18	±	±	NUM
dpc-5933	178	19	11.96	11.96	NUM
dpc-5933	178	20	to	to	ADP
dpc-5933	178	21	11.9	11.9	NUM
dpc-5933	178	22	±	±	NUM
dpc-5933	178	23	12.38	12.38	NUM
dpc-5933	178	24	,	,	PUNCT
dpc-5933	178	25	and	and	CCONJ
dpc-5933	178	26	pain	pain	NOUN
dpc-5933	178	27	nrs	nrs	PROPN
dpc-5933	178	28	improvement	improvement	NOUN
dpc-5933	178	29	from	from	ADP
dpc-5933	178	30	4.69	4.69	NUM
dpc-5933	178	31	±	±	NUM
dpc-5933	178	32	1.83	1.83	NUM
dpc-5933	178	33	to	to	ADP
dpc-5933	178	34	2.59	2.59	NUM
dpc-5933	178	35	±	±	NUM
dpc-5933	178	36	1.67	1.67	NUM
dpc-5933	178	37	.	.	PUNCT
dpc-5933	179	1	by	by	ADP
dpc-5933	179	2	week	week	NOUN
dpc-5933	179	3	16	16	NUM
dpc-5933	179	4	,	,	PUNCT
dpc-5933	179	5	70	70	NUM
dpc-5933	179	6	%	%	NOUN
dpc-5933	179	7	achieved	achieve	VERB
dpc-5933	179	8	ihs4	ihs4	PROPN
dpc-5933	179	9	-	-	PUNCT
dpc-5933	179	10	55	55	NUM
dpc-5933	179	11	,	,	PUNCT
dpc-5933	179	12	and	and	CCONJ
dpc-5933	179	13	60	60	NUM
dpc-5933	179	14	%	%	NOUN
dpc-5933	179	15	achieved	achieve	VERB
dpc-5933	179	16	nrs30	nrs30	PROPN
dpc-5933	179	17	.	.	PUNCT
dpc-5933	180	1	improvements	improvement	NOUN
dpc-5933	180	2	were	be	AUX
dpc-5933	180	3	reflected	reflect	VERB
dpc-5933	180	4	in	in	ADP
dpc-5933	180	5	a	a	DET
dpc-5933	180	6	-84.46	-84.46	ADJ
dpc-5933	180	7	±	±	NUM
dpc-5933	180	8	10.60	10.60	NUM
dpc-5933	180	9	%	%	NOUN
dpc-5933	180	10	reduction	reduction	NOUN
dpc-5933	180	11	in	in	ADP
dpc-5933	180	12	an	an	DET
dpc-5933	180	13	count	count	NOUN
dpc-5933	180	14	,	,	PUNCT
dpc-5933	180	15	an	an	DET
dpc-5933	180	16	ihs4	ihs4	NOUN
dpc-5933	180	17	decrease	decrease	NOUN
dpc-5933	180	18	to	to	ADP
dpc-5933	180	19	7.6	7.6	NUM
dpc-5933	180	20	±	±	NUM
dpc-5933	180	21	8.11	8.11	NUM
dpc-5933	180	22	,	,	PUNCT
dpc-5933	180	23	and	and	CCONJ
dpc-5933	180	24	a	a	DET
dpc-5933	180	25	pain	pain	NOUN
dpc-5933	180	26	nrs	nrs	NOUN
dpc-5933	180	27	decrease	decrease	NOUN
dpc-5933	180	28	to	to	ADP
dpc-5933	180	29	1.7	1.7	NUM
dpc-5933	180	30	±	±	NUM
dpc-5933	180	31	1.54	1.54	NUM
dpc-5933	180	32	.	.	PUNCT
dpc-5933	181	1	however	however	ADV
dpc-5933	181	2	,	,	PUNCT
dpc-5933	181	3	hiscr	hiscr	PROPN
dpc-5933	181	4	decreased	decrease	VERB
dpc-5933	181	5	from	from	ADP
dpc-5933	181	6	100	100	NUM
dpc-5933	181	7	%	%	NOUN
dpc-5933	181	8	to	to	PART
dpc-5933	181	9	90	90	NUM
dpc-5933	181	10	%	%	NOUN
dpc-5933	181	11	from	from	ADP
dpc-5933	181	12	week	week	NOUN
dpc-5933	181	13	8	8	NUM
dpc-5933	181	14	to	to	ADP
dpc-5933	181	15	week	week	NOUN
dpc-5933	181	16	16	16	NUM
dpc-5933	181	17	due	due	ADP
dpc-5933	181	18	to	to	ADP
dpc-5933	181	19	the	the	DET
dpc-5933	181	20	recurrence	recurrence	NOUN
dpc-5933	181	21	of	of	ADP
dpc-5933	181	22	an	an	DET
dpc-5933	181	23	abscess	abscess	NOUN
dpc-5933	181	24	in	in	ADP
dpc-5933	181	25	one	one	NUM
dpc-5933	181	26	male	male	ADJ
dpc-5933	181	27	patient	patient	NOUN
dpc-5933	181	28	.	.	PUNCT
dpc-5933	182	1	nonetheless	nonetheless	ADV
dpc-5933	182	2	,	,	PUNCT
dpc-5933	182	3	all	all	DET
dpc-5933	182	4	endpoints	endpoint	NOUN
dpc-5933	182	5	maintained	maintain	VERB
dpc-5933	182	6	their	their	PRON
dpc-5933	182	7	improvement	improvement	NOUN
dpc-5933	182	8	until	until	ADP
dpc-5933	182	9	week	week	NOUN
dpc-5933	182	10	48	48	NUM
dpc-5933	182	11	,	,	PUNCT
dpc-5933	182	12	with	with	ADP
dpc-5933	182	13	90	90	NUM
dpc-5933	182	14	%	%	NOUN
dpc-5933	182	15	of	of	ADP
dpc-5933	182	16	patients	patient	NOUN
dpc-5933	182	17	maintaining	maintain	VERB
dpc-5933	182	18	hiscr	hiscr	NOUN
dpc-5933	182	19	,	,	PUNCT
dpc-5933	182	20	90	90	NUM
dpc-5933	182	21	%	%	NOUN
dpc-5933	182	22	achieving	achieve	VERB
dpc-5933	182	23	ihs4	ihs4	PROPN
dpc-5933	182	24	-	-	PUNCT
dpc-5933	182	25	55	55	NUM
dpc-5933	182	26	,	,	PUNCT
dpc-5933	182	27	and	and	CCONJ
dpc-5933	182	28	60	60	NUM
dpc-5933	182	29	%	%	NOUN
dpc-5933	182	30	sustaining	sustain	VERB
dpc-5933	182	31	nrs30	nrs30	PROPN
dpc-5933	182	32	.	.	PUNCT
dpc-5933	183	1	moreover	moreover	ADV
dpc-5933	183	2	,	,	PUNCT
dpc-5933	183	3	an	an	DET
dpc-5933	183	4	count	count	NOUN
dpc-5933	183	5	was	be	AUX
dpc-5933	183	6	reduced	reduce	VERB
dpc-5933	183	7	by	by	ADP
dpc-5933	183	8	-92.93	-92.93	PROPN
dpc-5933	183	9	±	±	PROPN
dpc-5933	183	10	11.42	11.42	NUM
dpc-5933	183	11	%	%	NOUN
dpc-5933	183	12	,	,	PUNCT
dpc-5933	183	13	and	and	CCONJ
dpc-5933	183	14	ihs4	ihs4	PROPN
dpc-5933	183	15	decreased	decrease	VERB
dpc-5933	183	16	further	far	ADV
dpc-5933	183	17	to	to	ADP
dpc-5933	183	18	3.7	3.7	NUM
dpc-5933	183	19	±	±	NUM
dpc-5933	183	20	5.48	5.48	NUM
dpc-5933	183	21	,	,	PUNCT
dpc-5933	183	22	but	but	CCONJ
dpc-5933	183	23	pain	pain	NOUN
dpc-5933	183	24	nrs	nrs	PROPN
dpc-5933	183	25	increased	increase	VERB
dpc-5933	183	26	slightly	slightly	ADV
dpc-5933	183	27	,	,	PUNCT
dpc-5933	183	28	to	to	ADP
dpc-5933	183	29	1.99	1.99	NUM
dpc-5933	183	30	±	±	NUM
dpc-5933	183	31	1.6	1.6	NUM
dpc-5933	183	32	,	,	PUNCT
dpc-5933	183	33	due	due	ADP
dpc-5933	183	34	to	to	ADP
dpc-5933	183	35	the	the	DET
dpc-5933	183	36	aforementioned	aforementioned	ADJ
dpc-5933	183	37	relapse	relapse	NOUN
dpc-5933	183	38	.	.	PUNCT
dpc-5933	184	1	univariate	univariate	ADJ
dpc-5933	184	2	analyses	analysis	NOUN
dpc-5933	184	3	were	be	AUX
dpc-5933	184	4	conducted	conduct	VERB
dpc-5933	184	5	to	to	PART
dpc-5933	184	6	evaluate	evaluate	VERB
dpc-5933	184	7	the	the	DET
dpc-5933	184	8	impact	impact	NOUN
dpc-5933	184	9	of	of	ADP
dpc-5933	184	10	participants	participant	NOUN
dpc-5933	184	11	’	'	PUNCT
dpc-5933	184	12	demographic	demographic	ADJ
dpc-5933	184	13	characteristics	characteristic	NOUN
dpc-5933	184	14	on	on	ADP
dpc-5933	184	15	their	their	PRON
dpc-5933	184	16	responses	response	NOUN
dpc-5933	184	17	to	to	ADP
dpc-5933	184	18	secukinumab	secukinumab	NOUN
dpc-5933	184	19	administration	administration	NOUN
dpc-5933	184	20	.	.	PUNCT
dpc-5933	185	1	no	no	DET
dpc-5933	185	2	statistically	statistically	ADV
dpc-5933	185	3	significant	significant	ADJ
dpc-5933	185	4	correlation	correlation	NOUN
dpc-5933	185	5	was	be	AUX
dpc-5933	185	6	detected	detect	VERB
dpc-5933	185	7	between	between	ADP
dpc-5933	185	8	sex	sex	NOUN
dpc-5933	185	9	,	,	PUNCT
dpc-5933	185	10	age	age	NOUN
dpc-5933	185	11	,	,	PUNCT
dpc-5933	185	12	age	age	NOUN
dpc-5933	185	13	at	at	ADP
dpc-5933	185	14	onset	onset	NOUN
dpc-5933	185	15	,	,	PUNCT
dpc-5933	185	16	bmi	bmi	PROPN
dpc-5933	185	17	,	,	PUNCT
dpc-5933	185	18	smoking	smoking	NOUN
dpc-5933	185	19	habit	habit	NOUN
dpc-5933	185	20	,	,	PUNCT
dpc-5933	185	21	and	and	CCONJ
dpc-5933	185	22	prior	prior	ADV
dpc-5933	185	23	i&d	i&d	PROPN
dpc-5933	185	24	and	and	CCONJ
dpc-5933	185	25	hiscr	hiscr	NOUN
dpc-5933	185	26	,	,	PUNCT
dpc-5933	185	27	ihs4	ihs4	PROPN
dpc-5933	185	28	-	-	PUNCT
dpc-5933	185	29	55	55	NUM
dpc-5933	185	30	,	,	PUNCT
dpc-5933	185	31	mean	mean	VERB
dpc-5933	185	32	change	change	NOUN
dpc-5933	185	33	in	in	ADP
dpc-5933	185	34	an	an	DET
dpc-5933	185	35	count	count	NOUN
dpc-5933	185	36	from	from	ADP
dpc-5933	185	37	baseline	baseline	NOUN
dpc-5933	185	38	,	,	PUNCT
dpc-5933	185	39	and	and	CCONJ
dpc-5933	185	40	nrs30	nrs30	PROPN
dpc-5933	185	41	(	(	PUNCT
dpc-5933	185	42	p>0.05	p>0.05	NOUN
dpc-5933	185	43	)	)	PUNCT
dpc-5933	185	44	(	(	PUNCT
dpc-5933	185	45	table	table	NOUN
dpc-5933	185	46	s2	s2	PROPN
dpc-5933	185	47	)	)	PUNCT
dpc-5933	185	48	.	.	PUNCT
dpc-5933	186	1	patients	patient	NOUN
dpc-5933	186	2	with	with	ADP
dpc-5933	186	3	hurley	hurley	PROPN
dpc-5933	186	4	stage	stage	PROPN
dpc-5933	186	5	ii	ii	PROPN
dpc-5933	186	6	(	(	PUNCT
dpc-5933	186	7	moderate	moderate	PROPN
dpc-5933	186	8	hs	hs	PROPN
dpc-5933	186	9	)	)	PUNCT
dpc-5933	186	10	achieved	achieve	VERB
dpc-5933	186	11	ihs4	ihs4	PROPN
dpc-5933	186	12	-	-	PUNCT
dpc-5933	186	13	55	55	NUM
dpc-5933	186	14	responses	response	NOUN
dpc-5933	186	15	more	more	ADV
dpc-5933	186	16	rapidly	rapidly	ADV
dpc-5933	186	17	and	and	CCONJ
dpc-5933	186	18	to	to	ADP
dpc-5933	186	19	a	a	DET
dpc-5933	186	20	greater	great	ADJ
dpc-5933	186	21	extent	extent	NOUN
dpc-5933	186	22	than	than	ADP
dpc-5933	186	23	those	those	PRON
dpc-5933	186	24	with	with	ADP
dpc-5933	186	25	stage	stage	NOUN
dpc-5933	186	26	iii	iii	X
dpc-5933	186	27	(	(	PUNCT
dpc-5933	186	28	severe	severe	ADJ
dpc-5933	186	29	hs	h	NOUN
dpc-5933	186	30	)	)	PUNCT
dpc-5933	186	31	,	,	PUNCT
dpc-5933	186	32	with	with	ADP
dpc-5933	186	33	statistically	statistically	ADV
dpc-5933	186	34	significant	significant	ADJ
dpc-5933	186	35	differences	difference	NOUN
dpc-5933	186	36	at	at	ADP
dpc-5933	186	37	weeks	week	NOUN
dpc-5933	186	38	8	8	NUM
dpc-5933	186	39	and	and	CCONJ
dpc-5933	186	40	16	16	NUM
dpc-5933	186	41	(	(	PUNCT
dpc-5933	186	42	rr	rr	NOUN
dpc-5933	186	43	:	:	PUNCT
dpc-5933	186	44	0.00	0.00	NUM
dpc-5933	186	45	;	;	PUNCT
dpc-5933	186	46	95	95	NUM
dpc-5933	186	47	%	%	NOUN
dpc-5933	186	48	ci	ci	NOUN
dpc-5933	186	49	:	:	PUNCT
dpc-5933	186	50	0.00	0.00	NUM
dpc-5933	186	51	–	–	PUNCT
dpc-5933	186	52	0.71	0.71	NUM
dpc-5933	186	53	;	;	PUNCT
dpc-5933	186	54	p=0.033	p=0.033	NOUN
dpc-5933	186	55	;	;	PUNCT
dpc-5933	186	56	rr	rr	NOUN
dpc-5933	186	57	:	:	PUNCT
dpc-5933	186	58	0.00	0.00	NUM
dpc-5933	186	59	;	;	PUNCT
dpc-5933	186	60	95	95	NUM
dpc-5933	186	61	%	%	NOUN
dpc-5933	186	62	ci	ci	NOUN
dpc-5933	186	63	:	:	PUNCT
dpc-5933	186	64	0.00–0.56	0.00–0.56	NUM
dpc-5933	186	65	;	;	PUNCT
dpc-5933	186	66	p=0.0083	p=0.0083	NOUN
dpc-5933	186	67	;	;	PUNCT
dpc-5933	186	68	figure	figure	VERB
dpc-5933	186	69	  	  	SPACE
dpc-5933	186	70	3a	3a	NUM
dpc-5933	186	71	)	)	PUNCT
dpc-5933	186	72	.	.	PUNCT
dpc-5933	187	1	although	although	SCONJ
dpc-5933	187	2	moderate	moderate	ADJ
dpc-5933	187	3	patients	patient	NOUN
dpc-5933	187	4	showed	show	VERB
dpc-5933	187	5	higher	high	ADJ
dpc-5933	187	6	hiscr	hiscr	NOUN
dpc-5933	187	7	rates	rate	NOUN
dpc-5933	187	8	at	at	ADP
dpc-5933	187	9	week	week	NOUN
dpc-5933	187	10	4	4	NUM
dpc-5933	187	11	,	,	PUNCT
dpc-5933	187	12	the	the	DET
dpc-5933	187	13	difference	difference	NOUN
dpc-5933	187	14	was	be	AUX
dpc-5933	187	15	not	not	PART
dpc-5933	187	16	significant	significant	ADJ
dpc-5933	187	17	(	(	PUNCT
dpc-5933	187	18	p>0.05	p>0.05	NOUN
dpc-5933	187	19	;	;	PUNCT
dpc-5933	187	20	figure	figure	NOUN
dpc-5933	187	21	3b	3b	NUM
dpc-5933	187	22	)	)	PUNCT
dpc-5933	187	23	.	.	PUNCT
dpc-5933	188	1	a	a	DET
dpc-5933	188	2	relapse	relapse	NOUN
dpc-5933	188	3	in	in	ADP
dpc-5933	188	4	one	one	NUM
dpc-5933	188	5	male	male	ADJ
dpc-5933	188	6	patient	patient	NOUN
dpc-5933	188	7	at	at	ADP
dpc-5933	188	8	week	week	NOUN
dpc-5933	188	9	16	16	NUM
dpc-5933	188	10	lowered	lower	VERB
dpc-5933	188	11	the	the	DET
dpc-5933	188	12	hiscr	hiscr	NOUN
dpc-5933	188	13	rate	rate	NOUN
dpc-5933	188	14	in	in	ADP
dpc-5933	188	15	moderate	moderate	ADJ
dpc-5933	188	16	patients	patient	NOUN
dpc-5933	188	17	to	to	ADP
dpc-5933	188	18	80	80	NUM
dpc-5933	188	19	%	%	NOUN
dpc-5933	188	20	,	,	PUNCT
dpc-5933	188	21	but	but	CCONJ
dpc-5933	188	22	both	both	DET
dpc-5933	188	23	groups	group	NOUN
dpc-5933	188	24	maintained	maintain	VERB
dpc-5933	188	25	efficacy	efficacy	NOUN
dpc-5933	188	26	without	without	ADP
dpc-5933	188	27	further	further	ADJ
dpc-5933	188	28	significant	significant	ADJ
dpc-5933	188	29	differences	difference	NOUN
dpc-5933	188	30	.	.	PUNCT
dpc-5933	189	1	this	this	DET
dpc-5933	189	2	relapse	relapse	NOUN
dpc-5933	189	3	also	also	ADV
dpc-5933	189	4	impacted	impact	VERB
dpc-5933	189	5	the	the	DET
dpc-5933	189	6	an	an	DET
dpc-5933	189	7	count	count	NOUN
dpc-5933	189	8	and	and	CCONJ
dpc-5933	189	9	nrs30	nrs30	ADJ
dpc-5933	189	10	outcomes	outcome	NOUN
dpc-5933	189	11	.	.	PUNCT
dpc-5933	190	1	moderate	moderate	ADJ
dpc-5933	190	2	patients	patient	NOUN
dpc-5933	190	3	initially	initially	ADV
dpc-5933	190	4	showed	show	VERB
dpc-5933	190	5	a	a	DET
dpc-5933	190	6	greater	great	ADJ
dpc-5933	190	7	reduction	reduction	NOUN
dpc-5933	190	8	in	in	ADP
dpc-5933	190	9	an	an	DET
dpc-5933	190	10	count	count	NOUN
dpc-5933	190	11	up	up	ADP
dpc-5933	190	12	to	to	ADP
dpc-5933	190	13	week	week	NOUN
dpc-5933	190	14	16	16	NUM
dpc-5933	190	15	,	,	PUNCT
dpc-5933	190	16	after	after	ADP
dpc-5933	190	17	which	which	PRON
dpc-5933	190	18	severe	severe	ADJ
dpc-5933	190	19	patients	patient	NOUN
dpc-5933	190	20	showed	show	VERB
dpc-5933	190	21	more	more	ADJ
dpc-5933	190	22	improvement	improvement	NOUN
dpc-5933	190	23	,	,	PUNCT
dpc-5933	190	24	though	though	SCONJ
dpc-5933	190	25	differences	difference	NOUN
dpc-5933	190	26	original	original	ADJ
dpc-5933	190	27	article	article	NOUN
dpc-5933	190	28	|	|	ADV
dpc-5933	190	29	dermatol	dermatol	ADJ
dpc-5933	190	30	pract	pract	NOUN
dpc-5933	190	31	concept	concept	NOUN
dpc-5933	190	32	.	.	PUNCT
dpc-5933	191	1	2025;15(4):5933	2025;15(4):5933	NUM
dpc-5933	191	2	7	7	NUM
dpc-5933	191	3	figure	figure	NOUN
dpc-5933	191	4	2	2	NUM
dpc-5933	191	5	.	.	PUNCT
dpc-5933	192	1	the	the	DET
dpc-5933	192	2	effect	effect	NOUN
dpc-5933	192	3	of	of	ADP
dpc-5933	192	4	secukinumab	secukinumab	NOUN
dpc-5933	192	5	on	on	ADP
dpc-5933	192	6	moderate	moderate	ADJ
dpc-5933	192	7	-	-	PUNCT
dpc-5933	192	8	to	to	ADP
dpc-5933	192	9	-	-	PUNCT
dpc-5933	192	10	severe	severe	ADJ
dpc-5933	192	11	hs	hs	PROPN
dpc-5933	192	12	patients	patient	NOUN
dpc-5933	192	13	.	.	PUNCT
dpc-5933	193	1	treatment	treatment	NOUN
dpc-5933	193	2	responses	response	NOUN
dpc-5933	193	3	are	be	AUX
dpc-5933	193	4	illustrated	illustrate	VERB
dpc-5933	193	5	for	for	ADP
dpc-5933	193	6	hiscr	hiscr	NOUN
dpc-5933	193	7	(	(	PUNCT
dpc-5933	193	8	a	a	X
dpc-5933	193	9	)	)	PUNCT
dpc-5933	193	10	,	,	PUNCT
dpc-5933	193	11	mean	mean	VERB
dpc-5933	193	12	change	change	NOUN
dpc-5933	193	13	in	in	ADP
dpc-5933	193	14	abscess	abscess	NOUN
dpc-5933	193	15	and	and	CCONJ
dpc-5933	193	16	nodule	nodule	NOUN
dpc-5933	193	17	count	count	NOUN
dpc-5933	193	18	from	from	ADP
dpc-5933	193	19	baseline	baseline	PROPN
dpc-5933	193	20	(	(	PUNCT
dpc-5933	193	21	b	b	NOUN
dpc-5933	193	22	)	)	PUNCT
dpc-5933	193	23	,	,	PUNCT
dpc-5933	193	24	ihs4	ihs4	PROPN
dpc-5933	193	25	-	-	PUNCT
dpc-5933	193	26	55	55	NUM
dpc-5933	193	27	(	(	PUNCT
dpc-5933	193	28	c	c	NOUN
dpc-5933	193	29	)	)	PUNCT
dpc-5933	193	30	,	,	PUNCT
dpc-5933	193	31	ihs-4	ihs-4	NUM
dpc-5933	193	32	change	change	NOUN
dpc-5933	193	33	(	(	PUNCT
dpc-5933	193	34	d	d	NOUN
dpc-5933	193	35	)	)	PUNCT
dpc-5933	193	36	,	,	PUNCT
dpc-5933	193	37	nrs30	nrs30	NOUN
dpc-5933	193	38	(	(	PUNCT
dpc-5933	193	39	e	e	NOUN
dpc-5933	193	40	)	)	PUNCT
dpc-5933	193	41	,	,	PUNCT
dpc-5933	193	42	and	and	CCONJ
dpc-5933	193	43	pain	pain	NOUN
dpc-5933	193	44	nrs	nrs	PROPN
dpc-5933	193	45	change	change	NOUN
dpc-5933	193	46	(	(	PUNCT
dpc-5933	193	47	f	f	NOUN
dpc-5933	193	48	)	)	PUNCT
dpc-5933	193	49	.	.	PUNCT
dpc-5933	194	1	hiscr	hiscr	PROPN
dpc-5933	194	2	,	,	PUNCT
dpc-5933	194	3	hidradenitis	hidradenitis	PROPN
dpc-5933	194	4	suppurativa	suppurativa	PROPN
dpc-5933	194	5	clinical	clinical	ADJ
dpc-5933	194	6	response	response	NOUN
dpc-5933	194	7	;	;	PUNCT
dpc-5933	194	8	ihs4	ihs4	PROPN
dpc-5933	194	9	-	-	PUNCT
dpc-5933	194	10	55	55	NUM
dpc-5933	194	11	,	,	PUNCT
dpc-5933	194	12	a	a	DET
dpc-5933	194	13	55	55	NUM
dpc-5933	194	14	%	%	NOUN
dpc-5933	194	15	reduction	reduction	NOUN
dpc-5933	194	16	in	in	ADP
dpc-5933	194	17	the	the	DET
dpc-5933	194	18	international	international	ADJ
dpc-5933	194	19	hidradenitis	hidradenitis	PROPN
dpc-5933	194	20	suppurativa	suppurativa	PROPN
dpc-5933	194	21	severity	severity	PROPN
dpc-5933	194	22	score	score	NOUN
dpc-5933	194	23	system	system	NOUN
dpc-5933	194	24	;	;	PUNCT
dpc-5933	194	25	nrs30	nrs30	PROPN
dpc-5933	194	26	,	,	PUNCT
dpc-5933	194	27	a	a	DET
dpc-5933	194	28	30	30	NUM
dpc-5933	194	29	%	%	NOUN
dpc-5933	194	30	or	or	CCONJ
dpc-5933	194	31	more	more	ADJ
dpc-5933	194	32	reduction	reduction	NOUN
dpc-5933	194	33	and	and	CCONJ
dpc-5933	194	34	reduction	reduction	NOUN
dpc-5933	194	35	of	of	ADP
dpc-5933	194	36	two	two	NUM
dpc-5933	194	37	units	unit	NOUN
dpc-5933	194	38	or	or	CCONJ
dpc-5933	194	39	more	more	ADJ
dpc-5933	194	40	from	from	ADP
dpc-5933	194	41	baseline	baseline	NOUN
dpc-5933	194	42	in	in	ADP
dpc-5933	194	43	patient	patient	NOUN
dpc-5933	194	44	’s	’s	PART
dpc-5933	194	45	global	global	ADJ
dpc-5933	194	46	assessment	assessment	NOUN
dpc-5933	194	47	of	of	ADP
dpc-5933	194	48	skin	skin	NOUN
dpc-5933	194	49	pain	pain	NOUN
dpc-5933	194	50	on	on	ADP
dpc-5933	194	51	a	a	DET
dpc-5933	194	52	continuous	continuous	ADJ
dpc-5933	194	53	numeric	numeric	ADJ
dpc-5933	194	54	rating	rating	NOUN
dpc-5933	194	55	scale	scale	NOUN
dpc-5933	194	56	.	.	PUNCT
dpc-5933	194	57	were	be	AUX
dpc-5933	194	58	not	not	PART
dpc-5933	194	59	significant	significant	ADJ
dpc-5933	194	60	(	(	PUNCT
dpc-5933	194	61	p>0.05	p>0.05	NOUN
dpc-5933	194	62	;	;	PUNCT
dpc-5933	194	63	figure	figure	NOUN
dpc-5933	194	64	3c	3c	NUM
dpc-5933	194	65	)	)	PUNCT
dpc-5933	194	66	.	.	PUNCT
dpc-5933	195	1	nrs30	nrs30	PROPN
dpc-5933	195	2	rates	rate	NOUN
dpc-5933	195	3	were	be	AUX
dpc-5933	195	4	consistently	consistently	ADV
dpc-5933	195	5	higher	high	ADJ
dpc-5933	195	6	in	in	ADP
dpc-5933	195	7	moderate	moderate	ADJ
dpc-5933	195	8	patients	patient	NOUN
dpc-5933	195	9	across	across	ADP
dpc-5933	195	10	all	all	DET
dpc-5933	195	11	time	time	NOUN
dpc-5933	195	12	points	point	NOUN
dpc-5933	195	13	but	but	CCONJ
dpc-5933	195	14	dropped	drop	VERB
dpc-5933	195	15	from	from	ADP
dpc-5933	195	16	100	100	NUM
dpc-5933	195	17	%	%	NOUN
dpc-5933	195	18	to	to	PART
dpc-5933	195	19	80	80	NUM
dpc-5933	195	20	%	%	NOUN
dpc-5933	195	21	after	after	ADP
dpc-5933	195	22	the	the	DET
dpc-5933	195	23	relapse	relapse	NOUN
dpc-5933	195	24	,	,	PUNCT
dpc-5933	195	25	with	with	ADP
dpc-5933	195	26	no	no	DET
dpc-5933	195	27	statistically	statistically	ADV
dpc-5933	195	28	significant	significant	ADJ
dpc-5933	195	29	difference	difference	NOUN
dpc-5933	195	30	observed	observe	VERB
dpc-5933	195	31	(	(	PUNCT
dpc-5933	195	32	p>0.05	p>0.05	NOUN
dpc-5933	195	33	;	;	PUNCT
dpc-5933	195	34	figure	figure	NOUN
dpc-5933	195	35	3d	3d	NUM
dpc-5933	195	36	)	)	PUNCT
dpc-5933	195	37	.	.	PUNCT
dpc-5933	196	1	patients	patient	NOUN
dpc-5933	196	2	with	with	ADP
dpc-5933	196	3	a	a	DET
dpc-5933	196	4	treatment	treatment	NOUN
dpc-5933	196	5	delay	delay	NOUN
dpc-5933	196	6	of	of	ADP
dpc-5933	196	7	less	less	ADJ
dpc-5933	196	8	than	than	ADP
dpc-5933	196	9	10	10	NUM
dpc-5933	196	10	years	year	NOUN
dpc-5933	196	11	showed	show	VERB
dpc-5933	196	12	higher	high	ADJ
dpc-5933	196	13	ihs4	ihs4	PROPN
dpc-5933	196	14	-	-	PUNCT
dpc-5933	196	15	55	55	NUM
dpc-5933	196	16	response	response	NOUN
dpc-5933	196	17	rates	rate	NOUN
dpc-5933	196	18	at	at	ADP
dpc-5933	196	19	all	all	DET
dpc-5933	196	20	time	time	NOUN
dpc-5933	196	21	points	point	NOUN
dpc-5933	196	22	,	,	PUNCT
dpc-5933	196	23	with	with	ADP
dpc-5933	196	24	a	a	DET
dpc-5933	196	25	statistically	statistically	ADV
dpc-5933	196	26	significant	significant	ADJ
dpc-5933	196	27	difference	difference	NOUN
dpc-5933	196	28	at	at	ADP
dpc-5933	196	29	week	week	NOUN
dpc-5933	196	30	8	8	NUM
dpc-5933	196	31	(	(	PUNCT
dpc-5933	196	32	rr	rr	NOUN
dpc-5933	196	33	:	:	PUNCT
dpc-5933	196	34	0.2	0.2	NUM
dpc-5933	196	35	;	;	PUNCT
dpc-5933	196	36	95	95	NUM
dpc-5933	196	37	%	%	NOUN
dpc-5933	196	38	ci	ci	NOUN
dpc-5933	196	39	:	:	PUNCT
dpc-5933	196	40	0.03622–0.6610	0.03622–0.6610	NOUN
dpc-5933	196	41	;	;	PUNCT
dpc-5933	196	42	p=0.047	p=0.047	X
dpc-5933	196	43	;	;	PUNCT
dpc-5933	196	44	figure	figure	NOUN
dpc-5933	196	45	4a	4a	NUM
dpc-5933	196	46	)	)	PUNCT
dpc-5933	196	47	.	.	PUNCT
dpc-5933	197	1	hiscr	hiscr	NOUN
dpc-5933	197	2	rates	rate	NOUN
dpc-5933	197	3	were	be	AUX
dpc-5933	197	4	initially	initially	ADV
dpc-5933	197	5	higher	high	ADJ
dpc-5933	197	6	in	in	ADP
dpc-5933	197	7	this	this	DET
dpc-5933	197	8	group	group	NOUN
dpc-5933	197	9	at	at	ADP
dpc-5933	197	10	week	week	NOUN
dpc-5933	197	11	4	4	NUM
dpc-5933	197	12	but	but	CCONJ
dpc-5933	197	13	reversed	reverse	VERB
dpc-5933	197	14	after	after	ADP
dpc-5933	197	15	a	a	DET
dpc-5933	197	16	relapse	relapse	NOUN
dpc-5933	197	17	in	in	ADP
dpc-5933	197	18	one	one	NUM
dpc-5933	197	19	patient	patient	NOUN
dpc-5933	197	20	at	at	ADP
dpc-5933	197	21	week	week	NOUN
dpc-5933	197	22	16	16	NUM
dpc-5933	197	23	(	(	PUNCT
dpc-5933	197	24	figure	figure	NOUN
dpc-5933	197	25	4b	4b	PROPN
dpc-5933	197	26	)	)	PUNCT
dpc-5933	197	27	.	.	PUNCT
dpc-5933	198	1	an	an	DET
dpc-5933	198	2	count	count	NOUN
dpc-5933	198	3	changes	change	NOUN
dpc-5933	198	4	were	be	AUX
dpc-5933	198	5	comparable	comparable	ADJ
dpc-5933	198	6	between	between	ADP
dpc-5933	198	7	groups	group	NOUN
dpc-5933	198	8	throughout	throughout	ADP
dpc-5933	198	9	the	the	DET
dpc-5933	198	10	study	study	NOUN
dpc-5933	198	11	(	(	PUNCT
dpc-5933	198	12	p>0.05	p>0.05	NOUN
dpc-5933	198	13	;	;	PUNCT
dpc-5933	198	14	figure	figure	NOUN
dpc-5933	198	15	4c	4c	NOUN
dpc-5933	198	16	)	)	PUNCT
dpc-5933	198	17	.	.	PUNCT
dpc-5933	199	1	nrs30	nrs30	PROPN
dpc-5933	199	2	rates	rate	NOUN
dpc-5933	199	3	were	be	AUX
dpc-5933	199	4	consistently	consistently	ADV
dpc-5933	199	5	higher	high	ADJ
dpc-5933	199	6	in	in	ADP
dpc-5933	199	7	patients	patient	NOUN
dpc-5933	199	8	with	with	ADP
dpc-5933	199	9	shorter	short	ADJ
dpc-5933	199	10	treatment	treatment	NOUN
dpc-5933	199	11	delay	delay	NOUN
dpc-5933	199	12	,	,	PUNCT
dpc-5933	199	13	though	though	SCONJ
dpc-5933	199	14	not	not	PART
dpc-5933	199	15	statistically	statistically	ADV
dpc-5933	199	16	significant	significant	ADJ
dpc-5933	199	17	(	(	PUNCT
dpc-5933	199	18	p>0.05	p>0.05	NOUN
dpc-5933	199	19	;	;	PUNCT
dpc-5933	199	20	figure	figure	NOUN
dpc-5933	199	21	4d	4d	NUM
dpc-5933	199	22	)	)	PUNCT
dpc-5933	199	23	.	.	PUNCT
dpc-5933	200	1	biologics	biologic	NOUN
dpc-5933	200	2	-	-	PUNCT
dpc-5933	200	3	naïve	naïve	ADJ
dpc-5933	200	4	patients	patient	NOUN
dpc-5933	200	5	showed	show	VERB
dpc-5933	200	6	greater	great	ADJ
dpc-5933	200	7	improvement	improvement	NOUN
dpc-5933	200	8	in	in	ADP
dpc-5933	200	9	ihs4	ihs4	PROPN
dpc-5933	200	10	-	-	PUNCT
dpc-5933	200	11	55	55	NUM
dpc-5933	200	12	compared	compare	VERB
dpc-5933	200	13	to	to	ADP
dpc-5933	200	14	biologics	biologic	NOUN
dpc-5933	200	15	-	-	PUNCT
dpc-5933	200	16	experienced	experience	VERB
dpc-5933	200	17	ones	one	NOUN
dpc-5933	200	18	,	,	PUNCT
dpc-5933	200	19	with	with	ADP
dpc-5933	200	20	a	a	DET
dpc-5933	200	21	significant	significant	ADJ
dpc-5933	200	22	difference	difference	NOUN
dpc-5933	200	23	at	at	ADP
dpc-5933	200	24	week	week	NOUN
dpc-5933	200	25	16	16	NUM
dpc-5933	200	26	(	(	PUNCT
dpc-5933	200	27	rr	rr	NOUN
dpc-5933	200	28	:	:	PUNCT
dpc-5933	200	29	0.25	0.25	NUM
dpc-5933	200	30	;	;	PUNCT
dpc-5933	200	31	95	95	NUM
dpc-5933	200	32	%	%	NOUN
dpc-5933	200	33	ci	ci	NOUN
dpc-5933	200	34	:	:	PUNCT
dpc-5933	200	35	0.046–0.70	0.046–0.70	NOUN
dpc-5933	200	36	;	;	PUNCT
dpc-5933	200	37	p=0.033	p=0.033	NOUN
dpc-5933	200	38	;	;	PUNCT
dpc-5933	200	39	figure	figure	NOUN
dpc-5933	200	40	5a	5a	NUM
dpc-5933	200	41	)	)	PUNCT
dpc-5933	200	42	.	.	PUNCT
dpc-5933	201	1	hiscr	hiscr	NOUN
dpc-5933	201	2	rates	rate	NOUN
dpc-5933	201	3	were	be	AUX
dpc-5933	201	4	higher	high	ADJ
dpc-5933	201	5	in	in	ADP
dpc-5933	201	6	biologics	biologic	NOUN
dpc-5933	201	7	-	-	PUNCT
dpc-5933	201	8	naïve	naïve	ADJ
dpc-5933	201	9	patients	patient	NOUN
dpc-5933	201	10	at	at	ADP
dpc-5933	201	11	week	week	NOUN
dpc-5933	201	12	4	4	NUM
dpc-5933	201	13	but	but	CCONJ
dpc-5933	201	14	not	not	PART
dpc-5933	201	15	significantly	significantly	ADV
dpc-5933	201	16	(	(	PUNCT
dpc-5933	201	17	p>0.05	p>0.05	NOUN
dpc-5933	201	18	;	;	PUNCT
dpc-5933	201	19	figure	figure	NOUN
dpc-5933	201	20	5b	5b	NUM
dpc-5933	201	21	)	)	PUNCT
dpc-5933	201	22	.	.	PUNCT
dpc-5933	202	1	a	a	DET
dpc-5933	202	2	relapse	relapse	NOUN
dpc-5933	202	3	after	after	ADP
dpc-5933	202	4	week	week	NOUN
dpc-5933	202	5	16	16	NUM
dpc-5933	202	6	reduced	reduce	VERB
dpc-5933	202	7	their	their	PRON
dpc-5933	202	8	hiscr	hiscr	NOUN
dpc-5933	202	9	to	to	ADP
dpc-5933	202	10	80	80	NUM
dpc-5933	202	11	%	%	NOUN
dpc-5933	202	12	and	and	CCONJ
dpc-5933	202	13	impacted	impact	VERB
dpc-5933	202	14	an	an	DET
dpc-5933	202	15	count	count	NOUN
dpc-5933	202	16	and	and	CCONJ
dpc-5933	202	17	nrs30	nrs30	NOUN
dpc-5933	202	18	rates	rate	NOUN
dpc-5933	202	19	,	,	PUNCT
dpc-5933	202	20	but	but	CCONJ
dpc-5933	202	21	the	the	DET
dpc-5933	202	22	efficacy	efficacy	NOUN
dpc-5933	202	23	was	be	AUX
dpc-5933	202	24	maintained	maintain	VERB
dpc-5933	202	25	until	until	ADP
dpc-5933	202	26	the	the	DET
dpc-5933	202	27	end	end	NOUN
dpc-5933	202	28	of	of	ADP
dpc-5933	202	29	the	the	DET
dpc-5933	202	30	study	study	NOUN
dpc-5933	202	31	.	.	PUNCT
dpc-5933	203	1	an	an	DET
dpc-5933	203	2	count	count	NOUN
dpc-5933	203	3	declined	decline	VERB
dpc-5933	203	4	faster	fast	ADV
dpc-5933	203	5	in	in	ADP
dpc-5933	203	6	biologics	biologic	NOUN
dpc-5933	203	7	-	-	PUNCT
dpc-5933	203	8	naïve	naïve	ADJ
dpc-5933	203	9	patients	patient	NOUN
dpc-5933	203	10	early	early	ADV
dpc-5933	203	11	on	on	ADV
dpc-5933	203	12	,	,	PUNCT
dpc-5933	203	13	but	but	CCONJ
dpc-5933	203	14	the	the	DET
dpc-5933	203	15	difference	difference	NOUN
dpc-5933	203	16	was	be	AUX
dpc-5933	203	17	not	not	PART
dpc-5933	203	18	significant	significant	ADJ
dpc-5933	203	19	(	(	PUNCT
dpc-5933	203	20	p>0.05	p>0.05	NOUN
dpc-5933	203	21	;	;	PUNCT
dpc-5933	203	22	figure	figure	NOUN
dpc-5933	203	23	5c	5c	NUM
dpc-5933	203	24	)	)	PUNCT
dpc-5933	203	25	.	.	PUNCT
dpc-5933	204	1	nrs30	nrs30	PROPN
dpc-5933	204	2	rates	rate	NOUN
dpc-5933	204	3	were	be	AUX
dpc-5933	204	4	higher	high	ADJ
dpc-5933	204	5	in	in	ADP
dpc-5933	204	6	biologics	biologic	NOUN
dpc-5933	204	7	-	-	PUNCT
dpc-5933	204	8	naïve	naïve	ADJ
dpc-5933	204	9	patients	patient	NOUN
dpc-5933	204	10	at	at	ADP
dpc-5933	204	11	weeks	week	NOUN
dpc-5933	204	12	4–8	4–8	NUM
dpc-5933	204	13	,	,	PUNCT
dpc-5933	204	14	then	then	ADV
dpc-5933	204	15	equalized	equalize	VERB
dpc-5933	204	16	by	by	ADP
dpc-5933	204	17	week	week	NOUN
dpc-5933	204	18	16	16	NUM
dpc-5933	204	19	(	(	PUNCT
dpc-5933	204	20	figure	figure	NOUN
dpc-5933	204	21	5d	5d	NUM
dpc-5933	204	22	)	)	PUNCT
dpc-5933	204	23	.	.	PUNCT
dpc-5933	205	1	at	at	ADP
dpc-5933	205	2	week	week	NOUN
dpc-5933	205	3	48	48	NUM
dpc-5933	205	4	,	,	PUNCT
dpc-5933	205	5	relapse	relapse	NOUN
dpc-5933	205	6	lowered	lower	VERB
dpc-5933	205	7	the	the	DET
dpc-5933	205	8	nrs30	nrs30	NOUN
dpc-5933	205	9	rate	rate	NOUN
dpc-5933	205	10	from	from	ADP
dpc-5933	205	11	66.67	66.67	NUM
dpc-5933	205	12	%	%	NOUN
dpc-5933	205	13	to	to	ADP
dpc-5933	205	14	50	50	NUM
dpc-5933	205	15	%	%	NOUN
dpc-5933	205	16	.	.	PUNCT
dpc-5933	206	1	8	8	NUM
dpc-5933	206	2	original	original	ADJ
dpc-5933	206	3	article	article	NOUN
dpc-5933	206	4	|	|	ADV
dpc-5933	206	5	dermatol	dermatol	ADJ
dpc-5933	206	6	pract	pract	NOUN
dpc-5933	206	7	concept	concept	NOUN
dpc-5933	206	8	.	.	PUNCT
dpc-5933	207	1	2025;15(4):5933	2025;15(4):5933	NUM
dpc-5933	207	2	figure	figure	NOUN
dpc-5933	207	3	3	3	NUM
dpc-5933	207	4	.	.	PUNCT
dpc-5933	208	1	the	the	DET
dpc-5933	208	2	effect	effect	NOUN
dpc-5933	208	3	of	of	ADP
dpc-5933	208	4	secukinumab	secukinumab	NOUN
dpc-5933	208	5	,	,	PUNCT
dpc-5933	208	6	stratified	stratify	VERB
dpc-5933	208	7	by	by	ADP
dpc-5933	208	8	hurley	hurley	NOUN
dpc-5933	208	9	stage	stage	NOUN
dpc-5933	208	10	,	,	PUNCT
dpc-5933	208	11	on	on	ADP
dpc-5933	208	12	ihs4	ihs4	PROPN
dpc-5933	208	13	-	-	PUNCT
dpc-5933	208	14	55	55	NUM
dpc-5933	208	15	(	(	PUNCT
dpc-5933	208	16	a	a	NOUN
dpc-5933	208	17	)	)	PUNCT
dpc-5933	208	18	,	,	PUNCT
dpc-5933	208	19	hiscr	hiscr	NOUN
dpc-5933	208	20	(	(	PUNCT
dpc-5933	208	21	b	b	NOUN
dpc-5933	208	22	)	)	PUNCT
dpc-5933	208	23	,	,	PUNCT
dpc-5933	208	24	mean	mean	VERB
dpc-5933	208	25	change	change	NOUN
dpc-5933	208	26	in	in	ADP
dpc-5933	208	27	abscess	abscess	NOUN
dpc-5933	208	28	and	and	CCONJ
dpc-5933	208	29	nodule	nodule	NOUN
dpc-5933	208	30	count	count	NOUN
dpc-5933	208	31	(	(	PUNCT
dpc-5933	208	32	c	c	NOUN
dpc-5933	208	33	)	)	PUNCT
dpc-5933	208	34	,	,	PUNCT
dpc-5933	208	35	and	and	CCONJ
dpc-5933	208	36	nrs30	nrs30	NOUN
dpc-5933	208	37	(	(	PUNCT
dpc-5933	208	38	d	d	NOUN
dpc-5933	208	39	)	)	PUNCT
dpc-5933	208	40	.	.	PUNCT
dpc-5933	209	1	hiscr	hiscr	PROPN
dpc-5933	209	2	,	,	PUNCT
dpc-5933	209	3	hidradenitis	hidradenitis	PROPN
dpc-5933	209	4	suppurativa	suppurativa	PROPN
dpc-5933	209	5	clinical	clinical	ADJ
dpc-5933	209	6	response	response	NOUN
dpc-5933	209	7	;	;	PUNCT
dpc-5933	209	8	ihs4	ihs4	PROPN
dpc-5933	209	9	-	-	PUNCT
dpc-5933	209	10	55	55	NUM
dpc-5933	209	11	,	,	PUNCT
dpc-5933	209	12	a	a	DET
dpc-5933	209	13	55	55	NUM
dpc-5933	209	14	%	%	NOUN
dpc-5933	209	15	reduction	reduction	NOUN
dpc-5933	209	16	in	in	ADP
dpc-5933	209	17	the	the	DET
dpc-5933	209	18	international	international	ADJ
dpc-5933	209	19	hidradenitis	hidradenitis	PROPN
dpc-5933	209	20	suppurativa	suppurativa	PROPN
dpc-5933	209	21	severity	severity	PROPN
dpc-5933	209	22	score	score	NOUN
dpc-5933	209	23	system	system	NOUN
dpc-5933	209	24	;	;	PUNCT
dpc-5933	209	25	nrs30	nrs30	PROPN
dpc-5933	209	26	,	,	PUNCT
dpc-5933	209	27	a	a	DET
dpc-5933	209	28	30	30	NUM
dpc-5933	209	29	%	%	NOUN
dpc-5933	209	30	or	or	CCONJ
dpc-5933	209	31	more	more	ADJ
dpc-5933	209	32	reduction	reduction	NOUN
dpc-5933	209	33	and	and	CCONJ
dpc-5933	209	34	a	a	DET
dpc-5933	209	35	reduction	reduction	NOUN
dpc-5933	209	36	of	of	ADP
dpc-5933	209	37	two	two	NUM
dpc-5933	209	38	units	unit	NOUN
dpc-5933	209	39	or	or	CCONJ
dpc-5933	209	40	more	more	ADJ
dpc-5933	209	41	from	from	ADP
dpc-5933	209	42	baseline	baseline	NOUN
dpc-5933	209	43	in	in	ADP
dpc-5933	209	44	patient	patient	NOUN
dpc-5933	209	45	’s	’s	PART
dpc-5933	209	46	global	global	ADJ
dpc-5933	209	47	assessment	assessment	NOUN
dpc-5933	209	48	of	of	ADP
dpc-5933	209	49	skin	skin	NOUN
dpc-5933	209	50	pain	pain	NOUN
dpc-5933	209	51	on	on	ADP
dpc-5933	209	52	a	a	DET
dpc-5933	209	53	continuous	continuous	ADJ
dpc-5933	209	54	numeric	numeric	ADJ
dpc-5933	209	55	rating	rating	NOUN
dpc-5933	209	56	scale	scale	NOUN
dpc-5933	209	57	;	;	PUNCT
dpc-5933	209	58	*	*	PUNCT
dpc-5933	209	59	p<0.05	p<0.05	NOUN
dpc-5933	209	60	;	;	PUNCT
dpc-5933	209	61	ns	ns	NUM
dpc-5933	209	62	,	,	PUNCT
dpc-5933	209	63	no	no	DET
dpc-5933	209	64	significance	significance	NOUN
dpc-5933	209	65	.	.	PUNCT
dpc-5933	210	1	moreover	moreover	ADV
dpc-5933	210	2	,	,	PUNCT
dpc-5933	210	3	we	we	PRON
dpc-5933	210	4	compared	compare	VERB
dpc-5933	210	5	the	the	DET
dpc-5933	210	6	antibiotic	antibiotic	ADJ
dpc-5933	210	7	use	use	NOUN
dpc-5933	210	8	duration	duration	NOUN
dpc-5933	210	9	between	between	ADP
dpc-5933	210	10	hurley	hurley	PROPN
dpc-5933	210	11	stage	stage	PROPN
dpc-5933	210	12	ii	ii	PROPN
dpc-5933	210	13	and	and	CCONJ
dpc-5933	210	14	iii	iii	NUM
dpc-5933	210	15	patients	patient	NOUN
dpc-5933	210	16	(	(	PUNCT
dpc-5933	210	17	figure	figure	VERB
dpc-5933	210	18	6	6	NUM
dpc-5933	210	19	)	)	PUNCT
dpc-5933	210	20	.	.	PUNCT
dpc-5933	211	1	while	while	SCONJ
dpc-5933	211	2	the	the	DET
dpc-5933	211	3	duration	duration	NOUN
dpc-5933	211	4	of	of	ADP
dpc-5933	211	5	antibiotic	antibiotic	ADJ
dpc-5933	211	6	monotherapy	monotherapy	NOUN
dpc-5933	211	7	was	be	AUX
dpc-5933	211	8	similar	similar	ADJ
dpc-5933	211	9	between	between	ADP
dpc-5933	211	10	the	the	DET
dpc-5933	211	11	groups	group	NOUN
dpc-5933	211	12	(	(	PUNCT
dpc-5933	211	13	p>0.05	p>0.05	PROPN
dpc-5933	211	14	)	)	PUNCT
dpc-5933	211	15	,	,	PUNCT
dpc-5933	211	16	patients	patient	NOUN
dpc-5933	211	17	with	with	ADP
dpc-5933	211	18	severe	severe	ADJ
dpc-5933	211	19	disease	disease	NOUN
dpc-5933	211	20	had	have	VERB
dpc-5933	211	21	significantly	significantly	ADV
dpc-5933	211	22	longer	long	ADJ
dpc-5933	211	23	periods	period	NOUN
dpc-5933	211	24	of	of	ADP
dpc-5933	211	25	combined	combine	VERB
dpc-5933	211	26	antibiotic	antibiotic	ADJ
dpc-5933	211	27	use	use	NOUN
dpc-5933	211	28	than	than	ADP
dpc-5933	211	29	those	those	PRON
dpc-5933	211	30	with	with	ADP
dpc-5933	211	31	moderate	moderate	ADJ
dpc-5933	211	32	disease	disease	NOUN
dpc-5933	211	33	(	(	PUNCT
dpc-5933	211	34	p<0.05	p<0.05	NOUN
dpc-5933	211	35	)	)	PUNCT
dpc-5933	211	36	.	.	PUNCT
dpc-5933	212	1	notably	notably	ADV
dpc-5933	212	2	,	,	PUNCT
dpc-5933	212	3	moderate	moderate	ADJ
dpc-5933	212	4	patients	patient	NOUN
dpc-5933	212	5	had	have	VERB
dpc-5933	212	6	a	a	DET
dpc-5933	212	7	significantly	significantly	ADV
dpc-5933	212	8	longer	long	ADJ
dpc-5933	212	9	duration	duration	NOUN
dpc-5933	212	10	of	of	ADP
dpc-5933	212	11	antibiotic	antibiotic	ADJ
dpc-5933	212	12	cessation	cessation	NOUN
dpc-5933	212	13	than	than	SCONJ
dpc-5933	212	14	did	do	VERB
dpc-5933	212	15	severe	severe	ADJ
dpc-5933	212	16	cases	case	NOUN
dpc-5933	212	17	(	(	PUNCT
dpc-5933	212	18	p<0.05	p<0.05	NOUN
dpc-5933	212	19	)	)	PUNCT
dpc-5933	212	20	.	.	PUNCT
dpc-5933	213	1	regarding	regard	VERB
dpc-5933	213	2	adverse	adverse	ADJ
dpc-5933	213	3	events	event	NOUN
dpc-5933	213	4	,	,	PUNCT
dpc-5933	213	5	secukinumab	secukinumab	NOUN
dpc-5933	213	6	was	be	AUX
dpc-5933	213	7	well	well	ADV
dpc-5933	213	8	tolerated	tolerate	VERB
dpc-5933	213	9	,	,	PUNCT
dpc-5933	213	10	and	and	CCONJ
dpc-5933	213	11	no	no	DET
dpc-5933	213	12	patient	patient	NOUN
dpc-5933	213	13	reported	report	VERB
dpc-5933	213	14	any	any	DET
dpc-5933	213	15	non	non	ADJ
dpc-5933	213	16	-	-	ADJ
dpc-5933	213	17	serious	serious	ADJ
dpc-5933	213	18	or	or	CCONJ
dpc-5933	213	19	serious	serious	ADJ
dpc-5933	213	20	adverse	adverse	ADJ
dpc-5933	213	21	event	event	NOUN
dpc-5933	213	22	that	that	PRON
dpc-5933	213	23	could	could	AUX
dpc-5933	213	24	have	have	AUX
dpc-5933	213	25	led	lead	VERB
dpc-5933	213	26	to	to	ADP
dpc-5933	213	27	the	the	DET
dpc-5933	213	28	discontinuation	discontinuation	NOUN
dpc-5933	213	29	of	of	ADP
dpc-5933	213	30	participation	participation	NOUN
dpc-5933	213	31	in	in	ADP
dpc-5933	213	32	the	the	DET
dpc-5933	213	33	study	study	NOUN
dpc-5933	213	34	(	(	PUNCT
dpc-5933	213	35	table	table	NOUN
dpc-5933	213	36	3	3	NUM
dpc-5933	213	37	)	)	PUNCT
dpc-5933	213	38	.	.	PUNCT
dpc-5933	214	1	additionally	additionally	ADV
dpc-5933	214	2	,	,	PUNCT
dpc-5933	214	3	no	no	DET
dpc-5933	214	4	new	new	ADJ
dpc-5933	214	5	adverse	adverse	ADJ
dpc-5933	214	6	event	event	NOUN
dpc-5933	214	7	outside	outside	ADP
dpc-5933	214	8	of	of	ADP
dpc-5933	214	9	the	the	DET
dpc-5933	214	10	known	know	VERB
dpc-5933	214	11	safety	safety	NOUN
dpc-5933	214	12	profile	profile	NOUN
dpc-5933	214	13	of	of	ADP
dpc-5933	214	14	secukinumab	secukinumab	NOUN
dpc-5933	214	15	was	be	AUX
dpc-5933	214	16	reported	report	VERB
dpc-5933	214	17	during	during	ADP
dpc-5933	214	18	the	the	DET
dpc-5933	214	19	48	48	NUM
dpc-5933	214	20	weeks	week	NOUN
dpc-5933	214	21	of	of	ADP
dpc-5933	214	22	treatment	treatment	NOUN
dpc-5933	214	23	.	.	PUNCT
dpc-5933	215	1	notably	notably	ADV
dpc-5933	215	2	,	,	PUNCT
dpc-5933	215	3	the	the	DET
dpc-5933	215	4	longest	long	ADJ
dpc-5933	215	5	duration	duration	NOUN
dpc-5933	215	6	of	of	ADP
dpc-5933	215	7	treatment	treatment	NOUN
dpc-5933	215	8	maintenance	maintenance	NOUN
dpc-5933	215	9	without	without	ADP
dpc-5933	215	10	any	any	DET
dpc-5933	215	11	adverse	adverse	ADJ
dpc-5933	215	12	event	event	NOUN
dpc-5933	215	13	observed	observe	VERB
dpc-5933	215	14	during	during	ADP
dpc-5933	215	15	our	our	PRON
dpc-5933	215	16	patient	patient	ADJ
dpc-5933	215	17	monitoring	monitoring	NOUN
dpc-5933	215	18	was	be	AUX
dpc-5933	215	19	80	80	NUM
dpc-5933	215	20	weeks	week	NOUN
dpc-5933	215	21	.	.	PUNCT
dpc-5933	216	1	discussion	discussion	NOUN
dpc-5933	216	2	this	this	DET
dpc-5933	216	3	48	48	NUM
dpc-5933	216	4	-	-	PUNCT
dpc-5933	216	5	week	week	NOUN
dpc-5933	216	6	prospective	prospective	ADJ
dpc-5933	216	7	study	study	NOUN
dpc-5933	216	8	demonstrates	demonstrate	VERB
dpc-5933	216	9	the	the	DET
dpc-5933	216	10	robust	robust	ADJ
dpc-5933	216	11	efficacy	efficacy	NOUN
dpc-5933	216	12	of	of	ADP
dpc-5933	216	13	secukinumab	secukinumab	NOUN
dpc-5933	216	14	in	in	ADP
dpc-5933	216	15	managing	manage	VERB
dpc-5933	216	16	moderate	moderate	ADJ
dpc-5933	216	17	-	-	PUNCT
dpc-5933	216	18	to	to	ADP
dpc-5933	216	19	-	-	PUNCT
dpc-5933	216	20	severe	severe	ADJ
dpc-5933	216	21	hs	hs	PROPN
dpc-5933	216	22	in	in	ADP
dpc-5933	216	23	a	a	DET
dpc-5933	216	24	korean	korean	ADJ
dpc-5933	216	25	cohort	cohort	NOUN
dpc-5933	216	26	,	,	PUNCT
dpc-5933	216	27	providing	provide	VERB
dpc-5933	216	28	clinically	clinically	ADV
dpc-5933	216	29	relevant	relevant	ADJ
dpc-5933	216	30	insights	insight	NOUN
dpc-5933	216	31	into	into	ADP
dpc-5933	216	32	factors	factor	NOUN
dpc-5933	216	33	influencing	influence	VERB
dpc-5933	216	34	treatment	treatment	NOUN
dpc-5933	216	35	response	response	NOUN
dpc-5933	216	36	.	.	PUNCT
dpc-5933	217	1	our	our	PRON
dpc-5933	217	2	findings	finding	NOUN
dpc-5933	217	3	affirm	affirm	VERB
dpc-5933	217	4	the	the	DET
dpc-5933	217	5	significant	significant	ADJ
dpc-5933	217	6	therapeutic	therapeutic	ADJ
dpc-5933	217	7	potential	potential	NOUN
dpc-5933	217	8	of	of	ADP
dpc-5933	217	9	secukinumab	secukinumab	NOUN
dpc-5933	217	10	while	while	SCONJ
dpc-5933	217	11	highlighting	highlight	VERB
dpc-5933	217	12	the	the	DET
dpc-5933	217	13	role	role	NOUN
dpc-5933	217	14	of	of	ADP
dpc-5933	217	15	disease	disease	NOUN
dpc-5933	217	16	severity	severity	NOUN
dpc-5933	217	17	,	,	PUNCT
dpc-5933	217	18	treatment	treatment	NOUN
dpc-5933	217	19	timing	timing	NOUN
dpc-5933	217	20	,	,	PUNCT
dpc-5933	217	21	and	and	CCONJ
dpc-5933	217	22	prior	prior	ADJ
dpc-5933	217	23	biologics	biologic	NOUN
dpc-5933	217	24	exposure	exposure	NOUN
dpc-5933	217	25	in	in	ADP
dpc-5933	217	26	shaping	shape	VERB
dpc-5933	217	27	patient	patient	ADJ
dpc-5933	217	28	outcomes	outcome	NOUN
dpc-5933	217	29	.	.	PUNCT
dpc-5933	218	1	secukinumab	secukinumab	PROPN
dpc-5933	218	2	elicited	elicit	VERB
dpc-5933	218	3	rapid	rapid	ADJ
dpc-5933	218	4	and	and	CCONJ
dpc-5933	218	5	sustained	sustain	VERB
dpc-5933	218	6	clinical	clinical	ADJ
dpc-5933	218	7	responses	response	NOUN
dpc-5933	218	8	across	across	ADP
dpc-5933	218	9	key	key	ADJ
dpc-5933	218	10	endpoints	endpoint	NOUN
dpc-5933	218	11	,	,	PUNCT
dpc-5933	218	12	including	include	VERB
dpc-5933	218	13	hiscr	hiscr	NOUN
dpc-5933	218	14	,	,	PUNCT
dpc-5933	218	15	ihs4	ihs4	PROPN
dpc-5933	218	16	-	-	PUNCT
dpc-5933	218	17	55	55	NUM
dpc-5933	218	18	,	,	PUNCT
dpc-5933	218	19	and	and	CCONJ
dpc-5933	218	20	pain	pain	NOUN
dpc-5933	218	21	nrs30	nrs30	PROPN
dpc-5933	218	22	,	,	PUNCT
dpc-5933	218	23	with	with	ADP
dpc-5933	218	24	nearly	nearly	ADV
dpc-5933	218	25	all	all	PRON
dpc-5933	218	26	patients	patient	NOUN
dpc-5933	218	27	showing	show	VERB
dpc-5933	218	28	marked	mark	VERB
dpc-5933	218	29	improvements	improvement	NOUN
dpc-5933	218	30	by	by	ADP
dpc-5933	218	31	week	week	NOUN
dpc-5933	218	32	48	48	NUM
dpc-5933	218	33	.	.	PUNCT
dpc-5933	219	1	patients	patient	NOUN
dpc-5933	219	2	with	with	ADP
dpc-5933	219	3	hurley	hurley	PROPN
dpc-5933	219	4	stage	stage	PROPN
dpc-5933	219	5	ii	ii	PROPN
dpc-5933	219	6	disease	disease	NOUN
dpc-5933	219	7	,	,	PUNCT
dpc-5933	219	8	shorter	short	ADJ
dpc-5933	219	9	treatment	treatment	NOUN
dpc-5933	219	10	delays	delay	NOUN
dpc-5933	219	11	(	(	PUNCT
dpc-5933	219	12	<	<	X
dpc-5933	219	13	10	10	NUM
dpc-5933	219	14	years	year	NOUN
dpc-5933	219	15	)	)	PUNCT
dpc-5933	219	16	,	,	PUNCT
dpc-5933	219	17	and	and	CCONJ
dpc-5933	219	18	biologics	biologic	NOUN
dpc-5933	219	19	-	-	PUNCT
dpc-5933	219	20	naïve	naïve	ADJ
dpc-5933	219	21	status	status	NOUN
dpc-5933	219	22	exhibited	exhibit	VERB
dpc-5933	219	23	faster	fast	ADJ
dpc-5933	219	24	initial	initial	ADJ
dpc-5933	219	25	responses	response	NOUN
dpc-5933	219	26	,	,	PUNCT
dpc-5933	219	27	underscoring	underscore	VERB
dpc-5933	219	28	the	the	DET
dpc-5933	219	29	importance	importance	NOUN
dpc-5933	219	30	of	of	ADP
dpc-5933	219	31	early	early	ADJ
dpc-5933	219	32	intervention	intervention	NOUN
dpc-5933	219	33	and	and	CCONJ
dpc-5933	219	34	patient	patient	NOUN
dpc-5933	219	35	-	-	PUNCT
dpc-5933	219	36	specific	specific	ADJ
dpc-5933	219	37	treatment	treatment	NOUN
dpc-5933	219	38	planning	planning	NOUN
dpc-5933	219	39	.	.	PUNCT
dpc-5933	220	1	notably	notably	ADV
dpc-5933	220	2	,	,	PUNCT
dpc-5933	220	3	despite	despite	SCONJ
dpc-5933	220	4	these	these	DET
dpc-5933	220	5	early	early	ADJ
dpc-5933	220	6	differences	difference	NOUN
dpc-5933	220	7	,	,	PUNCT
dpc-5933	220	8	long	long	ADJ
dpc-5933	220	9	-	-	PUNCT
dpc-5933	220	10	term	term	NOUN
dpc-5933	220	11	outcomes	outcome	NOUN
dpc-5933	220	12	were	be	AUX
dpc-5933	220	13	favorable	favorable	ADJ
dpc-5933	220	14	across	across	ADP
dpc-5933	220	15	all	all	DET
dpc-5933	220	16	groups	group	NOUN
dpc-5933	220	17	,	,	PUNCT
dpc-5933	220	18	reinforcing	reinforce	VERB
dpc-5933	220	19	the	the	DET
dpc-5933	220	20	broad	broad	ADJ
dpc-5933	220	21	applicability	applicability	NOUN
dpc-5933	220	22	of	of	ADP
dpc-5933	220	23	secukinumab	secukinumab	NOUN
dpc-5933	220	24	in	in	ADP
dpc-5933	220	25	hs	hs	PROPN
dpc-5933	220	26	management	management	PROPN
dpc-5933	220	27	.	.	PUNCT
dpc-5933	221	1	the	the	DET
dpc-5933	221	2	variation	variation	NOUN
dpc-5933	221	3	in	in	ADP
dpc-5933	221	4	response	response	NOUN
dpc-5933	221	5	based	base	VERB
dpc-5933	221	6	on	on	ADP
dpc-5933	221	7	disease	disease	NOUN
dpc-5933	221	8	severity	severity	NOUN
dpc-5933	221	9	emphasizes	emphasize	VERB
dpc-5933	221	10	the	the	DET
dpc-5933	221	11	inherent	inherent	ADJ
dpc-5933	221	12	challenges	challenge	NOUN
dpc-5933	221	13	in	in	ADP
dpc-5933	221	14	treating	treat	VERB
dpc-5933	221	15	advanced	advanced	ADJ
dpc-5933	221	16	hs	h	NOUN
dpc-5933	221	17	.	.	PUNCT
dpc-5933	221	18	patients	patient	NOUN
dpc-5933	221	19	with	with	ADP
dpc-5933	221	20	hurley	hurley	PROPN
dpc-5933	221	21	stage	stage	PROPN
dpc-5933	221	22	ii	ii	PROPN
dpc-5933	221	23	disease	disease	NOUN
dpc-5933	221	24	achieved	achieve	VERB
dpc-5933	221	25	faster	fast	ADJ
dpc-5933	221	26	reductions	reduction	NOUN
dpc-5933	221	27	in	in	ADP
dpc-5933	221	28	inflammatory	inflammatory	ADJ
dpc-5933	221	29	nodules	nodule	NOUN
dpc-5933	221	30	and	and	CCONJ
dpc-5933	221	31	abscesses	abscess	NOUN
dpc-5933	221	32	,	,	PUNCT
dpc-5933	221	33	as	as	SCONJ
dpc-5933	221	34	evidenced	evidence	VERB
dpc-5933	221	35	by	by	ADP
dpc-5933	221	36	higher	high	ADJ
dpc-5933	221	37	ihs4	ihs4	PROPN
dpc-5933	221	38	-	-	PUNCT
dpc-5933	221	39	55	55	NUM
dpc-5933	221	40	rates	rate	NOUN
dpc-5933	221	41	at	at	ADP
dpc-5933	221	42	weeks	week	NOUN
dpc-5933	221	43	8	8	NUM
dpc-5933	221	44	and	and	CCONJ
dpc-5933	221	45	16	16	NUM
dpc-5933	221	46	,	,	PUNCT
dpc-5933	221	47	compared	compare	VERB
dpc-5933	221	48	to	to	ADP
dpc-5933	221	49	original	original	ADJ
dpc-5933	221	50	article	article	NOUN
dpc-5933	221	51	|	|	ADV
dpc-5933	221	52	dermatol	dermatol	ADJ
dpc-5933	221	53	pract	pract	NOUN
dpc-5933	221	54	concept	concept	NOUN
dpc-5933	221	55	.	.	PUNCT
dpc-5933	222	1	2025;15(4):5933	2025;15(4):5933	NUM
dpc-5933	222	2	9	9	NUM
dpc-5933	222	3	figure	figure	NOUN
dpc-5933	222	4	4	4	NUM
dpc-5933	222	5	.	.	PUNCT
dpc-5933	223	1	the	the	DET
dpc-5933	223	2	effect	effect	NOUN
dpc-5933	223	3	of	of	ADP
dpc-5933	223	4	secukinumab	secukinumab	NOUN
dpc-5933	223	5	,	,	PUNCT
dpc-5933	223	6	stratified	stratify	VERB
dpc-5933	223	7	by	by	ADP
dpc-5933	223	8	treatment	treatment	NOUN
dpc-5933	223	9	delay	delay	NOUN
dpc-5933	223	10	,	,	PUNCT
dpc-5933	223	11	on	on	ADP
dpc-5933	223	12	ihs4	ihs4	PROPN
dpc-5933	223	13	-	-	PUNCT
dpc-5933	223	14	55	55	NUM
dpc-5933	223	15	(	(	PUNCT
dpc-5933	223	16	a	a	NOUN
dpc-5933	223	17	)	)	PUNCT
dpc-5933	223	18	,	,	PUNCT
dpc-5933	223	19	hiscr	hiscr	NOUN
dpc-5933	223	20	(	(	PUNCT
dpc-5933	223	21	b	b	NOUN
dpc-5933	223	22	)	)	PUNCT
dpc-5933	223	23	,	,	PUNCT
dpc-5933	223	24	an	an	DET
dpc-5933	223	25	count	count	NOUN
dpc-5933	223	26	(	(	PUNCT
dpc-5933	223	27	c	c	NOUN
dpc-5933	223	28	)	)	PUNCT
dpc-5933	223	29	,	,	PUNCT
dpc-5933	223	30	and	and	CCONJ
dpc-5933	223	31	nrs30	nrs30	NOUN
dpc-5933	223	32	(	(	PUNCT
dpc-5933	223	33	d	d	NOUN
dpc-5933	223	34	)	)	PUNCT
dpc-5933	223	35	.	.	PUNCT
dpc-5933	224	1	hiscr	hiscr	PROPN
dpc-5933	224	2	,	,	PUNCT
dpc-5933	224	3	hidradenitis	hidradenitis	PROPN
dpc-5933	224	4	suppurativa	suppurativa	PROPN
dpc-5933	224	5	clinical	clinical	ADJ
dpc-5933	224	6	response	response	NOUN
dpc-5933	224	7	;	;	PUNCT
dpc-5933	224	8	ihs4	ihs4	PROPN
dpc-5933	224	9	-	-	PUNCT
dpc-5933	224	10	55	55	NUM
dpc-5933	224	11	,	,	PUNCT
dpc-5933	224	12	a	a	DET
dpc-5933	224	13	55	55	NUM
dpc-5933	224	14	%	%	NOUN
dpc-5933	224	15	reduction	reduction	NOUN
dpc-5933	224	16	in	in	ADP
dpc-5933	224	17	the	the	DET
dpc-5933	224	18	international	international	ADJ
dpc-5933	224	19	hidradenitis	hidradenitis	PROPN
dpc-5933	224	20	suppurativa	suppurativa	PROPN
dpc-5933	224	21	severity	severity	PROPN
dpc-5933	224	22	score	score	NOUN
dpc-5933	224	23	system	system	NOUN
dpc-5933	224	24	;	;	PUNCT
dpc-5933	224	25	nrs30	nrs30	PROPN
dpc-5933	224	26	,	,	PUNCT
dpc-5933	224	27	a	a	DET
dpc-5933	224	28	30	30	NUM
dpc-5933	224	29	%	%	NOUN
dpc-5933	224	30	or	or	CCONJ
dpc-5933	224	31	more	more	ADJ
dpc-5933	224	32	reduction	reduction	NOUN
dpc-5933	224	33	and	and	CCONJ
dpc-5933	224	34	a	a	DET
dpc-5933	224	35	reduction	reduction	NOUN
dpc-5933	224	36	of	of	ADP
dpc-5933	224	37	two	two	NUM
dpc-5933	224	38	units	unit	NOUN
dpc-5933	224	39	or	or	CCONJ
dpc-5933	224	40	more	more	ADJ
dpc-5933	224	41	from	from	ADP
dpc-5933	224	42	baseline	baseline	NOUN
dpc-5933	224	43	in	in	ADP
dpc-5933	224	44	patient	patient	NOUN
dpc-5933	224	45	’s	’s	PART
dpc-5933	224	46	global	global	ADJ
dpc-5933	224	47	assessment	assessment	NOUN
dpc-5933	224	48	of	of	ADP
dpc-5933	224	49	skin	skin	NOUN
dpc-5933	224	50	pain	pain	NOUN
dpc-5933	224	51	on	on	ADP
dpc-5933	224	52	a	a	DET
dpc-5933	224	53	continuous	continuous	ADJ
dpc-5933	224	54	numeric	numeric	ADJ
dpc-5933	224	55	rating	rating	NOUN
dpc-5933	224	56	scale	scale	NOUN
dpc-5933	224	57	;	;	PUNCT
dpc-5933	224	58	*	*	PUNCT
dpc-5933	224	59	p<0.05	p<0.05	NOUN
dpc-5933	224	60	;	;	PUNCT
dpc-5933	224	61	ns	ns	NUM
dpc-5933	224	62	,	,	PUNCT
dpc-5933	224	63	no	no	DET
dpc-5933	224	64	significance	significance	NOUN
dpc-5933	224	65	.	.	PUNCT
dpc-5933	225	1	those	those	PRON
dpc-5933	225	2	with	with	ADP
dpc-5933	225	3	hurley	hurley	PROPN
dpc-5933	225	4	stage	stage	PROPN
dpc-5933	225	5	iii	iii	PROPN
dpc-5933	225	6	disease	disease	NOUN
dpc-5933	225	7	,	,	PUNCT
dpc-5933	225	8	who	who	PRON
dpc-5933	225	9	exhibited	exhibit	VERB
dpc-5933	225	10	a	a	DET
dpc-5933	225	11	slower	slow	ADJ
dpc-5933	225	12	but	but	CCONJ
dpc-5933	225	13	steady	steady	ADJ
dpc-5933	225	14	trajectory	trajectory	NOUN
dpc-5933	225	15	of	of	ADP
dpc-5933	225	16	improvement	improvement	NOUN
dpc-5933	225	17	.	.	PUNCT
dpc-5933	226	1	the	the	DET
dpc-5933	226	2	limited	limited	ADJ
dpc-5933	226	3	efficacy	efficacy	NOUN
dpc-5933	226	4	of	of	ADP
dpc-5933	226	5	secukinumab	secukinumab	NOUN
dpc-5933	226	6	in	in	ADP
dpc-5933	226	7	addressing	address	VERB
dpc-5933	226	8	sinus	sinus	NOUN
dpc-5933	226	9	tracts	tract	NOUN
dpc-5933	226	10	—	—	PUNCT
dpc-5933	226	11	chronic	chronic	ADJ
dpc-5933	226	12	lesions	lesion	NOUN
dpc-5933	226	13	predominantly	predominantly	ADV
dpc-5933	226	14	observed	observe	VERB
dpc-5933	226	15	in	in	ADP
dpc-5933	226	16	severe	severe	ADJ
dpc-5933	226	17	hs	hs	PROPN
dpc-5933	226	18	—	—	PUNCT
dpc-5933	226	19	suggests	suggest	VERB
dpc-5933	226	20	the	the	DET
dpc-5933	226	21	involvement	involvement	NOUN
dpc-5933	226	22	of	of	ADP
dpc-5933	226	23	alternative	alternative	ADJ
dpc-5933	226	24	pathogenic	pathogenic	ADJ
dpc-5933	226	25	pathways	pathway	NOUN
dpc-5933	226	26	beyond	beyond	ADP
dpc-5933	226	27	il-17a	il-17a	PROPN
dpc-5933	226	28	.	.	PUNCT
dpc-5933	227	1	these	these	DET
dpc-5933	227	2	findings	finding	NOUN
dpc-5933	227	3	highlight	highlight	VERB
dpc-5933	227	4	the	the	DET
dpc-5933	227	5	need	need	NOUN
dpc-5933	227	6	for	for	ADP
dpc-5933	227	7	adjunctive	adjunctive	ADJ
dpc-5933	227	8	or	or	CCONJ
dpc-5933	227	9	combination	combination	NOUN
dpc-5933	227	10	therapies	therapy	NOUN
dpc-5933	227	11	targeting	target	VERB
dpc-5933	227	12	cytokines	cytokine	NOUN
dpc-5933	227	13	such	such	ADJ
dpc-5933	227	14	as	as	ADP
dpc-5933	227	15	tnf	tnf	PROPN
dpc-5933	227	16	-	-	PUNCT
dpc-5933	227	17	α	α	PROPN
dpc-5933	227	18	or	or	CCONJ
dpc-5933	227	19	other	other	ADJ
dpc-5933	227	20	profibrotic	profibrotic	ADJ
dpc-5933	227	21	mediators	mediator	NOUN
dpc-5933	227	22	,	,	PUNCT
dpc-5933	227	23	including	include	VERB
dpc-5933	227	24	hepatocyte	hepatocyte	NOUN
dpc-5933	227	25	growth	growth	NOUN
dpc-5933	227	26	factor	factor	NOUN
dpc-5933	227	27	,	,	PUNCT
dpc-5933	227	28	to	to	PART
dpc-5933	227	29	address	address	VERB
dpc-5933	227	30	the	the	DET
dpc-5933	227	31	complex	complex	ADJ
dpc-5933	227	32	pathophysiology	pathophysiology	NOUN
dpc-5933	227	33	of	of	ADP
dpc-5933	227	34	severe	severe	ADJ
dpc-5933	227	35	hs	hs	PROPN
dpc-5933	228	1	[	[	X
dpc-5933	228	2	21	21	NUM
dpc-5933	228	3	]	]	PUNCT
dpc-5933	228	4	.	.	PUNCT
dpc-5933	229	1	treatment	treatment	NOUN
dpc-5933	229	2	delay	delay	NOUN
dpc-5933	229	3	also	also	ADV
dpc-5933	229	4	emerged	emerge	VERB
dpc-5933	229	5	as	as	ADP
dpc-5933	229	6	a	a	DET
dpc-5933	229	7	pivotal	pivotal	ADJ
dpc-5933	229	8	determinant	determinant	NOUN
dpc-5933	229	9	of	of	ADP
dpc-5933	229	10	response	response	NOUN
dpc-5933	229	11	;	;	PUNCT
dpc-5933	229	12	patients	patient	NOUN
dpc-5933	229	13	initiating	initiate	VERB
dpc-5933	229	14	secukinumab	secukinumab	NOUN
dpc-5933	229	15	within	within	ADP
dpc-5933	229	16	10	10	NUM
dpc-5933	229	17	years	year	NOUN
dpc-5933	229	18	of	of	ADP
dpc-5933	229	19	disease	disease	NOUN
dpc-5933	229	20	onset	onset	NOUN
dpc-5933	229	21	showed	show	VERB
dpc-5933	229	22	significantly	significantly	ADV
dpc-5933	229	23	faster	fast	ADV
dpc-5933	229	24	and	and	CCONJ
dpc-5933	229	25	more	more	ADV
dpc-5933	229	26	pronounced	pronounced	ADJ
dpc-5933	229	27	improvements	improvement	NOUN
dpc-5933	229	28	in	in	ADP
dpc-5933	229	29	ihs4	ihs4	PROPN
dpc-5933	229	30	-	-	PUNCT
dpc-5933	229	31	55	55	NUM
dpc-5933	229	32	and	and	CCONJ
dpc-5933	229	33	pain	pain	NOUN
dpc-5933	229	34	nrs30	nrs30	PROPN
dpc-5933	229	35	outcomes	outcome	NOUN
dpc-5933	229	36	.	.	PUNCT
dpc-5933	230	1	these	these	DET
dpc-5933	230	2	findings	finding	NOUN
dpc-5933	230	3	align	align	VERB
dpc-5933	230	4	with	with	ADP
dpc-5933	230	5	the	the	DET
dpc-5933	230	6	concept	concept	NOUN
dpc-5933	230	7	of	of	ADP
dpc-5933	230	8	a	a	DET
dpc-5933	230	9	“	"	PUNCT
dpc-5933	230	10	therapeutic	therapeutic	ADJ
dpc-5933	230	11	window	window	NOUN
dpc-5933	230	12	of	of	ADP
dpc-5933	230	13	opportunity	opportunity	NOUN
dpc-5933	230	14	,	,	PUNCT
dpc-5933	230	15	”	"	PUNCT
dpc-5933	230	16	wherein	wherein	SCONJ
dpc-5933	230	17	early	early	ADJ
dpc-5933	230	18	biologics	biologic	NOUN
dpc-5933	230	19	intervention	intervention	NOUN
dpc-5933	230	20	may	may	AUX
dpc-5933	230	21	prevent	prevent	VERB
dpc-5933	230	22	irreversible	irreversible	ADJ
dpc-5933	230	23	disease	disease	NOUN
dpc-5933	230	24	progression	progression	NOUN
dpc-5933	230	25	characterized	characterize	VERB
dpc-5933	230	26	by	by	ADP
dpc-5933	230	27	fistula	fistula	NOUN
dpc-5933	230	28	formation	formation	NOUN
dpc-5933	230	29	and	and	CCONJ
dpc-5933	230	30	scarring	scarring	NOUN
dpc-5933	230	31	.	.	PUNCT
dpc-5933	231	1	to	to	PART
dpc-5933	231	2	illustrate	illustrate	VERB
dpc-5933	231	3	,	,	PUNCT
dpc-5933	231	4	a	a	DET
dpc-5933	231	5	retrospective	retrospective	ADJ
dpc-5933	231	6	italian	italian	ADJ
dpc-5933	231	7	cohort	cohort	NOUN
dpc-5933	231	8	found	find	VERB
dpc-5933	231	9	that	that	SCONJ
dpc-5933	231	10	longer	long	ADJ
dpc-5933	231	11	delays	delay	NOUN
dpc-5933	231	12	in	in	ADP
dpc-5933	231	13	adalimumab	adalimumab	NOUN
dpc-5933	231	14	initiation	initiation	NOUN
dpc-5933	231	15	correlated	correlate	VERB
dpc-5933	231	16	with	with	ADP
dpc-5933	231	17	poorer	poor	ADJ
dpc-5933	231	18	response	response	NOUN
dpc-5933	231	19	,	,	PUNCT
dpc-5933	231	20	and	and	CCONJ
dpc-5933	231	21	a	a	DET
dpc-5933	231	22	recent	recent	ADJ
dpc-5933	231	23	multicenter	multicenter	ADJ
dpc-5933	231	24	study	study	NOUN
dpc-5933	231	25	reported	report	VERB
dpc-5933	231	26	that	that	SCONJ
dpc-5933	231	27	high	high	ADJ
dpc-5933	231	28	“	"	PUNCT
dpc-5933	231	29	therapeutic	therapeutic	ADJ
dpc-5933	231	30	burden	burden	NOUN
dpc-5933	231	31	”	"	PUNCT
dpc-5933	231	32	(	(	PUNCT
dpc-5933	231	33	many	many	ADJ
dpc-5933	231	34	prior	prior	ADJ
dpc-5933	231	35	treatments	treatment	NOUN
dpc-5933	231	36	)	)	PUNCT
dpc-5933	231	37	was	be	AUX
dpc-5933	231	38	inversely	inversely	ADV
dpc-5933	231	39	related	relate	VERB
dpc-5933	231	40	to	to	AUX
dpc-5933	231	41	secukinumab	secukinumab	VERB
dpc-5933	231	42	response	response	NOUN
dpc-5933	232	1	[	[	X
dpc-5933	232	2	15,22	15,22	NUM
dpc-5933	232	3	]	]	PUNCT
dpc-5933	232	4	.	.	PUNCT
dpc-5933	233	1	these	these	DET
dpc-5933	233	2	data	datum	NOUN
dpc-5933	233	3	support	support	VERB
dpc-5933	233	4	our	our	PRON
dpc-5933	233	5	emphasis	emphasis	NOUN
dpc-5933	233	6	that	that	SCONJ
dpc-5933	233	7	prompt	prompt	ADJ
dpc-5933	233	8	recognition	recognition	NOUN
dpc-5933	233	9	and	and	CCONJ
dpc-5933	233	10	therapy	therapy	NOUN
dpc-5933	233	11	are	be	AUX
dpc-5933	233	12	crucial	crucial	ADJ
dpc-5933	233	13	to	to	ADP
dpc-5933	233	14	optimizing	optimize	VERB
dpc-5933	233	15	long	long	ADJ
dpc-5933	233	16	-	-	PUNCT
dpc-5933	233	17	term	term	NOUN
dpc-5933	233	18	outcomes	outcome	NOUN
dpc-5933	233	19	.	.	PUNCT
dpc-5933	234	1	prior	prior	ADJ
dpc-5933	234	2	biologics	biologic	NOUN
dpc-5933	234	3	exposure	exposure	NOUN
dpc-5933	234	4	further	far	ADV
dpc-5933	234	5	influenced	influence	VERB
dpc-5933	234	6	treatment	treatment	NOUN
dpc-5933	234	7	efficacy	efficacy	NOUN
dpc-5933	234	8	.	.	PUNCT
dpc-5933	235	1	biologics	biologic	NOUN
dpc-5933	235	2	-	-	PUNCT
dpc-5933	235	3	naïve	naïve	ADJ
dpc-5933	235	4	patients	patient	NOUN
dpc-5933	235	5	achieved	achieve	VERB
dpc-5933	235	6	superior	superior	ADJ
dpc-5933	235	7	ihs455	ihs455	PROPN
dpc-5933	235	8	rates	rate	NOUN
dpc-5933	235	9	at	at	ADP
dpc-5933	235	10	week	week	NOUN
dpc-5933	235	11	16	16	NUM
dpc-5933	235	12	compared	compare	VERB
dpc-5933	235	13	to	to	ADP
dpc-5933	235	14	those	those	PRON
dpc-5933	235	15	with	with	ADP
dpc-5933	235	16	prior	prior	ADJ
dpc-5933	235	17	biologics	biologic	NOUN
dpc-5933	235	18	failure	failure	NOUN
dpc-5933	235	19	,	,	PUNCT
dpc-5933	235	20	although	although	SCONJ
dpc-5933	235	21	response	response	NOUN
dpc-5933	235	22	rates	rate	NOUN
dpc-5933	235	23	between	between	ADP
dpc-5933	235	24	the	the	DET
dpc-5933	235	25	two	two	NUM
dpc-5933	235	26	groups	group	NOUN
dpc-5933	235	27	converged	converge	VERB
dpc-5933	235	28	by	by	ADP
dpc-5933	235	29	week	week	NOUN
dpc-5933	235	30	48	48	NUM
dpc-5933	235	31	.	.	PUNCT
dpc-5933	236	1	this	this	DET
dpc-5933	236	2	observation	observation	NOUN
dpc-5933	236	3	suggests	suggest	VERB
dpc-5933	236	4	that	that	SCONJ
dpc-5933	236	5	prior	prior	ADJ
dpc-5933	236	6	biologics	biologic	NOUN
dpc-5933	236	7	failure	failure	NOUN
dpc-5933	236	8	may	may	AUX
dpc-5933	236	9	indicate	indicate	VERB
dpc-5933	236	10	more	more	ADJ
dpc-5933	236	11	refractory	refractory	NOUN
dpc-5933	236	12	disease	disease	NOUN
dpc-5933	236	13	phenotypes	phenotype	NOUN
dpc-5933	236	14	,	,	PUNCT
dpc-5933	236	15	potentially	potentially	ADV
dpc-5933	236	16	necessitating	necessitate	VERB
dpc-5933	236	17	more	more	ADV
dpc-5933	236	18	prolonged	prolonged	ADJ
dpc-5933	236	19	or	or	CCONJ
dpc-5933	236	20	intensified	intensify	VERB
dpc-5933	236	21	therapeutic	therapeutic	ADJ
dpc-5933	236	22	regimens	regimen	NOUN
dpc-5933	236	23	.	.	PUNCT
dpc-5933	237	1	nevertheless	nevertheless	ADV
dpc-5933	237	2	,	,	PUNCT
dpc-5933	237	3	the	the	DET
dpc-5933	237	4	comparable	comparable	ADJ
dpc-5933	237	5	longterm	longterm	PROPN
dpc-5933	237	6	efficacy	efficacy	NOUN
dpc-5933	237	7	observed	observe	VERB
dpc-5933	237	8	in	in	ADP
dpc-5933	237	9	both	both	DET
dpc-5933	237	10	groups	group	NOUN
dpc-5933	237	11	underscores	underscore	VERB
dpc-5933	237	12	secukinumab	secukinumab	NOUN
dpc-5933	237	13	’s	’s	PART
dpc-5933	237	14	therapeutic	therapeutic	ADJ
dpc-5933	237	15	versatility	versatility	NOUN
dpc-5933	237	16	in	in	ADP
dpc-5933	237	17	both	both	DET
dpc-5933	237	18	treatment	treatment	NOUN
dpc-5933	237	19	-	-	PUNCT
dpc-5933	237	20	naïve	naïve	ADJ
dpc-5933	237	21	and	and	CCONJ
dpc-5933	237	22	biologics	biologic	NOUN
dpc-5933	237	23	-	-	PUNCT
dpc-5933	237	24	experienced	experience	VERB
dpc-5933	237	25	populations	population	NOUN
dpc-5933	237	26	.	.	PUNCT
dpc-5933	238	1	an	an	DET
dpc-5933	238	2	additional	additional	ADJ
dpc-5933	238	3	strength	strength	NOUN
dpc-5933	238	4	of	of	ADP
dpc-5933	238	5	secukinumab	secukinumab	NOUN
dpc-5933	238	6	therapy	therapy	NOUN
dpc-5933	238	7	observed	observe	VERB
dpc-5933	238	8	in	in	ADP
dpc-5933	238	9	this	this	DET
dpc-5933	238	10	study	study	NOUN
dpc-5933	238	11	was	be	AUX
dpc-5933	238	12	the	the	DET
dpc-5933	238	13	significant	significant	ADJ
dpc-5933	238	14	reduction	reduction	NOUN
dpc-5933	238	15	in	in	ADP
dpc-5933	238	16	systemic	systemic	ADJ
dpc-5933	238	17	antibiotic	antibiotic	ADJ
dpc-5933	238	18	usage	usage	NOUN
dpc-5933	238	19	.	.	PUNCT
dpc-5933	239	1	nearly	nearly	ADV
dpc-5933	239	2	all	all	DET
dpc-5933	239	3	patients	patient	NOUN
dpc-5933	239	4	discontinued	discontinue	VERB
dpc-5933	239	5	or	or	CCONJ
dpc-5933	239	6	transitioned	transition	VERB
dpc-5933	239	7	to	to	ADP
dpc-5933	239	8	antibiotic	antibiotic	ADJ
dpc-5933	239	9	monotherapy	monotherapy	NOUN
dpc-5933	239	10	,	,	PUNCT
dpc-5933	239	11	with	with	SCONJ
dpc-5933	239	12	the	the	DET
dpc-5933	239	13	effect	effect	NOUN
dpc-5933	239	14	being	be	AUX
dpc-5933	239	15	particularly	particularly	ADV
dpc-5933	239	16	pronounced	pronounce	VERB
dpc-5933	239	17	in	in	ADP
dpc-5933	239	18	those	those	PRON
dpc-5933	239	19	with	with	ADP
dpc-5933	239	20	moderate	moderate	ADJ
dpc-5933	239	21	disease	disease	NOUN
dpc-5933	239	22	.	.	PUNCT
dpc-5933	240	1	this	this	DET
dpc-5933	240	2	highlights	highlight	NOUN
dpc-5933	240	3	secukinumab	secukinumab	PROPN
dpc-5933	240	4	’s	’s	PART
dpc-5933	240	5	immunomodulatory	immunomodulatory	ADJ
dpc-5933	240	6	capabilities	capability	NOUN
dpc-5933	240	7	in	in	ADP
dpc-5933	240	8	mitigating	mitigate	VERB
dpc-5933	240	9	the	the	DET
dpc-5933	240	10	inflammatory	inflammatory	ADJ
dpc-5933	240	11	drivers	driver	NOUN
dpc-5933	240	12	of	of	ADP
dpc-5933	240	13	hs	hs	PROPN
dpc-5933	240	14	and	and	CCONJ
dpc-5933	240	15	in	in	ADP
dpc-5933	240	16	reducing	reduce	VERB
dpc-5933	240	17	reliance	reliance	NOUN
dpc-5933	240	18	on	on	ADP
dpc-5933	240	19	systemic	systemic	ADJ
dpc-5933	240	20	antibiotics	antibiotic	NOUN
dpc-5933	240	21	[	[	X
dpc-5933	240	22	4	4	NUM
dpc-5933	240	23	]	]	PUNCT
dpc-5933	240	24	.	.	PUNCT
dpc-5933	241	1	given	give	VERB
dpc-5933	241	2	the	the	DET
dpc-5933	241	3	increasing	increase	VERB
dpc-5933	241	4	global	global	ADJ
dpc-5933	241	5	concern	concern	NOUN
dpc-5933	241	6	over	over	ADP
dpc-5933	241	7	antimicrobial	antimicrobial	ADJ
dpc-5933	241	8	resistance	resistance	NOUN
dpc-5933	241	9	,	,	PUNCT
dpc-5933	241	10	this	this	DET
dpc-5933	241	11	finding	finding	NOUN
dpc-5933	241	12	is	be	AUX
dpc-5933	241	13	10	10	NUM
dpc-5933	241	14	original	original	ADJ
dpc-5933	241	15	article	article	NOUN
dpc-5933	241	16	|	|	ADV
dpc-5933	241	17	dermatol	dermatol	ADJ
dpc-5933	241	18	pract	pract	NOUN
dpc-5933	241	19	concept	concept	NOUN
dpc-5933	241	20	.	.	PUNCT
dpc-5933	242	1	2025;15(4):5933	2025;15(4):5933	NUM
dpc-5933	242	2	figure	figure	NOUN
dpc-5933	242	3	5	5	NUM
dpc-5933	242	4	.	.	PUNCT
dpc-5933	243	1	the	the	DET
dpc-5933	243	2	effect	effect	NOUN
dpc-5933	243	3	of	of	ADP
dpc-5933	243	4	secukinumab	secukinumab	NOUN
dpc-5933	243	5	,	,	PUNCT
dpc-5933	243	6	stratified	stratify	VERB
dpc-5933	243	7	by	by	ADP
dpc-5933	243	8	prior	prior	ADJ
dpc-5933	243	9	biologics	biologic	NOUN
dpc-5933	243	10	use	use	VERB
dpc-5933	243	11	,	,	PUNCT
dpc-5933	243	12	on	on	ADP
dpc-5933	243	13	ihs4	ihs4	PROPN
dpc-5933	243	14	-	-	PUNCT
dpc-5933	243	15	55	55	NUM
dpc-5933	243	16	(	(	PUNCT
dpc-5933	243	17	a	a	NOUN
dpc-5933	243	18	)	)	PUNCT
dpc-5933	243	19	,	,	PUNCT
dpc-5933	243	20	hiscr	hiscr	NOUN
dpc-5933	243	21	(	(	PUNCT
dpc-5933	243	22	b	b	NOUN
dpc-5933	243	23	)	)	PUNCT
dpc-5933	243	24	,	,	PUNCT
dpc-5933	243	25	an	an	DET
dpc-5933	243	26	count	count	NOUN
dpc-5933	243	27	(	(	PUNCT
dpc-5933	243	28	c	c	NOUN
dpc-5933	243	29	)	)	PUNCT
dpc-5933	243	30	,	,	PUNCT
dpc-5933	243	31	and	and	CCONJ
dpc-5933	243	32	nrs30	nrs30	NOUN
dpc-5933	243	33	(	(	PUNCT
dpc-5933	243	34	d	d	NOUN
dpc-5933	243	35	)	)	PUNCT
dpc-5933	243	36	.	.	PUNCT
dpc-5933	244	1	hiscr	hiscr	PROPN
dpc-5933	244	2	,	,	PUNCT
dpc-5933	244	3	hidradenitis	hidradenitis	PROPN
dpc-5933	244	4	suppurativa	suppurativa	PROPN
dpc-5933	244	5	clinical	clinical	ADJ
dpc-5933	244	6	response	response	NOUN
dpc-5933	244	7	;	;	PUNCT
dpc-5933	244	8	ihs4	ihs4	PROPN
dpc-5933	244	9	-	-	PUNCT
dpc-5933	244	10	55	55	NUM
dpc-5933	244	11	,	,	PUNCT
dpc-5933	244	12	a	a	DET
dpc-5933	244	13	55	55	NUM
dpc-5933	244	14	%	%	NOUN
dpc-5933	244	15	reduction	reduction	NOUN
dpc-5933	244	16	in	in	ADP
dpc-5933	244	17	the	the	DET
dpc-5933	244	18	international	international	ADJ
dpc-5933	244	19	hidradenitis	hidradenitis	PROPN
dpc-5933	244	20	suppurativa	suppurativa	PROPN
dpc-5933	244	21	severity	severity	PROPN
dpc-5933	244	22	score	score	NOUN
dpc-5933	244	23	system	system	NOUN
dpc-5933	244	24	,	,	PUNCT
dpc-5933	244	25	an	an	PRON
dpc-5933	244	26	,	,	PUNCT
dpc-5933	244	27	abscess	abscess	NOUN
dpc-5933	244	28	and	and	CCONJ
dpc-5933	244	29	nodule	nodule	NOUN
dpc-5933	244	30	count	count	NOUN
dpc-5933	244	31	;	;	PUNCT
dpc-5933	244	32	nrs30	nrs30	PROPN
dpc-5933	244	33	,	,	PUNCT
dpc-5933	244	34	a	a	DET
dpc-5933	244	35	30	30	NUM
dpc-5933	244	36	%	%	NOUN
dpc-5933	244	37	or	or	CCONJ
dpc-5933	244	38	more	more	ADJ
dpc-5933	244	39	reduction	reduction	NOUN
dpc-5933	244	40	and	and	CCONJ
dpc-5933	244	41	a	a	DET
dpc-5933	244	42	reduction	reduction	NOUN
dpc-5933	244	43	of	of	ADP
dpc-5933	244	44	two	two	NUM
dpc-5933	244	45	units	unit	NOUN
dpc-5933	244	46	or	or	CCONJ
dpc-5933	244	47	more	more	ADJ
dpc-5933	244	48	from	from	ADP
dpc-5933	244	49	baseline	baseline	NOUN
dpc-5933	244	50	in	in	ADP
dpc-5933	244	51	patient	patient	NOUN
dpc-5933	244	52	’s	’s	PART
dpc-5933	244	53	global	global	ADJ
dpc-5933	244	54	assessment	assessment	NOUN
dpc-5933	244	55	of	of	ADP
dpc-5933	244	56	skin	skin	NOUN
dpc-5933	244	57	pain	pain	NOUN
dpc-5933	244	58	on	on	ADP
dpc-5933	244	59	a	a	DET
dpc-5933	244	60	continuous	continuous	ADJ
dpc-5933	244	61	numeric	numeric	ADJ
dpc-5933	244	62	rating	rating	NOUN
dpc-5933	244	63	scale	scale	NOUN
dpc-5933	244	64	;	;	PUNCT
dpc-5933	244	65	*	*	PUNCT
dpc-5933	244	66	p<0.05	p<0.05	NOUN
dpc-5933	244	67	;	;	PUNCT
dpc-5933	244	68	ns	ns	NUM
dpc-5933	244	69	,	,	PUNCT
dpc-5933	244	70	no	no	DET
dpc-5933	244	71	significance	significance	NOUN
dpc-5933	244	72	.	.	PUNCT
dpc-5933	245	1	figure	figure	NOUN
dpc-5933	245	2	6	6	NUM
dpc-5933	245	3	.	.	PUNCT
dpc-5933	246	1	the	the	DET
dpc-5933	246	2	duration	duration	NOUN
dpc-5933	246	3	of	of	ADP
dpc-5933	246	4	systemic	systemic	ADJ
dpc-5933	246	5	antibiotic	antibiotic	ADJ
dpc-5933	246	6	treatment	treatment	NOUN
dpc-5933	246	7	stratified	stratify	VERB
dpc-5933	246	8	by	by	ADP
dpc-5933	246	9	hurley	hurley	PROPN
dpc-5933	246	10	stage	stage	NOUN
dpc-5933	246	11	after	after	ADP
dpc-5933	246	12	the	the	DET
dpc-5933	246	13	administration	administration	NOUN
dpc-5933	246	14	of	of	ADP
dpc-5933	246	15	secukinumab	secukinumab	NOUN
dpc-5933	246	16	.	.	PUNCT
dpc-5933	247	1	#	#	SYM
dpc-5933	247	2	#	#	NOUN
dpc-5933	247	3	p<0.01	p<0.01	PROPN
dpc-5933	247	4	,	,	PUNCT
dpc-5933	247	5	mann	mann	PROPN
dpc-5933	247	6	-	-	PUNCT
dpc-5933	247	7	whitney	whitney	PROPN
dpc-5933	247	8	test	test	NOUN
dpc-5933	247	9	;	;	PUNCT
dpc-5933	247	10	*	*	PUNCT
dpc-5933	247	11	*	*	PUNCT
dpc-5933	247	12	p<0.01	p<0.01	PROPN
dpc-5933	247	13	,	,	PUNCT
dpc-5933	247	14	independent	independent	ADJ
dpc-5933	247	15	t	t	NOUN
dpc-5933	247	16	-	-	PUNCT
dpc-5933	247	17	test	test	NOUN
dpc-5933	247	18	;	;	PUNCT
dpc-5933	247	19	ns	ns	X
dpc-5933	247	20	,	,	PUNCT
dpc-5933	247	21	no	no	DET
dpc-5933	247	22	significance	significance	NOUN
dpc-5933	247	23	.	.	PUNCT
dpc-5933	248	1	clinically	clinically	ADV
dpc-5933	248	2	significant	significant	ADJ
dpc-5933	248	3	.	.	PUNCT
dpc-5933	249	1	however	however	ADV
dpc-5933	249	2	,	,	PUNCT
dpc-5933	249	3	further	further	ADJ
dpc-5933	249	4	studies	study	NOUN
dpc-5933	249	5	incorporating	incorporate	VERB
dpc-5933	249	6	direct	direct	ADJ
dpc-5933	249	7	comparisons	comparison	NOUN
dpc-5933	249	8	between	between	ADP
dpc-5933	249	9	antibiotic	antibiotic	ADJ
dpc-5933	249	10	usage	usage	NOUN
dpc-5933	249	11	preand	preand	NOUN
dpc-5933	249	12	post	post	NOUN
dpc-5933	249	13	treatment	treatment	NOUN
dpc-5933	249	14	are	be	AUX
dpc-5933	249	15	warranted	warrant	VERB
dpc-5933	249	16	to	to	PART
dpc-5933	249	17	substantiate	substantiate	VERB
dpc-5933	249	18	these	these	DET
dpc-5933	249	19	observations	observation	NOUN
dpc-5933	249	20	.	.	PUNCT
dpc-5933	250	1	another	another	DET
dpc-5933	250	2	novelty	novelty	NOUN
dpc-5933	250	3	stemming	stem	VERB
dpc-5933	250	4	from	from	ADP
dpc-5933	250	5	our	our	PRON
dpc-5933	250	6	study	study	NOUN
dpc-5933	250	7	is	be	AUX
dpc-5933	250	8	the	the	DET
dpc-5933	250	9	demonstration	demonstration	NOUN
dpc-5933	250	10	of	of	ADP
dpc-5933	250	11	secukinumab	secukinumab	NOUN
dpc-5933	250	12	efficacy	efficacy	NOUN
dpc-5933	250	13	on	on	ADP
dpc-5933	250	14	korean	korean	PROPN
dpc-5933	250	15	hs	hs	PROPN
dpc-5933	250	16	patients	patient	NOUN
dpc-5933	250	17	,	,	PUNCT
dpc-5933	250	18	a	a	DET
dpc-5933	250	19	subgroup	subgroup	NOUN
dpc-5933	250	20	with	with	ADP
dpc-5933	250	21	various	various	ADJ
dpc-5933	250	22	features	feature	NOUN
dpc-5933	250	23	distinct	distinct	ADJ
dpc-5933	250	24	from	from	ADP
dpc-5933	250	25	those	those	PRON
dpc-5933	250	26	of	of	ADP
dpc-5933	250	27	the	the	DET
dpc-5933	250	28	global	global	ADJ
dpc-5933	250	29	population	population	NOUN
dpc-5933	250	30	.	.	PUNCT
dpc-5933	251	1	nationwide	nationwide	ADJ
dpc-5933	251	2	data	datum	NOUN
dpc-5933	251	3	showed	show	VERB
dpc-5933	251	4	that	that	SCONJ
dpc-5933	251	5	the	the	DET
dpc-5933	251	6	incidence	incidence	NOUN
dpc-5933	251	7	of	of	ADP
dpc-5933	251	8	hs	hs	PROPN
dpc-5933	251	9	in	in	ADP
dpc-5933	251	10	korea	korea	PROPN
dpc-5933	251	11	rose	rise	VERB
dpc-5933	251	12	six	six	NUM
dpc-5933	251	13	-	-	NOUN
dpc-5933	251	14	fold	fold	NOUN
dpc-5933	251	15	between	between	ADP
dpc-5933	251	16	2003	2003	NUM
dpc-5933	251	17	and	and	CCONJ
dpc-5933	251	18	2019	2019	NUM
dpc-5933	251	19	(	(	PUNCT
dpc-5933	251	20	from	from	ADP
dpc-5933	251	21	11.7	11.7	NUM
dpc-5933	251	22	to	to	PART
dpc-5933	251	23	78.8	78.8	NUM
dpc-5933	251	24	cases	case	NOUN
dpc-5933	251	25	per	per	ADP
dpc-5933	251	26	million	million	NUM
dpc-5933	251	27	person	person	NOUN
dpc-5933	251	28	-	-	PUNCT
dpc-5933	251	29	years	year	NOUN
dpc-5933	251	30	)	)	PUNCT
dpc-5933	251	31	,	,	PUNCT
dpc-5933	251	32	but	but	CCONJ
dpc-5933	251	33	overall	overall	ADJ
dpc-5933	251	34	prevalence	prevalence	NOUN
dpc-5933	251	35	remained	remain	VERB
dpc-5933	251	36	low	low	ADJ
dpc-5933	251	37	(	(	PUNCT
dpc-5933	251	38	0.06	0.06	NUM
dpc-5933	251	39	%	%	NOUN
dpc-5933	251	40	)	)	PUNCT
dpc-5933	251	41	,	,	PUNCT
dpc-5933	251	42	and	and	CCONJ
dpc-5933	251	43	the	the	DET
dpc-5933	251	44	disease	disease	NOUN
dpc-5933	251	45	was	be	AUX
dpc-5933	251	46	male	male	NOUN
dpc-5933	251	47	-	-	PUNCT
dpc-5933	251	48	predominant	predominant	ADJ
dpc-5933	251	49	(	(	PUNCT
dpc-5933	251	50	female	female	NOUN
dpc-5933	251	51	-	-	PUNCT
dpc-5933	251	52	to	to	ADP
dpc-5933	251	53	-	-	PUNCT
dpc-5933	251	54	male	male	NOUN
dpc-5933	251	55	ratio	ratio	NOUN
dpc-5933	251	56	of	of	ADP
dpc-5933	251	57	about	about	ADP
dpc-5933	251	58	1:1.6	1:1.6	NUM
dpc-5933	251	59	)	)	PUNCT
dpc-5933	252	1	[	[	X
dpc-5933	252	2	23,24	23,24	NUM
dpc-5933	252	3	]	]	PUNCT
dpc-5933	252	4	.	.	PUNCT
dpc-5933	253	1	in	in	ADP
dpc-5933	253	2	contrast	contrast	NOUN
dpc-5933	253	3	,	,	PUNCT
dpc-5933	253	4	most	most	ADJ
dpc-5933	253	5	north	north	ADJ
dpc-5933	253	6	american	american	ADJ
dpc-5933	253	7	and	and	CCONJ
dpc-5933	253	8	european	european	ADJ
dpc-5933	253	9	cohorts	cohort	NOUN
dpc-5933	253	10	reported	report	VERB
dpc-5933	253	11	a	a	DET
dpc-5933	253	12	prevalence	prevalence	NOUN
dpc-5933	253	13	of	of	ADP
dpc-5933	253	14	0.1–1.0	0.1–1.0	NOUN
dpc-5933	253	15	%	%	NOUN
dpc-5933	253	16	and	and	CCONJ
dpc-5933	253	17	a	a	DET
dpc-5933	253	18	femaleto	femaleto	NOUN
dpc-5933	253	19	-	-	PUNCT
dpc-5933	253	20	male	male	NOUN
dpc-5933	253	21	ratio	ratio	NOUN
dpc-5933	253	22	of	of	ADP
dpc-5933	253	23	roughly	roughly	ADV
dpc-5933	253	24	3:1	3:1	NUM
dpc-5933	253	25	[	[	X
dpc-5933	253	26	25	25	NUM
dpc-5933	253	27	]	]	PUNCT
dpc-5933	253	28	.	.	PUNCT
dpc-5933	254	1	these	these	DET
dpc-5933	254	2	demographic	demographic	ADJ
dpc-5933	254	3	differences	difference	NOUN
dpc-5933	254	4	underline	underline	VERB
dpc-5933	254	5	the	the	DET
dpc-5933	254	6	importance	importance	NOUN
dpc-5933	254	7	of	of	ADP
dpc-5933	254	8	region	region	NOUN
dpc-5933	254	9	-	-	PUNCT
dpc-5933	254	10	specific	specific	ADJ
dpc-5933	254	11	real	real	ADJ
dpc-5933	254	12	-	-	PUNCT
dpc-5933	254	13	world	world	NOUN
dpc-5933	254	14	data	datum	NOUN
dpc-5933	254	15	such	such	ADJ
dpc-5933	254	16	as	as	ADP
dpc-5933	254	17	ours	our	NOUN
dpc-5933	254	18	when	when	SCONJ
dpc-5933	254	19	evaluating	evaluate	VERB
dpc-5933	254	20	treatment	treatment	NOUN
dpc-5933	254	21	response	response	NOUN
dpc-5933	254	22	.	.	PUNCT
dpc-5933	255	1	from	from	ADP
dpc-5933	255	2	a	a	DET
dpc-5933	255	3	safety	safety	NOUN
dpc-5933	255	4	perspective	perspective	NOUN
dpc-5933	255	5	,	,	PUNCT
dpc-5933	255	6	secukinumab	secukinumab	NOUN
dpc-5933	255	7	was	be	AUX
dpc-5933	255	8	well	well	ADV
dpc-5933	255	9	tolerated	tolerate	VERB
dpc-5933	255	10	,	,	PUNCT
dpc-5933	255	11	with	with	ADP
dpc-5933	255	12	no	no	DET
dpc-5933	255	13	serious	serious	ADJ
dpc-5933	255	14	adverse	adverse	ADJ
dpc-5933	255	15	event	event	NOUN
dpc-5933	255	16	or	or	CCONJ
dpc-5933	255	17	treatment	treatment	NOUN
dpc-5933	255	18	discontinuation	discontinuation	NOUN
dpc-5933	255	19	reported	report	VERB
dpc-5933	255	20	during	during	ADP
dpc-5933	255	21	the	the	DET
dpc-5933	255	22	study	study	NOUN
dpc-5933	255	23	period	period	NOUN
dpc-5933	255	24	.	.	PUNCT
dpc-5933	256	1	these	these	DET
dpc-5933	256	2	findings	finding	NOUN
dpc-5933	256	3	are	be	AUX
dpc-5933	256	4	consistent	consistent	ADJ
dpc-5933	256	5	with	with	ADP
dpc-5933	256	6	data	datum	NOUN
dpc-5933	256	7	from	from	ADP
dpc-5933	256	8	pivotal	pivotal	ADJ
dpc-5933	256	9	rcts	rct	NOUN
dpc-5933	256	10	,	,	PUNCT
dpc-5933	256	11	including	include	VERB
dpc-5933	256	12	the	the	DET
dpc-5933	256	13	sunshine	sunshine	NOUN
dpc-5933	256	14	and	and	CCONJ
dpc-5933	256	15	sunrise	sunrise	VERB
dpc-5933	256	16	trials	trial	NOUN
dpc-5933	256	17	,	,	PUNCT
dpc-5933	256	18	which	which	PRON
dpc-5933	256	19	reported	report	VERB
dpc-5933	256	20	favorable	favorable	ADJ
dpc-5933	256	21	safety	safety	NOUN
dpc-5933	256	22	profiles	profile	NOUN
dpc-5933	256	23	[	[	X
dpc-5933	256	24	9	9	NUM
dpc-5933	256	25	]	]	PUNCT
dpc-5933	256	26	.	.	PUNCT
dpc-5933	257	1	although	although	SCONJ
dpc-5933	257	2	vigilance	vigilance	NOUN
dpc-5933	257	3	remains	remain	VERB
dpc-5933	257	4	necessary	necessary	ADJ
dpc-5933	257	5	,	,	PUNCT
dpc-5933	257	6	particularly	particularly	ADV
dpc-5933	257	7	in	in	ADP
dpc-5933	257	8	patients	patient	NOUN
dpc-5933	257	9	with	with	ADP
dpc-5933	257	10	coexisting	coexist	VERB
dpc-5933	257	11	inflammatory	inflammatory	ADJ
dpc-5933	257	12	bowel	bowel	NOUN
dpc-5933	257	13	disease	disease	NOUN
dpc-5933	257	14	[	[	X
dpc-5933	257	15	9,26	9,26	X
dpc-5933	257	16	]	]	X
dpc-5933	257	17	,	,	PUNCT
dpc-5933	257	18	the	the	DET
dpc-5933	257	19	safety	safety	NOUN
dpc-5933	257	20	and	and	CCONJ
dpc-5933	257	21	tolerability	tolerability	NOUN
dpc-5933	257	22	of	of	ADP
dpc-5933	257	23	secukinumab	secukinumab	NOUN
dpc-5933	257	24	affirm	affirm	NOUN
dpc-5933	257	25	its	its	PRON
dpc-5933	257	26	suitability	suitability	NOUN
dpc-5933	257	27	for	for	ADP
dpc-5933	257	28	long	long	ADJ
dpc-5933	257	29	-	-	PUNCT
dpc-5933	257	30	term	term	NOUN
dpc-5933	257	31	management	management	NOUN
dpc-5933	257	32	of	of	ADP
dpc-5933	257	33	hs	hs	PROPN
dpc-5933	257	34	.	.	PROPN
dpc-5933	257	35	in	in	ADP
dpc-5933	257	36	spite	spite	NOUN
dpc-5933	257	37	of	of	ADP
dpc-5933	257	38	promising	promise	VERB
dpc-5933	257	39	results	result	NOUN
dpc-5933	257	40	regarding	regard	VERB
dpc-5933	257	41	biologic	biologic	NOUN
dpc-5933	257	42	therapy	therapy	NOUN
dpc-5933	257	43	,	,	PUNCT
dpc-5933	257	44	optimal	optimal	ADJ
dpc-5933	257	45	hs	hs	PROPN
dpc-5933	257	46	management	management	PROPN
dpc-5933	257	47	still	still	ADV
dpc-5933	257	48	requires	require	VERB
dpc-5933	257	49	a	a	DET
dpc-5933	257	50	multidisciplinary	multidisciplinary	ADJ
dpc-5933	257	51	approach	approach	NOUN
dpc-5933	257	52	.	.	PUNCT
dpc-5933	258	1	hs	hs	PROPN
dpc-5933	258	2	patients	patient	NOUN
dpc-5933	258	3	benefit	benefit	VERB
dpc-5933	258	4	from	from	ADP
dpc-5933	258	5	comprehensive	comprehensive	ADJ
dpc-5933	258	6	care	care	NOUN
dpc-5933	258	7	original	original	ADJ
dpc-5933	258	8	article	article	NOUN
dpc-5933	258	9	|	|	ADV
dpc-5933	258	10	dermatol	dermatol	ADJ
dpc-5933	258	11	pract	pract	NOUN
dpc-5933	258	12	concept	concept	NOUN
dpc-5933	258	13	.	.	PUNCT
dpc-5933	259	1	2025;15(4):5933	2025;15(4):5933	NUM
dpc-5933	259	2	11	11	NUM
dpc-5933	259	3	table	table	NOUN
dpc-5933	259	4	3	3	NUM
dpc-5933	259	5	.	.	PUNCT
dpc-5933	259	6	adverse	adverse	ADJ
dpc-5933	259	7	events	event	NOUN
dpc-5933	259	8	during	during	ADP
dpc-5933	259	9	48	48	NUM
dpc-5933	259	10	weeks	week	NOUN
dpc-5933	259	11	of	of	ADP
dpc-5933	259	12	secukinumab	secukinumab	NOUN
dpc-5933	259	13	treatment	treatment	NOUN
dpc-5933	259	14	in	in	ADP
dpc-5933	259	15	moderate	moderate	ADJ
dpc-5933	259	16	to	to	AUX
dpc-5933	259	17	-	-	PUNCT
dpc-5933	259	18	severe	severe	ADJ
dpc-5933	259	19	hs	hs	PROPN
dpc-5933	259	20	patients	patient	NOUN
dpc-5933	259	21	.	.	PUNCT
dpc-5933	260	1	adverse	adverse	ADJ
dpc-5933	260	2	event	event	NOUN
dpc-5933	260	3	patients	patient	NOUN
dpc-5933	260	4	(	(	PUNCT
dpc-5933	260	5	n=10	n=10	NOUN
dpc-5933	260	6	)	)	PUNCT
dpc-5933	260	7	patients	patient	NOUN
dpc-5933	260	8	with	with	ADP
dpc-5933	260	9	any	any	DET
dpc-5933	260	10	adverse	adverse	ADJ
dpc-5933	260	11	event	event	NOUN
dpc-5933	260	12	,	,	PUNCT
dpc-5933	260	13	n	n	PROPN
dpc-5933	260	14	(	(	PUNCT
dpc-5933	260	15	%	%	INTJ
dpc-5933	260	16	)	)	PUNCT
dpc-5933	260	17	0	0	NUM
dpc-5933	260	18	(	(	PUNCT
dpc-5933	260	19	0.0	0.0	NUM
dpc-5933	260	20	)	)	PUNCT
dpc-5933	260	21	common	common	ADJ
dpc-5933	260	22	adverse	adverse	ADJ
dpc-5933	260	23	events	event	NOUN
dpc-5933	260	24	,	,	PUNCT
dpc-5933	260	25	n	n	CCONJ
dpc-5933	260	26	(	(	PUNCT
dpc-5933	260	27	%	%	INTJ
dpc-5933	260	28	)	)	PUNCT
dpc-5933	260	29	headache	headache	NOUN
dpc-5933	260	30	0	0	NUM
dpc-5933	260	31	(	(	PUNCT
dpc-5933	260	32	0.0	0.0	NUM
dpc-5933	260	33	)	)	PUNCT
dpc-5933	260	34	nasopharyngitis	nasopharyngitis	NOUN
dpc-5933	260	35	0	0	NUM
dpc-5933	260	36	(	(	PUNCT
dpc-5933	260	37	0.0	0.0	NUM
dpc-5933	260	38	)	)	PUNCT
dpc-5933	260	39	patients	patient	NOUN
dpc-5933	260	40	with	with	ADP
dpc-5933	260	41	serious	serious	ADJ
dpc-5933	260	42	or	or	CCONJ
dpc-5933	260	43	other	other	ADJ
dpc-5933	260	44	significant	significant	ADJ
dpc-5933	260	45	event	event	NOUN
dpc-5933	260	46	,	,	PUNCT
dpc-5933	260	47	n	n	PROPN
dpc-5933	260	48	(	(	PUNCT
dpc-5933	260	49	%	%	INTJ
dpc-5933	260	50	)	)	PUNCT
dpc-5933	260	51	death	death	NOUN
dpc-5933	260	52	0	0	NUM
dpc-5933	260	53	(	(	PUNCT
dpc-5933	260	54	0.0	0.0	NUM
dpc-5933	260	55	)	)	PUNCT
dpc-5933	260	56	non	non	ADJ
dpc-5933	260	57	-	-	ADJ
dpc-5933	260	58	fatal	fatal	ADJ
dpc-5933	260	59	serious	serious	ADJ
dpc-5933	260	60	adverse	adverse	ADJ
dpc-5933	260	61	event	event	NOUN
dpc-5933	260	62	0	0	NUM
dpc-5933	260	63	(	(	PUNCT
dpc-5933	260	64	0.0	0.0	NUM
dpc-5933	260	65	)	)	PUNCT
dpc-5933	260	66	discontinued	discontinue	VERB
dpc-5933	260	67	study	study	NOUN
dpc-5933	260	68	treatment	treatment	NOUN
dpc-5933	260	69	due	due	ADP
dpc-5933	260	70	to	to	ADP
dpc-5933	260	71	any	any	DET
dpc-5933	260	72	adverse	adverse	ADJ
dpc-5933	260	73	event	event	NOUN
dpc-5933	260	74	0	0	NUM
dpc-5933	260	75	(	(	PUNCT
dpc-5933	260	76	0.0	0.0	NUM
dpc-5933	260	77	)	)	PUNCT
dpc-5933	260	78	adverse	adverse	ADJ
dpc-5933	260	79	events	event	NOUN
dpc-5933	260	80	of	of	ADP
dpc-5933	260	81	special	special	ADJ
dpc-5933	260	82	interest	interest	NOUN
dpc-5933	260	83	,	,	PUNCT
dpc-5933	260	84	n	n	PROPN
dpc-5933	260	85	(	(	PUNCT
dpc-5933	260	86	%	%	INTJ
dpc-5933	260	87	)	)	PUNCT
dpc-5933	260	88	infections	infection	NOUN
dpc-5933	260	89	and	and	CCONJ
dpc-5933	260	90	infestations	infestation	NOUN
dpc-5933	260	91	by	by	ADP
dpc-5933	260	92	system	system	NOUN
dpc-5933	260	93	organ	organ	NOUN
dpc-5933	260	94	class	class	NOUN
dpc-5933	260	95	0	0	NUM
dpc-5933	260	96	(	(	PUNCT
dpc-5933	260	97	0.0	0.0	NUM
dpc-5933	260	98	)	)	PUNCT
dpc-5933	260	99	upper	upper	ADJ
dpc-5933	260	100	respiratory	respiratory	ADJ
dpc-5933	260	101	tract	tract	NOUN
dpc-5933	260	102	infection	infection	NOUN
dpc-5933	260	103	0	0	NUM
dpc-5933	260	104	(	(	PUNCT
dpc-5933	260	105	0.0	0.0	NUM
dpc-5933	260	106	)	)	PUNCT
dpc-5933	260	107	fungal	fungal	ADJ
dpc-5933	260	108	infectious	infectious	ADJ
dpc-5933	260	109	disorders	disorder	NOUN
dpc-5933	260	110	0	0	NUM
dpc-5933	260	111	(	(	PUNCT
dpc-5933	260	112	0.0	0.0	NUM
dpc-5933	260	113	)	)	PUNCT
dpc-5933	260	114	candida	candida	NOUN
dpc-5933	260	115	infection	infection	NOUN
dpc-5933	260	116	0	0	NUM
dpc-5933	260	117	(	(	PUNCT
dpc-5933	260	118	0.0	0.0	NUM
dpc-5933	260	119	)	)	PUNCT
dpc-5933	260	120	hypersensitivity	hypersensitivity	NOUN
dpc-5933	260	121	0	0	NUM
dpc-5933	260	122	(	(	PUNCT
dpc-5933	260	123	0.0	0.0	NUM
dpc-5933	260	124	)	)	PUNCT
dpc-5933	260	125	malignant	malignant	ADJ
dpc-5933	260	126	or	or	CCONJ
dpc-5933	260	127	unspecified	unspecified	ADJ
dpc-5933	260	128	tumor	tumor	NOUN
dpc-5933	260	129	0	0	NUM
dpc-5933	261	1	(	(	PUNCT
dpc-5933	261	2	0.0	0.0	NUM
dpc-5933	261	3	)	)	PUNCT
dpc-5933	261	4	major	major	ADJ
dpc-5933	261	5	adverse	adverse	ADJ
dpc-5933	261	6	cardiovascular	cardiovascular	ADJ
dpc-5933	261	7	event	event	NOUN
dpc-5933	261	8	0	0	NUM
dpc-5933	261	9	(	(	PUNCT
dpc-5933	261	10	0.0	0.0	NUM
dpc-5933	261	11	)	)	PUNCT
dpc-5933	261	12	inflammatory	inflammatory	ADJ
dpc-5933	261	13	bowel	bowel	NOUN
dpc-5933	261	14	disease	disease	NOUN
dpc-5933	261	15	0	0	NUM
dpc-5933	262	1	(	(	PUNCT
dpc-5933	262	2	0.0	0.0	NUM
dpc-5933	262	3	)	)	PUNCT
dpc-5933	262	4	pathways	pathway	NOUN
dpc-5933	262	5	,	,	PUNCT
dpc-5933	262	6	including	include	VERB
dpc-5933	262	7	smoking	smoking	NOUN
dpc-5933	262	8	cessation	cessation	NOUN
dpc-5933	262	9	,	,	PUNCT
dpc-5933	262	10	weight	weight	NOUN
dpc-5933	262	11	management	management	NOUN
dpc-5933	262	12	,	,	PUNCT
dpc-5933	262	13	metabolic	metabolic	NOUN
dpc-5933	262	14	monitoring	monitoring	NOUN
dpc-5933	262	15	,	,	PUNCT
dpc-5933	262	16	and	and	CCONJ
dpc-5933	262	17	psychosocial	psychosocial	ADJ
dpc-5933	262	18	support	support	NOUN
dpc-5933	262	19	,	,	PUNCT
dpc-5933	262	20	in	in	ADP
dpc-5933	262	21	addition	addition	NOUN
dpc-5933	262	22	to	to	ADP
dpc-5933	262	23	targeted	target	VERB
dpc-5933	262	24	medical	medical	ADJ
dpc-5933	262	25	therapy	therapy	NOUN
dpc-5933	262	26	[	[	X
dpc-5933	262	27	27	27	NUM
dpc-5933	262	28	]	]	PUNCT
dpc-5933	262	29	.	.	PUNCT
dpc-5933	263	1	therefore	therefore	ADV
dpc-5933	263	2	,	,	PUNCT
dpc-5933	263	3	modern	modern	ADJ
dpc-5933	263	4	consensus	consensus	NOUN
dpc-5933	263	5	statements	statement	NOUN
dpc-5933	263	6	emphasize	emphasize	VERB
dpc-5933	263	7	that	that	SCONJ
dpc-5933	263	8	optimal	optimal	ADJ
dpc-5933	263	9	hs	hs	PROPN
dpc-5933	263	10	care	care	PROPN
dpc-5933	263	11	extends	extend	VERB
dpc-5933	263	12	beyond	beyond	ADP
dpc-5933	263	13	dermatologic	dermatologic	ADJ
dpc-5933	263	14	therapy	therapy	NOUN
dpc-5933	263	15	and	and	CCONJ
dpc-5933	263	16	should	should	AUX
dpc-5933	263	17	integrate	integrate	VERB
dpc-5933	263	18	surgery	surgery	NOUN
dpc-5933	263	19	,	,	PUNCT
dpc-5933	263	20	wound	wound	NOUN
dpc-5933	263	21	-	-	PUNCT
dpc-5933	263	22	care	care	NOUN
dpc-5933	263	23	nursing	nursing	NOUN
dpc-5933	263	24	,	,	PUNCT
dpc-5933	263	25	pain	pain	NOUN
dpc-5933	263	26	specialists	specialist	NOUN
dpc-5933	263	27	,	,	PUNCT
dpc-5933	263	28	dieticians	dietician	NOUN
dpc-5933	263	29	,	,	PUNCT
dpc-5933	263	30	psychologists	psychologist	NOUN
dpc-5933	263	31	,	,	PUNCT
dpc-5933	263	32	and	and	CCONJ
dpc-5933	263	33	primary	primary	ADJ
dpc-5933	263	34	care	care	NOUN
dpc-5933	263	35	physicians	physician	NOUN
dpc-5933	263	36	[	[	X
dpc-5933	263	37	28	28	NUM
dpc-5933	263	38	]	]	PUNCT
dpc-5933	263	39	.	.	PUNCT
dpc-5933	264	1	in	in	ADP
dpc-5933	264	2	practice	practice	NOUN
dpc-5933	264	3	,	,	PUNCT
dpc-5933	264	4	a	a	DET
dpc-5933	264	5	combined	combine	VERB
dpc-5933	264	6	medical	medical	ADJ
dpc-5933	264	7	-	-	PUNCT
dpc-5933	264	8	surgical	surgical	ADJ
dpc-5933	264	9	strategy	strategy	NOUN
dpc-5933	264	10	may	may	AUX
dpc-5933	264	11	yield	yield	VERB
dpc-5933	264	12	better	well	ADJ
dpc-5933	264	13	outcomes	outcome	NOUN
dpc-5933	264	14	:	:	PUNCT
dpc-5933	264	15	perioperative	perioperative	ADJ
dpc-5933	264	16	use	use	NOUN
dpc-5933	264	17	of	of	ADP
dpc-5933	264	18	adalimumab	adalimumab	NOUN
dpc-5933	264	19	has	have	AUX
dpc-5933	264	20	been	be	AUX
dpc-5933	264	21	shown	show	VERB
dpc-5933	264	22	to	to	PART
dpc-5933	264	23	improve	improve	VERB
dpc-5933	264	24	hiscr	hiscr	NOUN
dpc-5933	264	25	rates	rate	NOUN
dpc-5933	264	26	after	after	ADP
dpc-5933	264	27	excisional	excisional	ADJ
dpc-5933	264	28	surgery	surgery	NOUN
dpc-5933	264	29	without	without	ADP
dpc-5933	264	30	increasing	increase	VERB
dpc-5933	264	31	complications	complication	NOUN
dpc-5933	264	32	[	[	X
dpc-5933	264	33	29	29	NUM
dpc-5933	264	34	]	]	PUNCT
dpc-5933	264	35	.	.	PUNCT
dpc-5933	265	1	hence	hence	ADV
dpc-5933	265	2	,	,	PUNCT
dpc-5933	265	3	our	our	PRON
dpc-5933	265	4	findings	finding	NOUN
dpc-5933	265	5	support	support	VERB
dpc-5933	265	6	the	the	DET
dpc-5933	265	7	paradigm	paradigm	NOUN
dpc-5933	265	8	that	that	PRON
dpc-5933	265	9	secukinumab	secukinumab	NOUN
dpc-5933	265	10	can	can	AUX
dpc-5933	265	11	allow	allow	VERB
dpc-5933	265	12	many	many	ADJ
dpc-5933	265	13	patients	patient	NOUN
dpc-5933	265	14	to	to	PART
dpc-5933	265	15	discontinue	discontinue	VERB
dpc-5933	265	16	long	long	ADJ
dpc-5933	265	17	-	-	PUNCT
dpc-5933	265	18	term	term	NOUN
dpc-5933	265	19	antibiotics	antibiotic	NOUN
dpc-5933	265	20	,	,	PUNCT
dpc-5933	265	21	facilitating	facilitate	VERB
dpc-5933	265	22	coordination	coordination	NOUN
dpc-5933	265	23	with	with	ADP
dpc-5933	265	24	surgeons	surgeon	NOUN
dpc-5933	265	25	for	for	ADP
dpc-5933	265	26	excisional	excisional	ADJ
dpc-5933	265	27	procedures	procedure	NOUN
dpc-5933	265	28	.	.	PUNCT
dpc-5933	266	1	additionally	additionally	ADV
dpc-5933	266	2	,	,	PUNCT
dpc-5933	266	3	differences	difference	NOUN
dpc-5933	266	4	in	in	ADP
dpc-5933	266	5	biologics	biologic	NOUN
dpc-5933	266	6	availability	availability	NOUN
dpc-5933	266	7	across	across	ADP
dpc-5933	266	8	health	health	NOUN
dpc-5933	266	9	systems	system	NOUN
dpc-5933	266	10	may	may	AUX
dpc-5933	266	11	constitute	constitute	VERB
dpc-5933	266	12	an	an	DET
dpc-5933	266	13	impact	impact	NOUN
dpc-5933	266	14	on	on	ADP
dpc-5933	266	15	secukinumab	secukinumab	NOUN
dpc-5933	266	16	utilization	utilization	NOUN
dpc-5933	266	17	.	.	PUNCT
dpc-5933	267	1	the	the	DET
dpc-5933	267	2	european	european	PROPN
dpc-5933	267	3	academy	academy	PROPN
dpc-5933	267	4	of	of	ADP
dpc-5933	267	5	dermatology	dermatology	NOUN
dpc-5933	267	6	and	and	CCONJ
dpc-5933	267	7	venereology	venereology	NOUN
dpc-5933	267	8	(	(	PUNCT
dpc-5933	267	9	eadv	eadv	ADJ
dpc-5933	267	10	)	)	PUNCT
dpc-5933	267	11	has	have	AUX
dpc-5933	267	12	provided	provide	VERB
dpc-5933	267	13	guidelines	guideline	NOUN
dpc-5933	267	14	for	for	ADP
dpc-5933	267	15	biologic	biologic	NOUN
dpc-5933	267	16	therapy	therapy	NOUN
dpc-5933	267	17	as	as	ADP
dpc-5933	267	18	second	second	ADJ
dpc-5933	267	19	-	-	PUNCT
dpc-5933	267	20	line	line	NOUN
dpc-5933	267	21	treatment	treatment	NOUN
dpc-5933	267	22	for	for	ADP
dpc-5933	267	23	hs	hs	PROPN
dpc-5933	267	24	,	,	PUNCT
dpc-5933	267	25	notably	notably	ADV
dpc-5933	267	26	adalimumab	adalimumab	NOUN
dpc-5933	267	27	and	and	CCONJ
dpc-5933	267	28	secukinumab	secukinumab	NOUN
dpc-5933	267	29	[	[	X
dpc-5933	267	30	30	30	NUM
dpc-5933	267	31	]	]	PUNCT
dpc-5933	267	32	.	.	PUNCT
dpc-5933	268	1	the	the	DET
dpc-5933	268	2	eadv	eadv	ADV
dpc-5933	268	3	additionally	additionally	ADV
dpc-5933	268	4	complemented	complement	VERB
dpc-5933	268	5	bimekizumab	bimekizumab	NOUN
dpc-5933	268	6	,	,	PUNCT
dpc-5933	268	7	further	far	ADV
dpc-5933	268	8	expanding	expand	VERB
dpc-5933	268	9	options	option	NOUN
dpc-5933	268	10	[	[	X
dpc-5933	268	11	30	30	NUM
dpc-5933	268	12	]	]	PUNCT
dpc-5933	268	13	.	.	PUNCT
dpc-5933	269	1	the	the	DET
dpc-5933	269	2	fda	fda	PROPN
dpc-5933	269	3	in	in	ADP
dpc-5933	269	4	the	the	DET
dpc-5933	269	5	united	united	PROPN
dpc-5933	269	6	states	states	PROPN
dpc-5933	269	7	also	also	ADV
dpc-5933	269	8	approved	approve	VERB
dpc-5933	269	9	secukinumab	secukinumab	NOUN
dpc-5933	269	10	as	as	ADP
dpc-5933	269	11	an	an	DET
dpc-5933	269	12	authorized	authorized	ADJ
dpc-5933	269	13	treatment	treatment	NOUN
dpc-5933	269	14	for	for	ADP
dpc-5933	269	15	moderate	moderate	ADJ
dpc-5933	269	16	-	-	PUNCT
dpc-5933	269	17	to	to	ADP
dpc-5933	269	18	-	-	PUNCT
dpc-5933	269	19	severe	severe	ADJ
dpc-5933	269	20	hs	hs	PROPN
dpc-5933	269	21	,	,	PUNCT
dpc-5933	269	22	along	along	ADP
dpc-5933	269	23	with	with	ADP
dpc-5933	269	24	the	the	DET
dpc-5933	269	25	already	already	ADV
dpc-5933	269	26	authorized	authorize	VERB
dpc-5933	269	27	adalimumab	adalimumab	NOUN
dpc-5933	269	28	[	[	X
dpc-5933	269	29	16	16	NUM
dpc-5933	269	30	]	]	PUNCT
dpc-5933	269	31	.	.	PUNCT
dpc-5933	270	1	in	in	ADP
dpc-5933	270	2	those	those	DET
dpc-5933	270	3	settings	setting	NOUN
dpc-5933	270	4	,	,	PUNCT
dpc-5933	270	5	adalimumab	adalimumab	NOUN
dpc-5933	270	6	or	or	CCONJ
dpc-5933	270	7	secukinumab	secukinumab	NOUN
dpc-5933	270	8	could	could	AUX
dpc-5933	270	9	be	be	AUX
dpc-5933	270	10	administered	administer	VERB
dpc-5933	270	11	first	first	ADJ
dpc-5933	270	12	-	-	PUNCT
dpc-5933	270	13	line	line	NOUN
dpc-5933	270	14	;	;	PUNCT
dpc-5933	270	15	inadequate	inadequate	ADJ
dpc-5933	270	16	responders	responder	NOUN
dpc-5933	270	17	may	may	AUX
dpc-5933	270	18	switch	switch	VERB
dpc-5933	270	19	to	to	ADP
dpc-5933	270	20	the	the	DET
dpc-5933	270	21	remaining	remain	VERB
dpc-5933	270	22	option	option	NOUN
dpc-5933	270	23	before	before	ADP
dpc-5933	270	24	relying	rely	VERB
dpc-5933	270	25	on	on	ADP
dpc-5933	270	26	prolonged	prolong	VERB
dpc-5933	270	27	antibiotics	antibiotic	NOUN
dpc-5933	270	28	or	or	CCONJ
dpc-5933	270	29	surgery	surgery	NOUN
dpc-5933	270	30	.	.	PUNCT
dpc-5933	271	1	by	by	ADP
dpc-5933	271	2	contrast	contrast	NOUN
dpc-5933	271	3	,	,	PUNCT
dpc-5933	271	4	korean	korean	ADJ
dpc-5933	271	5	patients	patient	NOUN
dpc-5933	271	6	currently	currently	ADV
dpc-5933	271	7	have	have	VERB
dpc-5933	271	8	routine	routine	ADJ
dpc-5933	271	9	access	access	NOUN
dpc-5933	271	10	to	to	ADP
dpc-5933	271	11	mainly	mainly	ADV
dpc-5933	271	12	adalimumab	adalimumab	VERB
dpc-5933	271	13	for	for	ADP
dpc-5933	271	14	hs	h	NOUN
dpc-5933	271	15	.	.	PUNCT
dpc-5933	272	1	our	our	PRON
dpc-5933	272	2	data	datum	NOUN
dpc-5933	272	3	,	,	PUNCT
dpc-5933	272	4	therefore	therefore	ADV
dpc-5933	272	5	,	,	PUNCT
dpc-5933	272	6	provide	provide	VERB
dpc-5933	272	7	early	early	ADJ
dpc-5933	272	8	evidence	evidence	NOUN
dpc-5933	272	9	to	to	PART
dpc-5933	272	10	support	support	VERB
dpc-5933	272	11	policy	policy	NOUN
dpc-5933	272	12	discussions	discussion	NOUN
dpc-5933	272	13	on	on	ADP
dpc-5933	272	14	widening	widen	VERB
dpc-5933	272	15	biologics	biologic	NOUN
dpc-5933	272	16	availability	availability	NOUN
dpc-5933	272	17	in	in	ADP
dpc-5933	272	18	korea	korea	PROPN
dpc-5933	272	19	and	and	CCONJ
dpc-5933	272	20	in	in	ADP
dpc-5933	272	21	asia	asia	PROPN
dpc-5933	272	22	in	in	ADP
dpc-5933	272	23	general	general	ADJ
dpc-5933	272	24	,	,	PUNCT
dpc-5933	272	25	where	where	SCONJ
dpc-5933	272	26	the	the	DET
dpc-5933	272	27	male	male	NOUN
dpc-5933	272	28	-	-	PUNCT
dpc-5933	272	29	predominant	predominant	ADJ
dpc-5933	272	30	,	,	PUNCT
dpc-5933	272	31	often	often	ADV
dpc-5933	272	32	deeply	deeply	ADV
dpc-5933	272	33	tunnelling	tunnel	VERB
dpc-5933	272	34	phenotype	phenotype	NOUN
dpc-5933	272	35	may	may	AUX
dpc-5933	272	36	particularly	particularly	ADV
dpc-5933	272	37	benefit	benefit	VERB
dpc-5933	272	38	from	from	ADP
dpc-5933	272	39	timely	timely	ADJ
dpc-5933	272	40	escalation	escalation	NOUN
dpc-5933	272	41	[	[	X
dpc-5933	272	42	23,24	23,24	ADP
dpc-5933	272	43	]	]	PUNCT
dpc-5933	272	44	.	.	PUNCT
dpc-5933	273	1	however	however	ADV
dpc-5933	273	2	,	,	PUNCT
dpc-5933	273	3	this	this	DET
dpc-5933	273	4	study	study	NOUN
dpc-5933	273	5	is	be	AUX
dpc-5933	273	6	limited	limit	VERB
dpc-5933	273	7	by	by	ADP
dpc-5933	273	8	its	its	PRON
dpc-5933	273	9	small	small	ADJ
dpc-5933	273	10	sample	sample	NOUN
dpc-5933	273	11	size	size	NOUN
dpc-5933	273	12	,	,	PUNCT
dpc-5933	273	13	lack	lack	NOUN
dpc-5933	273	14	of	of	ADP
dpc-5933	273	15	a	a	DET
dpc-5933	273	16	control	control	NOUN
dpc-5933	273	17	group	group	NOUN
dpc-5933	273	18	,	,	PUNCT
dpc-5933	273	19	and	and	CCONJ
dpc-5933	273	20	potential	potential	ADJ
dpc-5933	273	21	confounding	confound	VERB
dpc-5933	273	22	factors	factor	NOUN
dpc-5933	273	23	such	such	ADJ
dpc-5933	273	24	as	as	ADP
dpc-5933	273	25	demographic	demographic	ADJ
dpc-5933	273	26	imbalances	imbalance	NOUN
dpc-5933	273	27	.	.	PUNCT
dpc-5933	274	1	these	these	DET
dpc-5933	274	2	limitations	limitation	NOUN
dpc-5933	274	3	underscore	underscore	VERB
dpc-5933	274	4	the	the	DET
dpc-5933	274	5	need	need	NOUN
dpc-5933	274	6	for	for	ADP
dpc-5933	274	7	larger	large	ADJ
dpc-5933	274	8	multicenter	multicenter	NOUN
dpc-5933	274	9	studies	study	NOUN
dpc-5933	274	10	with	with	ADP
dpc-5933	274	11	robust	robust	ADJ
dpc-5933	274	12	control	control	NOUN
dpc-5933	274	13	measures	measure	NOUN
dpc-5933	274	14	to	to	PART
dpc-5933	274	15	validate	validate	VERB
dpc-5933	274	16	these	these	DET
dpc-5933	274	17	findings	finding	NOUN
dpc-5933	274	18	and	and	CCONJ
dpc-5933	274	19	further	far	ADV
dpc-5933	274	20	delineate	delineate	VERB
dpc-5933	274	21	the	the	DET
dpc-5933	274	22	optimal	optimal	ADJ
dpc-5933	274	23	use	use	NOUN
dpc-5933	274	24	of	of	ADP
dpc-5933	274	25	secukinumab	secukinumab	NOUN
dpc-5933	274	26	in	in	ADP
dpc-5933	274	27	hs	hs	PROPN
dpc-5933	274	28	.	.	PUNCT
dpc-5933	274	29	future	future	ADJ
dpc-5933	274	30	investigations	investigation	NOUN
dpc-5933	274	31	should	should	AUX
dpc-5933	274	32	also	also	ADV
dpc-5933	274	33	explore	explore	VERB
dpc-5933	274	34	the	the	DET
dpc-5933	274	35	integration	integration	NOUN
dpc-5933	274	36	of	of	ADP
dpc-5933	274	37	complementary	complementary	ADJ
dpc-5933	274	38	therapeutic	therapeutic	ADJ
dpc-5933	274	39	approaches	approach	NOUN
dpc-5933	274	40	to	to	PART
dpc-5933	274	41	enhance	enhance	VERB
dpc-5933	274	42	outcomes	outcome	NOUN
dpc-5933	274	43	,	,	PUNCT
dpc-5933	274	44	particularly	particularly	ADV
dpc-5933	274	45	in	in	ADP
dpc-5933	274	46	patients	patient	NOUN
dpc-5933	274	47	with	with	ADP
dpc-5933	274	48	advanced	advanced	ADJ
dpc-5933	274	49	disease	disease	NOUN
dpc-5933	274	50	or	or	CCONJ
dpc-5933	274	51	refractory	refractory	NOUN
dpc-5933	274	52	lesions	lesion	NOUN
dpc-5933	274	53	.	.	PUNCT
dpc-5933	275	1	despite	despite	SCONJ
dpc-5933	275	2	these	these	DET
dpc-5933	275	3	drawbacks	drawback	NOUN
dpc-5933	275	4	,	,	PUNCT
dpc-5933	275	5	our	our	PRON
dpc-5933	275	6	small	small	ADJ
dpc-5933	275	7	cohort	cohort	NOUN
dpc-5933	275	8	yields	yield	VERB
dpc-5933	275	9	useful	useful	ADJ
dpc-5933	275	10	real	real	ADJ
dpc-5933	275	11	-	-	PUNCT
dpc-5933	275	12	world	world	NOUN
dpc-5933	275	13	insights	insight	NOUN
dpc-5933	275	14	,	,	PUNCT
dpc-5933	275	15	partially	partially	ADV
dpc-5933	275	16	from	from	ADP
dpc-5933	275	17	our	our	PRON
dpc-5933	275	18	extensive	extensive	ADJ
dpc-5933	275	19	period	period	NOUN
dpc-5933	275	20	of	of	ADP
dpc-5933	275	21	follow	follow	NOUN
dpc-5933	275	22	-	-	PUNCT
dpc-5933	275	23	up	up	NOUN
dpc-5933	275	24	(	(	PUNCT
dpc-5933	275	25	48	48	NUM
dpc-5933	275	26	weeks	week	NOUN
dpc-5933	275	27	)	)	PUNCT
dpc-5933	275	28	.	.	PUNCT
dpc-5933	276	1	in	in	ADP
dpc-5933	276	2	addition	addition	NOUN
dpc-5933	276	3	,	,	PUNCT
dpc-5933	276	4	the	the	DET
dpc-5933	276	5	overall	overall	ADJ
dpc-5933	276	6	response	response	NOUN
dpc-5933	276	7	rate	rate	NOUN
dpc-5933	276	8	and	and	CCONJ
dpc-5933	276	9	safety	safety	NOUN
dpc-5933	276	10	profile	profile	NOUN
dpc-5933	276	11	of	of	ADP
dpc-5933	276	12	secukinumab	secukinumab	NOUN
dpc-5933	276	13	in	in	ADP
dpc-5933	276	14	our	our	PRON
dpc-5933	276	15	patients	patient	NOUN
dpc-5933	276	16	align	align	VERB
dpc-5933	276	17	with	with	ADP
dpc-5933	276	18	those	those	PRON
dpc-5933	276	19	reported	report	VERB
dpc-5933	276	20	in	in	ADP
dpc-5933	276	21	larger	large	ADJ
dpc-5933	276	22	studies	study	NOUN
dpc-5933	276	23	,	,	PUNCT
dpc-5933	276	24	supporting	support	VERB
dpc-5933	276	25	external	external	ADJ
dpc-5933	276	26	consistency	consistency	NOUN
dpc-5933	276	27	[	[	X
dpc-5933	276	28	14,15,31	14,15,31	NUM
dpc-5933	276	29	]	]	PUNCT
dpc-5933	276	30	.	.	PUNCT
dpc-5933	277	1	notably	notably	ADV
dpc-5933	277	2	,	,	PUNCT
dpc-5933	277	3	the	the	DET
dpc-5933	277	4	phase	phase	NOUN
dpc-5933	277	5	3	3	NUM
dpc-5933	277	6	sunshine	sunshine	NOUN
dpc-5933	277	7	/	/	SYM
dpc-5933	277	8	sunrise	sunrise	NOUN
dpc-5933	277	9	trials	trial	NOUN
dpc-5933	277	10	in	in	ADP
dpc-5933	277	11	north	north	PROPN
dpc-5933	277	12	america	america	PROPN
dpc-5933	277	13	and	and	CCONJ
dpc-5933	277	14	europe	europe	PROPN
dpc-5933	277	15	showed	show	VERB
dpc-5933	277	16	that	that	SCONJ
dpc-5933	277	17	secukinumab	secukinumab	NOUN
dpc-5933	277	18	achieved	achieve	VERB
dpc-5933	277	19	hiscr	hiscr	NOUN
dpc-5933	277	20	in	in	ADP
dpc-5933	277	21	42–45	42–45	NUM
dpc-5933	277	22	%	%	NOUN
dpc-5933	277	23	of	of	ADP
dpc-5933	277	24	patients	patient	NOUN
dpc-5933	277	25	at	at	ADP
dpc-5933	277	26	16	16	NUM
dpc-5933	277	27	weeks	week	NOUN
dpc-5933	277	28	,	,	PUNCT
dpc-5933	277	29	with	with	ADP
dpc-5933	277	30	effectiveness	effectiveness	NOUN
dpc-5933	277	31	achieved	achieve	VERB
dpc-5933	277	32	in	in	ADP
dpc-5933	277	33	both	both	PRON
dpc-5933	277	34	tnf	tnf	PROPN
dpc-5933	277	35	-	-	PUNCT
dpc-5933	277	36	naïve	naïve	PROPN
dpc-5933	277	37	and	and	CCONJ
dpc-5933	277	38	tnf	tnf	PROPN
dpc-5933	277	39	-	-	PUNCT
dpc-5933	277	40	experienced	experience	VERB
dpc-5933	277	41	groups	group	NOUN
dpc-5933	277	42	[	[	X
dpc-5933	277	43	9	9	NUM
dpc-5933	277	44	]	]	PUNCT
dpc-5933	277	45	.	.	PUNCT
dpc-5933	278	1	similarly	similarly	ADV
dpc-5933	278	2	,	,	PUNCT
dpc-5933	278	3	real	real	ADJ
dpc-5933	278	4	-	-	PUNCT
dpc-5933	278	5	world	world	NOUN
dpc-5933	278	6	studies	study	NOUN
dpc-5933	278	7	have	have	AUX
dpc-5933	278	8	reported	report	VERB
dpc-5933	278	9	good	good	ADJ
dpc-5933	278	10	clinical	clinical	ADJ
dpc-5933	278	11	responses	response	NOUN
dpc-5933	278	12	and	and	CCONJ
dpc-5933	278	13	safety	safety	NOUN
dpc-5933	278	14	with	with	ADP
dpc-5933	278	15	il-17	il-17	X
dpc-5933	278	16	–	–	PUNCT
dpc-5933	278	17	targeted	target	VERB
dpc-5933	278	18	therapy	therapy	NOUN
dpc-5933	278	19	[	[	X
dpc-5933	278	20	10	10	NUM
dpc-5933	278	21	-	-	SYM
dpc-5933	278	22	16	16	NUM
dpc-5933	278	23	]	]	PUNCT
dpc-5933	278	24	.	.	PUNCT
dpc-5933	279	1	observed	observed	ADJ
dpc-5933	279	2	trends	trend	NOUN
dpc-5933	279	3	in	in	ADP
dpc-5933	279	4	our	our	PRON
dpc-5933	279	5	data	datum	NOUN
dpc-5933	279	6	,	,	PUNCT
dpc-5933	279	7	namely	namely	ADV
dpc-5933	279	8	higher	high	ADJ
dpc-5933	279	9	response	response	NOUN
dpc-5933	279	10	likelihood	likelihood	NOUN
dpc-5933	279	11	in	in	ADP
dpc-5933	279	12	patients	patient	NOUN
dpc-5933	279	13	with	with	ADP
dpc-5933	279	14	lower	low	ADJ
dpc-5933	279	15	prior	prior	ADJ
dpc-5933	279	16	therapeutic	therapeutic	ADJ
dpc-5933	279	17	burden	burden	NOUN
dpc-5933	279	18	,	,	PUNCT
dpc-5933	279	19	align	align	VERB
dpc-5933	279	20	with	with	ADP
dpc-5933	279	21	the	the	DET
dpc-5933	279	22	“	"	PUNCT
dpc-5933	279	23	window	window	NOUN
dpc-5933	279	24	of	of	ADP
dpc-5933	279	25	opportunity	opportunity	NOUN
dpc-5933	279	26	”	"	PUNCT
dpc-5933	279	27	concept	concept	NOUN
dpc-5933	279	28	and	and	CCONJ
dpc-5933	279	29	are	be	AUX
dpc-5933	279	30	similar	similar	ADJ
dpc-5933	279	31	to	to	ADP
dpc-5933	279	32	predictors	predictor	NOUN
dpc-5933	279	33	identified	identify	VERB
dpc-5933	279	34	in	in	ADP
dpc-5933	279	35	other	other	ADJ
dpc-5933	279	36	analyses	analysis	NOUN
dpc-5933	279	37	[	[	X
dpc-5933	279	38	15	15	NUM
dpc-5933	279	39	]	]	PUNCT
dpc-5933	279	40	.	.	PUNCT
dpc-5933	280	1	finally	finally	ADV
dpc-5933	280	2	,	,	PUNCT
dpc-5933	280	3	our	our	PRON
dpc-5933	280	4	study	study	NOUN
dpc-5933	280	5	also	also	ADV
dpc-5933	280	6	noted	note	VERB
dpc-5933	280	7	a	a	DET
dpc-5933	280	8	reduction	reduction	NOUN
dpc-5933	280	9	in	in	ADP
dpc-5933	280	10	antibiotic	antibiotic	ADJ
dpc-5933	280	11	dependence	dependence	NOUN
dpc-5933	280	12	following	follow	VERB
dpc-5933	280	13	secukinumab	secukinumab	NOUN
dpc-5933	280	14	treatment	treatment	NOUN
dpc-5933	280	15	,	,	PUNCT
dpc-5933	280	16	which	which	PRON
dpc-5933	280	17	is	be	AUX
dpc-5933	280	18	consistent	consistent	ADJ
dpc-5933	280	19	with	with	ADP
dpc-5933	280	20	evidence	evidence	NOUN
dpc-5933	280	21	that	that	SCONJ
dpc-5933	280	22	secukinumab	secukinumab	NOUN
dpc-5933	280	23	is	be	AUX
dpc-5933	280	24	effective	effective	ADJ
dpc-5933	280	25	regardless	regardless	ADV
dpc-5933	280	26	of	of	ADP
dpc-5933	280	27	concomitant	concomitant	ADJ
dpc-5933	280	28	antibiotic	antibiotic	ADJ
dpc-5933	280	29	use	use	NOUN
dpc-5933	280	30	[	[	X
dpc-5933	280	31	32	32	NUM
dpc-5933	280	32	]	]	PUNCT
dpc-5933	280	33	.	.	PUNCT
dpc-5933	281	1	conclusion	conclusion	NOUN
dpc-5933	281	2	secukinumab	secukinumab	NOUN
dpc-5933	281	3	showed	show	VERB
dpc-5933	281	4	strong	strong	ADJ
dpc-5933	281	5	efficacy	efficacy	NOUN
dpc-5933	281	6	in	in	ADP
dpc-5933	281	7	korean	korean	ADJ
dpc-5933	281	8	patients	patient	NOUN
dpc-5933	281	9	with	with	ADP
dpc-5933	281	10	moderate	moderate	ADJ
dpc-5933	281	11	-	-	PUNCT
dpc-5933	281	12	to	to	ADP
dpc-5933	281	13	-	-	PUNCT
dpc-5933	281	14	severe	severe	ADJ
dpc-5933	281	15	hidradenitis	hidradenitis	NOUN
dpc-5933	281	16	suppurativa	suppurativa	NOUN
dpc-5933	281	17	in	in	ADP
dpc-5933	281	18	real	real	ADJ
dpc-5933	281	19	-	-	PUNCT
dpc-5933	281	20	world	world	NOUN
dpc-5933	281	21	settings	setting	NOUN
dpc-5933	281	22	.	.	PUNCT
dpc-5933	282	1	patients	patient	NOUN
dpc-5933	282	2	with	with	ADP
dpc-5933	282	3	hurley	hurley	PROPN
dpc-5933	282	4	stage	stage	PROPN
dpc-5933	282	5	iii	iii	PROPN
dpc-5933	282	6	,	,	PUNCT
dpc-5933	282	7	longer	long	ADJ
dpc-5933	282	8	treatment	treatment	NOUN
dpc-5933	282	9	delays	delay	NOUN
dpc-5933	282	10	,	,	PUNCT
dpc-5933	282	11	or	or	CCONJ
dpc-5933	282	12	prior	prior	ADJ
dpc-5933	282	13	biologics	biologic	NOUN
dpc-5933	282	14	use	use	NOUN
dpc-5933	282	15	had	have	VERB
dpc-5933	282	16	slower	slow	ADJ
dpc-5933	282	17	and	and	CCONJ
dpc-5933	282	18	less	less	ADV
dpc-5933	282	19	pronounced	pronounced	ADJ
dpc-5933	282	20	responses	response	NOUN
dpc-5933	282	21	than	than	SCONJ
dpc-5933	282	22	did	do	VERB
dpc-5933	282	23	those	those	PRON
dpc-5933	282	24	with	with	ADP
dpc-5933	282	25	stage	stage	NOUN
dpc-5933	282	26	ii	ii	PROPN
dpc-5933	282	27	,	,	PUNCT
dpc-5933	282	28	shorter	short	ADJ
dpc-5933	282	29	delays	delay	NOUN
dpc-5933	282	30	,	,	PUNCT
dpc-5933	282	31	or	or	CCONJ
dpc-5933	282	32	no	no	DET
dpc-5933	282	33	biologics	biologic	NOUN
dpc-5933	282	34	history	history	NOUN
dpc-5933	282	35	.	.	PUNCT
dpc-5933	283	1	these	these	DET
dpc-5933	283	2	findings	finding	NOUN
dpc-5933	283	3	highlight	highlight	VERB
dpc-5933	283	4	the	the	DET
dpc-5933	283	5	benefits	benefit	NOUN
dpc-5933	283	6	of	of	ADP
dpc-5933	283	7	early	early	ADJ
dpc-5933	283	8	intervention	intervention	NOUN
dpc-5933	283	9	.	.	PUNCT
dpc-5933	284	1	continued	continue	VERB
dpc-5933	284	2	treatment	treatment	NOUN
dpc-5933	284	3	also	also	ADV
dpc-5933	284	4	significantly	significantly	ADV
dpc-5933	284	5	reduced	reduce	VERB
dpc-5933	284	6	the	the	DET
dpc-5933	284	7	need	need	NOUN
dpc-5933	284	8	for	for	ADP
dpc-5933	284	9	systemic	systemic	ADJ
dpc-5933	284	10	antibiotics	antibiotic	NOUN
dpc-5933	284	11	,	,	PUNCT
dpc-5933	284	12	suggesting	suggest	VERB
dpc-5933	284	13	secukinumab	secukinumab	NOUN
dpc-5933	284	14	’s	’s	PART
dpc-5933	284	15	potential	potential	NOUN
dpc-5933	284	16	to	to	PART
dpc-5933	284	17	decrease	decrease	VERB
dpc-5933	284	18	antimicrobial	antimicrobial	ADJ
dpc-5933	284	19	dependence	dependence	NOUN
dpc-5933	284	20	.	.	PUNCT
dpc-5933	285	1	overall	overall	ADJ
dpc-5933	285	2	,	,	PUNCT
dpc-5933	285	3	secukinumab	secukinumab	NOUN
dpc-5933	285	4	appears	appear	VERB
dpc-5933	285	5	to	to	PART
dpc-5933	285	6	be	be	AUX
dpc-5933	285	7	an	an	DET
dpc-5933	285	8	effective	effective	ADJ
dpc-5933	285	9	option	option	NOUN
dpc-5933	285	10	for	for	ADP
dpc-5933	285	11	hs	hs	PROPN
dpc-5933	285	12	,	,	PUNCT
dpc-5933	285	13	warranting	warrant	VERB
dpc-5933	285	14	further	further	ADJ
dpc-5933	285	15	large	large	ADJ
dpc-5933	285	16	-	-	PUNCT
dpc-5933	285	17	scale	scale	NOUN
dpc-5933	285	18	studies	study	NOUN
dpc-5933	285	19	to	to	PART
dpc-5933	285	20	validate	validate	VERB
dpc-5933	285	21	these	these	DET
dpc-5933	285	22	results	result	NOUN
dpc-5933	285	23	and	and	CCONJ
dpc-5933	285	24	explore	explore	VERB
dpc-5933	285	25	factors	factor	NOUN
dpc-5933	285	26	influencing	influence	VERB
dpc-5933	285	27	treatment	treatment	NOUN
dpc-5933	285	28	response	response	NOUN
dpc-5933	285	29	for	for	ADP
dpc-5933	285	30	more	more	ADJ
dpc-5933	285	31	personalized	personalized	ADJ
dpc-5933	285	32	care	care	NOUN
dpc-5933	285	33	.	.	PUNCT
dpc-5933	286	1	12	12	NUM
dpc-5933	286	2	original	original	ADJ
dpc-5933	286	3	article	article	NOUN
dpc-5933	286	4	|	|	ADV
dpc-5933	286	5	dermatol	dermatol	ADJ
dpc-5933	286	6	pract	pract	NOUN
dpc-5933	286	7	concept	concept	NOUN
dpc-5933	286	8	.	.	PUNCT
dpc-5933	287	1	2025;15(4):5933	2025;15(4):5933	NUM
dpc-5933	287	2	10	10	NUM
dpc-5933	287	3	.	.	PUNCT
dpc-5933	288	1	prussick	prussick	PROPN
dpc-5933	288	2	l	l	PROPN
dpc-5933	288	3	,	,	PUNCT
dpc-5933	288	4	rothstein	rothstein	PROPN
dpc-5933	288	5	b	b	PROPN
dpc-5933	288	6	,	,	PUNCT
dpc-5933	288	7	joshipura	joshipura	X
dpc-5933	288	8	d	d	NOUN
dpc-5933	288	9	,	,	PUNCT
dpc-5933	288	10	et	et	PROPN
dpc-5933	288	11	al	al	PROPN
dpc-5933	288	12	.	.	PROPN
dpc-5933	288	13	open	open	ADJ
dpc-5933	288	14	-	-	PUNCT
dpc-5933	288	15	label	label	NOUN
dpc-5933	288	16	,	,	PUNCT
dpc-5933	288	17	investigator	investigator	NOUN
dpc-5933	288	18	initiated	initiate	VERB
dpc-5933	288	19	,	,	PUNCT
dpc-5933	288	20	single	single	ADJ
dpc-5933	288	21	-	-	PUNCT
dpc-5933	288	22	site	site	NOUN
dpc-5933	288	23	exploratory	exploratory	ADJ
dpc-5933	288	24	trial	trial	NOUN
dpc-5933	288	25	evaluating	evaluating	NOUN
dpc-5933	288	26	secukinumab	secukinumab	NOUN
dpc-5933	288	27	,	,	PUNCT
dpc-5933	288	28	an	an	DET
dpc-5933	288	29	anti	anti	ADJ
dpc-5933	288	30	-	-	ADJ
dpc-5933	288	31	interleukin-17a	interleukin-17a	ADJ
dpc-5933	288	32	monoclonal	monoclonal	NOUN
dpc-5933	288	33	antibody	antibody	NOUN
dpc-5933	288	34	,	,	PUNCT
dpc-5933	288	35	for	for	ADP
dpc-5933	288	36	patients	patient	NOUN
dpc-5933	288	37	with	with	ADP
dpc-5933	288	38	moderate	moderate	ADJ
dpc-5933	288	39	-	-	PUNCT
dpc-5933	288	40	to	to	ADP
dpc-5933	288	41	-	-	PUNCT
dpc-5933	288	42	severe	severe	ADJ
dpc-5933	288	43	hidradenitis	hidradenitis	PROPN
dpc-5933	288	44	suppurativa	suppurativa	PROPN
dpc-5933	288	45	.	.	PUNCT
dpc-5933	289	1	br	br	PROPN
dpc-5933	290	1	j	j	PROPN
dpc-5933	290	2	dermatol	dermatol	NOUN
dpc-5933	290	3	.	.	PUNCT
dpc-5933	291	1	2019;181(3):609	2019;181(3):609	NOUN
dpc-5933	291	2	-	-	SYM
dpc-5933	291	3	611	611	NUM
dpc-5933	291	4	.	.	PUNCT
dpc-5933	292	1	doi:10.1111	doi:10.1111	ADJ
dpc-5933	292	2	/	/	SYM
dpc-5933	292	3	bjd.17822	bjd.17822	NOUN
dpc-5933	292	4	.	.	PUNCT
dpc-5933	293	1	pmid	pmid	NOUN
dpc-5933	293	2	:	:	PUNCT
dpc-5933	293	3	30801662	30801662	NUM
dpc-5933	293	4	11	11	NUM
dpc-5933	293	5	.	.	PUNCT
dpc-5933	294	1	casseres	cassere	NOUN
dpc-5933	294	2	rg	rg	PROPN
dpc-5933	294	3	,	,	PUNCT
dpc-5933	294	4	prussick	prussick	ADJ
dpc-5933	294	5	l	l	NOUN
dpc-5933	294	6	,	,	PUNCT
dpc-5933	294	7	zancanaro	zancanaro	NOUN
dpc-5933	294	8	p	p	X
dpc-5933	294	9	,	,	PUNCT
dpc-5933	294	10	et	et	PROPN
dpc-5933	294	11	al	al	PROPN
dpc-5933	294	12	.	.	PROPN
dpc-5933	294	13	secukinumab	secukinumab	PROPN
dpc-5933	294	14	in	in	ADP
dpc-5933	294	15	the	the	DET
dpc-5933	294	16	treatment	treatment	NOUN
dpc-5933	294	17	of	of	ADP
dpc-5933	294	18	moderate	moderate	ADJ
dpc-5933	294	19	to	to	ADP
dpc-5933	294	20	severe	severe	ADJ
dpc-5933	294	21	hidradenitis	hidradenitis	PROPN
dpc-5933	294	22	suppurativa	suppurativa	NOUN
dpc-5933	294	23	:	:	PUNCT
dpc-5933	294	24	results	result	NOUN
dpc-5933	294	25	of	of	ADP
dpc-5933	294	26	an	an	DET
dpc-5933	294	27	open	open	ADJ
dpc-5933	294	28	-	-	PUNCT
dpc-5933	294	29	label	label	NOUN
dpc-5933	294	30	trial	trial	NOUN
dpc-5933	294	31	.	.	PUNCT
dpc-5933	295	1	j	j	PROPN
dpc-5933	295	2	am	be	AUX
dpc-5933	295	3	acad	acad	ADJ
dpc-5933	295	4	dermatol	dermatol	NOUN
dpc-5933	295	5	.	.	PUNCT
dpc-5933	296	1	2020;82(6	2020;82(6	NUM
dpc-5933	296	2	):	):	PUNCT
dpc-5933	296	3	1524	1524	NUM
dpc-5933	296	4	-	-	SYM
dpc-5933	296	5	1526	1526	NUM
dpc-5933	296	6	.	.	PUNCT
dpc-5933	297	1	doi:10.1016	doi:10.1016	PROPN
dpc-5933	297	2	/	/	SYM
dpc-5933	297	3	j.jaad.2020.02.005	j.jaad.2020.02.005	PROPN
dpc-5933	297	4	.	.	PUNCT
dpc-5933	298	1	pmid:32044410	pmid:32044410	PROPN
dpc-5933	298	2	12	12	NUM
dpc-5933	298	3	.	.	PUNCT
dpc-5933	299	1	reguiai	reguiai	PROPN
dpc-5933	300	1	z	z	NOUN
dpc-5933	300	2	,	,	PUNCT
dpc-5933	300	3	fougerousse	fougerousse	PROPN
dpc-5933	300	4	ac	ac	PROPN
dpc-5933	300	5	,	,	PUNCT
dpc-5933	300	6	maccari	maccari	PROPN
dpc-5933	300	7	f	f	PROPN
dpc-5933	300	8	,	,	PUNCT
dpc-5933	300	9	becherel	becherel	PROPN
dpc-5933	300	10	pa	pa	PROPN
dpc-5933	300	11	.	.	PROPN
dpc-5933	300	12	effectiveness	effectiveness	NOUN
dpc-5933	300	13	of	of	ADP
dpc-5933	300	14	secukinumab	secukinumab	NOUN
dpc-5933	300	15	in	in	ADP
dpc-5933	300	16	hidradenitis	hidradenitis	PROPN
dpc-5933	300	17	suppurativa	suppurativa	PROPN
dpc-5933	300	18	:	:	PUNCT
dpc-5933	300	19	an	an	DET
dpc-5933	300	20	open	open	ADJ
dpc-5933	300	21	study	study	NOUN
dpc-5933	300	22	(	(	PUNCT
dpc-5933	300	23	20	20	NUM
dpc-5933	300	24	cases	case	NOUN
dpc-5933	300	25	)	)	PUNCT
dpc-5933	300	26	.	.	PUNCT
dpc-5933	301	1	j	j	PROPN
dpc-5933	301	2	eur	eur	PROPN
dpc-5933	301	3	acad	acad	PROPN
dpc-5933	301	4	dermatol	dermatol	NOUN
dpc-5933	301	5	venereol	venereol	NOUN
dpc-5933	301	6	.	.	PUNCT
dpc-5933	302	1	2020;34(11):e750	2020;34(11):e750	X
dpc-5933	302	2	-	-	PUNCT
dpc-5933	302	3	e751	e751	PROPN
dpc-5933	302	4	.	.	PUNCT
dpc-5933	303	1	doi:10.1111	doi:10.1111	PROPN
dpc-5933	303	2	/	/	SYM
dpc-5933	303	3	jdv.16605	jdv.16605	PROPN
dpc-5933	303	4	.	.	PUNCT
dpc-5933	304	1	pmid:32401354	pmid:32401354	NOUN
dpc-5933	304	2	13	13	NUM
dpc-5933	304	3	.	.	PUNCT
dpc-5933	305	1	ribero	ribero	PROPN
dpc-5933	305	2	s	s	PROPN
dpc-5933	305	3	,	,	PUNCT
dpc-5933	305	4	ramondetta	ramondetta	VERB
dpc-5933	305	5	a	a	DET
dpc-5933	305	6	,	,	PUNCT
dpc-5933	305	7	fabbrocini	fabbrocini	NOUN
dpc-5933	305	8	g	g	NOUN
dpc-5933	305	9	,	,	PUNCT
dpc-5933	305	10	et	et	PROPN
dpc-5933	305	11	al	al	PROPN
dpc-5933	305	12	.	.	PROPN
dpc-5933	305	13	effectiveness	effectiveness	NOUN
dpc-5933	305	14	of	of	ADP
dpc-5933	305	15	secukinumab	secukinumab	NOUN
dpc-5933	305	16	in	in	ADP
dpc-5933	305	17	the	the	DET
dpc-5933	305	18	treatment	treatment	NOUN
dpc-5933	305	19	of	of	ADP
dpc-5933	305	20	moderate	moderate	ADJ
dpc-5933	305	21	-	-	PUNCT
dpc-5933	305	22	severe	severe	ADJ
dpc-5933	305	23	hidradenitis	hidradenitis	NOUN
dpc-5933	305	24	suppurativa	suppurativa	NOUN
dpc-5933	305	25	:	:	PUNCT
dpc-5933	305	26	results	result	VERB
dpc-5933	305	27	from	from	ADP
dpc-5933	305	28	an	an	DET
dpc-5933	305	29	italian	italian	ADJ
dpc-5933	305	30	multicentric	multicentric	ADJ
dpc-5933	305	31	retrospective	retrospective	ADJ
dpc-5933	305	32	study	study	NOUN
dpc-5933	305	33	in	in	ADP
dpc-5933	305	34	a	a	DET
dpc-5933	305	35	real	real	ADJ
dpc-5933	305	36	-	-	PUNCT
dpc-5933	305	37	life	life	NOUN
dpc-5933	305	38	setting	setting	NOUN
dpc-5933	305	39	.	.	PUNCT
dpc-5933	306	1	j	j	PROPN
dpc-5933	306	2	eur	eur	PROPN
dpc-5933	306	3	acad	acad	PROPN
dpc-5933	306	4	dermatol	dermatol	NOUN
dpc-5933	306	5	venereol	venereol	NOUN
dpc-5933	306	6	.	.	PUNCT
dpc-5933	307	1	2021;35(7):e441	2021;35(7):e441	AUX
dpc-5933	307	2	-	-	PUNCT
dpc-5933	307	3	e442	e442	PROPN
dpc-5933	307	4	.	.	PUNCT
dpc-5933	308	1	doi:10.1111	doi:10.1111	PROPN
dpc-5933	308	2	/	/	SYM
dpc-5933	308	3	jdv.17178	jdv.17178	NOUN
dpc-5933	308	4	.	.	PUNCT
dpc-5933	309	1	pmid:3359	pmid:3359	ADV
dpc-5933	309	2	4790	4790	NUM
dpc-5933	309	3	14	14	NUM
dpc-5933	309	4	.	.	PUNCT
dpc-5933	310	1	fernandez	fernandez	NOUN
dpc-5933	310	2	-	-	PUNCT
dpc-5933	310	3	crehuet	crehuet	NOUN
dpc-5933	310	4	p	p	NOUN
dpc-5933	310	5	,	,	PUNCT
dpc-5933	310	6	haselgruber	haselgruber	PROPN
dpc-5933	310	7	s	s	PROPN
dpc-5933	310	8	,	,	PUNCT
dpc-5933	310	9	padial	padial	ADJ
dpc-5933	310	10	-	-	PUNCT
dpc-5933	310	11	gomez	gomez	NOUN
dpc-5933	310	12	a	a	X
dpc-5933	310	13	,	,	PUNCT
dpc-5933	310	14	et	et	PROPN
dpc-5933	310	15	al	al	PROPN
dpc-5933	310	16	.	.	PUNCT
dpc-5933	310	17	short	short	ADJ
dpc-5933	310	18	-	-	PUNCT
dpc-5933	310	19	term	term	NOUN
dpc-5933	310	20	effectiveness	effectiveness	NOUN
dpc-5933	310	21	,	,	PUNCT
dpc-5933	310	22	safety	safety	NOUN
dpc-5933	310	23	,	,	PUNCT
dpc-5933	310	24	and	and	CCONJ
dpc-5933	310	25	potential	potential	ADJ
dpc-5933	310	26	predictors	predictor	NOUN
dpc-5933	310	27	of	of	ADP
dpc-5933	310	28	response	response	NOUN
dpc-5933	310	29	of	of	ADP
dpc-5933	310	30	secukinumab	secukinumab	NOUN
dpc-5933	310	31	in	in	ADP
dpc-5933	310	32	patients	patient	NOUN
dpc-5933	310	33	with	with	ADP
dpc-5933	310	34	severe	severe	ADJ
dpc-5933	310	35	hidradenitis	hidradenitis	PROPN
dpc-5933	310	36	suppurativa	suppurativa	PROPN
dpc-5933	310	37	refractory	refractory	NOUN
dpc-5933	310	38	to	to	ADP
dpc-5933	310	39	biologic	biologic	NOUN
dpc-5933	310	40	therapy	therapy	NOUN
dpc-5933	310	41	:	:	PUNCT
dpc-5933	310	42	a	a	DET
dpc-5933	310	43	multicenter	multicenter	ADJ
dpc-5933	310	44	observational	observational	ADJ
dpc-5933	310	45	retrospective	retrospective	ADJ
dpc-5933	310	46	study	study	NOUN
dpc-5933	310	47	.	.	PUNCT
dpc-5933	311	1	dermatol	dermatol	NOUN
dpc-5933	311	2	ther	ther	ADV
dpc-5933	311	3	(	(	PUNCT
dpc-5933	311	4	heidelb	heidelb	NOUN
dpc-5933	311	5	)	)	PUNCT
dpc-5933	311	6	.	.	PUNCT
dpc-5933	312	1	2023;13(4):1029	2023;13(4):1029	NUM
dpc-5933	312	2	-	-	SYM
dpc-5933	312	3	1038	1038	NUM
dpc-5933	312	4	.	.	PUNCT
dpc-5933	313	1	doi:10.1007	doi:10.1007	PROPN
dpc-5933	313	2	/	/	SYM
dpc-5933	313	3	s13555	s13555	PROPN
dpc-5933	313	4	-	-	PUNCT
dpc-5933	313	5	02300906	02300906	NUM
dpc-5933	313	6	-	-	SYM
dpc-5933	313	7	2	2	NUM
dpc-5933	313	8	.	.	PUNCT
dpc-5933	313	9	pmid:36892752	pmid:36892752	VERB
dpc-5933	313	10	15	15	NUM
dpc-5933	313	11	.	.	PUNCT
dpc-5933	314	1	haselgruber	haselgruber	PROPN
dpc-5933	314	2	s	s	PROPN
dpc-5933	314	3	,	,	PUNCT
dpc-5933	314	4	fernandez	fernandez	NOUN
dpc-5933	314	5	-	-	PUNCT
dpc-5933	314	6	crehuet	crehuet	NOUN
dpc-5933	314	7	-	-	PUNCT
dpc-5933	314	8	serrano	serrano	NOUN
dpc-5933	314	9	p	p	NOUN
dpc-5933	314	10	,	,	PUNCT
dpc-5933	314	11	fernandez	fernandez	PROPN
dpc-5933	314	12	ballesteros	ballesteros	PROPN
dpc-5933	314	13	md	md	PROPN
dpc-5933	314	14	,	,	PUNCT
dpc-5933	314	15	et	et	PROPN
dpc-5933	314	16	al	al	PROPN
dpc-5933	314	17	.	.	PUNCT
dpc-5933	314	18	insights	insight	NOUN
dpc-5933	314	19	into	into	ADP
dpc-5933	314	20	the	the	DET
dpc-5933	314	21	window	window	NOUN
dpc-5933	314	22	of	of	ADP
dpc-5933	314	23	opportunity	opportunity	NOUN
dpc-5933	314	24	and	and	CCONJ
dpc-5933	314	25	outcome	outcome	NOUN
dpc-5933	314	26	measures	measure	NOUN
dpc-5933	314	27	in	in	ADP
dpc-5933	314	28	patients	patient	NOUN
dpc-5933	314	29	with	with	ADP
dpc-5933	314	30	moderate	moderate	ADJ
dpc-5933	314	31	to	to	ADP
dpc-5933	314	32	severe	severe	ADJ
dpc-5933	314	33	hidradenitis	hidradenitis	PROPN
dpc-5933	314	34	suppurativa	suppurativa	NOUN
dpc-5933	314	35	treated	treat	VERB
dpc-5933	314	36	with	with	ADP
dpc-5933	314	37	secukinumab	secukinumab	NOUN
dpc-5933	314	38	:	:	PUNCT
dpc-5933	314	39	a	a	DET
dpc-5933	314	40	real	real	ADJ
dpc-5933	314	41	-	-	PUNCT
dpc-5933	314	42	world	world	NOUN
dpc-5933	314	43	study	study	NOUN
dpc-5933	314	44	.	.	PUNCT
dpc-5933	315	1	dermatol	dermatol	NOUN
dpc-5933	315	2	ther	ther	ADV
dpc-5933	315	3	(	(	PUNCT
dpc-5933	315	4	heidelb	heidelb	NOUN
dpc-5933	315	5	)	)	PUNCT
dpc-5933	315	6	.	.	PUNCT
dpc-5933	316	1	2024;14(7):1875	2024;14(7):1875	PROPN
dpc-5933	316	2	-	-	SYM
dpc-5933	316	3	1890	1890	NUM
dpc-5933	316	4	.	.	PUNCT
dpc-5933	317	1	doi:10.1007	doi:10.1007	PROPN
dpc-5933	317	2	/	/	SYM
dpc-5933	317	3	s13555	s13555	PROPN
dpc-5933	317	4	-	-	PUNCT
dpc-5933	317	5	024	024	NUM
dpc-5933	317	6	-	-	PUNCT
dpc-5933	317	7	01209	01209	NUM
dpc-5933	317	8	-	-	PUNCT
dpc-5933	317	9	w.	w.	NOUN
dpc-5933	317	10	pmid:38896382	pmid:38896382	PROPN
dpc-5933	317	11	16	16	NUM
dpc-5933	317	12	.	.	PUNCT
dpc-5933	318	1	martora	martora	PROPN
dpc-5933	318	2	f	f	PROPN
dpc-5933	318	3	,	,	PUNCT
dpc-5933	318	4	marasca	marasca	PROPN
dpc-5933	318	5	c	c	PROPN
dpc-5933	318	6	,	,	PUNCT
dpc-5933	318	7	cacciapuoti	cacciapuoti	PROPN
dpc-5933	318	8	s	s	PROPN
dpc-5933	318	9	,	,	PUNCT
dpc-5933	318	10	et	et	PROPN
dpc-5933	318	11	al	al	PROPN
dpc-5933	318	12	.	.	PROPN
dpc-5933	318	13	secukinumab	secukinumab	PROPN
dpc-5933	318	14	in	in	ADP
dpc-5933	318	15	hidradenitis	hidradenitis	PROPN
dpc-5933	318	16	suppurativa	suppurativa	NOUN
dpc-5933	318	17	patients	patient	NOUN
dpc-5933	318	18	who	who	PRON
dpc-5933	318	19	failed	fail	VERB
dpc-5933	318	20	adalimumab	adalimumab	NOUN
dpc-5933	318	21	:	:	PUNCT
dpc-5933	318	22	a	a	DET
dpc-5933	318	23	52	52	NUM
dpc-5933	318	24	-	-	PUNCT
dpc-5933	318	25	week	week	NOUN
dpc-5933	318	26	real	real	ADJ
dpc-5933	318	27	-	-	PUNCT
dpc-5933	318	28	life	life	NOUN
dpc-5933	318	29	study	study	NOUN
dpc-5933	318	30	.	.	PUNCT
dpc-5933	319	1	clin	clin	PROPN
dpc-5933	319	2	cosmet	cosmet	PROPN
dpc-5933	319	3	investig	investig	NOUN
dpc-5933	319	4	dermatol	dermatol	NOUN
dpc-5933	319	5	.	.	PUNCT
dpc-5933	320	1	2024;17:159	2024;17:159	NUM
dpc-5933	320	2	-	-	PUNCT
dpc-5933	320	3	166	166	NUM
dpc-5933	320	4	.	.	PUNCT
dpc-5933	320	5	doi:10.2147	doi:10.2147	NOUN
dpc-5933	320	6	/	/	SYM
dpc-5933	320	7	ccid.s449367	ccid.s449367	PROPN
dpc-5933	320	8	.	.	PUNCT
dpc-5933	321	1	pmid	pmid	NOUN
dpc-5933	321	2	:	:	PUNCT
dpc-5933	321	3	38283798	38283798	NUM
dpc-5933	321	4	17	17	NUM
dpc-5933	321	5	.	.	PUNCT
dpc-5933	322	1	calao	calao	PROPN
dpc-5933	322	2	m	m	PROPN
dpc-5933	322	3	,	,	PUNCT
dpc-5933	322	4	wilson	wilson	PROPN
dpc-5933	322	5	jl	jl	PROPN
dpc-5933	322	6	,	,	PUNCT
dpc-5933	322	7	spelman	spelman	PROPN
dpc-5933	322	8	l	l	PROPN
dpc-5933	322	9	,	,	PUNCT
dpc-5933	322	10	et	et	PROPN
dpc-5933	322	11	al	al	PROPN
dpc-5933	322	12	.	.	PROPN
dpc-5933	322	13	hidradenitis	hidradenitis	PROPN
dpc-5933	322	14	suppurativa	suppurativa	PROPN
dpc-5933	322	15	(	(	PUNCT
dpc-5933	322	16	hs	hs	NOUN
dpc-5933	322	17	)	)	PUNCT
dpc-5933	322	18	prevalence	prevalence	NOUN
dpc-5933	322	19	,	,	PUNCT
dpc-5933	322	20	demographics	demographic	NOUN
dpc-5933	322	21	and	and	CCONJ
dpc-5933	322	22	management	management	NOUN
dpc-5933	322	23	pathways	pathway	NOUN
dpc-5933	322	24	in	in	ADP
dpc-5933	322	25	australia	australia	PROPN
dpc-5933	322	26	:	:	PUNCT
dpc-5933	322	27	a	a	DET
dpc-5933	322	28	population	population	NOUN
dpc-5933	322	29	-	-	PUNCT
dpc-5933	322	30	based	base	VERB
dpc-5933	322	31	cross	cross	ADJ
dpc-5933	322	32	-	-	ADJ
dpc-5933	322	33	sectional	sectional	ADJ
dpc-5933	322	34	study	study	NOUN
dpc-5933	322	35	.	.	PUNCT
dpc-5933	323	1	plos	plos	PROPN
dpc-5933	323	2	one	one	NUM
dpc-5933	323	3	.	.	PUNCT
dpc-5933	324	1	2018;13(7):e0200683	2018;13(7):e0200683	X
dpc-5933	324	2	.	.	PUNCT
dpc-5933	324	3	doi:10.1371	doi:10.1371	PROPN
dpc-5933	324	4	/	/	SYM
dpc-5933	324	5	journal.pone.0200683	journal.pone.0200683	PROPN
dpc-5933	324	6	.	.	PUNCT
dpc-5933	325	1	pmid	pmid	NOUN
dpc-5933	325	2	:	:	PUNCT
dpc-5933	325	3	30040827	30040827	NUM
dpc-5933	325	4	18	18	NUM
dpc-5933	325	5	.	.	PUNCT
dpc-5933	326	1	kimball	kimball	PROPN
dpc-5933	326	2	ab	ab	PROPN
dpc-5933	326	3	,	,	PUNCT
dpc-5933	326	4	sobell	sobell	PROPN
dpc-5933	326	5	jm	jm	PROPN
dpc-5933	326	6	,	,	PUNCT
dpc-5933	326	7	zouboulis	zouboulis	PROPN
dpc-5933	326	8	cc	cc	PROPN
dpc-5933	326	9	,	,	PUNCT
dpc-5933	326	10	et	et	PROPN
dpc-5933	326	11	al	al	PROPN
dpc-5933	326	12	.	.	PUNCT
dpc-5933	327	1	hiscr	hiscr	PROPN
dpc-5933	327	2	(	(	PUNCT
dpc-5933	327	3	hidradenitis	hidradenitis	NOUN
dpc-5933	327	4	suppurativa	suppurativa	PROPN
dpc-5933	327	5	clinical	clinical	ADJ
dpc-5933	327	6	response	response	NOUN
dpc-5933	327	7	):	):	PUNCT
dpc-5933	327	8	a	a	DET
dpc-5933	327	9	novel	novel	ADJ
dpc-5933	327	10	clinical	clinical	ADJ
dpc-5933	327	11	endpoint	endpoint	NOUN
dpc-5933	327	12	to	to	PART
dpc-5933	327	13	evaluate	evaluate	VERB
dpc-5933	327	14	therapeutic	therapeutic	ADJ
dpc-5933	327	15	outcomes	outcome	NOUN
dpc-5933	327	16	in	in	ADP
dpc-5933	327	17	patients	patient	NOUN
dpc-5933	327	18	with	with	ADP
dpc-5933	327	19	hidradenitis	hidradenitis	PROPN
dpc-5933	327	20	suppurativa	suppurativa	NOUN
dpc-5933	327	21	from	from	ADP
dpc-5933	327	22	the	the	DET
dpc-5933	327	23	placebo	placebo	NOUN
dpc-5933	327	24	-	-	PUNCT
dpc-5933	327	25	controlled	control	VERB
dpc-5933	327	26	portion	portion	NOUN
dpc-5933	327	27	of	of	ADP
dpc-5933	327	28	a	a	DET
dpc-5933	327	29	phase	phase	NOUN
dpc-5933	327	30	2	2	NUM
dpc-5933	327	31	adalimumab	adalimumab	NOUN
dpc-5933	327	32	study	study	NOUN
dpc-5933	327	33	.	.	PUNCT
dpc-5933	328	1	j	j	PROPN
dpc-5933	328	2	eur	eur	PROPN
dpc-5933	328	3	acad	acad	PROPN
dpc-5933	328	4	dermatol	dermatol	NOUN
dpc-5933	328	5	venereol	venereol	NOUN
dpc-5933	328	6	.	.	PUNCT
dpc-5933	329	1	2016;30(6):989	2016;30(6):989	NUM
dpc-5933	329	2	-	-	SYM
dpc-5933	329	3	94	94	NUM
dpc-5933	329	4	.	.	PUNCT
dpc-5933	330	1	doi:10.1111	doi:10.1111	NOUN
dpc-5933	330	2	/	/	SYM
dpc-5933	330	3	jdv.13216	jdv.13216	PROPN
dpc-5933	330	4	.	.	PROPN
dpc-5933	330	5	pmid:26201313	pmid:26201313	PROPN
dpc-5933	331	1	19	19	NUM
dpc-5933	331	2	.	.	PUNCT
dpc-5933	331	3	zouboulis	zouboulis	PROPN
dpc-5933	331	4	cc	cc	PROPN
dpc-5933	331	5	,	,	PUNCT
dpc-5933	331	6	tzellos	tzellos	ADP
dpc-5933	331	7	t	t	PROPN
dpc-5933	331	8	,	,	PUNCT
dpc-5933	331	9	kyrgidis	kyrgidis	PROPN
dpc-5933	331	10	a	a	PRON
dpc-5933	331	11	,	,	PUNCT
dpc-5933	331	12	et	et	PROPN
dpc-5933	331	13	al	al	PROPN
dpc-5933	331	14	.	.	PROPN
dpc-5933	331	15	development	development	PROPN
dpc-5933	331	16	and	and	CCONJ
dpc-5933	331	17	validation	validation	NOUN
dpc-5933	331	18	of	of	ADP
dpc-5933	331	19	the	the	DET
dpc-5933	331	20	international	international	ADJ
dpc-5933	331	21	hidradenitis	hidradenitis	PROPN
dpc-5933	331	22	suppurativa	suppurativa	PROPN
dpc-5933	331	23	severity	severity	NOUN
dpc-5933	331	24	score	score	NOUN
dpc-5933	331	25	system	system	NOUN
dpc-5933	331	26	(	(	PUNCT
dpc-5933	331	27	ihs4	ihs4	PROPN
dpc-5933	331	28	)	)	PUNCT
dpc-5933	331	29	,	,	PUNCT
dpc-5933	331	30	a	a	DET
dpc-5933	331	31	novel	novel	ADJ
dpc-5933	331	32	dynamic	dynamic	ADJ
dpc-5933	331	33	scoring	scoring	NOUN
dpc-5933	331	34	system	system	NOUN
dpc-5933	331	35	to	to	PART
dpc-5933	331	36	assess	assess	VERB
dpc-5933	331	37	hs	hs	PROPN
dpc-5933	331	38	severity	severity	PROPN
dpc-5933	331	39	.	.	PUNCT
dpc-5933	332	1	br	br	PROPN
dpc-5933	332	2	j	j	PROPN
dpc-5933	332	3	dermatol	dermatol	NOUN
dpc-5933	332	4	.	.	PUNCT
dpc-5933	333	1	2017;177(5):1401	2017;177(5):1401	NUM
dpc-5933	333	2	-	-	SYM
dpc-5933	333	3	1409	1409	NUM
dpc-5933	333	4	.	.	PUNCT
dpc-5933	334	1	doi:10.1111	doi:10.1111	NOUN
dpc-5933	334	2	/bjd.15748	/bjd.15748	PROPN
dpc-5933	334	3	.	.	PUNCT
dpc-5933	335	1	pmid:28636793	pmid:28636793	PROPN
dpc-5933	335	2	20	20	NUM
dpc-5933	335	3	.	.	PUNCT
dpc-5933	335	4	tzellos	tzellos	ADP
dpc-5933	335	5	t	t	PROPN
dpc-5933	335	6	,	,	PUNCT
dpc-5933	335	7	van	van	PROPN
dpc-5933	335	8	straalen	straalen	ADJ
dpc-5933	335	9	kr	kr	PROPN
dpc-5933	335	10	,	,	PUNCT
dpc-5933	335	11	kyrgidis	kyrgidi	VERB
dpc-5933	335	12	a	a	PRON
dpc-5933	335	13	,	,	PUNCT
dpc-5933	335	14	et	et	PROPN
dpc-5933	335	15	al	al	PROPN
dpc-5933	335	16	.	.	PROPN
dpc-5933	335	17	development	development	PROPN
dpc-5933	335	18	and	and	CCONJ
dpc-5933	335	19	validation	validation	NOUN
dpc-5933	335	20	of	of	ADP
dpc-5933	335	21	ihs4	ihs4	PROPN
dpc-5933	335	22	-	-	PUNCT
dpc-5933	335	23	55	55	NUM
dpc-5933	335	24	,	,	PUNCT
dpc-5933	335	25	an	an	DET
dpc-5933	335	26	ihs4	ihs4	PROPN
dpc-5933	335	27	dichotomous	dichotomous	ADJ
dpc-5933	335	28	outcome	outcome	NOUN
dpc-5933	335	29	to	to	PART
dpc-5933	335	30	assess	assess	VERB
dpc-5933	335	31	treatment	treatment	NOUN
dpc-5933	335	32	effect	effect	NOUN
dpc-5933	335	33	for	for	ADP
dpc-5933	335	34	hidradenitis	hidradenitis	PROPN
dpc-5933	335	35	suppurativa	suppurativa	PROPN
dpc-5933	335	36	.	.	PUNCT
dpc-5933	336	1	j	j	PROPN
dpc-5933	336	2	eur	eur	PROPN
dpc-5933	336	3	acad	acad	PROPN
dpc-5933	336	4	dermatol	dermatol	NOUN
dpc-5933	336	5	venereol	venereol	NOUN
dpc-5933	336	6	.	.	PUNCT
dpc-5933	337	1	2023;37(2):395	2023;37(2):395	PROPN
dpc-5933	337	2	-	-	SYM
dpc-5933	337	3	401	401	NUM
dpc-5933	337	4	.	.	PUNCT
dpc-5933	338	1	doi:10.1111	doi:10.1111	PROPN
dpc-5933	338	2	/	/	SYM
dpc-5933	338	3	jdv.18632	jdv.18632	PROPN
dpc-5933	338	4	.	.	PUNCT
dpc-5933	339	1	pmid:36184889	pmid:36184889	PROPN
dpc-5933	339	2	21	21	NUM
dpc-5933	339	3	.	.	PUNCT
dpc-5933	340	1	shishido	shishido	PROPN
dpc-5933	340	2	-	-	PUNCT
dpc-5933	340	3	takahashi	takahashi	PROPN
dpc-5933	340	4	n	n	CCONJ
dpc-5933	340	5	,	,	PUNCT
dpc-5933	340	6	garcet	garcet	PROPN
dpc-5933	340	7	s	s	PROPN
dpc-5933	340	8	,	,	PUNCT
dpc-5933	340	9	cueto	cueto	PROPN
dpc-5933	341	1	i	i	PROPN
dpc-5933	341	2	,	,	PUNCT
dpc-5933	341	3	et	et	PROPN
dpc-5933	341	4	al	al	PROPN
dpc-5933	341	5	.	.	PROPN
dpc-5933	341	6	hepatocyte	hepatocyte	PROPN
dpc-5933	341	7	growth	growth	NOUN
dpc-5933	341	8	factor	factor	NOUN
dpc-5933	341	9	has	have	VERB
dpc-5933	341	10	unique	unique	ADJ
dpc-5933	341	11	functions	function	NOUN
dpc-5933	341	12	in	in	ADP
dpc-5933	341	13	keratinocytes	keratinocyte	NOUN
dpc-5933	341	14	that	that	PRON
dpc-5933	341	15	differ	differ	VERB
dpc-5933	341	16	acknowledgments	acknowledgment	NOUN
dpc-5933	341	17	:	:	PUNCT
dpc-5933	341	18	the	the	DET
dpc-5933	341	19	drug	drug	NOUN
dpc-5933	341	20	(	(	PUNCT
dpc-5933	341	21	secukinumab	secukinumab	NOUN
dpc-5933	341	22	)	)	PUNCT
dpc-5933	341	23	was	be	AUX
dpc-5933	341	24	granted	grant	VERB
dpc-5933	341	25	by	by	ADP
dpc-5933	341	26	novartis	novartis	PROPN
dpc-5933	341	27	under	under	ADP
dpc-5933	341	28	a	a	DET
dpc-5933	341	29	managed	manage	VERB
dpc-5933	341	30	access	access	NOUN
dpc-5933	341	31	program	program	NOUN
dpc-5933	341	32	(	(	PUNCT
dpc-5933	341	33	map	map	NOUN
dpc-5933	341	34	)	)	PUNCT
dpc-5933	341	35	.	.	PUNCT
dpc-5933	342	1	this	this	DET
dpc-5933	342	2	work	work	NOUN
dpc-5933	342	3	was	be	AUX
dpc-5933	342	4	supported	support	VERB
dpc-5933	342	5	by	by	ADP
dpc-5933	342	6	the	the	DET
dpc-5933	342	7	technology	technology	NOUN
dpc-5933	342	8	innovation	innovation	NOUN
dpc-5933	342	9	program	program	NOUN
dpc-5933	342	10	(	(	PUNCT
dpc-5933	342	11	or	or	CCONJ
dpc-5933	342	12	industrial	industrial	ADJ
dpc-5933	342	13	strategic	strategic	ADJ
dpc-5933	342	14	technology	technology	NOUN
dpc-5933	342	15	development	development	NOUN
dpc-5933	342	16	program	program	NOUN
dpc-5933	342	17	-	-	PUNCT
dpc-5933	342	18	novel	novel	NOUN
dpc-5933	342	19	microbiome	microbiome	NOUN
dpc-5933	342	20	therapy	therapy	NOUN
dpc-5933	342	21	for	for	ADP
dpc-5933	342	22	hidradenitis	hidradenitis	PROPN
dpc-5933	342	23	suppurativa	suppurativa	PROPN
dpc-5933	342	24	and	and	CCONJ
dpc-5933	342	25	severe	severe	ADJ
dpc-5933	342	26	acne	acne	NOUN
dpc-5933	342	27	based	base	VERB
dpc-5933	342	28	on	on	ADP
dpc-5933	342	29	integrative	integrative	ADJ
dpc-5933	342	30	microbiome	microbiome	ADJ
dpc-5933	342	31	multiomics	multiomic	NOUN
dpc-5933	342	32	approach	approach	NOUN
dpc-5933	342	33	)	)	PUNCT
dpc-5933	342	34	(	(	PUNCT
dpc-5933	342	35	20024192	20024192	NUM
dpc-5933	342	36	)	)	PUNCT
dpc-5933	342	37	funded	fund	VERB
dpc-5933	342	38	by	by	ADP
dpc-5933	342	39	the	the	DET
dpc-5933	342	40	ministry	ministry	PROPN
dpc-5933	342	41	of	of	ADP
dpc-5933	342	42	trade	trade	PROPN
dpc-5933	342	43	,	,	PUNCT
dpc-5933	342	44	industry	industry	NOUN
dpc-5933	342	45	&	&	CCONJ
dpc-5933	342	46	energy	energy	NOUN
dpc-5933	342	47	(	(	PUNCT
dpc-5933	342	48	motie	motie	PROPN
dpc-5933	342	49	,	,	PUNCT
dpc-5933	342	50	korea	korea	PROPN
dpc-5933	342	51	)	)	PUNCT
dpc-5933	342	52	.	.	PUNCT
dpc-5933	343	1	this	this	DET
dpc-5933	343	2	study	study	NOUN
dpc-5933	343	3	was	be	AUX
dpc-5933	343	4	supported	support	VERB
dpc-5933	343	5	by	by	ADP
dpc-5933	343	6	an	an	DET
dpc-5933	343	7	mef	mef	NOUN
dpc-5933	343	8	fellowship	fellowship	NOUN
dpc-5933	343	9	conducted	conduct	VERB
dpc-5933	343	10	as	as	ADP
dpc-5933	343	11	part	part	NOUN
dpc-5933	343	12	of	of	ADP
dpc-5933	343	13	“	"	PUNCT
dpc-5933	343	14	education	education	NOUN
dpc-5933	343	15	and	and	CCONJ
dpc-5933	343	16	research	research	NOUN
dpc-5933	343	17	capacity	capacity	NOUN
dpc-5933	343	18	building	building	NOUN
dpc-5933	343	19	project	project	NOUN
dpc-5933	343	20	at	at	ADP
dpc-5933	343	21	university	university	NOUN
dpc-5933	343	22	of	of	ADP
dpc-5933	343	23	medicine	medicine	NOUN
dpc-5933	343	24	and	and	CCONJ
dpc-5933	343	25	pharmacy	pharmacy	NOUN
dpc-5933	343	26	at	at	ADP
dpc-5933	343	27	ho	ho	PROPN
dpc-5933	343	28	chi	chi	PROPN
dpc-5933	343	29	minh	minh	PROPN
dpc-5933	343	30	city	city	PROPN
dpc-5933	343	31	”	"	PUNCT
dpc-5933	343	32	implemented	implement	VERB
dpc-5933	343	33	by	by	ADP
dpc-5933	343	34	the	the	DET
dpc-5933	343	35	korea	korea	PROPN
dpc-5933	343	36	international	international	PROPN
dpc-5933	343	37	cooperation	cooperation	PROPN
dpc-5933	343	38	agency	agency	PROPN
dpc-5933	343	39	(	(	PUNCT
dpc-5933	343	40	koica	koica	PROPN
dpc-5933	343	41	)	)	PUNCT
dpc-5933	343	42	in	in	ADP
dpc-5933	343	43	2025	2025	NUM
dpc-5933	343	44	.	.	PUNCT
dpc-5933	344	1	(	(	PUNCT
dpc-5933	344	2	no	no	NOUN
dpc-5933	344	3	.	.	NOUN
dpc-5933	344	4	2021	2021	NUM
dpc-5933	344	5	-	-	PUNCT
dpc-5933	344	6	00020	00020	NUM
dpc-5933	344	7	-	-	PUNCT
dpc-5933	344	8	4	4	NUM
dpc-5933	344	9	)	)	PUNCT
dpc-5933	344	10	.	.	PUNCT
dpc-5933	345	1	references	reference	NOUN
dpc-5933	345	2	1	1	NUM
dpc-5933	345	3	.	.	PUNCT
dpc-5933	345	4	goldburg	goldburg	PROPN
dpc-5933	345	5	sr	sr	PROPN
dpc-5933	345	6	,	,	PUNCT
dpc-5933	345	7	strober	strober	ADV
dpc-5933	345	8	be	be	AUX
dpc-5933	345	9	,	,	PUNCT
dpc-5933	345	10	payette	payette	PROPN
dpc-5933	345	11	mj	mj	PROPN
dpc-5933	345	12	.	.	PROPN
dpc-5933	345	13	hidradenitis	hidradenitis	PROPN
dpc-5933	345	14	suppurativa	suppurativa	PROPN
dpc-5933	345	15	:	:	PUNCT
dpc-5933	345	16	epidemiology	epidemiology	NOUN
dpc-5933	345	17	,	,	PUNCT
dpc-5933	345	18	clinical	clinical	ADJ
dpc-5933	345	19	presentation	presentation	NOUN
dpc-5933	345	20	,	,	PUNCT
dpc-5933	345	21	and	and	CCONJ
dpc-5933	345	22	pathogenesis	pathogenesis	NOUN
dpc-5933	345	23	.	.	PUNCT
dpc-5933	346	1	j	j	PROPN
dpc-5933	346	2	am	be	AUX
dpc-5933	346	3	acad	acad	ADJ
dpc-5933	346	4	dermatol	dermatol	NOUN
dpc-5933	346	5	.	.	PUNCT
dpc-5933	347	1	2020;82(5):1045	2020;82(5):1045	NUM
dpc-5933	347	2	-	-	SYM
dpc-5933	347	3	1058	1058	NUM
dpc-5933	347	4	.	.	PUNCT
dpc-5933	347	5	doi:10.1016	doi:10.1016	PROPN
dpc-5933	347	6	/	/	PUNCT
dpc-5933	347	7	j.jaad	j.jaad	PROPN
dpc-5933	347	8	.2019.08.090	.2019.08.090	PROPN
dpc-5933	347	9	.	.	PUNCT
dpc-5933	348	1	pmid:31604104	pmid:31604104	X
dpc-5933	349	1	2	2	X
dpc-5933	349	2	.	.	X
dpc-5933	349	3	zouboulis	zouboulis	PROPN
dpc-5933	349	4	cc	cc	PROPN
dpc-5933	349	5	,	,	PUNCT
dpc-5933	349	6	bechara	bechara	PROPN
dpc-5933	349	7	fg	fg	PROPN
dpc-5933	349	8	,	,	PUNCT
dpc-5933	349	9	dickinson	dickinson	NOUN
dpc-5933	349	10	-	-	PUNCT
dpc-5933	349	11	blok	blok	PROPN
dpc-5933	349	12	jl	jl	PROPN
dpc-5933	349	13	,	,	PUNCT
dpc-5933	349	14	et	et	PROPN
dpc-5933	349	15	al	al	PROPN
dpc-5933	349	16	.	.	PROPN
dpc-5933	349	17	hidradenitis	hidradenitis	PROPN
dpc-5933	349	18	suppurativa	suppurativa	PROPN
dpc-5933	349	19	/	/	SYM
dpc-5933	349	20	acne	acne	NOUN
dpc-5933	349	21	inversa	inversa	NOUN
dpc-5933	349	22	:	:	PUNCT
dpc-5933	349	23	a	a	DET
dpc-5933	349	24	practical	practical	ADJ
dpc-5933	349	25	framework	framework	NOUN
dpc-5933	349	26	for	for	ADP
dpc-5933	349	27	treatment	treatment	NOUN
dpc-5933	349	28	optimization	optimization	NOUN
dpc-5933	349	29	systematic	systematic	ADJ
dpc-5933	349	30	review	review	NOUN
dpc-5933	349	31	and	and	CCONJ
dpc-5933	349	32	recommendations	recommendation	NOUN
dpc-5933	349	33	from	from	ADP
dpc-5933	349	34	the	the	DET
dpc-5933	349	35	hs	hs	PROPN
dpc-5933	349	36	alliance	alliance	PROPN
dpc-5933	349	37	working	working	PROPN
dpc-5933	349	38	group	group	NOUN
dpc-5933	349	39	.	.	PUNCT
dpc-5933	350	1	j	j	PROPN
dpc-5933	350	2	eur	eur	PROPN
dpc-5933	350	3	acad	acad	PROPN
dpc-5933	350	4	dermatol	dermatol	NOUN
dpc-5933	350	5	venereol	venereol	NOUN
dpc-5933	350	6	.	.	PUNCT
dpc-5933	351	1	2019;33(1):19	2019;33(1):19	NUM
dpc-5933	351	2	-	-	SYM
dpc-5933	351	3	31	31	NUM
dpc-5933	351	4	.	.	PUNCT
dpc-5933	352	1	doi:10.1111	doi:10.1111	NOUN
dpc-5933	352	2	/	/	SYM
dpc-5933	352	3	jdv.15233	jdv.15233	PROPN
dpc-5933	352	4	.	.	PUNCT
dpc-5933	353	1	pmid:30176066	pmid:30176066	PROPN
dpc-5933	353	2	3	3	NUM
dpc-5933	353	3	.	.	PUNCT
dpc-5933	353	4	snyder	snyder	PROPN
dpc-5933	353	5	cl	cl	PROPN
dpc-5933	353	6	,	,	PUNCT
dpc-5933	353	7	chen	chen	PROPN
dpc-5933	353	8	sx	sx	PROPN
dpc-5933	353	9	,	,	PUNCT
dpc-5933	353	10	porter	porter	NOUN
dpc-5933	353	11	ml	ml	NOUN
dpc-5933	353	12	.	.	PUNCT
dpc-5933	354	1	obstacles	obstacle	NOUN
dpc-5933	354	2	to	to	ADP
dpc-5933	354	3	early	early	ADJ
dpc-5933	354	4	diagnosis	diagnosis	NOUN
dpc-5933	354	5	and	and	CCONJ
dpc-5933	354	6	treatment	treatment	NOUN
dpc-5933	354	7	of	of	ADP
dpc-5933	354	8	hidradenitis	hidradenitis	PROPN
dpc-5933	354	9	suppurativa	suppurativa	NOUN
dpc-5933	354	10	:	:	PUNCT
dpc-5933	354	11	current	current	ADJ
dpc-5933	354	12	perspectives	perspective	NOUN
dpc-5933	354	13	on	on	ADP
dpc-5933	354	14	improving	improve	VERB
dpc-5933	354	15	clinical	clinical	ADJ
dpc-5933	354	16	management	management	NOUN
dpc-5933	354	17	.	.	PUNCT
dpc-5933	355	1	clin	clin	PROPN
dpc-5933	355	2	cosmet	cosmet	PROPN
dpc-5933	355	3	investig	investig	NOUN
dpc-5933	355	4	dermatol	dermatol	NOUN
dpc-5933	355	5	.	.	PUNCT
dpc-5933	356	1	2023;16:1833	2023;16:1833	NUM
dpc-5933	356	2	-	-	SYM
dpc-5933	356	3	1841	1841	NUM
dpc-5933	356	4	.	.	PUNCT
dpc-5933	357	1	doi:10.2147	doi:10.2147	NOUN
dpc-5933	357	2	/	/	SYM
dpc-5933	357	3	ccid.s301794	ccid.s301794	NOUN
dpc-5933	357	4	.	.	PUNCT
dpc-5933	358	1	pmid:37483473	pmid:37483473	NOUN
dpc-5933	358	2	4	4	NUM
dpc-5933	358	3	.	.	NUM
dpc-5933	359	1	prens	prens	PROPN
dpc-5933	359	2	e	e	PROPN
dpc-5933	359	3	,	,	PUNCT
dpc-5933	359	4	deckers	deckers	PROPN
dpc-5933	359	5	i.	i.	PROPN
dpc-5933	359	6	pathophysiology	pathophysiology	PROPN
dpc-5933	359	7	of	of	ADP
dpc-5933	359	8	hidradenitis	hidradenitis	PROPN
dpc-5933	359	9	suppurativa	suppurativa	PROPN
dpc-5933	359	10	:	:	PUNCT
dpc-5933	359	11	an	an	DET
dpc-5933	359	12	update	update	NOUN
dpc-5933	359	13	.	.	PUNCT
dpc-5933	360	1	j	j	PROPN
dpc-5933	360	2	am	be	AUX
dpc-5933	360	3	acad	acad	ADJ
dpc-5933	360	4	dermatol	dermatol	NOUN
dpc-5933	360	5	.	.	PUNCT
dpc-5933	361	1	2015;73(5	2015;73(5	NUM
dpc-5933	361	2	suppl	suppl	ADJ
dpc-5933	361	3	1):s8	1):s8	NUM
dpc-5933	361	4	-	-	SYM
dpc-5933	361	5	11	11	NUM
dpc-5933	361	6	.	.	PUNCT
dpc-5933	362	1	doi:10.1016	doi:10.1016	PROPN
dpc-5933	362	2	/	/	SYM
dpc-5933	362	3	j.jaad.2015.07.045	j.jaad.2015.07.045	PROPN
dpc-5933	362	4	.	.	PROPN
dpc-5933	363	1	pmid:26470623	pmid:26470623	PROPN
dpc-5933	363	2	5	5	NUM
dpc-5933	363	3	.	.	PUNCT
dpc-5933	364	1	alikhan	alikhan	PROPN
dpc-5933	364	2	a	a	PROPN
dpc-5933	364	3	,	,	PUNCT
dpc-5933	364	4	sayed	sayed	ADJ
dpc-5933	364	5	c	c	PROPN
dpc-5933	364	6	,	,	PUNCT
dpc-5933	364	7	alavi	alavi	VERB
dpc-5933	364	8	a	a	PRON
dpc-5933	364	9	,	,	PUNCT
dpc-5933	364	10	et	et	PROPN
dpc-5933	364	11	al	al	PROPN
dpc-5933	364	12	.	.	PROPN
dpc-5933	365	1	north	north	PROPN
dpc-5933	365	2	american	american	PROPN
dpc-5933	365	3	clinical	clinical	ADJ
dpc-5933	365	4	management	management	NOUN
dpc-5933	365	5	guidelines	guideline	NOUN
dpc-5933	365	6	for	for	ADP
dpc-5933	365	7	hidradenitis	hidradenitis	PROPN
dpc-5933	365	8	suppurativa	suppurativa	NOUN
dpc-5933	365	9	:	:	PUNCT
dpc-5933	365	10	a	a	DET
dpc-5933	365	11	publication	publication	NOUN
dpc-5933	365	12	from	from	ADP
dpc-5933	365	13	the	the	DET
dpc-5933	365	14	united	united	PROPN
dpc-5933	365	15	states	states	PROPN
dpc-5933	365	16	and	and	CCONJ
dpc-5933	365	17	canadian	canadian	ADJ
dpc-5933	365	18	hidradenitis	hidradenitis	PROPN
dpc-5933	365	19	suppurativa	suppurativa	PROPN
dpc-5933	365	20	foundations	foundation	NOUN
dpc-5933	365	21	:	:	PUNCT
dpc-5933	365	22	part	part	PROPN
dpc-5933	365	23	ii	ii	PROPN
dpc-5933	365	24	:	:	PUNCT
dpc-5933	365	25	topical	topical	ADJ
dpc-5933	365	26	,	,	PUNCT
dpc-5933	365	27	intralesional	intralesional	ADJ
dpc-5933	365	28	,	,	PUNCT
dpc-5933	365	29	and	and	CCONJ
dpc-5933	365	30	systemic	systemic	ADJ
dpc-5933	365	31	medical	medical	ADJ
dpc-5933	365	32	management	management	NOUN
dpc-5933	365	33	.	.	PUNCT
dpc-5933	366	1	j	j	PROPN
dpc-5933	366	2	am	be	AUX
dpc-5933	366	3	acad	acad	ADJ
dpc-5933	366	4	dermatol	dermatol	NOUN
dpc-5933	366	5	.	.	PUNCT
dpc-5933	367	1	2019;81(1):91	2019;81(1):91	NUM
dpc-5933	367	2	-	-	SYM
dpc-5933	367	3	101	101	NUM
dpc-5933	368	1	.	.	PUNCT
dpc-5933	368	2	doi:10.1016	doi:10.1016	PROPN
dpc-5933	368	3	/	/	SYM
dpc-5933	368	4	j.jaad.2019.02.068	j.jaad.2019.02.068	PROPN
dpc-5933	368	5	.	.	PROPN
dpc-5933	368	6	pmid:30872149	pmid:30872149	PROPN
dpc-5933	368	7	6	6	NUM
dpc-5933	368	8	.	.	PUNCT
dpc-5933	368	9	zouboulis	zouboulis	PROPN
dpc-5933	368	10	cc	cc	PROPN
dpc-5933	368	11	.	.	PROPN
dpc-5933	368	12	adalimumab	adalimumab	NOUN
dpc-5933	368	13	for	for	ADP
dpc-5933	368	14	the	the	DET
dpc-5933	368	15	treatment	treatment	NOUN
dpc-5933	368	16	of	of	ADP
dpc-5933	368	17	hidradenitis	hidradenitis	PROPN
dpc-5933	368	18	suppurativa	suppurativa	PROPN
dpc-5933	368	19	/	/	SYM
dpc-5933	368	20	acne	acne	NOUN
dpc-5933	368	21	inversa	inversa	NOUN
dpc-5933	368	22	.	.	PUNCT
dpc-5933	369	1	expert	expert	NOUN
dpc-5933	369	2	rev	rev	VERB
dpc-5933	369	3	clin	clin	PROPN
dpc-5933	369	4	immunol	immunol	NOUN
dpc-5933	369	5	.	.	PUNCT
dpc-5933	370	1	2016;12(10):1015	2016;12(10):1015	X
dpc-5933	370	2	-	-	SYM
dpc-5933	370	3	26	26	NUM
dpc-5933	370	4	.	.	PUNCT
dpc-5933	371	1	doi:10.1080/1744666x.2016.1221762	doi:10.1080/1744666x.2016.1221762	NOUN
dpc-5933	371	2	.	.	PUNCT
dpc-5933	372	1	pmid:27531618	pmid:27531618	PROPN
dpc-5933	372	2	7	7	NUM
dpc-5933	372	3	.	.	PUNCT
dpc-5933	373	1	prens	prens	PROPN
dpc-5933	373	2	lm	lm	PROPN
dpc-5933	373	3	,	,	PUNCT
dpc-5933	373	4	bouwman	bouwman	NOUN
dpc-5933	373	5	k	k	PROPN
dpc-5933	373	6	,	,	PUNCT
dpc-5933	373	7	aarts	aart	NOUN
dpc-5933	373	8	p	p	NOUN
dpc-5933	373	9	,	,	PUNCT
dpc-5933	374	1	et	et	PROPN
dpc-5933	374	2	al	al	PROPN
dpc-5933	374	3	.	.	PROPN
dpc-5933	374	4	adalimumab	adalimumab	PROPN
dpc-5933	374	5	and	and	CCONJ
dpc-5933	374	6	infliximab	infliximab	PROPN
dpc-5933	374	7	survival	survival	NOUN
dpc-5933	374	8	in	in	ADP
dpc-5933	374	9	patients	patient	NOUN
dpc-5933	374	10	with	with	ADP
dpc-5933	374	11	hidradenitis	hidradenitis	PROPN
dpc-5933	374	12	suppurativa	suppurativa	PROPN
dpc-5933	374	13	:	:	PUNCT
dpc-5933	374	14	a	a	DET
dpc-5933	374	15	daily	daily	ADJ
dpc-5933	374	16	practice	practice	NOUN
dpc-5933	374	17	cohort	cohort	NOUN
dpc-5933	374	18	study	study	NOUN
dpc-5933	374	19	.	.	PUNCT
dpc-5933	375	1	br	br	PROPN
dpc-5933	375	2	j	j	PROPN
dpc-5933	375	3	dermatol	dermatol	NOUN
dpc-5933	375	4	.	.	PUNCT
dpc-5933	376	1	2021;185(1):177	2021;185(1):177	NUM
dpc-5933	376	2	-	-	SYM
dpc-5933	376	3	184	184	NUM
dpc-5933	376	4	.	.	PUNCT
dpc-5933	377	1	doi:10.1111	doi:10.1111	ADJ
dpc-5933	377	2	/	/	SYM
dpc-5933	377	3	bjd.19863	bjd.19863	PROPN
dpc-5933	377	4	.	.	PUNCT
dpc-5933	378	1	pmid:33544917	pmid:33544917	NOUN
dpc-5933	378	2	8	8	NUM
dpc-5933	378	3	.	.	PUNCT
dpc-5933	378	4	ruggiero	ruggiero	PROPN
dpc-5933	379	1	a	a	PRON
dpc-5933	379	2	,	,	PUNCT
dpc-5933	379	3	martora	martora	PROPN
dpc-5933	379	4	f	f	X
dpc-5933	379	5	,	,	PUNCT
dpc-5933	379	6	picone	picone	PROPN
dpc-5933	379	7	v	v	PROPN
dpc-5933	379	8	,	,	PUNCT
dpc-5933	379	9	marano	marano	PROPN
dpc-5933	379	10	l	l	PROPN
dpc-5933	379	11	,	,	PUNCT
dpc-5933	379	12	fabbrocini	fabbrocini	NOUN
dpc-5933	379	13	g	g	PROPN
dpc-5933	379	14	,	,	PUNCT
dpc-5933	379	15	marasca	marasca	PROPN
dpc-5933	379	16	c.	c.	PROPN
dpc-5933	379	17	paradoxical	paradoxical	PROPN
dpc-5933	379	18	hidradenitis	hidradenitis	PROPN
dpc-5933	379	19	suppurativa	suppurativa	NOUN
dpc-5933	379	20	during	during	ADP
dpc-5933	379	21	biologic	biologic	NOUN
dpc-5933	379	22	therapy	therapy	NOUN
dpc-5933	379	23	,	,	PUNCT
dpc-5933	379	24	an	an	DET
dpc-5933	379	25	emerging	emerge	VERB
dpc-5933	379	26	challenge	challenge	NOUN
dpc-5933	379	27	:	:	PUNCT
dpc-5933	379	28	a	a	DET
dpc-5933	379	29	systematic	systematic	ADJ
dpc-5933	379	30	review	review	NOUN
dpc-5933	379	31	.	.	PUNCT
dpc-5933	380	1	biomedicines	biomedicine	NOUN
dpc-5933	380	2	.	.	PUNCT
dpc-5933	381	1	2022;10(2):455	2022;10(2):455	NUM
dpc-5933	381	2	.	.	PUNCT
dpc-5933	382	1	doi:10.3390	doi:10.3390	PROPN
dpc-5933	382	2	/	/	SYM
dpc-5933	382	3	biomedicines10020455	biomedicines10020455	PROPN
dpc-5933	382	4	.	.	PUNCT
dpc-5933	383	1	pmid:35203664	pmid:35203664	NOUN
dpc-5933	383	2	9	9	NUM
dpc-5933	383	3	.	.	PUNCT
dpc-5933	383	4	kimball	kimball	PROPN
dpc-5933	383	5	ab	ab	PROPN
dpc-5933	383	6	,	,	PUNCT
dpc-5933	383	7	jemec	jemec	PROPN
dpc-5933	383	8	gbe	gbe	PROPN
dpc-5933	383	9	,	,	PUNCT
dpc-5933	383	10	alavi	alavi	VERB
dpc-5933	383	11	a	a	DET
dpc-5933	383	12	,	,	PUNCT
dpc-5933	383	13	et	et	PROPN
dpc-5933	383	14	al	al	PROPN
dpc-5933	383	15	.	.	PROPN
dpc-5933	383	16	secukinumab	secukinumab	PROPN
dpc-5933	383	17	in	in	ADP
dpc-5933	383	18	moderate	moderate	ADJ
dpc-5933	383	19	to	to	ADP
dpc-5933	383	20	-	-	PUNCT
dpc-5933	383	21	severe	severe	ADJ
dpc-5933	383	22	hidradenitis	hidradenitis	NOUN
dpc-5933	383	23	suppurativa	suppurativa	NOUN
dpc-5933	383	24	(	(	PUNCT
dpc-5933	383	25	sunshine	sunshine	NOUN
dpc-5933	383	26	and	and	CCONJ
dpc-5933	383	27	sunrise	sunrise	VERB
dpc-5933	383	28	):	):	PUNCT
dpc-5933	383	29	week	week	NOUN
dpc-5933	383	30	16	16	NUM
dpc-5933	383	31	and	and	CCONJ
dpc-5933	383	32	week	week	NOUN
dpc-5933	383	33	52	52	NUM
dpc-5933	383	34	results	result	NOUN
dpc-5933	383	35	of	of	ADP
dpc-5933	383	36	two	two	NUM
dpc-5933	383	37	identical	identical	ADJ
dpc-5933	383	38	,	,	PUNCT
dpc-5933	383	39	multicentre	multicentre	NOUN
dpc-5933	383	40	,	,	PUNCT
dpc-5933	383	41	randomised	randomise	VERB
dpc-5933	383	42	,	,	PUNCT
dpc-5933	383	43	placebo	placebo	NOUN
dpc-5933	383	44	-	-	PUNCT
dpc-5933	383	45	controlled	control	VERB
dpc-5933	383	46	,	,	PUNCT
dpc-5933	383	47	double	double	ADJ
dpc-5933	383	48	-	-	PUNCT
dpc-5933	383	49	blind	blind	ADJ
dpc-5933	383	50	phase	phase	NOUN
dpc-5933	383	51	3	3	NUM
dpc-5933	383	52	trials	trial	NOUN
dpc-5933	383	53	.	.	PUNCT
dpc-5933	384	1	lancet	lancet	NOUN
dpc-5933	384	2	.	.	PUNCT
dpc-5933	385	1	2023;401(10378):747	2023;401(10378):747	NUM
dpc-5933	385	2	-	-	SYM
dpc-5933	385	3	761	761	NUM
dpc-5933	385	4	.	.	PUNCT
dpc-5933	386	1	doi:10.1016	doi:10.1016	PROPN
dpc-5933	386	2	/	/	SYM
dpc-5933	387	1	s0140	s0140	PROPN
dpc-5933	387	2	-	-	PUNCT
dpc-5933	387	3	6736(23)00	6736(23)00	NUM
dpc-5933	387	4	022	022	NUM
dpc-5933	387	5	-	-	SYM
dpc-5933	387	6	3	3	NUM
dpc-5933	387	7	.	.	PUNCT
dpc-5933	387	8	pmid:36746171	pmid:36746171	NOUN
dpc-5933	387	9	original	original	ADJ
dpc-5933	387	10	article	article	NOUN
dpc-5933	387	11	|	|	ADV
dpc-5933	387	12	dermatol	dermatol	ADJ
dpc-5933	387	13	pract	pract	NOUN
dpc-5933	387	14	concept	concept	NOUN
dpc-5933	387	15	.	.	PUNCT
dpc-5933	388	1	2025;15(4):5933	2025;15(4):5933	NUM
dpc-5933	388	2	13	13	NUM
dpc-5933	388	3	27	27	NUM
dpc-5933	388	4	.	.	PUNCT
dpc-5933	389	1	touhouche	touhouche	VERB
dpc-5933	389	2	at	at	ADP
dpc-5933	389	3	,	,	PUNCT
dpc-5933	389	4	chaput	chaput	NOUN
dpc-5933	389	5	b	b	NOUN
dpc-5933	389	6	,	,	PUNCT
dpc-5933	389	7	rouquet	rouquet	PROPN
dpc-5933	389	8	rm	rm	PROPN
dpc-5933	389	9	,	,	PUNCT
dpc-5933	389	10	et	et	PROPN
dpc-5933	389	11	al	al	PROPN
dpc-5933	389	12	.	.	PROPN
dpc-5933	389	13	integrated	integrate	VERB
dpc-5933	389	14	multidisciplinary	multidisciplinary	ADJ
dpc-5933	389	15	approach	approach	NOUN
dpc-5933	389	16	to	to	ADP
dpc-5933	389	17	hidradenitis	hidradenitis	PROPN
dpc-5933	389	18	suppurativa	suppurativa	PROPN
dpc-5933	389	19	in	in	ADP
dpc-5933	389	20	clinical	clinical	ADJ
dpc-5933	389	21	practice	practice	NOUN
dpc-5933	389	22	.	.	PUNCT
dpc-5933	390	1	int	int	NOUN
dpc-5933	390	2	j	j	PROPN
dpc-5933	390	3	womens	womens	PROPN
dpc-5933	390	4	dermatol	dermatol	NOUN
dpc-5933	390	5	.	.	PUNCT
dpc-5933	391	1	2020;6(3):164	2020;6(3):164	NUM
dpc-5933	391	2	-	-	SYM
dpc-5933	391	3	168	168	NUM
dpc-5933	391	4	.	.	PUNCT
dpc-5933	392	1	doi	doi	NOUN
dpc-5933	392	2	:	:	PUNCT
dpc-5933	392	3	10.1016	10.1016	NUM
dpc-5933	392	4	/	/	SYM
dpc-5933	392	5	j.ijwd.2020.02.006	j.ijwd.2020.02.006	PROPN
dpc-5933	392	6	.	.	PUNCT
dpc-5933	393	1	pmid	pmid	NOUN
dpc-5933	393	2	:	:	PUNCT
dpc-5933	393	3	32637537	32637537	NUM
dpc-5933	393	4	.	.	PUNCT
dpc-5933	394	1	28	28	NUM
dpc-5933	394	2	.	.	PUNCT
dpc-5933	395	1	marzano	marzano	PROPN
dpc-5933	395	2	av	av	PROPN
dpc-5933	395	3	,	,	PUNCT
dpc-5933	395	4	magnoni	magnoni	NOUN
dpc-5933	395	5	c	c	NOUN
dpc-5933	395	6	,	,	PUNCT
dpc-5933	395	7	micali	micali	NOUN
dpc-5933	395	8	g	g	PROPN
dpc-5933	395	9	,	,	PUNCT
dpc-5933	395	10	et	et	PROPN
dpc-5933	395	11	al	al	PROPN
dpc-5933	395	12	.	.	PUNCT
dpc-5933	395	13	improving	improve	VERB
dpc-5933	395	14	hidradenitis	hidradenitis	PROPN
dpc-5933	395	15	suppurativa	suppurativa	PROPN
dpc-5933	395	16	management	management	NOUN
dpc-5933	395	17	:	:	PUNCT
dpc-5933	395	18	consensus	consensus	NOUN
dpc-5933	395	19	statements	statement	NOUN
dpc-5933	395	20	from	from	ADP
dpc-5933	395	21	physicians	physician	NOUN
dpc-5933	395	22	and	and	CCONJ
dpc-5933	395	23	patients	patient	NOUN
dpc-5933	395	24	’	’	PART
dpc-5933	395	25	perspectives	perspective	NOUN
dpc-5933	395	26	.	.	PUNCT
dpc-5933	396	1	arch	arch	ADJ
dpc-5933	396	2	dermatol	dermatol	NOUN
dpc-5933	396	3	res	re	NOUN
dpc-5933	396	4	.	.	PUNCT
dpc-5933	397	1	2024;316(8):577	2024;316(8):577	NUM
dpc-5933	397	2	.	.	PUNCT
dpc-5933	397	3	doi	doi	NOUN
dpc-5933	397	4	:	:	PUNCT
dpc-5933	397	5	10.1007	10.1007	NUM
dpc-5933	397	6	/	/	SYM
dpc-5933	397	7	s00403	s00403	NOUN
dpc-5933	397	8	-	-	PUNCT
dpc-5933	397	9	024	024	NUM
dpc-5933	397	10	-	-	PUNCT
dpc-5933	397	11	03316	03316	NUM
dpc-5933	397	12	-	-	SYM
dpc-5933	397	13	2	2	NUM
dpc-5933	397	14	.	.	PUNCT
dpc-5933	398	1	pmid	pmid	NOUN
dpc-5933	398	2	:	:	PUNCT
dpc-5933	398	3	39180694	39180694	NUM
dpc-5933	398	4	.	.	PUNCT
dpc-5933	399	1	29	29	NUM
dpc-5933	399	2	.	.	PUNCT
dpc-5933	400	1	ocker	ocker	PROPN
dpc-5933	400	2	l	l	PROPN
dpc-5933	400	3	,	,	PUNCT
dpc-5933	400	4	abu	abu	PROPN
dpc-5933	400	5	rached	rache	VERB
dpc-5933	400	6	n	n	PROPN
dpc-5933	400	7	,	,	PUNCT
dpc-5933	400	8	seifert	seifert	PROPN
dpc-5933	400	9	c	c	PROPN
dpc-5933	400	10	,	,	PUNCT
dpc-5933	400	11	scheel	scheel	PROPN
dpc-5933	400	12	c	c	NOUN
dpc-5933	400	13	,	,	PUNCT
dpc-5933	400	14	bechara	bechara	PROPN
dpc-5933	400	15	fg	fg	PROPN
dpc-5933	400	16	.	.	PUNCT
dpc-5933	400	17	current	current	ADJ
dpc-5933	400	18	medical	medical	ADJ
dpc-5933	400	19	and	and	CCONJ
dpc-5933	400	20	surgical	surgical	ADJ
dpc-5933	400	21	treatment	treatment	NOUN
dpc-5933	400	22	of	of	ADP
dpc-5933	400	23	hidradenitis	hidradenitis	PROPN
dpc-5933	400	24	suppurativa	suppurativa	PROPN
dpc-5933	400	25	-	-	PUNCT
dpc-5933	400	26	a	a	DET
dpc-5933	400	27	comprehensive	comprehensive	ADJ
dpc-5933	400	28	review	review	NOUN
dpc-5933	400	29	.	.	PUNCT
dpc-5933	401	1	j	j	PROPN
dpc-5933	401	2	clin	clin	PROPN
dpc-5933	401	3	med	me	VERB
dpc-5933	401	4	.	.	PUNCT
dpc-5933	402	1	2022;11(23)doi:10.3390/	2022;11(23)doi:10.3390/	NUM
dpc-5933	402	2	jcm11237240	jcm11237240	NOUN
dpc-5933	402	3	.	.	PUNCT
dpc-5933	403	1	pmid:36498816	pmid:36498816	PROPN
dpc-5933	403	2	30	30	NUM
dpc-5933	403	3	.	.	PUNCT
dpc-5933	404	1	zouboulis	zouboulis	PROPN
dpc-5933	404	2	cc	cc	PROPN
dpc-5933	404	3	,	,	PUNCT
dpc-5933	404	4	bechara	bechara	PROPN
dpc-5933	404	5	fg	fg	PROPN
dpc-5933	404	6	,	,	PUNCT
dpc-5933	404	7	benhadou	benhadou	NOUN
dpc-5933	404	8	f	f	NOUN
dpc-5933	404	9	,	,	PUNCT
dpc-5933	404	10	et	et	PROPN
dpc-5933	404	11	al	al	PROPN
dpc-5933	404	12	.	.	PROPN
dpc-5933	405	1	european	european	PROPN
dpc-5933	405	2	s2k	s2k	PROPN
dpc-5933	405	3	guidelines	guideline	NOUN
dpc-5933	405	4	for	for	ADP
dpc-5933	405	5	hidradenitis	hidradenitis	PROPN
dpc-5933	405	6	suppurativa	suppurativa	PROPN
dpc-5933	405	7	/	/	SYM
dpc-5933	405	8	acne	acne	NOUN
dpc-5933	405	9	inversa	inversa	NOUN
dpc-5933	405	10	part	part	NOUN
dpc-5933	405	11	2	2	NUM
dpc-5933	405	12	:	:	PUNCT
dpc-5933	405	13	treatment	treatment	NOUN
dpc-5933	405	14	.	.	PUNCT
dpc-5933	406	1	j	j	PROPN
dpc-5933	406	2	eur	eur	PROPN
dpc-5933	406	3	acad	acad	PROPN
dpc-5933	406	4	dermatol	dermatol	NOUN
dpc-5933	406	5	venereol	venereol	NOUN
dpc-5933	406	6	.	.	PUNCT
dpc-5933	407	1	2025;39(5):899	2025;39(5):899	NUM
dpc-5933	407	2	-	-	SYM
dpc-5933	407	3	941	941	NUM
dpc-5933	407	4	.	.	PUNCT
dpc-5933	408	1	doi:10.1111	doi:10.1111	ADJ
dpc-5933	408	2	/	/	SYM
dpc-5933	408	3	jdv.20472	jdv.20472	PROPN
dpc-5933	408	4	.	.	NOUN
dpc-5933	409	1	pmid:39699926	pmid:39699926	PROPN
dpc-5933	409	2	31	31	NUM
dpc-5933	409	3	.	.	PUNCT
dpc-5933	410	1	erbagci	erbagci	NOUN
dpc-5933	410	2	e	e	PROPN
dpc-5933	410	3	,	,	PUNCT
dpc-5933	410	4	bakay	bakay	PROPN
dpc-5933	410	5	osk	osk	PROPN
dpc-5933	410	6	,	,	PUNCT
dpc-5933	410	7	hapa	hapa	PROPN
dpc-5933	410	8	fa	fa	PROPN
dpc-5933	410	9	.	.	PROPN
dpc-5933	410	10	secukinumab	secukinumab	PROPN
dpc-5933	410	11	treatment	treatment	NOUN
dpc-5933	410	12	in	in	ADP
dpc-5933	410	13	patients	patient	NOUN
dpc-5933	410	14	with	with	ADP
dpc-5933	410	15	hidradenitis	hidradenitis	PROPN
dpc-5933	410	16	suppurativa	suppurativa	NOUN
dpc-5933	410	17	in	in	ADP
dpc-5933	410	18	real	real	ADJ
dpc-5933	410	19	-	-	PUNCT
dpc-5933	410	20	world	world	NOUN
dpc-5933	410	21	clinical	clinical	ADJ
dpc-5933	410	22	settings	setting	NOUN
dpc-5933	410	23	:	:	PUNCT
dpc-5933	410	24	a	a	DET
dpc-5933	410	25	multicenter	multicenter	ADJ
dpc-5933	410	26	study	study	NOUN
dpc-5933	410	27	.	.	PUNCT
dpc-5933	411	1	dermatol	dermatol	NOUN
dpc-5933	411	2	pract	pract	PROPN
dpc-5933	411	3	concept	concept	NOUN
dpc-5933	411	4	.	.	PUNCT
dpc-5933	412	1	2025;15(1	2025;15(1	NUM
dpc-5933	412	2	)	)	PUNCT
dpc-5933	412	3	.	.	PUNCT
dpc-5933	413	1	doi:10.5826	doi:10.5826	PROPN
dpc-5933	413	2	/	/	SYM
dpc-5933	413	3	dpc.1501a4915	dpc.1501a4915	NOUN
dpc-5933	413	4	.	.	PUNCT
dpc-5933	414	1	pmid:40117600	pmid:40117600	ADP
dpc-5933	414	2	32	32	NUM
dpc-5933	414	3	.	.	PUNCT
dpc-5933	415	1	kokolakis	kokolakis	PROPN
dpc-5933	415	2	g	g	PROPN
dpc-5933	415	3	,	,	PUNCT
dpc-5933	415	4	martorell	martorell	VERB
dpc-5933	415	5	a	a	PRON
dpc-5933	415	6	,	,	PUNCT
dpc-5933	415	7	kerdel	kerdel	PROPN
dpc-5933	415	8	f	f	PROPN
dpc-5933	415	9	,	,	PUNCT
dpc-5933	415	10	et	et	PROPN
dpc-5933	415	11	al	al	PROPN
dpc-5933	415	12	.	.	PROPN
dpc-5933	416	1	42981	42981	NUM
dpc-5933	416	2	secukinumab	secukinumab	NOUN
dpc-5933	416	3	and	and	CCONJ
dpc-5933	416	4	concomitant	concomitant	ADJ
dpc-5933	416	5	antibiotic	antibiotic	ADJ
dpc-5933	416	6	use	use	NOUN
dpc-5933	416	7	in	in	ADP
dpc-5933	416	8	patients	patient	NOUN
dpc-5933	416	9	with	with	ADP
dpc-5933	416	10	moderate	moderate	ADJ
dpc-5933	416	11	-	-	PUNCT
dpc-5933	416	12	tosevere	tosevere	NOUN
dpc-5933	416	13	hidradenitis	hidradenitis	PROPN
dpc-5933	416	14	suppurativa	suppurativa	PROPN
dpc-5933	416	15	:	:	PUNCT
dpc-5933	416	16	week	week	NOUN
dpc-5933	416	17	16	16	NUM
dpc-5933	416	18	efficacy	efficacy	NOUN
dpc-5933	416	19	and	and	CCONJ
dpc-5933	416	20	safety	safety	NOUN
dpc-5933	416	21	results	result	NOUN
dpc-5933	416	22	from	from	ADP
dpc-5933	416	23	the	the	DET
dpc-5933	416	24	phase	phase	NOUN
dpc-5933	416	25	3	3	NUM
dpc-5933	416	26	sunshine	sunshine	NOUN
dpc-5933	416	27	and	and	CCONJ
dpc-5933	416	28	sunrise	sunrise	VERB
dpc-5933	416	29	trials	trial	NOUN
dpc-5933	416	30	.	.	PUNCT
dpc-5933	417	1	j	j	PROPN
dpc-5933	417	2	am	be	AUX
dpc-5933	417	3	acad	acad	ADJ
dpc-5933	417	4	dermatol	dermatol	NOUN
dpc-5933	417	5	.	.	PUNCT
dpc-5933	418	1	2023;89(3):ab85	2023;89(3):ab85	X
dpc-5933	418	2	.	.	PUNCT
dpc-5933	418	3	doi:10.1016	doi:10.1016	PROPN
dpc-5933	418	4	/	/	SYM
dpc-5933	418	5	j.jaad.2023.07.345	j.jaad.2023.07.345	PROPN
dpc-5933	418	6	.	.	PUNCT
dpc-5933	419	1	from	from	ADP
dpc-5933	419	2	those	those	PRON
dpc-5933	419	3	of	of	ADP
dpc-5933	419	4	il-17a	il-17a	PROPN
dpc-5933	419	5	and	and	CCONJ
dpc-5933	419	6	tnf	tnf	PROPN
dpc-5933	419	7	and	and	CCONJ
dpc-5933	419	8	may	may	AUX
dpc-5933	419	9	contribute	contribute	VERB
dpc-5933	419	10	to	to	ADP
dpc-5933	419	11	inflammatory	inflammatory	ADJ
dpc-5933	419	12	pathways	pathway	NOUN
dpc-5933	419	13	in	in	ADP
dpc-5933	419	14	hidradenitis	hidradenitis	PROPN
dpc-5933	419	15	suppurativa	suppurativa	PROPN
dpc-5933	419	16	.	.	PUNCT
dpc-5933	420	1	j	j	PROPN
dpc-5933	420	2	invest	invest	VERB
dpc-5933	420	3	dermatol	dermatol	NOUN
dpc-5933	420	4	.	.	PUNCT
dpc-5933	421	1	2024;145(3):536	2024;145(3):536	NUM
dpc-5933	421	2	-	-	PUNCT
dpc-5933	421	3	547.e7	547.e7	NUM
dpc-5933	421	4	.	.	PUNCT
dpc-5933	422	1	doi:10.1016	doi:10.1016	PROPN
dpc-5933	422	2	/	/	SYM
dpc-5933	422	3	j.jid.2024.07.005	j.jid.2024.07.005	PROPN
dpc-5933	422	4	.	.	PUNCT
dpc-5933	423	1	pmid:39038532	pmid:39038532	NOUN
dpc-5933	423	2	22	22	NUM
dpc-5933	423	3	.	.	PUNCT
dpc-5933	424	1	marzano	marzano	PROPN
dpc-5933	424	2	a	a	PRON
dpc-5933	424	3	,	,	PUNCT
dpc-5933	424	4	genovese	genovese	NOUN
dpc-5933	424	5	g	g	NOUN
dpc-5933	424	6	,	,	PUNCT
dpc-5933	424	7	casazza	casazza	NOUN
dpc-5933	424	8	g	g	NOUN
dpc-5933	424	9	,	,	PUNCT
dpc-5933	424	10	et	et	PROPN
dpc-5933	424	11	al	al	PROPN
dpc-5933	424	12	.	.	PROPN
dpc-5933	424	13	evidence	evidence	NOUN
dpc-5933	424	14	for	for	ADP
dpc-5933	424	15	a	a	DET
dpc-5933	424	16	‘	'	PUNCT
dpc-5933	424	17	window	window	NOUN
dpc-5933	424	18	of	of	ADP
dpc-5933	424	19	opportunity’in	opportunity’in	PROPN
dpc-5933	424	20	hidradenitis	hidradenitis	PROPN
dpc-5933	424	21	suppurativa	suppurativa	PROPN
dpc-5933	424	22	treated	treat	VERB
dpc-5933	424	23	with	with	ADP
dpc-5933	424	24	adalimumab	adalimumab	NOUN
dpc-5933	424	25	:	:	PUNCT
dpc-5933	424	26	a	a	DET
dpc-5933	424	27	retrospective	retrospective	ADJ
dpc-5933	424	28	,	,	PUNCT
dpc-5933	424	29	real	real	ADJ
dpc-5933	424	30	-	-	PUNCT
dpc-5933	424	31	life	life	NOUN
dpc-5933	424	32	multicentre	multicentre	NOUN
dpc-5933	424	33	cohort	cohort	NOUN
dpc-5933	424	34	study	study	NOUN
dpc-5933	424	35	.	.	PUNCT
dpc-5933	425	1	br	br	PROPN
dpc-5933	425	2	j	j	PROPN
dpc-5933	425	3	dermatol	dermatol	NOUN
dpc-5933	425	4	.	.	PUNCT
dpc-5933	426	1	2021;184(1):133	2021;184(1):133	NUM
dpc-5933	426	2	-	-	SYM
dpc-5933	426	3	140	140	NUM
dpc-5933	426	4	.	.	PUNCT
dpc-5933	426	5	doi	doi	NOUN
dpc-5933	426	6	:	:	PUNCT
dpc-5933	426	7	10.1111	10.1111	NUM
dpc-5933	426	8	/	/	SYM
dpc-5933	426	9	bjd.1898	bjd.1898	PROPN
dpc-5933	426	10	.	.	PUNCT
dpc-5933	427	1	pmid	pmid	NOUN
dpc-5933	427	2	:	:	PUNCT
dpc-5933	427	3	32119111	32119111	NUM
dpc-5933	427	4	.	.	PUNCT
dpc-5933	428	1	23	23	NUM
dpc-5933	428	2	.	.	PUNCT
dpc-5933	429	1	lee	lee	PROPN
dpc-5933	429	2	jh	jh	PROPN
dpc-5933	429	3	,	,	PUNCT
dpc-5933	429	4	kwon	kwon	PROPN
dpc-5933	429	5	hs	hs	PROPN
dpc-5933	429	6	,	,	PUNCT
dpc-5933	429	7	jung	jung	PROPN
dpc-5933	429	8	hm	hm	PROPN
dpc-5933	429	9	,	,	PUNCT
dpc-5933	429	10	kim	kim	PROPN
dpc-5933	429	11	gm	gm	PROPN
dpc-5933	429	12	,	,	PUNCT
dpc-5933	429	13	bae	bae	PROPN
dpc-5933	429	14	jm	jm	PROPN
dpc-5933	429	15	.	.	PROPN
dpc-5933	430	1	prevalence	prevalence	NOUN
dpc-5933	430	2	and	and	CCONJ
dpc-5933	430	3	comorbidities	comorbiditie	NOUN
dpc-5933	430	4	associated	associate	VERB
dpc-5933	430	5	with	with	ADP
dpc-5933	430	6	hidradenitis	hidradenitis	PROPN
dpc-5933	430	7	suppurativa	suppurativa	PROPN
dpc-5933	430	8	in	in	ADP
dpc-5933	430	9	korea	korea	PROPN
dpc-5933	430	10	:	:	PUNCT
dpc-5933	430	11	a	a	DET
dpc-5933	430	12	nationwide	nationwide	ADJ
dpc-5933	430	13	population	population	NOUN
dpc-5933	430	14	-	-	PUNCT
dpc-5933	430	15	based	base	VERB
dpc-5933	430	16	study	study	NOUN
dpc-5933	430	17	.	.	PUNCT
dpc-5933	431	1	j	j	PROPN
dpc-5933	431	2	eur	eur	PROPN
dpc-5933	431	3	acad	acad	PROPN
dpc-5933	431	4	dermatol	dermatol	NOUN
dpc-5933	431	5	venereol	venereol	NOUN
dpc-5933	431	6	.	.	PUNCT
dpc-5933	432	1	2018;32(10):1784	2018;32(10):1784	NUM
dpc-5933	432	2	-	-	SYM
dpc-5933	432	3	1790	1790	NUM
dpc-5933	432	4	.	.	PUNCT
dpc-5933	433	1	doi:10.1111	doi:10.1111	PROPN
dpc-5933	433	2	/	/	SYM
dpc-5933	433	3	jdv.15071	jdv.15071	PROPN
dpc-5933	433	4	.	.	PUNCT
dpc-5933	434	1	pmid:29761904	pmid:29761904	NOUN
dpc-5933	435	1	24	24	NUM
dpc-5933	435	2	.	.	PUNCT
dpc-5933	435	3	lee	lee	PROPN
dpc-5933	435	4	jw	jw	PROPN
dpc-5933	435	5	,	,	PUNCT
dpc-5933	435	6	heo	heo	PROPN
dpc-5933	435	7	yw	yw	PROPN
dpc-5933	435	8	,	,	PUNCT
dpc-5933	435	9	lee	lee	PROPN
dpc-5933	435	10	jh	jh	PROPN
dpc-5933	435	11	,	,	PUNCT
dpc-5933	435	12	lee	lee	PROPN
dpc-5933	435	13	s.	s.	PROPN
dpc-5933	435	14	epidemiology	epidemiology	PROPN
dpc-5933	435	15	and	and	CCONJ
dpc-5933	435	16	comorbidity	comorbidity	NOUN
dpc-5933	435	17	of	of	ADP
dpc-5933	435	18	hidradenitis	hidradenitis	PROPN
dpc-5933	435	19	suppurativa	suppurativa	PROPN
dpc-5933	435	20	in	in	ADP
dpc-5933	435	21	korea	korea	PROPN
dpc-5933	435	22	for	for	ADP
dpc-5933	435	23	17	17	NUM
dpc-5933	435	24	years	year	NOUN
dpc-5933	435	25	:	:	PUNCT
dpc-5933	435	26	a	a	DET
dpc-5933	435	27	nationwide	nationwide	ADJ
dpc-5933	435	28	population	population	NOUN
dpc-5933	435	29	-	-	PUNCT
dpc-5933	435	30	based	base	VERB
dpc-5933	435	31	cohort	cohort	NOUN
dpc-5933	435	32	study	study	NOUN
dpc-5933	435	33	.	.	PUNCT
dpc-5933	436	1	j	j	PROPN
dpc-5933	436	2	dermatol	dermatol	NOUN
dpc-5933	436	3	.	.	PUNCT
dpc-5933	437	1	2023;50(6):778786	2023;50(6):778786	NUM
dpc-5933	437	2	.	.	PUNCT
dpc-5933	438	1	doi:10.1111/1346	doi:10.1111/1346	NOUN
dpc-5933	438	2	-	-	PUNCT
dpc-5933	438	3	8138.16747	8138.16747	NUM
dpc-5933	438	4	.	.	PUNCT
dpc-5933	439	1	pmid:36806098	pmid:36806098	PROPN
dpc-5933	439	2	25	25	NUM
dpc-5933	439	3	.	.	PUNCT
dpc-5933	439	4	alotaibi	alotaibi	PROPN
dpc-5933	440	1	hm	hm	INTJ
dpc-5933	440	2	.	.	PUNCT
dpc-5933	440	3	incidence	incidence	NOUN
dpc-5933	440	4	,	,	PUNCT
dpc-5933	440	5	risk	risk	NOUN
dpc-5933	440	6	factors	factor	NOUN
dpc-5933	440	7	,	,	PUNCT
dpc-5933	440	8	and	and	CCONJ
dpc-5933	440	9	prognosis	prognosis	NOUN
dpc-5933	440	10	of	of	ADP
dpc-5933	440	11	hidradenitis	hidradenitis	PROPN
dpc-5933	440	12	suppurativa	suppurativa	NOUN
dpc-5933	440	13	across	across	ADP
dpc-5933	440	14	the	the	DET
dpc-5933	440	15	globe	globe	NOUN
dpc-5933	440	16	:	:	PUNCT
dpc-5933	440	17	insights	insight	NOUN
dpc-5933	440	18	from	from	ADP
dpc-5933	440	19	the	the	DET
dpc-5933	440	20	literature	literature	NOUN
dpc-5933	440	21	.	.	PUNCT
dpc-5933	441	1	clin	clin	PROPN
dpc-5933	441	2	cosmet	cosmet	PROPN
dpc-5933	441	3	investig	investig	NOUN
dpc-5933	441	4	dermatol	dermatol	NOUN
dpc-5933	441	5	.	.	PUNCT
dpc-5933	442	1	2023;16:545	2023;16:545	NUM
dpc-5933	442	2	-	-	SYM
dpc-5933	442	3	552	552	NUM
dpc-5933	442	4	.	.	PUNCT
dpc-5933	442	5	doi:10.2147	doi:10.2147	NOUN
dpc-5933	442	6	/ccid.s402453	/ccid.s402453	PROPN
dpc-5933	442	7	.	.	PUNCT
dpc-5933	443	1	pmid:36891064	pmid:36891064	PROPN
dpc-5933	443	2	26	26	NUM
dpc-5933	443	3	.	.	PUNCT
dpc-5933	444	1	berg	berg	PROPN
dpc-5933	444	2	sh	sh	PROPN
dpc-5933	444	3	,	,	PUNCT
dpc-5933	444	4	balogh	balogh	PROPN
dpc-5933	444	5	ea	ea	PROPN
dpc-5933	444	6	,	,	PUNCT
dpc-5933	444	7	ghamrawi	ghamrawi	PROPN
dpc-5933	444	8	ri	ri	PROPN
dpc-5933	444	9	,	,	PUNCT
dpc-5933	444	10	feldman	feldman	PROPN
dpc-5933	444	11	sr	sr	PROPN
dpc-5933	444	12	.	.	PUNCT
dpc-5933	445	1	a	a	DET
dpc-5933	445	2	review	review	NOUN
dpc-5933	445	3	of	of	ADP
dpc-5933	445	4	secukinumab	secukinumab	NOUN
dpc-5933	445	5	in	in	ADP
dpc-5933	445	6	psoriasis	psoriasis	NOUN
dpc-5933	445	7	treatment	treatment	NOUN
dpc-5933	445	8	.	.	PUNCT
dpc-5933	446	1	immunotherapy	immunotherapy	NOUN
dpc-5933	446	2	.	.	PUNCT
dpc-5933	447	1	2021;13(3	2021;13(3	NUM
dpc-5933	447	2	):	):	PUNCT
dpc-5933	447	3	201	201	NUM
dpc-5933	447	4	-	-	SYM
dpc-5933	447	5	216	216	NUM
dpc-5933	447	6	.	.	PUNCT
dpc-5933	447	7	doi:10.2217	doi:10.2217	PROPN
dpc-5933	447	8	/	/	SYM
dpc-5933	447	9	imt-2020	imt-2020	PROPN
dpc-5933	447	10	-	-	PUNCT
dpc-5933	447	11	0195	0195	NUM
dpc-5933	447	12	.	.	PUNCT
dpc-5933	448	1	pmid:33203276	pmid:33203276	ADP
dpc-5933	448	2	14	14	NUM
dpc-5933	448	3	original	original	ADJ
dpc-5933	448	4	article	article	NOUN
dpc-5933	448	5	|	|	ADV
dpc-5933	448	6	dermatol	dermatol	ADJ
dpc-5933	448	7	pract	pract	NOUN
dpc-5933	448	8	concept	concept	NOUN
dpc-5933	448	9	.	.	PUNCT
dpc-5933	449	1	2025;15(4):5933	2025;15(4):5933	NUM